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Background: Licensed ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel,
Switzerland) and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany) and unlicensed
bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland) are used to
treat macula oedema due to central retinal vein occlusion, but their relative clinical effectiveness,
cost-effectiveness and impact on the UK NHS and Personal Social Services have never been directly
compared over the typical disease treatment period.
Objective: The objective was to compare the clinical effectiveness and cost-effectiveness of three
intravitreal antivascular endothelial growth factor agents for the management of macula oedema due
to central retinal vein occlusion.
Design: This was a three-arm, double-masked, randomised controlled non-inferiority trial.
Setting: The trial was set in 44 UK NHS ophthalmology departments, between 2014 and 2018.
Participants: A total of 463 patients with visual impairment due to macula oedema secondary to
central retinal vein occlusion were included in the trial.
Interventions: The participants were treated with repeated intravitreal injections of ranibizumab
(n = 155), aflibercept (n = 154) or bevacizumab (n = 154).
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Main outcome measures: The primary outcome was an increase in the best corrected visual acuity
letter score from baseline to 100 weeks in the trial eye. The null hypothesis that aflibercept and
bevacizumab are each inferior to ranibizumab was tested with a non-inferiority margin of –5 visual
acuity letters over 100 weeks. Secondary outcomes included additional visual acuity, and imaging
outcomes, Visual Function Questionnaire-25, EuroQol-5 Dimensions with and without a vision bolt-on,
and drug side effects. Cost-effectiveness was estimated using treatment costs and Visual Function
Questionnaire-Utility Index to measure quality-adjusted life-years.
Results: The adjusted mean changes at 100 weeks in the best corrected visual acuity letter scores were
as follows – ranibizumab, 12.5 letters (standard deviation 21.1 letters); aflibercept, 15.1 letters (standard
deviation 18.7 letters); and bevacizumab, 9.8 letters (standard deviation 21.4 letters). Aflibercept was
non-inferior to ranibizumab in the intention-to-treat population (adjusted mean best corrected visual
acuity difference 2.23 letters, 95% confidence interval –2.17 to 6.63 letters; p = 0.0006), but not
superior. The study was unable to demonstrate that bevacizumab was non-inferior to ranibizumab in
the intention-to-treat population (adjusted mean best corrected visual acuity difference –1.73 letters,
95% confidence interval –6.12 to 2.67 letters; p = 0.071). A post hoc analysis was unable to demonstrate
that bevacizumab was non-inferior to aflibercept in the intention-to-treat population (adjusted mean
best corrected visual acuity difference was –3.96 letters, 95% confidence interval –8.34 to 0.42 letters;
p = 0.32). All per-protocol population results were the same. Fewer injections were required with
aflibercept (10.0) than with ranibizumab (11.8) (difference in means –1.8, 95% confidence interval
–2.9 to –0.8). A post hoc analysis showed that more bevacizumab than aflibercept injections were
required (difference in means 1.6, 95% confidence interval 0.5 to 2.7). There were no new safety
concerns. The model- and trial-based cost-effectiveness analyses estimated that bevacizumab was
the most cost-effective treatment at a threshold of £20,000–30,000 per quality-adjusted life-year.
Limitations: The comparison of aflibercept and bevacizumab was a post hoc analysis.
Conclusion: The study showed aflibercept to be non-inferior to ranibizumab. However, the possibility
that bevacizumab is worse than ranibizumab and aflibercept by 5 visual acuity letters cannot be
ruled out. Bevacizumab is an economically attractive treatment alternative and would lead to
substantial cost savings to the NHS and other health-care systems. However, uncertainty about its
relative effectiveness should be discussed comprehensively with patients, their representatives and
funders before treatment is considered.
Future work: To obtain extensive patient feedback and discuss with all stakeholders future
bevacizumab NHS use.
Trial registration: Current Controlled Trials ISRCTN13623634.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 38. See the NIHR Journals Library website for further project information.
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Plain English summary
The eye functions like a camera. The retina, at the back of the eye, is the camera film, and thecentre, the macula, allows us to see fine details. Approximately 6500 people each year in England
and Wales are affected by fluid leaking out of congested tiny blood vessels, causing macular swelling or
oedema. The cause is blockage of the main vein that normally drains blood from the retina.
Three drugs, injected into the eye in tiny amounts every 4–8 weeks, have been shown to improve the vision
of people with this condition. Two drugs, ranibizumab (0.5 mg/0.05ml Lucentis®; Novartis International AG,
Basel, Switzerland) and aflibercept (2 mg/0.05ml Eylea®; Bayer AG, Leverkusen, Germany), are licensed for
UK use, but the third, bevacizumab (1.25mg/0.05ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland),
is not, even though it is much cheaper and used extensively worldwide. To our knowledge, no trials have
compared the three drugs over the typical 2-year treatment period.
This multicentre, Phase III, double-masked, randomised controlled non-inferiority trial comparing the
clinical effectiveness and cost-effectiveness of intravitreal therapy with ranibizumab (Lucentis) versus
aflibercept (Eylea) versus bevacizumab (Avastin) for macular oedema due to central retinal Vein Occlusion
(LEAVO) was designed to compare ranibizumab, aflibercept and bevacizumab in this type of macular
oedema. The trial showed that all three drugs improved vision a lot, but bevacizumab improved vision to
a slightly lesser degree than the other two drugs. All patients should be aware of these findings before
considering their treatment options.
A comparison of the costs and benefits of ranibizumab, aflibercept and bevacizumab, using data from
the trial and other sources, found that all three led to similar improvements in quality of life. Because
aflibercept and ranibizumab are so much more expensive, they may be poor value for money. If patients,
their representatives and funders all agree, it may be possible to treat this type of macular oedema with
bevacizumab, which is cheaper, keeping the other agents available if needed.
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Approximately 5200 cases of visual impairment due to central retinal vein occlusion-related macular
oedema occur yearly in England and Wales and require treatment with repeated intraocular injections
of antivascular endothelial growth factor agents. Treatment typically lasts for 2 years. Two agents,
ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International AG, Basel, Switzerland) and aflibercept
(2 mg/0.05 ml Eylea®; Bayer AG, Leverkusen, Germany), are licensed and recommended by the National
Institute for Health and Care Excellence.
An alternative low-cost option, unlicensed bevacizumab (1.25 mg/0.05 ml Avastin®; F. Hoffmann-La
Roche AG, Basel, Switzerland), is utilised globally. All three antivascular endothelial growth factor
agents are also used in the treatment of other retinal disorders. Despite clinical evidence that
bevacizumab is non-inferior to ranibizumab and is cost-effective in neovascular age-related macular
degeneration and diabetic macular oedema, it is not used in the NHS. The reasons for this include a
lack of clinical evidence in certain indications, concerns over whether or not high-quality bevacizumab
could be manufactured on the scale required for NHS use and the fact that it is not licensed or
recommended by the National Institute for Health and Care Excellence. Therefore, in 2012, the
National Institute for Health and Care Excellence Decision Support Unit recommended further
comparative studies of these agents in retinal diseases, resulting, in 2014, in the development of
this multicentre, Phase III, double-masked, randomised controlled non-inferiority trial comparing
the clinical effectiveness and cost-effectiveness of intravitreal therapy with ranibizumab (Lucentis)
versus aflibercept (Eylea) versus bevacizumab (Avastin) for macular oedema due to central retinal Vein
Occlusion (LEAVO). No new antivascular endothelial growth factor agents or other treatments have
superseded antivascular endothelial growth factor agents in vein occlusion-related macula oedema.
Since LEAVO was initiated, the US Study of Comparative Treatments for Retinal Vein Occlusion 2
(SCORE2) trial (Scott IU, VanVeldhuisen PC, Ip MS, Blodi BA, Oden NL, Awh CC, et al. Effect of
bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central
retinal vein occlusion: the SCORE2 randomized clinical trial. JAMA 2017;317:2072–87) reported the
non-inferiority of bevacizumab to aflibercept with respect to visual acuity at 6 months in 362 patients
with macula oedema due to central retinal vein occlusion or hemiretinal vein occlusion. A systematic
review of antivascular endothelial growth factor therapy confirmed that there were no randomised
controlled trials comparing all three antivascular endothelial growth factor agents in vein occlusion.
LEAVO is, therefore, the first randomised controlled trial, to our knowledge, that has evaluated
the comparative clinical effectiveness and cost-effectiveness of these three antivascular endothelial
growth factor agents in central retinal vein occlusion-related macula oedema over the typical duration
of the disease.
Objectives
The following research questions were addressed in this trial:
l Is bevacizumab non-inferior to ranibizumab in eyes with macula oedema due to central retinal vein
occlusion in terms of best corrected visual acuity at 100 weeks?
l Is aflibercept non-inferior to ranibizumab in eyes with macula oedema due to central retinal vein
occlusion in terms of the best corrected visual acuity at 100 weeks?
l What is the short-term and long-term cost-effectiveness of aflibercept and bevacizumab versus
ranibizumab in the treatment of macula oedema due to central retinal vein occlusion?
DOI: 10.3310/hta25380 Health Technology Assessment 2021 Vol. 25 No. 38
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Hykin et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,




This was a multicentre, prospective, three-arm, double-masked, randomised controlled non-inferiority
trial to evaluate the clinical effectiveness, cost-effectiveness and side-effect profile of three antivascular
endothelial growth factor agents in the management of central retinal vein occlusion-related macula
oedema over 100 weeks.
Setting
The trial was set in the ophthalmology departments of 44 UK NHS trust hospitals.
Participants
Participants were adults with visual impairment due to central retinal vein occlusion-related
macula oedema of < 12 months’ duration, with a visual acuity letter score in the study eye of between
19 (≈ 3/60 Snellen) and 78 (≈ 6/9 Snellen) and spectral-domain optical coherence tomography central
subfield thickness of ≥ 320 µm.
Interventions
Using a web-based randomisation service, eligible patients were allocated (1 : 1 : 1) to repeated
intravitreal injections of ranibizumab, aflibercept or bevacizumab by the method of minimisation,
with the following factors: visual acuity (19–38, 39–58 or 59–78 Early Treatment Diabetic Retinopathy
Study letters), disease duration (< 3 months, 3–6 months or > 6 months) and treatment naive (yes or no).
Participants in all trial arms had a mandated injection at baseline and at 4, 8 and 12 weeks. From weeks
16 to 96, treatment was given if one or more of the predefined re-treatment criteria were met; the
criteria were a decrease in visual acuity of > 5 letters between the previous and the current visit,
attributed to an increase in optical coherence tomography central subfield thickness; an increase in
visual acuity of > 5 letters between the previous and the current visit; an optical coherence tomography
central subfield thickness of ≥ 320 µm due to intraretinal or subretinal fluid; and an optical coherence
tomography central subfield thickness increase of > 50 µm from the lowest previous measurement.
From week 24, the visit interval could be increased from 4 to 8 weeks if re-treatment criteria were not
met at three consecutive visits. Re-treatment was withheld if visual acuity was > 83 letters; it could be
suspended if there was minimal response to three consecutive injections and could be restarted if clinical
deterioration occurred.
Follow-up
Participants were followed up for 100 weeks.
Clinical outcomes
The primary outcome was the change in refracted visual acuity letter score from baseline to 100 weeks
in the study eye. Secondary outcomes in the study eye included a gain of ≥ 10 and ≥ 15 visual acuity
letters, losses of < 15 or ≥ 30 visual acuity letters at 52 and 100 weeks, change in optical coherence
tomography central subfield thickness from baseline to 52 and 100 weeks, optical coherence tomography
central subfield thickness of < 320 µm at 52 and 100 weeks, and the number of injections by 100 weeks.
Adverse events were recorded over the weeks.
Statistical analysis
Part of this section has been reproduced from Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J,
Ramu J, et al. Clinical effectiveness of intravitreal therapy with ranibizumab vs aflibercept vs bevacizumab
for macular edema secondary to central retinal vein occlusion: a randomized clinical trial. JAMA Ophthalmol
2019;137:1256–64. This is an open access article distributed under the terms of the CC-BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium. The text includes minor additions and formatting changes to the original.
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The standard deviation was anticipated to be 14.3 letters, based on the available data, and the
sample size was set at 459 patients for at least 80% power to detect non-inferiority against a
margin of –5 Early Treatment Diabetic Retinopathy Study letters for each intervention compared
with ranibizumab using a two-sided 95% confidence interval from an analysis-of-covariance test with
adjustment for baseline visual acuity. The primary outcome of refracted visual acuity was compared
between the aflibercept and ranibizumab groups and between the bevacizumab and ranibizumab
groups, primarily at the 100-week point, adjusting for baseline using a linear mixed-effects model
and allowing for within-patient correlation of repeated measures over time using an unstructured
covariance matrix. All participants with at least one milestone visit were included in the model;
therefore, those without follow-up data did not contribute to the analysis. Fixed effects included the
main effects and interactions with ‘time’ (defined as milestone visits at 12, 24, 52, 76 and 100 weeks)
of treatment group, disease duration (< 3 or ≥ 3 months), the baseline of the outcome and its missing
indicator required for the missing indicator method. The test for non-inferiority was one-sided at the
2.5% significance level, and presented as an estimated effect with two-sided 95% confidence intervals
compared with the non-inferiority margin of –5 letters. The per-protocol population was defined
as a subset of the intention-to-treat population who were eligible and received minimal sufficient
treatment exposure, defined as four treatments correctly assessed and received during the first
six visits. For the analysis of the primary outcome, the mixed-effects model was re-fitted in the
per-protocol population. Non-inferiority was declared if the estimated 95% confidence interval for
the difference in means lay wholly above the margin of –5 letters in both the intention-to-treat and
the per-protocol analysis models, primarily at 100 weeks and secondarily at 52 weeks (and implicitly
one-sided p < 0.025 for both). Analyses were completed according to the intention-to-treat strategy
under a missing-at-random assumption, together with a principled sensitivity analysis in the full
intention-to-treat and per-protocol populations. This assessed sensitivity to the handling of missing
100-week data using three recommended scenarios affecting either any or all groups. Secondary
continuous outcomes were analysed only on the intention-to-treat basis, for superiority, and with the
same model specification as for the primary outcome, except with baseline visual acuity represented
by its minimisation categories, and reported as adjusted differences in means. Safety and Antiplatelet
Trialists’ Collaboration events were reported as proportions and compared between groups, with
Wilson’s 95% confidence intervals for rare events. All superiority tests were two-sided at the 5%
significance level and effect sizes were interpreted cautiously with 95% confidence intervals.
Health economic analysis
The primary health economic analysis was a model-based cost–utility analysis adopting a lifetime
horizon and an NHS payer perspective, using discrete event simulation modelling. The model utilised
data from LEAVO, which were supplemented with evidence from external sources. Cost-effectiveness
was expressed in terms of the incremental cost per quality-adjusted life-year, estimated using the
Visual Function Questionnaire-Utility Index, the EuroQol-5 Dimensions and the EuroQol-5 Dimensions
with vision bolt-on. A within-trial analysis was conducted as a secondary analysis. Scenario analyses
considered the impact of price discounts for aflibercept and ranibizumab.
Results
Between December 2014 and 2016, eligibility was determined for 586 patients; 463 patients were
randomly assigned to receive ranibizumab (n = 155), aflibercept (n = 154) or bevacizumab (n = 154).
Participants’ baseline characteristics were similar between the treatment groups. A total of 454 and
443 participants were included in the prespecified intention-to-treat and per-protocol linear mixed-
effects models, and the 100-week visit was completed by 135 (87.1%) participants in the ranibizumab
group, 133 (86.4%) participants in the aflibercept group and 139 (90.3%) participants in the
bevacizumab group.
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Clinical results
The mean gain in visual acuity letter score was ranibizumab +12.5 (standard deviation 21.1), aflibercept
+15.1 (standard deviation 18.7) and bevacizumab +9.8 (standard deviation 21.4) at 100 weeks. At
100 weeks, the trial was unable to demonstrate that bevacizumab was non-inferior to ranibizumab
in either the intention-to-treat (adjusted mean best corrected visual acuity difference–1.73 letters,
95% confidence interval –6.12 to 2.67 letters; p = 0.071) or the per-protocol population (adjusted
mean best corrected visual acuity difference–1.67 letters, 95% confidence interval –6.02 to 2.68 letters;
p = 0.066). Aflibercept was non-inferior to ranibizumab in both the intention-to-treat (adjusted mean
best corrected visual acuity difference 2.23 letters, 95% confidence interval –2.17 to 6.63 letters,
p = 0.0006) and the per-protocol populations (adjusted mean best corrected visual acuity difference
was 3.49 letters, 95% confidence interval –0.91 to 7.88 letters; p < 0.0001), but it was not superior.
At 52 weeks, aflibercept and bevacizumab were non-inferior to ranibizumab. The proportions of
participants in the three groups who had a best corrected visual acuity letter gain of ≥ 15 were
similar: 47% in the ranibizumab group, 52% in the aflibercept group and 45% in the bevacizumab
group. There were no differences across the groups in the proportion of patients who had ≥ 10 best
corrected visual acuity letter gain or < 15 best corrected visual acuity letter loss.
The adjusted difference in optical coherence tomography central subfield thickness at 100 weeks
for aflibercept versus ranibizumab was –29.3 (95% confidence interval –60.9 to 2.3), whereas for
bevacizumab versus ranibizumab, it was 21.9 (95% confidence interval –9.7 to 53.4). However, a
significantly greater proportion of participants had an optical coherence tomography central subfield
thickness of < 320 µm at 52 weeks in the aflibercept group (76%) than in the ranibizumab group
(63%), a mean difference of 12.4% (95% confidence interval 1.7% to 23.1%). This was also the case
at 100 weeks for aflibercept (81%) compared with ranibizumab (66%), a mean difference of 15.3%
(95% confidence interval 4.9% to 25.7%), but for bevacizumab compared with ranibizumab a difference
was found only at week 24 (mean difference –18.7%, 95% confidence interval –30.1% to –7.4%).
The corresponding proportions at 52 weeks and 100 weeks for bevacizumab were –10.7% (95%
confidence interval –22.3% to 0.9%) and –7.4% (95% confidence interval –18.9% to 4.1%).
By 100 weeks, participants in the ranibizumab group had received a mean of 11.8 injections, compared
with 10.0 injections received by participants in the aflibercept group and 11.5 injections received
by those in the bevacizumab group. The difference between the aflibercept and ranibizumab groups
was significant at week 24 (mean difference –0.4, 95% confidence interval –0.6 to –0.2), week 52
(mean difference –1.1, 95% confidence interval –1.6 to –0.5) and week 100 (mean difference –1.9,
95% confidence interval –2.9 to –0.8). There was one case of infectious endophthalmitis in the
bevacizumab group. The frequency of all ocular adverse and Antiplatelet Trialists’ Collaboration-
defined events occurred with an expected, and similar, frequency in the three groups.
Aflibercept became a standard of care after LEAVO was initiated, so the comparative effectiveness
of aflibercept and bevacizumab became highly relevant and a post hoc analysis was conducted. This
analysis showed that bevacizumab was not non-inferior to aflibercept in both the intention-to-treat
(adjusted mean best corrected visual acuity difference–3.96 letters, 95% confidence interval –8.34 to
0.42 letters; p = 0.32) and the per-protocol populations (adjusted mean best corrected visual acuity
difference –5.15 letters, 95% confidence interval –9.52 to –0.79 letters; p = 0.47).
Economic results
The main findings of the model-based and within-trial cost–utility analyses suggest that bevacizumab is
an economically attractive alternative to the licensed products ranibizumab and aflibercept.
The model-based economic analysis found that all three antivascular endothelial growth factor agents
generated similar quality-adjusted life-years. Aflibercept generated the highest costs, followed by
ranibizumab and then bevacizumab. Using the Visual Function Questionnaire-Utility Index, bevacizumab
generated more quality-adjusted life-years than ranibizumab and aflibercept. The mean difference in
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quality-adjusted life-years between ranibizumab and bevacizumab was –0.044 (95% confidence interval
–0.074 to 0.013), and the mean difference in costs was £11,873 (95% confidence interval £11,458 to
£12,288), so bevacizumab was said to dominate ranibizumab, and the 95% confidence interval for
the incremental net monetary benefit at £30,000 per quality-adjusted life-year was –£14,316 to
–£12,067. The mean difference in quality-adjusted life-years between aflibercept and bevacizumab
was –0.109 (95% confidence interval –0.161 to –0.057), and the mean difference in costs was £4800
(95% confidence interval £4445 to £5154), so bevacizumab was said to dominate aflibercept, and the
95% confidence interval for the incremental net monetary benefit at £30,000 per quality-adjusted life-
year was –£21,864 to –£18,040. The mean difference in quality-adjusted life-years between aflibercept
and ranibizumab was –0.065 (95% confidence interval –0.097 to –0.033), and the mean difference
in costs was £4800 (95% confidence interval £4445 to £5154), so ranibizumab was said to dominate
aflibercept, and the 95% confidence interval for the incremental net monetary benefit at £30,000
per quality-adjusted life-year was –£7917 to –£5603. The finding that bevacizumab was the most
cost-effective intervention was robust to scenario analyses. The costs of aflibercept and ranibizumab
would need to be discounted by at least 95% to be comparable to the cost of bevacizumab (at £28 per
injection over a patient’s lifetime).
In the within-trial base-case analysis, the difference in mean total costs was £1245 between aflibercept and
ranibizumab (95% confidence interval £421 to £2070), –£6760 between bevacizumab and ranibizumab
(95% confidence interval –£7546 to –£5973) and £7984 between aflibercept and bevacizumab (95%
confidence interval £7209 to £8759). Bevacizumab was dominant (less costly and with no difference in
benefit) compared with ranibizumab, with a probability of cost-effectiveness of 1.00 at the £20,000 per
quality-adjusted life-year threshold. Aflibercept was more costly than ranibizumab, with a mean quality-
adjusted life-year difference of 0.004 (95% confidence interval –0.0430 to 0.0518), an incremental cost-
effectiveness ratio of £283,595 per quality-adjusted life-year gained and a probability of cost-effectiveness
of 0.04 at the £20,000 per quality-adjusted life-year threshold. Aflibercept was dominated by bevacizumab
(more costly, with a mean quality-adjusted life-year difference of –0.015, 95% confidence interval –0.0618
to 0.0322) with a probability of cost-effectiveness of 0.00 at both the £20,000 and the £30,000 per quality-
adjusted life-year thresholds.
Conclusions
All three antivascular endothelial growth factor agents are effective therapies for macula oedema
secondary to central retinal vein occlusion, with no differences from a safety perspective. Although
aflibercept was demonstrated to be non-inferior to ranibizumab, the trial was unable to demonstrate
that bevacizumab was non-inferior to either, meaning that we cannot rule out the possibility that
bevacizumab may be worse by 5 visual acuity letters. However, patients’ health-related quality-of-life
assessments were similar across treatment groups, and bevacizumab was found to be the most
cost-effective option. The trial results are, therefore, divergent. We believe that bevacizumab could
be introduced into the NHS as a first-line agent for this condition only after a review of these results
and in agreement with patients, their representatives and funders. If patients are fully informed
and understand the clinical results of the trial, as our small post-trial patient questionnaire suggests,
a majority may consent to bevacizumab treatment with the proviso that licensed medications be
available to them as an option if their response to bevacizumab is less than expected. If adopted,
bevacizumab would result in substantial savings to the NHS, and potentially to health-care systems
around the world.
Trial registration
This trial is registered as ISRCTN13623634.
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Retinal vein occlusion (RVO) is the second most common retinal vascular disorder,1,2 after diabetic
retinopathy, and comprises branch RVO, hemiretinal vein occlusion and central retinal vein occlusion
(CRVO). CRVO has a prevalence of 0.08–0.41%3–5 and a 15-year cumulative incidence rate of 0.5%.6,7
Approximately 6860 people develop CRVO every year in England and Wales, of these, 5150 develop
visual impairment due to macula oedema (MO), which is unlikely to improve spontaneously8–11 and is
therefore potentially eligible for treatment, according to the National Institute for Health and Care
Excellence (NICE).12,13
Central retinal vein occlusion is characterised by retinal haemorrhages, venous dilatation and tortuosity
in all four quadrants of the retina.1,7 An increase in hydrostatic pressure at the venous end of the retinal
capillary network reduces retinal perfusion, upregulating the production of vascular endothelial growth
factor (VEGF), which, in turn, increases retinal capillary permeability and is probably the major cause of
MO,14 although the raised hydrostatic pressure per se probably plays a part.7 VEGF promotes iris and
retinal neovascularisation in severe cases. The characteristic presentation of CRVO is sudden painless
unilateral decrease in vision due to MO.8 In severe cases, vision is affected by macular ischaemia or the
development of iris neovascularisation and, subsequently, neovascular glaucoma with elevated intraocular
pressure, pain, redness and visual loss if the condition is left untreated. CRVO may be bilateral in 5% of
cases, and the risk of developing RVO in the contralateral eye within 12 months is approximately 5%.7,8
Central retinal vein occlusion has two distinct clinical subtypes.7,8 Non-ischaemic CRVO is characterised
by a visual acuity of ≥ 6/30, no relative afferent pupillary defect (RAPD), mild to moderate retinal venous
dilatation and tortuosity, and intraretinal haemorrhage and MO. Ischaemic CRVO is characterised by a
visual acuity of ≤ 6/36, the presence of a RAPD, and intraretinal haemorrhage with venous dilatation
and tortuosity greater than the Central Vein Occlusion Study (CVOS) standard photograph,15 with
complications that include MO, macular ischaemia, retinal ischaemia, iris and retinal neovascularisation
and neovascular glaucoma.16 Optical coherence tomography (OCT) confirms and characterises the MO,
and fundus fluorescein angiography (FFA) confirms and characterises the extent of macular and retinal
ischaemia and the presence of retinal neovascularisation; both investigations guide management.7,8
Novel morphological OCT biomarkers for CRVO have been identified that may provide important
diagnostic and prognostic information, although, to our knowledge, none has been utilised in a large
prospective clinical trial to date.17–19 Conventional seven-field FFA is semiquantitative and, if the total
area of angiographic non-perfusion is at least 10 disc areas in size, the prognosis is less good than for
the non-ischaemic subtype.20,21 More recently, wide-angled FFA has allowed a greater proportion of
the peripheral retina to be imaged, although the exact amount and distribution of non-perfusion that
characterises the subtypes of CRVO have not been well defined.22,23 Eyes with larger areas of retinal
ischaemia on conventional FFA are more prone to neovascular complications.20 Approximately 15–20%
of cases present with ischaemic CRVO, and in 25–34% of cases non-ischaemic CRVO converts to the
ischaemic subtype within 3 years.20,24 Neovascular complications such as iris neovascularisation are
typically managed using a combination of retinal laser therapy and anti-VEGF therapy.7,8
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In non-inferiority ophthalmology clinical trials, the primary outcome has typically been a visual acuity
difference of –5 Early Treatment Diabetic Retinopathy Study (ETDRS) letters. This is thought to
represent a meaningful difference between two treatments, based on the following:
l Most patients in a busy clinic setting can reliably distinguish an 8-letter (1.5-line) difference on an
ETDRS visual acuity chart, but they may perform better than this in a clinical trial setting.25
l A 5-letter (1-line) improvement in mean visual acuity in retinal studies typically results in a 50%
increase in the number of patients gaining 15-letter (3-line) improvement in visual acuity, suggesting
that this is a meaningful difference.26
l The choice of a 5-letter margin was 32% higher than the available estimated 12-month placebo-
controlled effect of 6.6 letters for ranibizumab (0.5 mg/0.05 ml Lucentis®; Novartis International
AG, Basel, Switzerland), the standard (comparator) treatment in this multicentre, double-masked,
randomised controlled non-inferiority trial comparing the clinical effectiveness and cost-effectiveness
of intravitreal therapy with ranibizumab (Lucentis) versus aflibercept (Eylea) versus bevacizumab
(Avastin) for macular oedema due to central retinal Vein Occlusion (LEAVO). This margin choice
was, therefore, consistent with maintaining assay sensitivity sufficiently to be able to declare
non-inferiority [see www.journalslibrary.nihr.ac.uk/programmes/hta/119203/#/documentation
(accessed 14 July 2020)].
l This margin was accepted by the funder.
Although a 4-letter change has been used as a non-inferiority margin, this was not common practice
at the time LEAVO was designed, and we wanted to ensure that LEAVO would be as similar as
possible to alternative comparable studies of anti-VEGF therapy in CRVO [e.g. Study of Comparative
Treatments for Retinal Vein Occlusion 2 (SCORE2)27].
Central retinal vein occlusion-related macular oedema and antivascular
endothelial growth factor therapy
Visual impairment in CRVO is primarily due to MO; it is typically significant, resolution is likely to
occur in only the mildest non-ischaemic cases24 and the anatomical improvement of MO may not result
in a corresponding improvement in visual acuity.8 Presenting visual acuity is typically a good predictor
of final visual outcome: patients who present with an initial visual acuity of ≥ 6/12 will probably retain
good vision, whereas 80% of those who present with a visual acuity of ≤ 6/60 do not improve to > 6/60.20
The natural history arm of the CVOS showed no change in mean baseline visual acuity over 3 years;20
this finding is supported by the sham arms in the Ranibizumab for the Treatment of Macular Edema
after Central Retinal Vein OcclUsIon Study: Evaluation of Efficacy and Safety (CRUISE),9 GALILEO28–30
and COPERNICUS10,28,30,31 licensing trials for ranibizumab and aflibercept (2 mg/0.05 ml Eylea®; Bayer AG,
Leverkusen, Germany), in which patients who were initiated on treatment 6 months after randomisation
to sham did not achieve as large visual gains as participants randomised to prompt therapy. Therefore,
prompt treatment is typically recommended to maximise visual outcomes.
First-line therapy for MO is repeated intravitreal injections of anti-VEGF agents to block the action
of VEGF, thereby reducing capillary permeability.9,32–38 Early studies excluded patients with ischaemic
CRVO33,39 as it was questionable whether or not a significant improvement in vision would result from
anti-VEGF therapy. More recent (2017) studies40 did not exclude such patients, and this is the approach
we adopted in LEAVO to ensure that our study population fully reflected a general UK population
likely to present for treatment.
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To date, three anti-VEGF agents have been used in the treatment of MO due to CRVO:
1. Ranibizumab is a humanised, affinity-matured VEGF antibody fragment that binds to and neutralises
all isoforms of VEGF-A. Ranibizumab was the first anti-VEGF therapy to demonstrate improved
visual outcomes in patients with neovascular age-related macular degeneration (nvAMD),41,42 and in
2012 it was licensed by the US Food and Drug Administration (FDA) and the European Medicines
Agency (EMA) for MO due to CRVO. This was based on the CRUISE data9 that showed that
monthly intraocular ranibizumab therapy improved the mean best corrected visual acuity (BCVA)
by +15 ETDRS letters at 6 months and a pro re nata regimen with monthly monitoring improved
the mean BCVA by +14 ETDRS letters by 12 months.9 In an open-label extension [An Open-Label,
Multicentre Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with
Choroidal Neovascularization Secondary to Age-Related Macular Degeneration or Macular Oedema
Secondary to Retinal Vein Occlusion Who Have Completed a Genentech-Sponsored Ranibizumab
study (HORIZON)] from months 12 to 24, the mean visual acuity in CRVO only patients reduced
by 4.1 letters with an average of 3.5 injections in 12 months. Ranibizumab was well tolerated: 6.5%
of patients had some degree of cataract after 2 years and < 1% had a rise in intraocular pressure.38
2. Aflibercept is a fusion protein of the key domains of VEGF receptors 1 and 2 and human IgG Fc that
blocks all VEGF-A isoforms and placental growth factor. In 2014, it was licensed by the FDA and
the EMA for CRVO based on the GALILEO and COPERNICUS studies, which showed a mean gain
of +16.2 letters in BVCA at 12 months and a mean gain of +13.0 letters in BCVA at 24 months,
with 60% gaining ≥ 15 letters at 12 months and 49.1% gaining ≥ 15 letters at 24 months.29–31
Despite these results, and the fact that it was non-inferior to ranibizumab when given every
8 weeks after a loading phase in nvAMD, suggesting improved cost-effectiveness,43 no clinical
trial had been undertaken to directly compare aflibercept with ranibizumab or bevacizumab
(1.25 mg/0.05 ml Avastin®; F. Hoffmann-La Roche AG, Basel, Switzerland), even though NICE
recommended aflibercept for MO due to CRVO [NICE technology appraisal (TA) guidance 30512].
Cumulative safety data have not, to date, shown an increased risk of any ocular or systemic
adverse events (AEs) with aflibercept compared with other drugs used for these indications.
3. Bevacizumab is a monoclonal antibody that also inhibits VEGF; it is licensed by the EMA for
the treatment of cancer but is used off-label for treatment in the eye. However, it was crucial to
fully assess bevacizumab’s suitability for intraocular use because (1) it is substantially cheaper than
ranibizumb and aflibercept when divided by a compounding pharmacy into multiple doses from a
single 4-ml vial; (2) it was found by the Decision Support Unit44 to be used in NHS trusts across
the UK for nvAMD, diabetic macula oedema (DMO), RVO and other less common indications, such
as choroidal neovascularisation due to myopia and retinal dystrophies; (3) it is widely used in UK
private practice; and (4) there have been concerns about possible systemic side effects following
intraocular injection of bevacizumab.45 Bevacizumab was found to be non-inferior to ranibizumab
in terms of macular dysfunction and final visual acuity over 2 years in two large clinical trials: the
Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)45 trial and the Comparison of
Age-related macular degeneration Treatments Trials (CATT).46 These trials also found no increased
risk of local or systemic side effects with bevacizumab compared with ranibizumab; although more
patients receiving bevacizumab were hospitalised due to serious adverse events (SAEs), the
investigators thought that these SAEs were unrelated to bevacizumab.47
Two independent reviews48,49 had previously suggested an increase in bevacizumab-related side effects,
increasing the need to compare the safety of bevacizumab directly with that of ranibizumab. NICE
Technology appraisal (TA) 28313 (on ranibizumab) and NICE TA30512 (on aflibercept) for MO secondary
to CRVO recommended that additional head-to-head trials including bevacizumab were needed for RVO
to carefully examine clinical effectiveness and cost-effectiveness. Therefore, it was proposed that LEAVO
be conducted in MO due to CRVO to (1) compare the clinical effectiveness of ranibizumab, aflibercept
and bevacizumab in a pragmatic trial over 24 months that followed up patients over the natural history of
the disease, (2) compare the cost-effectiveness of the agents in a trial that closely resembled clinical practice
and (3) describe the safety profile of each agent in terms of ocular and systemic AEs over 24 months.
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Evidence update post LEAVO initiation
Ranibizumab, aflibercept and bevacizumab continue to be used in many countries for multiple retinal
diseases, with bevacizumab the most frequently given anti-VEGF agent worldwide, as the licensed
alternatives remain too costly. Despite convincing case series and early trials employing bevacizumab,
full-scale randomised controlled trials (RCTs) were commissioned and completed by the UK National
Institute for Health Research (NIHR) and the US National Institutes of Health to compare bevacizumab
with ranibizumab in nvAMD45,46 prior to the licensing of aflibercept. To our knowledge, no RCTs have
compared all three agents for nvAMD. Nevertheless, after a review of all the available evidence,
the NICE Guideline Committee reported that all three agents were of equivalent efficacy and had
similar side effects,50 and systematic reviews found no differences in the risk of vision-threatening
complications or systemic AEs.51,52
Despite this, bevacizumab has not achieved widespread use in the UK. The reasons for this include
no clear position on the issue from NHS England or the Medicines and Healthcare products Regulatory
Agency (MHRA); likely conflicts of interest among key stakeholders, including physicians; and the belief
in some quarters that bevacizumab is an unlicensed medication, rather than a licensed medication being
used in an off-label indication. Most recently, a UK judicial review (the Whipple judgement, September
2018), brought by the manufacturers of aflibercept and ranibizumab against north of England Clinical
Commissioning Groups that had adopted a policy that off-label bevacizumab should be the preferred
option for the treatment of nvAMD, ruled that this was lawful.53 However, this outcome is now subject
to appeal by the manufacturers and the uncertainty continues, which is frustrating as the economic case
for bevacizumab is overwhelming. The only retinal condition for which the three anti-VEGF agents have
been compared is DMO. The visual gains at 2 years in eyes with moderate and severe visual loss (visual
acuity of ≤ 20/50) occurred earlier and were greater in eyes receiving aflibercept therapy. However,
among patients with mild initial visual impairment, visual gains were similar across treatment arms,
suggesting that bevacizumab could be used for these patients.54
Robust data remain lacking on long-term comparisons of outcomes with anti-VEGF agents for MO due
to CRVO. After the initiation of LEAVO, the secondary outcomes of the randomised, double-masked,
Phase III licensing trials of aflibercept for CRVO, the COPERNICUS and GALILEO studies, became
available. These showed that the visual and anatomic improvements after fixed monthly dosing through
to week 24 and continued pro re nata dosing with monthly monitoring from week 24 to week 52 were
largely maintained up to 100 weeks if monitored every 8 weeks, and diminished if monitored quarterly
from week 52 to week 100.29–31 The 12-month single-arm study of an individualised dosing regimen
of ranibizumab driven by stabilisation criteria in 357 patients with CRVO also resulted in significant
gain in visual acuity (CRYSTAL).55 The mean number of injections by 12 months was 8.8, with better
outcomes in eyes with CRVO of < 3 months’ duration and lower baseline visual acuity. The visual
outcomes were similar in eyes with and eyes without baseline macular ischaemia. The study also
showed that visual acuity could be stabilised with visual acuity-guided re-treatment criteria up
to 100 weeks.56
Although these trials compared each anti-VEGF agent with sham treatment for MO due to CRVO,
RCTs comparing these agents over a longer term have been limited. A RCT comparing aflibercept and
ranibizumab on a treat-and-extend regimen over 18 months showed that the frequency of injections
was significantly lower in the aflibercept arm than in the ranibizumab arm.57 The SCORE2 study group
randomised 362 patients with MO due to CRVO or hemiretinal vein occlusion 1 : 1 to receive monthly
aflibercept or bevacizumab for 6 months, and reported that intravitreal bevacizumab was non-inferior
to aflibercept with respect to visual acuity.27 The participants who responded well to monthly aflibercept
and those who responded well to bevacizumab for 6 months in SCORE2 were further randomised to
receive either monthly injections or treat-and-extend regimens of aflibercept (for those who responded
INTRODUCTION
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well to aflibercept) and bevacizumab (for those who responded well to bevacizumab). The 12-month
outcome showed that the treat-and-extend arm of each anti-VEGF agent required up to two fewer
injections from 6 to 12 months than the monthly mandated treatment arms, although the difference in
visual outcomes showed significant variability.58 A RCT comparing aflibercept and bevacizumab on a one
plus pro re nata basis found that those in the aflibercept arm required fewer injections at 12 months.59
The COMRADE-C trial was a Phase IIIb, multicentre, double-masked, randomised clinical trial that
compared a ranibizumab loading phase followed by pro re nata dosing with 0.7 mg of dexamethasone,
given only at baseline, for MO due to CRVO, and showed a favourable outcome with ranibizumab.60
A 2019 systematic review61 evaluating the effectiveness and adverse effects of ranibizumab, aflibercept
and bevacizumab in three common retinal conditions, including RVO, reported that none of the 17 included
studies showed a clinically important difference (i.e. ≥ 5 letters) in visual acuity gains between agents. There
was insufficient evidence to compare bevacizumab and ranibizumab in RVO. Overall, the authors reported
that no agent had a clear advantage over another in effectiveness or safety, but in two trials61 both
aflibercept and ranibizumab were significantly less cost-effective than repackaged bevacizumab.61
Another systematic review and network analysis of 11 RCTs of the three anti-VEGF agents for RVO
found no statistically significant differences in the proportion of patients who gained at least 15 letters
in BCVA, in the mean change from baseline in BCVA, or in the mean change from baseline in central
macular thickness at 6 months.62 However, to date, no RCTs have compared all three anti-VEGF agents
for treating this condition over the at least 2-year duration of the disease.
To our knowledge, the LEAVO trial is the first RCT evaluating the comparative clinical effectiveness,
cost-effectiveness and relative safety of these three anti-VEGF agents for CRVO-related MO over
100 weeks. In summary, if bevacizumab was shown in LEAVO to be non-inferior to ranibizumab, and
aflibercept was non-inferior to ranibizumab, with no new safety concerns, it could be considered for
NHS use in MO due to CRVO. In addition, this would provide evidence of its equivalence to the
licensed medications in multiple indications and lend substantial support to the case for using
bevacizumab in the treatment of nvAMD and other retinal diseases.
Clinical trial objective
The objective of the trial was to compare the relative clinical effectiveness and cost-effectiveness of
the anti-VEGF agents bevacizumab (investigational treatment), aflibercept (investigational treatment)
and ranibizumab (standard care) in MO due to CRVO over 100 weeks. The trial was intended to
determine if bevacizumab or aflibercept was as effective as ranibizumab in reducing visual loss from
MO due to CRVO, whether or not they had an equivalent side-effect profile and whether or not either
could be considered or recommended for NHS treatment based on non-inferior clinical effectiveness
and superior cost-effectiveness.
Primary objectives
l To determine whether or not bevacizumab is non-inferior to ranibizumab in treating visual loss due
to MO secondary to CRVO.
l To determine whether or not aflibercept is non-inferior to ranibizumab in treating visual loss due to
MO secondary to CRVO.
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Secondary objectives
l To determine the difference between arms in terms of mean change in BCVA at 52 weeks.
l To determine the difference between arms in the proportion of participants with ≥ 15 ETDRS letter
improvement (appreciable visual gain), ≥ 10-letter improvement, < 15-letter loss and ≥ 30-letter loss
(severe visual loss) at 52 and 100 weeks.
l To determine the difference between arms in the proportion of participants with ≥ 73 ETDRS
letters or > 6/12 Snellen equivalent (i.e. approximate driving visual acuity), ≤ 58 ETDRS letters
(≤ 6/24) and ≤ 19 letters (≤ 3/60) [Certificate of Vision Impairment (CVI) partial and severe visual
impairment] at 52 and 100 weeks.
l To determine the difference between arms in the mean change in OCT central subfield thickness
(CST) and macular volume at 52 and 100 weeks.
l To determine the difference between arms in the proportion of participants with an OCT CST of
< 320 µm [as measured with the Spectralis® (Heidelberg Engineering, Inc., Franklin, MA, USA) or
equivalent] at 52 and 100 weeks (key guide to subsequent NHS clinical practice).
l To determine the differences between arms in the mean number of intravitreal injections given to
each participant at 100 weeks.
l To determine any differences in the relative effectiveness of the investigational treatments and
comparator on quality of life and resource use, reported as incremental cost-effectiveness ratios
(ICERs), at 52 and 100 weeks.
l To detect any differences in the prevalence of local and systemic side effects at 100 weeks.
l To determine the differences between arms at 100 weeks in the proportion of (1) persistent
non-responders who develop a change in retinal non-perfusion, compared with screening, and
(2) participants who develop anterior and posterior segment neovascularisation.
l To determine the differences between arms in terms of mean change in BCVA at 100 weeks.
l To determine the differences between arms in changes in area of non-perfusion at 100 weeks and
OCT anatomical features from baseline to 100 weeks.
INTRODUCTION




LEAVO was a Phase III, randomised, controlled, double-masked, non-inferiority clinical trial conducted
to evaluate the relative clinical effectiveness and cost-effectiveness of intravitreal bevacizumab and
aflibercept, compared with ranibizumab, for MO due to CRVO. The intention was to randomise
459 participants with MO due to CRVO in at least one eye in a ratio of 1 : 1 : 1 to ranibizumab
(0.5 mg/0.05 ml), aflibercept (2.0 mg/0.05 ml) and bevacizumab (1.25 mg/0.05 ml), all of which would
be administered by repeated intravitreal injection, and to follow up these participants for 100 weeks.
The study was conducted in the UK NHS across 44 ophthalmology centres that had staff with expertise
in retinal disorders and a proven track record of effectiveness research.2
Participants
The trial population, from which the trial sample was drawn, was adults aged ≥ 18 years with MO
secondary to CRVO of < 12 months’ duration who attended one of the 44 NHS ophthalmology centres.
The complete inclusion and exclusion criteria are listed in the following sections.
Selection of participants
Inclusion criteria
l Subjects of either sex aged ≥ 18 years.
l Clinical diagnosis of centre-involving MO due to CRVO.
l Central retinal vein occlusion of ≤ 12 months’ duration.
l Best corrected visual acuity ETDRS letter score in the trial eye of between 78 (approximate Snellen
equivalent: 20/32) and 19 (approximate Snellen equivalent: 20/400).
l Optical coherence tomography CST of > 320 µm (as measured with the Spectralis) (or equivalent
with an alternative OCT device) predominantly due to MO secondary to CRVO in the trial eye.
l Media clarity, pupillary dilatation and subject co-operation sufficient for adequate fundus imaging of
the trial eye.
l Best corrected visual acuity ETDRS letter score in the non-trial eye of ≥ 14 (approximate Snellen
equivalent: 20/600).
Exclusion criteria
The following applied to the trial eye only, unless specifically stated otherwise:
l Macular oedema considered to be caused by a condition other than CRVO (e.g. DMO,
Irvine–Gass syndrome).
l An ocular condition present that, in the opinion of the investigator, might have affected MO or
altered visual acuity during the trial (e.g. vitreomacular traction).
l Any diabetic retinopathy or DMO on baseline clinical examination of the trial eye.
l Moderate or severe non-proliferative diabetic retinopathy or quiescent, treated or active
proliferative diabetic retinopathy or MO in the non-trial eye. Note that mild non-proliferative
diabetic retinopathy only was permissible in the non-trial eye.
l History of treatment for MO due to CRVO in the previous 90 days with intravitreal or peribulbar
corticosteroids or in the previous 60 days with anti-VEGF drugs or more than six prior anti-VEGF
treatments in the previous 12 months.
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l Active iris or angle neovascularisation, neovascular glaucoma, untreated neovascularisation disc
(NVD), neovascularisation elsewhere (NVE) and vitreous haemorrhage or treatment for these
conditions in the previous month.
l Uncontrolled glaucoma (i.e. eye pressure of > 30 mmHg) either untreated or being treated with
antiglaucoma medication at screening.
l Any active periocular or intraocular infection or inflammation (e.g. conjunctivitis, keratitis, scleritis,
uveitis, endophthalmitis).
Systemic exclusion criteria
l Uncontrolled blood pressure, defined as a systolic value of > 170 mmHg and a diastolic value
of > 110 mmHg.
l Myocardial infarction, stroke, transient ischaemic attack, acute congestive cardiac failure or any
acute coronary event < 3 months before randomisation.
l Women of childbearing potential, unless they were using an effective method of contraception
during the trial and for 6 months after their last injection for the trial. Effective contraception was
defined as one of the following:63
¢ Barrier method – condoms or occlusive cap with spermicides.
¢ True abstinence – when in line with the preferred and usual lifestyle of the subject. Periodic
abstinence (e.g. calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal
were not acceptable methods of contraception.
¢ Tubal ligation or bilateral oophorectomy (with or without hysterectomy).
¢ Male partner sterilisation. The vasectomised male partner should be the only partner of the
female participant.
¢ Use of established oral, injected or implanted hormonal methods of contraception and
intrauterine device.
l Pregnant or lactating women.
l Men who did not agree to an effective form of contraception for the duration of the trial and for
6 months after their last injection for the trial.
l Hypersensitivity to the active ingredients of aflibercept, bevacizumab or ranibizumab, or to any of
the excipients of these drugs.
l Hypersensitivity to Chinese hamster ovary cell products or other recombinant human or
humanised antibodies.
l A condition that, in the opinion of the investigator, would preclude participation in the trial.
l Participation in an investigational trial involving an investigational medicinal product within 90 days
of randomisation.
Rescreening of patients2
Patients could be rescreened in the following circumstances:
l Patients who did not meet the BCVA or OCT CST inclusion criteria could be rescreened a minimum
of 4 weeks after their last screening visit if they were thought to meet the eligibility criteria.
l Individuals who did not meet other modifiable inclusion criteria, for example blood pressure, could
be rescreened a minimum of 2 weeks after the last screening visit.
All assessments performed at the initial screening visit were repeated during the rescreening visit,
except FFA if the rescreening visit was within 10 weeks of the original screening visit. If a patient
was found to be eligible on rescreening and was randomised, their initial entry on the electronic
case report form (eCRF) system was updated, rather a ‘new’ patient being created on the system.
This avoided such patients being incorrectly counted twice in the Consolidated Standards of Reporting
Trials (CONSORT) diagram.
METHODS
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Recruitment
The trial recruited participants from 44 UK ophthalmology centres over 24 months. Recruitment was
competitive; however, each site was allocated a minimum target number of participants to recruit and
was encouraged to exceed this if possible. Sites were set up strategically: larger sites with greater
capacity were initiated first to maximise early recruitment and to ensure that the recruitment period
was fully utilised. Eligible patients were invited to participate via their local clinics, or in an invitation
letter. At each site, participants were identified from subspecialty retinal, general and eye casualty
clinics. Once identified, potential participants underwent a clinical examination, followed by discussion
of the trial with an experienced trial clinician, and were provided with the patient information sheet.2
Trial procedures
Informed consent procedure
The principal investigator or designated subinvestigator was responsible for ensuring that a patient was
fully consented after being provided with an adequate explanation of the aims, methods, anticipated
benefits and potential hazards of the trial. Patients were advised that any data collected would be held
and used in accordance with the Data Protection Act 1998.64 Patients were given at least 24 hours after
receiving the patient information sheet to consider taking part. The principal investigator or designee
recorded in the medical notes the date when the patient information sheet was given to the patient
and the facts that patients were under no obligation to enter the trial and that they could withdraw
at any time without giving a reason. No clinical trial procedures were conducted before consent
was taken from a participant; consent denoted enrolment in the trial. A copy of the signed informed
consent form was given to the participant. The original signed form was retained at the trial site and a
copy was placed in the medical notes. If new safety information resulted in significant changes in the
risk/benefit assessment, or if there were significant changes to the protocol or patient information
sheet, participants were consented again as appropriate.
Randomisation
Only one eye of each participant was randomised to the trial. In 95% of cases, one eye was affected
by CRVO and so was the ‘worse-seeing eye’ and was randomised. On rare occasions, participants had
bilateral CRVO that met the eligibility criteria. In these cases, the worse-seeing eye was randomised
unless the participant opted for randomisation of the ‘better-seeing eye’. The plan was to recruit 459
adult participants with MO due to CRVO and to randomise them 1 : 1 : 1 at the level of the individual
using the method of minimisation incorporating a random element. The three stratifying factors were
(1) visual acuity, stratified by screening BCVA letter score [of ≤ 38 (approximate Snellen equivalent:
≤ 6/60), 39–58 (approximate Snellen equivalent: 6/48 to 6/24) or ≥ 59 (approximate Snellen equivalent:
≥ 6/18)]; (2) duration of disease, from date of CRVO diagnosis to commencement of therapy (< 3, 3–6 or
> 6 months); and (3) treatment naive versus previous treatment. Each participant was randomised to
one of three arms: bevacizumab, aflibercept or ranibizumab.2
A patient identification number (PIN) was generated by registering a patient on the MACRO eCRF
system (InferMed Macro; Elsevier Ltd, Amsterdam, the Netherlands), after consent had been obtained.
Randomisation was carried out in a bespoke web-based randomisation system hosted at the King’s
Clinical Trials Unit (KCTU). A unique PIN was generated in the MACRO program; this was recorded
on all source data worksheets and was used to identify a participant throughout the trial.2,63 The trial
manager allocated all authorised site staff a username and password for the randomisation system.
All authorised staff members, who were typically the principal investigator or designee, logged in
to the randomisation system and entered a participant’s details, including the unique PIN. Once a
participant had been randomised, the system automatically generated e-mails to key staff in the
trial. Unmasked e-mails sent to site pharmacies alerted them to a participant’s treatment arm:
ranibizumab, aflibercept or bevacizumab. The pharmacy department used the e-mail to cross-check
the trial prescription to ensure that the correct medication was dispensed for the correct participant.
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Additional masked e-mails were generated from the randomisation system and sent to key trial site
staff,63 and unmasked e-mails were sent to the emergency unmasking service (ESMS Global Ltd,
London, UK) and unmasked trial management staff.2
Masking of treatment allocation
In randomisation process, only the pharmacy at a local trial site was informed by e-mail of a subject’s
treatment allocation; a copy of the e-mail was sent to the emergency unmasking service (ESMS Global
Ltd) and to unmasked trial management staff. The trial drug that a participant received was transferred
to the dedicated injection room in an opaque masking bag designed to securely and safely transport
medication. A unique seal was attached to the bag before it left the pharmacy. The bag had a safe
zipped compartment containing a printed form detailing a participant’s unique PIN, their date of
birth, the date the drug was dispensed and the injection batch number. Before a participant entered
the injection room, the unmasked injector broke the seal and took the drug out of the masking bag.
Bevacizumab was provided in a prefilled syringe, but ranibizumab and aflibercept were provided in a
vial and drawn into a syringe by the unmasked injector. The syringe was placed on the injection trolley
out of view of the participant, who was then invited into the room and asked to lie on the bed, and
then received the injection. During the trial the manufacturer of ranibizumab began to provide the
drug, in a unique prefilled syringe and vials ceased to be available. In this situation, the unmasked
injector took care not to allow the participant to see the syringe either before or after the injection
had been given. This was achieved by administering the injection while the participant was lying down
and the injection was given via the pars plana in any quadrant of the eye, with the syringe brought to
and taken away from the injection site via a participant’s inferotemporal field of vision so that it did
not pass across their line of sight. The unmasked injector signed the source notes to the effect that
the treatment in the masked bag had been administered to the participant, without specifying the
treatment, and also signed the printed form that was in the masking bag. The empty syringe with
needle and vial were disposed of in the injection room. The masking bag and completed printed form
were returned to the pharmacy. The outer packaging of the drug was disposed of in the injection room.2
The clinical assessment team, including the site principal investigator, optometrist (i.e. assessor
of the primary outcome), site trial co-ordinator, clinical investigator, clinical assessment trial nurse
and ophthalmic technician, remained masked throughout the trial, as there was no record of a
participant’s treatment arm in the source notes or the case report form (CRF). Similarly, co-ordinators
or administrators completing questionnaires with participants in person (or, in extreme circumstances,
only over the telephone at specific time points) had details of a participant’s PIN only. If, at any time,
information regarding treatment allocation was shared with the outcome assessors, this was recorded
in the trial master file, and the person(s) involved met with the site principal investigator to ensure
that no repetition occurred and undertook not to convey this information either to the participant or
to others involved in the project. Certain secondary outcomes (e.g. interpretation of FFA) occurred at
the remote Network of Ophthalmic Reading Centres (NetwORC) UK (Belfast, UK), where the assessors
were masked to the treatment allocation. These masking procedures avoided both performance and
detection bias. We have described the completeness of outcome data for each outcome, including any
unmasking in error, reasons for attrition and exclusions from the analysis.2 The trial statisticians had
access to the accumulating outcome data that were required for reporting to the Data Monitoring and
Ethics Committee (DMEC). Both trial statisticians attended both the open and the closed DMEC meetings.
Screening and baseline assessment
A patient had to receive the patient information sheet not later than 24 hours before the screening
assessment. The screening and baseline visits could be undertaken on the same day, provided that
all test results were available. A patient could return within 10 days of screening for the baseline
assessment, at which point the screening procedures were still valid and were not repeated at baseline
(see Appendix 3, Table 29).
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Milestone and non-milestone visits
Trial milestone assessments, when key research data were collected, occurred at baseline and at weeks
12, 24, 52, 76 and 100. These visits, as well as treatment visits at weeks 4 and 8, were calculated and
agreed with a participant prior to randomisation (with flexibility of 0 to 14 days for weeks 4, 8 and 12,
and of –14 to 14 days for weeks 24, 52, 76 and 100, from the date of randomisation). It was mandatory
for all participants to attend all milestone visits, even if a milestone visit fell < 4 weeks after a treatment
visit or if a participant was being followed up every 8 weeks and the next milestone visit fell during the
8-week interval. The intervening trial treatment visits were deliberately flexible to allow normal clinical
practice treatment follow-up to be accommodated. All data from the trial milestone visits were entered
into the eCRF. For regular treatment visits, only the following information was entered into the eCRF:
BCVA; OCT CST; whether or not an injection was given; and, if no injection was given, the reason why.
At milestone visits, refracted visual acuity was tested and health economic questionnaires were completed;
colour photography was undertaken at baseline and at weeks 52 and 100; and FFA was undertaken at
baseline and at week 100, in addition to the clinical examination and OCT tests performed at all other
trial visits (see Appendix 3, Table 29).
Trial assessments and methods
Participant demographics, medical and ophthalmic history
This information was retrieved from the participant, from hospital medical records or from a general
practitioner. Data included age, sex and ethnic background. Data were also collected on clinically
relevant medical history and management in the preceding 24 months, and on any ocular history
and treatment.2
Visual acuity tests
Visual acuity tests were performed by a certified optometrist in a certified visual acuity testing lane
using validated ETDRS vision charts and standard operating procedures.65,66 Refracted visual acuity
was carried out in both eyes at screening,63 at weeks 12, 24, 52, 76 and 100, and at the point of
withdrawal. For all other visits, the visual acuity was tested with the previous most recent protocol
refraction. Visual acuity examiners were masked to the treatment. The visual acuity scores were
recorded in the eCRF2 (see Appendix 4).
Standard ophthalmic examination
A standard ophthalmic examination using slit-lamp biomicroscopy included an undilated examination
for neovascularisation of the iris (NVI), RAPD and tonometry in both eyes at all visits. Dilated fundus
examination was performed in both eyes at all milestone visits (i.e. at screening, at baseline, at weeks
12, 24, 52, 76 and 100, and at the point of withdrawal). At all other visits, dilated fundus examination
was performed in the trial eye and, at the discretion of the investigator, in the non-trial eye. Gonioscopy,
if indicated, was carried out prior to dilatation at any visit.2
Spectral-domain optical coherence tomography
The CST and total macular volume in both eyes were recorded in the eCRF from the spectral-domain
optical coherence tomography (SD-OCT) thickness map at every visit, and, if applicable, at the point
of withdrawal.63 Any SD-OCT machine could be used for the trial, but the same model of SD-OCT
machine had to be used for each individual throughout the period of the trial. SD-OCT images at
screening and at weeks 52 and 100 only were transferred to and read by masked graders at the
independent NetwORC UK. NetwORC UK provided each site with a trial imaging protocol on how
to acquire SD-OCT images, colour fundus photographs and fundus fluorescein angiographs and
how to transfer these to NetwORC UK to them. Initial grading of all OCT images at baseline and at
weeks 52 and 100 was performed by NetwORC UK. The grading took into account intraretinal oedema,
classified as diffuse, cystic or mixed; determined subretinal fluid as being present or absent; and
determined vitreoretinal interface abnormalities as being present (as either an epiretinal membrane
DOI: 10.3310/hta25380 Health Technology Assessment 2021 Vol. 25 No. 38
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Hykin et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
11
or vitreomacular traction) or absent. Following the contract variation, additional grading parameters
were assessed at NetwORC UK in collaboration with specialised retinal graders at Moorfields Eye
Hospital, utilising additional definitions and analyses that had been developed while the trial was in
progress.1,67,68 Only images captured using a Spectralis OCT machine had sufficient detail to support
the enhanced grading definitions. Retinal morphology was assessed using the Spectralis® Heidelberg
Macular Raster OCT device (Heidelberg Engineering, Inc.) of 31 line scans, 30 × 25 mm in size, at
an interscan distance of 240 µm or the equivalent for alternative devices. MO was graded using the
entire line-scan series and the central 1500 µm, that is seven scans were employed for vitreomacular
interface abnormality and subretinal detachment or equivalent. The remaining parameters were
graded using the central 1000 µm only, that is central five-line scans only. A magnification of 300%
was used to assess the ellipsoid zone (EZ), disorganisation of the retinal inner layers (DRIL)67,68 and
hyperreflective foci (HRF),69,70 with 100% magnification for the remaining parameters. HRF, external
limiting membrane (ELM), EZ and cone outer segment tips (COSTs) were graded as positive only if the
foveal line showed involvement of the foveal depression such that it was distorted, lessened or absent.2
For the grading of normal and abnormal individual morphological features, see Appendix 5, Specific
grading of individual morphological optical coherence tomography features, and Figures 22 and 23.
Colour fundus photography
Non-stereo, seven-field conventional or wide-angle colour fundus photography (CFP) was performed at
screening and at weeks 52 and 100 in the trial eye. CFP confirmed the diagnosis of CRVO and assisted
interpretation of features identified by FFA, for example to differentiate between non-perfusion and
masking due to haemorrhage. If applicable, CFP was also performed at the point of withdrawal, and
at any other trial visit, as per investigator discretion. Colour fundus photographs were transferred
to and read by masked graders at the independent NetwORC UK. Either a colour camera capable of
taking seven-field colour fundus photographs or a wide-angle system was used, but the same model of
camera was used for each individual throughout the trial. The colour photographs were graded by the
NetwORC UK.2
Fundus fluorescein angiography
Non-stereo, seven-field conventional or wide-angle FFA was performed at screening and at week 100
in the trial eye. Any FFA system capable of taking seven-field FFA pictures or a wide-angle system
was allowed, but the same system had to be used in the same individual throughout the trial.2 FFA
was used to quantify the degree of retinal ischaemia and for identification of retinal neovascularisation
(see Appendix 5, Fundus fluorescein angiography grading). Pseudo-anonymised FFA images were transferred
to NetwORC UK, where the standard NetwORC UK 13-sector grid (see Appendix 5, Figure 24) was applied
over the wide-angle or montaged seven-field angiography pictures at baseline and at 100 weeks. The first
100 gradings were double-graded. Discrepancies were adjudicated. Subsequently, one in every eight
gradings was double-graded. Kappa values for key fields (e.g. detection of new vessels on the disc and
new vessels elsewhere) were required to be > 0.8. Any graders who did not achieve this were required
to undergo additional training. Each sector in the grid was semiquantified in terms of percentage
of non-perfusion (nil, 1–25%, 26–50%, 51–75% and 76–100%), and all available sets of images
were analysed to identify how many participants in each arm had experienced a two-step increase
(e.g. zero to 26–50%, or 26–50% to 76–100%) in one to five or more sectors (see Appendix 5, Figure 24).
This technique was used in preference to the ischaemic index, which estimates the ratio of ischaemic
to total retinal area but is very susceptible to image quality and is applicable to wide-angled images
only.22 Therefore, during the trial we used the concentric rings method, which displays superimposed
concentric circles, centred on the fovea.23,71,72 The innermost circle was 1 disc diameter (DD) in size,
and is not graded as it represents the foveal avascular zone. The second circle, representing the macular
ring (ring M), has a radius of 2.5 DD. Each of the subsequent rings (rings 1, 2, 3 and 4) is placed at
increments of 2.5 DD in radius from the foveal centre. Each of these rings is subdivided into 12 equal
segments.23 To calculate the size of the concentric rings required, we assumed that the mean axial
length was 24 mm, and excluded 2 mm from this to account for the cornea and part of the anterior
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
12
chamber. In the model eye, the radius was 11 mm (diameter 22 mm); therefore, the full circumference
would have been 69.1 mm (π = 3.142). The wide-angled imaging system (Optos®; Optos, Inc., Marlborough,
MA, USA) was able to image 200 degrees of the retina; we used this to calculate the average diameter
of retina obtained in a single central image. This was calculated to be 38.4 mm. Using the DD of 1.8 mm,
this meant that the diameter of the image was 21.3 DD. A diameter of 21.3 DD resulted in the need for
a macular ring plus three/four further rings.23 Based on our validation study, we identified that ring 4
was gradable, but the superior and inferior segments of rings 3 and 4 were ungradable because the
ultra-wide field image had better clarity in the horizontal meridian. For details of this method, see
Appendix 5, Figure 25.
Health economic questionnaires
The following quality-of-life and resource use questionnaires were administered at baseline, at 12,
24, 52, 76 and 100 weeks, and at the point of withdrawal: the National Eye Institute Visual Function
Questionnaire-25 items (VFQ-25), EuroQol-5 Dimensions (EQ-5D), EuroQol-5 Dimensions with vision
bolt-on (EQ-5D-V), and a bespoke resource use questionnaire [see www.journalslibrary.nihr.ac.uk/
programmes/hta/119203/#/documentation (accessed 14 July 2020)].
Treatment allocation guess form
Participants and masked optometrists were asked to complete a treatment allocation guess form at
week 100, or at the point of withdrawal, to assess how well participant and assessor masking worked
in the trial.2
Definition of the end of the trial
Participants were enrolled in the trial for approximately 100 weeks from the point of randomisation.
The end of the trial was defined as the last participant’s last trial visit.
Treatment procedures
Treatment schedule
After mandated administration in all three trial arms at baseline and at 4, 8 and 12 weeks, further pro
re nata intervention was administered at weeks 16 and 20 if re-treatment criteria were met and if
visual acuity was ≤ 83 letters.
Regardless of whether a treatment was given, the participant was reviewed in 4 weeks. From weeks 24
to 96, the interval was initially 4 weeks (with a visit window of –14 to 14 days), with the potential for
the interval to increase to 8 weeks (with a visit window of –14 to 14 days) if criteria for ‘stability’ were
achieved. ‘Stability’ was defined as three successive visits from week 16 onwards at which treatment
criteria were not met, and so the first time at which treatment could be deferred for 8 weeks was week 24.
Similarly, ‘success’ was defined as an ETDRS letter score of > 83 letters, and if this was present at any
re-treatment visit from week 16 onwards, treatment was not given at that visit and the participant was
reviewed subsequently. The review occurred 4 weeks later if the initial visit was at 16 weeks, 20 weeks or
any other visit if treatment had been given at this or the preceding visit. If no treatment had been given
at these two visits, the participant was reviewed 8 weeks later. If, at any subsequent visit, re-treatment
criteria were met and BCVA was ≤ 83 ETDRS letters, then re-treatment was commenced (Figure 1). At
each visit between weeks 24 and 96 inclusive, ‘non-responder treatment suspension’ criteria could be met.
If so, the principal investigator, or their designee, at their discretion, could suspend treatment to prevent
therapy in a participant who had not responded to at least their last three injections. If the criteria for
restarting therapy after ‘non-responder treatment suspension’ were met, then the participant had to
resume therapy. If re-treatment criteria were met at one of the visits that took place every 8 weeks or
at an unscheduled visit, then visits every 4 weeks were resumed. Treatment could be ‘deferred’ in certain
circumstances, but the participant was asked to still attend the milestone visits.
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Re-treatment criteria
Criteria were met if one or more of the following was present:
l a decrease in visual acuity of ≥ 6 letters between the current and most recent visit, attributed to an
increase in OCT CST
l an increase in visual acuity of ≥ 6 letters between the current and most recent visit
l OCT CST of > 320 µm (on Spectralis, or of > 300 µm on other machines) because of intraretinal or
subretinal fluid
l an OCT CST increase of > 50 µm from the lowest previous measurement.
Investigational medicinal products
Comparator: ranibizumab (0.5 mg/0.05 ml)
Ranibizumab is a humanised recombinant monoclonal antibody fragment that binds to VEGF A,
preventing receptor interaction and blocking downstream action of VEGF, that is increased vascular
permeability, leading to MO in CRVO. It is licensed by the EMA, and NICE has recommended it for
use in the treatment of nvAMD, DMO and RVO. NICE TA28313 for MO due to RVO was issued in
May 2013. Ranibizumab has been the mainstay of routine clinical care for this condition since the third
quarter of 2013 and was the comparator in this trial. It was supplied to each site hospital pharmacy
directly from the manufacturer as a part of routine hospital stock.2
Intervention: aflibercept (2.0 mg/0.05 ml)
Aflibercept is a fusion protein that includes the key binding domains of human VEGF receptors 1 and 2
with human IgG Fc and acts as a dummy receptor for all VEGF isoforms and placental growth factor,
preventing increased permeability and MO in CRVO. At initiation of this trial, it was licensed by the
EMA, and NICE has recommended it for nvAMD. NICE TA30512 was published in February 2014;
NICE recommends this drug as first-line use for CRVO-related MO. Aflibercept was supplied in a glass



























FIGURE 1 Re-treatment algorithm for weeks 24–96 of the trial.
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Intervention: bevacizumab (1.25 mg/0.05 ml)
Bevacizumab is a full-length humanised monoclonal antibody that binds to VEGF A, forming a protein
complex incapable of binding to the VEGF receptor, thus blocking downstream VEGF action. In
this trial, bevacizumab was supplied in a prefilled plastic syringe in a sealed package to each trial site
pharmacy from the Liverpool and Broadgreen Pharmacy Aseptic Unit, Royal Liverpool University
Hospital, Liverpool, UK.2
Site pharmacy storage, ordering and handling procedures of investigational medicinal products
A trial medication dispensing and return log was maintained by the trial site pharmacies. Administration
records from these sites were retained by the pharmacy and monitored by the trial manager to ensure
that accurate CRF data were recorded. The randomisation system was linked to the investigational
medicinal product (IMP) supply. Each site pharmacy was also responsible for appropriate storage,
dispensing, disposal, and recall and destruction logs, in accordance with good manufacturing practice73
and good clinical practice,74 and the site hospital pharmacy’s approved policies for IMP accountability
and management. Furthermore, each site pharmacy maintained a record of trial drug administration,
based on the pre-printed form signed by the unmasked investigator that was returned to the pharmacy
at each centre.2
Investigational medicinal product accountability
Used and unused trial study medication and study medication accountability
Each masking bag contained a pre-printed form that listed the details of the participant’s unique PIN,
date of birth, date the drug was dispensed and injection batch number. After performing the intravitreal
injection, the unmasked injector signed this form to confirm that the drug had been given to the
allocated patient, and they then returned it in the masking bag to the pharmacy. All used drug vials
and syringes were disposed of in the injection room and not returned to the pharmacy. Pharmacies in
each site maintained a trial medication dispensing log, including date dispensed, batch number, expiry
date and return log. The return log was compiled from the form signed by the unmasked injector. In
addition, the trial-specific prescriptions were maintained in the pharmacy file for audit purposes. Any
administration errors were reported to the chief investigator and trial statistician. In the event that an
injection was not given as scheduled, the reason was documented in the participant’s notes and the CRF.
The trial monitor checked the pharmacy records against the eCRF. All records were reconciled with the
investigator site file at the end of the trial.2
Description and justification of route of administration and dosage of investigational
medicinal product
The approved route of administration (i.e. by intravitreal injection through the pars plana of the eye)
was used in all cases under sterile conditions in a designated treatment area in accordance with the
guidelines75 for intravitreal injection of the Royal College of Ophthalmologists and any approved
procedures at the individual site hospital. The injection could be performed by the unmasked injector(s)
only, who was (were) on the hospital site LEAVO delegation log and was (were) experienced in
intravitreal injection procedures. The dosages of ranibizumab (0.5 mg/0.05 ml) and aflibercept (2.0 mg/
0.05 ml) used in this trial were approved by the EMA, and NICE recommends these doses of these
agents for intraocular use.12,13 The dosage of bevacizumab (1.25 mg/0.05 ml) was the dosage used in
the IVAN clinical trial and the CATT of treating wet age-related macular degeneration (AMD), and the
standard dose used in clinical practice. Post-injection checks were conducted in accordance with local
hospital policy and included a visual acuity, intraocular pressure or optic nerve head perfusion check,
or a combination of these. The interval between two doses of all three drugs was not recommended to
be less than 4 weeks.2
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Management of complications
Complications, such as the development of ischaemic CRVO, neovascularisation of the angle, NVI,
neovascular glaucoma (NVG), NVE and NVD, in the trial eye were recorded as AEs. The diagnosis
and management of these complications of CRVO in the trial were at investigator discretion and
based on local practice. Laser therapy formed the mainstay of therapy and was recorded as a
concomitant procedure.7,8
Recording and reporting of adverse events and reactions
Routine reporting
The MHRA definitions of AEs and SAEs were adopted for this trial. AEs were reported by the site in
the AEs log in the eCRF. All SAEs, serious adverse reactions and suspected unexpected serious adverse
reactions (SUSARs) were recorded and reported on the SAE form to the chief investigator/delegate
within 24 hours of learning of their occurrence. A record of this notification (including date of notification)
was clearly documented to provide an audit trail. In the case of incomplete information at the time of
initial reporting, a follow-up report was provided as soon as the information became available. The sites
responded promptly to any queries raised by the chief investigator/delegate. The principal investigator/
delegate, who had to be a clinician at the site, assessed the relationship of the SAE to any of the trial
interventions. The chief investigator was responsible for assessing the expected or unexpected nature of
all serious adverse reactions. The chief investigator/delegate, with the support of the KCTU, ensured that
Moorfields Eye Hospital, as sponsor, was made aware of any SUSARs and serious adverse reactions that
occurred. The chief investigator/delegate, in conjunction with the sponsor, was responsible for reporting
all SUSARs to the MHRA and relevant ethics committee within the appropriate time frame.
All principal investigators were informed of all SAEs that were assessed as fulfilling the criteria for a
SUSAR (i.e. possibly, probably or definitely related to any trial intervention, and unexpected as per the
summary of product characteristics or the protocol).2
Planned ‘hospitalisations’, non-emergency procedures and adverse event reporting
Some AEs met the definition of serious but did not need to be reported on a SAE report form. Common
ophthalmology- and non-ophthalmology-related events that resulted in planned, non-emergency
hospital admissions for the investigation or treatment of those events and that were not possibly,
probably or definitely related to the IMPs did not need to be reported on a SAE report form. These
events were recorded on the AE form and the investigation and treatment of ophthalmology-related
events were recorded on the ophthalmology-related concomitant procedure forms. All concomitant
medications were recorded on the concomitant medication form. These forms were updated following
each trial visit to ensure that the independent DMEC received accurate reports of the occurrence and
treatment of AEs.2
Pregnancy
In the event that a female participant became pregnant, this was reported to the KCTU on a pregnancy
form sent by fax or e-mail as soon as the investigator became aware of it. The pregnancy was monitored
to determine outcome. Any information related to the pregnancy following the initial report was
reported on a follow-up pregnancy form.2
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Data were handled, computerised and stored in accordance with the Data Protection Act 1998.64
Participants were identified via a unique PIN, their date of birth and their initials. Identifiable information
was stored in the eCRF and did not leave the site. Any participant contact information was stored in the
site on password-protected computers or in secured locations with restricted access.
Data collection tools and source document identification
Written informed consent was obtained before screening and other trial-specific procedures were
performed. SAE data were collected on paper SAE report forms and e-mailed or faxed to the KCTU.
Summary details of SAEs were transcribed to the AE section of the eCRF. For all other data collected,
source data worksheets were used for each patient and data were entered onto the eCRF database.
Source data worksheets were reconciled at the end of the trial with a patient’s NHS medical notes in
the recruiting site. During the trial, critical clinical information was written in the medical notes to
ensure that informed medical decisions could be made in the absence of the trial team. Trial-related
clinical letters were copied to the medical notes during the trial. It was the responsibility of the
principal investigator and his/her team to ensure that the accuracy of all data entered in the
worksheets and the eCRF was in accordance with good clinical practice. The delegation log identified
all those personnel with responsibilities for data collection and handling, including those who had
access to the trial database. The principal investigator was responsible for ensuring that source
data worksheets were filed in a suitably secure location so that source data verification could be
undertaken throughout the trial.2
Data handling and analysis
All trial data and site files were kept on site in a secure location with restricted access.
The trial used an eCRF created using the InferMed MACRO database system. Data were managed
using this system. The eCRF was created in collaboration with the trial statistician and the chief
investigator and maintained by the KCTU. It was hosted on a dedicated secure server in King’s College
London. This system is regulatory compliant; has a full audit trail, data discrepancy functionality and
database lock functionality; and supports real-time data cleaning and reporting. The trial manager was
responsible for providing usernames and passwords to permitted local trial personnel. Only those
authorised by the trial manager were able to use the system.2,63
Quality assurance
The trial incorporated a range of data management quality assurance functions. The eCRF system
contained a range of validations defined by the trial team that alerted sites to inconsistencies in the
data being entered, which were monitored by the trial manager. The trial manager provided trial training
and ongoing trial support, and conducted regular monitoring visits at each site, checking source data
for transcription errors. Any necessary alterations to entered data were date- and time-stamped in the
eCRF. A detailed monitoring plan and data management plan was developed and updated as the trial
progressed, detailing the quality control and quality assurance checks to be undertaken.2
Database lock and record-keeping
Prior to database lock, the trial manager reviewed any outstanding warnings on the eCRF and resolved
or closed these, as appropriate. Local trial personnel resolved any queries that arose. Once all queries
were resolved, no further changes were made to the database unless specifically requested by the trial
office in response to the statistician’s data checks. The trial principal investigator reviewed all of the
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data for each participant and provided e-mail sign-off to verify that all data were complete and correct.
At this point, all data were formally locked for analysis. At the end of the trial, each site was supplied
with a CD-ROM containing the eCRF data for their site. This was filed locally for any future regulatory
inspection or internal audit. The chief investigator is the custodian for the data generated from the trial
and is responsible for archiving the original data. All data will be archived for at least 5 years from the
end of the trial and will be archived in accordance with sponsor’s and regulatory requirements. Principal
investigators were responsible for securely archiving local data generated, essential documents and
source data in accordance with local requirements, but for at least 5 years from the end of the trial.2
Statistical considerations
Sample size calculation
Bevacizumab and aflibercept were hypothesised to be substantially inferior to ranibizumab if, in each
case, the mean of the primary outcome (i.e. change in BCVA ETDRS letter score) was worse by a margin
of 5 letters, a previously used non-inferiority margin,26,76 representing the minimum visual acuity change
that a patient may distinguish. A similar CRVO population9 reported a standard deviation (SD) of 14.3
letters in the ranibizumab (0.5 mg) arm; the 12-month rate of those lost to follow-up was 8.4% in the
ranibizumab arms (0.5 mg and 0.3 mg). In the absence of 24-month data, we assumed a comparable SD
of 14.3 letters at 100 weeks, and allowed for 15% dropout. The two null hypotheses, that bevacizumab
was substantially inferior to ranibizumab, and that aflibercept was substantially inferior to ranibizumab,
were each planned to be rejected if the estimated 95% confidence interval (CI) for the difference in
treatment means was wholly above the 5-letter margin in each case. Assuming equal efficacy, there
was 80% power to reject each null hypothesis and to declare non-inferiority, with 130 followed-up
patients analysed per arm. Allowing for 15% missing data at 100 weeks, 459 patients were planned
to be randomised to the three arms (equal allocation ratio of 153 participants per arm). Sample size
calculations were performed using nQuery Advisor version 4.0 (Statistical Solutions, Saugus, MA, USA).
The primary method of analysis was a linear mixed-effects (LME) model with adjustment for baseline,
which was expected, other things being equal, to increase the power to detect non-inferiority. The
primary method of analysis included all available refracted data of the primary outcome up to and
including 100 weeks, including data from the 15% of participants who we anticipated could miss the
100-week primary outcome end point.2
Statistical considerations
The trial statisticians were responsible for all statistical aspects of the trial, from design through to
analysis and dissemination.2 A detailed statistical analysis plan was completed before the start of
the trial; it was commented on by the DMEC and approved by the Trial Steering Committee (TSC).
The plan was accompanied by a health economics analysis plan, and was updated and re-approved
by the TSC when the protocol was amended.
Target population
The target population, to which inferences from the end of this trial were intended to generalise,
was adult patients with MO due to CRVO.
Trial population
The trial population, from which the trial sample was drawn, was further defined to be adults aged
≥ 18 years, with visual impairment due to CRVO-related MO of < 12 months’ duration, who attended
one of the 44 ophthalmology centres in the UK that had staff with expertise in retinal disorders and
a proven track record of effective research. Only one eye per participant was included in the trial.
METHODS
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Hypotheses
The hypotheses refer to the populations of relevant patients, rather than to trial subjects:
l The working hypothesis – the so-called ‘working hypothesis’ was the hypothesis that motivated the
trial, which the trial results may or may not support. It was that the change in BCVA is non-inferior
in patients treated with either aflibercept or bevacizumab, compared with patients treated
with ranibizumab.
l The statistical null hypothesis 1 – bevacizumab is inferior to ranibizumab in eyes with MO due to
CRVO at 100 weeks.
l The statistical null hypothesis 2 – aflibercept is inferior to ranibizumab in eyes with MO due to
CRVO at 100 weeks.
l Statistical alternative hypothesis 1 – bevacizumab is non-inferior to ranibizumab in eyes with MO
due to CRVO at 100 weeks.
l Statistical alternative hypothesis 2 – aflibercept is non-inferior to ranibizumab in eyes with MO due
to CRVO at 100 weeks.
Treatment arms
The trial was randomised with equal allocation of participants in a 1 : 1 : 1 ratio to the three arms
(see Chapter 2, Randomisation).
Trial samples
Intention to treat
The achieved trial sample comprised those patients who consented to participate and were actually
randomised to the trial.63 These patients were the trial subjects. This randomised trial sample was also
the trial intention-to-treat (ITT) population. The ITT principle states that every subject will be analysed
according to the treatment group to which they are randomised. In this trial, subjects’ data were
analysed according to the ITT strategy,77 under which at least one analysis is recommended to be based
on the ITT population. The trial ITT population comprised all randomised participants, regardless of
whether there was an error in their eligibility (inclusion/exclusion), whether they had withdrawn post
randomisation and whether the correct trial treatments or other interventions were received.63
Per protocol
A per-protocol set of subjects was also included. These were defined as the subset found to be eligible
at entry and who had minimal sufficient exposure to the treatment regimen, defined as four treatments
correctly assessed and received during the first six visits up to week 20. For each of the first four visits,
a correct treatment was defined as receiving the injection. For the fifth and sixth visits, a correctly
assessed and received treatment was defined to be the receipt of an injection if this was indicated to
be required by the re-treatment criteria, or the non-receipt of an injection if this was indicated by the
re-treatment criteria.
The main reason for having a per-protocol set was that this was a non-inferiority trial, and so the use of the
full analysis set would not generally be conservative [see the International Conference on Harmonisation
(ICH) guidance, E9, section 5.2.378]. As Lesaffre79 states, ‘dropouts and a poor conduct of the study might
direct the results of the two arms towards each other’. Although this can be interpreted as an indication
that the per-protocol analysis is the conservative choice for non-inferiority studies, Garrett80 states that
‘The perceived conservative nature of the PP [per protocol] population appears to be much more a
reflection of reduced patient numbers than the presence of bias, while bias can be in either direction
depending on the pattern of violations’. Moreover, with two active treatments, it may be more likely
that any bias affecting both treatments is reduced, in comparison with a placebo-controlled trial.63
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Prominence
Non-inferiority was declared only if both the ITT and the per-protocol analyses supported a non-
inferiority conclusion. The Committee on Proprietary Medical Products Points-to-Consider and several
other papers support this.63 The requirement to declare non-inferiority in both the ITT and the per-




The primary outcome was BCVA in the trial eye, measured in ETDRS letter score at 4 m at 100 weeks.
Measurements of BCVA at milestone visits were included in the analysis of the primary outcome.
Any BCVA measurement was excluded from the analysis if it is was > 3 SDs below the mean at that
time point (including all measurements) and taken within 3 months of the occurrence of a vitreous
haemorrhage, or was from another cause unrelated to maculopathy secondary to CRVO (e.g. NVG).
Secondary outcomes
The secondary efficacy outcome measures are listed in the following sections according to their type of
variable. They were formally analysed at 52 and 100 weeks, but also measured at other time points.
Continuous outcome variables
l Visual acuity and clinical outcomes:
¢ change from baseline in ETDRS letter score measured at 4 m at 52 weeks
¢ change from baseline in mean OCT CST at 52 and 100 weeks
¢ change from baseline in macular volume at 52 and 100 weeks
¢ number of injections performed in the trial eye by 100 weeks
¢ change in retinal non-perfusion as assessed by mean disc area of non-perfusion at 100 weeks.
l Patient-reported outcomes:
¢ National Eye Institute VFQ-25 composite score, distance and near subscales at 52 and
100 weeks.
¢ quality of life (measured using the EQ-5D and the EQ-5D-V) at 52 and 100 weeks.
l Economic reported outcomes (detailed in the health economics analysis plan):
¢ quality-of-life scales (measured using the VFQ-25, the EQ-5D and the EQ-5D-V) at 0, 12, 24, 52,
76 and 100 weeks.
¢ resource use at 0, 12, 24, 52, 76 and 100 weeks.
Categorical outcome variables
l Visual acuity and clinical outcomes:
¢ participants with ≥ 15 ETDRS letter improvement (appreciable visual gain), ≥ 10-letter
improvement, < 15-letter loss and ≥ 30-letter loss (severe visual loss) at 52 and 100 weeks
¢ participants with ≥ 73 ETDRS letters, or > 6/12 Snellen equivalent (i.e. approximate driving
visual acuity), ≤ 58 letters (≤ 6/24 Snellen equivalent) and ≤ 19 letters (≤ 3/60 Snellen
equivalent) (CVI partial and severe visual impairment) at 52 and 100 weeks
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
20
¢ participants with OCT CST of < 320 µm (on the Spectralis, or of < 300 µm on other machines) at
52 and 100 weeks (key guide to subsequent NHS clinical practice)
¢ participants with the anatomical OCT features of diffuse intraretinal oedema, intraretinal cystic
change, subretinal fluid or vitreomacular interface abnormality (either vitreomacular traction or
epiretinal membrane) over time and at 100 weeks
¢ participants with a change in retinal non-perfusion at 100 weeks.
l Safety and tolerability:
¢ prevalence of local and systemic side effects at 100 weeks
¢ participants who were persistent non-responders and who developed anterior and posterior
segment neovascularisation at 100 weeks.
Subgroup variables
Three subgroup variables were considered: (1) baseline visual acuity (low, moderate and high: ≤ 38
letters, 39–58 letters and 59–78 letters, respectively), (2) disease duration (< 3 months or ≥ 3 months)
and (3) ischaemic compared with non-ischaemic. These variables were based on the fact that the visual
gain in the worse-vision group may be higher than that achieved by the better-vision group, and this
effect may differ between arms. The shorter the duration of disease, the better the visual acuity
outcomes, and this may have varied between treatment arms.
Outcomes requiring derivation
The VFQ-25 is a validated tool for assessing vision-related quality of life. It consists of a base set of
25 vision-targeted questions, representing 11 vision-related subscales, plus an additional single-item
question rating general health. The overall composite score is computed as the simple average of the
vision-targeted subscale scores, excluding the general health rating question. The overall score can
range from 0 (worst possible score) to 100 (best possible score).
The EQ-5D and the EQ-5D-V
The EQ-5D is a generic instrument for describing and valuing health. It is based on a descriptive
system that defines health in terms of five dimensions (mobility, self-care, usual activities,
pain/discomfort and anxiety/depression). Each dimension [in the EuroQol-5 Dimensions, five-level
version (EQ-5D-5L)] has five response categories corresponding to ‘no problems’, ‘slight problems’,
‘moderate problems’, ‘severe problems’ and ‘unable to/extreme problems’. A preference-based score
ranges from states worse than dead (< 0) to 1 (full health), anchoring dead at 0. In addition, the EQ-5D
includes a visual analogue scale, which records a respondent’s self-rated health on a vertical scale
where the end points are labelled ‘best imaginable health state’ (marked as 100) and ‘worst imaginable
health state’ (marked as 0). The EQ-5D-V is similar to the EQ-5D-5L, but with another dimension
(vision) added to overcome perceived inadequacies in a particular population.
More information is given in Chapter 4, Health-related quality-of-life measures.
Defining outliers
Outliers are observations that have extreme values relative to other observations under the same
conditions. An outlier was defined as a data point at least 4 SDs from the mean of its distribution of
values observed across other participants. A ‘bivariate outlier’ for checking was defined as a pair of
successive serial data points of the same measure for a participant whose difference was at least 4 SDs
from the mean of all participants’ such differences. Simple plots of successive pairs of serial measures
were used throughout the 24-month period to help identify outliers for data-checking.63
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Handling outliers
Outliers were identified for further investigation by looking at the distributions of the data using
histograms, scatterplots or box plots. Univariate tests for the compatibility of the distribution with a
normal distribution were not undertaken because they can be too sensitive to departures that are
often not relevant to the comparison of means (central limit theorem).
Once an outlier was found, a masked member of the team with sufficient clinical experience was involved
in the decision about whether a data value was impossible or implausible or plausible. If an outlier was
impossible, then it was set to missing. If an outlier was clinically plausible, then the outlier remained.
If an outlier was clinically implausible (but possible), then it was not ignored or deleted, but was retained
for the ITT analysis. If outliers remained in the distribution of a variable, then data transformations or
non-parametric methods of analysis were considered. A sensitivity analysis was undertaken to check
whether or not the outlier was influential by obtaining results with and then without the inclusion of the
outlier. If the conclusions changed, then this was noted.63
Baseline comparability of randomised groups
Baseline descriptions of participants by treatment and overall were summarised. No significance testing
was carried out as any differences found might have been chance-generated and not for hypothesised
reasons. Continuous variables, such as OCT CST values and VFQ-25 scores, were summarised using
means and SDs and/or medians and interquartile ranges (IQRs) for variables presenting a skewed
distribution. Categorical variables, such as the proportion of participants gaining ≥ 15 BCVA letters
or participants with OCT CST of < 320 µm, were described using numbers and percentages.
Comparison of rates of adherence and follow-up
High compliance and low attrition rates were anticipated for this trial based on previous clinical trial
experience. In CRUISE (a study on CRVO), 91.6% of participants completed the active treatment arms
at 12 months, and withdrawals were mainly due to physician and patient decisions.8 A cumulative
dropout of approximately 15% by year 2 was predicted for LEAVO and this was reflected in the sample
size calculations. Nevertheless, compliance rates and attrition rates were compared and reported by
arm using Fisher’s exact test.
Analysis covariates
The ICH E9 guideline78 recommends that consideration be given to accounting for randomisation
stratifiers by adjusting for them as covariates in the linear model. This tends to improve the precision
of estimated treatment effects. Therefore, for continuous outcomes, the analysis included adjustment
for the randomisation stratifiers of screening BCVA letter score (three levels) and disease duration
(two levels). This excluded the third stratifier of previous treatment (eye treatment naive vs. had
received previous treatment), because the numbers of participants who had received previous
treatment was very small; this was approved in the statistical analysis plan [see www.journalslibrary.
nihr.ac.uk/programmes/hta/119203/#/documentation (accessed 14 July 2020)] by the TSC.
Baseline
The corresponding baseline measure for a continuous outcome is also often predictive of the outcome
at follow-up. Therefore ‘baseline’ (if a baseline measure was collected) was included as an additional
covariate when modelling continuous outcomes.63 This was the case for visual acuity and CST.
Statistical model
The following description of the statistical analysis was applied to obtain results for each of the two
investigational treatments, bevacizumab and aflibercept, compared with the standard treatment,
ranibizumab.
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Primary outcome analysis
Part of this section is reproduced from Hykin et al.2 This is an open access article distributed under the
terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted
use, distribution, and reproduction in any medium. The text includes minor additions and formatting
changes to the original.
The primary efficacy measure was the change from baseline in refracted BCVA in the trial eye, using
the ETDRS letter score, at 100 weeks. The continuous primary outcome was a participant’s longitudinal
change in BCVA from baseline to 100 weeks. As more fully described later, this baseline is adjusted
for as a continuous covariate. This analysis approach gives results equivalent to those of an approach
in which the primary outcome is instead defined to be the cross-sectional 100-week measurement
in the same participants. Of these two equivalent approaches, we chose to analyse BCVA and other
continuous outcomes at the cross-sectional measurement point. This is convenient, because it means
that, if a baseline measurement is missing in a participant with a 100-week outcome, the end point
is not considered to be missing. The primary outcome may, therefore, be referred to later as the
100-week visual acuity, rather than as the change in BCVA from baseline to 100 weeks.
The primary outcome was analysed using a LME model incorporating the five post-baseline
measurements of the refracted BCVA outcome (at 12, 24, 52, 76 and 100 weeks). This mixed model
was, by definition, a mix of random- and fixed-effect terms. The random effect in the model was
the participant, represented as a random intercept at each follow-up time point, with allowance for
within-participant correlation in the adjusted post-baseline outcomes. The fixed effects in the model
were the main effect terms for arm; the two stratifiers, visual acuity and disease duration; ‘time’;
and the baseline of the outcome and its missing indicator required for the missing indicator method.
The other fixed effects in the model were the interactions between ‘time’ and each of the other fixed
effects in the model. This model allowed the treatment effect to be formally tested at 52 weeks and
at the primary time point of 100 weeks, and estimated at 24 and 76 weeks.63
Intention-to-treat strategy
Outcome data were valid and included if the BCVA measure was refracted. All randomised subjects
who provided at least one post-baseline valid measurement were included.63
Per-protocol analysis
For the analysis of the primary outcome, the mixed-effects model was refitted in a reduced per-
protocol population, as described in Chapter 2, Per protocol.63 Only valid (refracted) measurements were
included, and so the per-protocol analysis was a subset of the outcome measurements in the 52- and
100-week ITT analysis LME model.
Concluding non-inferiority
Non-inferiority was concluded only if this had been declared by both the ITT analysis and the
per-protocol analysis at 100 weeks. Non-inferiority was also assessed secondarily in the ITT and
per-protocol populations at 52 weeks from the same models. Non-inferiority was declared if the
estimated 95% CI for the difference in means lay wholly above the margin of –5 letters in both the
ITT and per-protocol analysis models, primarily at 100 weeks and secondarily at 52 weeks.
Superiority
If non-inferiority was concluded, superiority was assessed from the ITT LME model by reporting the
p-value from the two-sided test of the hypothesis of a zero difference in population means using a 5%
significance level without the need for correction for multiple testing.63 In addition, it was planned that,
if both investigative treatments were considered non-inferior to the standard treatment at 100 weeks,
the investigative treatments would be assessed for superiority relative to each other.
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Subgroup analysis
The two subgroup variables were assessed by extending the primary outcome model to include an
interaction between arm and each categorical subgroup variable.63 Subgroup variables with more than
two categories that were ordinal were entered as linear in the interaction. The treatment effects were
presented in each subgroup category with a 95% CI.
Sensitivity to missing data
An expert missing-data group concluded that, rather than statisticians reacting to missing data at
the end of a trial, there should be comprehensive, proactive planning for handling missing data at the
stage of designing trials. The group recommended that there should be consideration of missing-data
mechanisms (e.g. missing at random), and, if the missing data may be informative, that appropriate
sensitivity analyses be undertaken to investigate the robustness of the inferences to the different
assumptions made by the main analysis. It has also been recommended that analyses allowing for
non-response and low intervention uptake (or compliance) are best specified in advance and included
in the analysis plan. As it is expected that compliance will be high from the fear of loss of sight, and as
non-inferiority is concluded only when declared in both a compliant per-protocol population and a less
compliant ITT population, the focus was the handling of missing data.63
A sensitivity analysis was undertaken to assess the possibility of alternative plausible values of
treatment effect arising from potential mishandling of missing data in the primary analysis model.
The LME model for the primary outcome analysis described above was the first of a two-part approach
called the ITT strategy, in which a second analysis examined the sensitivity of the results to missing
data in the full randomised, ITT population. This met the ideal of ITT. The approach to missing data
taken in the trial followed the published implementation paper81 of the ITT strategy. This was then also
applied again to the per-protocol population so that the non-inferiority conclusion could be reassessed
under the sensitivity analysis.63
For the sensitivity analysis, we prespecified a range for best visual acuity from –20 letters to 20 letters,
over which the mean of the unobserved outcome data might depart (or be different) from the mean of
the observed outcome data.82 In other words, this range could be thought of as the extent to which a
typical subject for whom data are missing may, on average, have had a different estimated treatment
effect compared with the corresponding subject for whom outcome data were observed (given the same
baseline covariates and follow-up data in the LME model). The range (–20 to 20 letters) was chosen
to represent both negative and positive departures that could potentially arise as the ‘net effect’
of alternative reasons that may be unknown, such as dropout as a result of no anticipated further
improvement, or dropout as a result of no improvement so far, together with no anticipated
achievable improvement.63
This range of 40 letters (from –20 to 20) was generously wide for exploring the sensitivity of the main
results to departures from the missing-at-random assumption, because 20 letters (as the maximum
departure in either direction) is larger than the detectable between-arm treatment effect of 3 lines
(15 letters) seen in superiority trials (difference in means), which is a sizeable shift in the mean of the
distribution for dropouts, compared with completers.
At the end of the trial, the fractions of individuals for whom data were missing for visual acuity at 100
weeks were available in each arm: fi (for intervention) and fc (for control). The parameter representing
excess visual acuity in those missing, compared with those observed, δ, will take values by passing across
the range –20 to 20. Three scenarios were undertaken in the sensitivity analysis.77,81,82 These reflected
whether or not departures from the missing-at-random assumption applied in the intervention arms
only (aflibercept and bevacizumab), in the control arm only (ranibizumab), or in both arms equally and
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
in the same direction (thereby potentially cancelling out across the sensitivity range, if the dropout rate
were to be the same in both arms):63
l Scenario 1 – the treatment effect from the LME model will be increased by fiδ.
l Scenario 2 – the treatment effect from the LME model will be increased by –fcδ.
l Scenario 3 – the treatment effect from the LME model will be increased by (fi – fc)δ.
Sensitivity analysis to use of concomitant treatments
The use of concomitant treatments was monitored by the DMEC.63 It was planned that, if necessary,
a sensitivity analysis would be undertaken to examine the robustness of the 100-week per-protocol
analysis to the use of concomitant treatments.
Secondary outcome analysis
Secondary outcome analyses (see Appendix 3, Table 28) were on an ITT basis only. All tests were
two-sided at the 5% significance level and were interpreted cautiously, with a focus on interpreting
effect sizes with 95% CIs. Safety outcomes were reported as unadjusted patient proportions and as
rates within and between arms, with 95% CIs, using exact methods when appropriate. Significance
tests were used sparingly and were restricted, when possible, to addressing stated hypotheses.
Analysis of continuous outcomes
As for the primary outcome, the analyses of continuous secondary outcomes were compared between
arms at 100 weeks using the LME model. The baseline was adjusted for as a covariate, for outcomes
for which this was collected at baseline. The missing indicator method was used when there were
missing data at baseline. The remaining stratifiers were adjusted for in their categorical form. Time was
represented as categorical contrasts in main effect form and in interaction with all other fixed effects.
For skewed outcomes, 95% CIs were obtained using the non-parametric bootstrap percentile method.63
Analysis of binary outcomes
For the binary outcomes, such as the proportion of participants with a ≥ 15 ETDRS letter improvement,
differences between two proportions with 95% CIs have been used. Safety outcomes have been reported
as unadjusted patient proportions and as rates within and between arms, with 95% CIs, using exact
methods when appropriate.63
Safety meta-analysis
It was not possible to perform a safety meta-analysis because of the lack of comparative outcome
data for anti-VEGF therapy in CRVO. Two other comparative studies were completed during LEAVO:
the multicentre SCORE227 clinical trial, which compared aflibercept and bevacizumab, given by
mandated monthly injection over 6 months, and a small comparative study59 of aflibercept versus
bevacizumab in 50 patients with MO due to CRVO who were followed up for 12 months. The latter
trial did not publish any tabulated AE data and was discounted. A direct comparison was made with
the SCORE2 safety data by comparing them with the first 6 months of LEAVO safety data; this
information is presented in the results (see Chapter 3, Comparison with SCORE2 safety data).
Patient and public involvement
As a result of consulting the user involvement officer from the Research Design Service London prior
to trial start-up, we (1) consulted the Diabetes Research Network online lay member panel, (2) met
with the Central and East London Comprehensive Local Research Network (CLRN) lay member group
and (3) formed a service user advisory group of RVO patients. They were asked to comment on the
non-expert summary, asked to comment on a brief Microsoft PowerPoint® (Microsoft Corporation,
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Redmond, WA, USA) overview of the project, asked specific questions and asked to give comments.
Overall, they were very supportive; felt that the trial was of benefit to patients; and said that they
would definitely participate, although they felt that the dexamethasone intravitreal implant (Ozurdex®;
Allergan plc, Dublin, Ireland), originally intended to be a trial arm, should be excluded because of its
limited efficacy and side-effect profile. In addition, they thought that aflibercept should be included as
it may reduce the frequency of visits and invasive procedures (e.g. dilating and checking the non-trial
eye at each visit, which should be avoided when possible), and that they would wish to help in the
development of the patient information sheet. This feedback led to us removing Ozurdex from the
project; including aflibercept as a third trial arm; minimising trial research visits to six in 2 years; and
not dilating the non-trial eye at each visit, to help participants work and commute after their trial visit
and to enhance our participant retention activities. The UK RVO service user group helped in the
development of the patient information sheet and consent form, reviewing and refining these to make
them more accessible and easily understood by all potential participants. One member of the patient
group became a member of the TSC, attending every meeting and actively contributing to each.
Once the LEAVO clinical and health economic outcomes were available, the members of the CRVO
service user group at Moorfields, additional RVO patients, members of the renamed Barts Health/
Queen Mary University of London (QMUL) lay panel and patients with a history of eye disease from
the Barts Health/QMUL extended users group were sent a cover letter and questionnaire regarding
the trial, which had been reviewed and agreed with the Barts Health/QMUL lay panel chairperson
and Moorfields Eye Hospital Biomedical Research Centre patient and public involvement lead. See
Chapter 3, Patient and public involvement, for the results. A member of the Royal National Institute of
Blind People served as a member of the TSC.
Trial committees
Trial Steering Committee
The TSC was the committee responsible for monitoring the overall integrity, conduct and safety of the trial.
It monitored trial progress, investigated any SAEs, and took account of regular reports from the DMEC and
communication from the Trial Management Group (TMG). Ultimate responsibility for any decision required
on the trial’s continuation lay with the TSC. The TSC comprised an independent chairperson, a professor
of statistics, an independent ophthalmologist and general physician, a consultant in public health, a senior
Department of Health and Social Care policy-maker and two patient representatives. TSC meetings were
held at least annually and arranged by the chief investigator and the trial manager in conjunction with the
chairperson. For a list of committee members, see Appendix 2. A representative of Moorfields Eye Hospital
(the sponsor) was invited to each meeting.2
Data Monitoring and Ethics Committee
An independent DMEC of three individuals, one professor of statistics and two retina specialists,
met regularly to safeguard the interests of trial participants, assess the safety and efficacy of the
interventions during the trial, and monitor the overall conduct of the clinical trial (see Appendix 2).
Its terms of reference were to receive and review the progress and accruing data of the trial and
to provide the TSC with advice and recommendations on trial conduct. The trial would have been
discontinued on the basis of new safety information, or for other reasons given by the DMEC and/or
TSC, sponsor, regulatory authority or Research Ethics Committee concerned. All data reviewed by
the DMEC determined safety issues. All serious adverse reactions were reported to the KCTU within
24 hours of learning of their occurrence.2
Trial Management Group and site monitoring
The TMG was responsible for monitoring the delivery of the trial on a day-to-day basis, and was
supported and managed via the KCTU. The TMG membership consisted of the chief investigator,
the co-lead, the trial manager, the data manager, the lead and trial statisticians and senior members of
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
26
the KCTU. Other members of the wider research team were also invited on a meeting-by-meeting
basis, depending on the scope covered. Trial conduct and data collected were monitored by a
combination of central review and site monitoring visits to ensure that these were in accordance with
good clinical practice. Trial site monitoring was undertaken by the trial manager, the assistant trial
manager and an experienced KCTU trial monitor. The main areas of focus were consent, SAEs and
essential documents in trial site files.
Site monitoring included:
l reviewing all consent forms in the site file and medical notes
l source data verifying SAEs against medical records
l source data verifying a proportion of the primary outcome measure against medical records
l checking essential documents in the investigator site file and trial files.
Central reviews included:
l ensuring accuracy and completeness of all applications for trial authorisations and submissions of
progress/safety reports, prior to submission
l ensuring that all documentation essential for trial initiation was in place prior to site authorisation
l reporting and following up all monitoring findings with the appropriate persons in a timely manner.
The investigators and institutions also permitted trial-related monitoring, audits, Research Ethics
Committee review and regulatory inspections, providing direct access to source data/documents. Trial
participants were informed of this during the informed consent discussion. Participants consented to
provide access to their medical notes.
Approvals, reporting and compliance
The trial was approved by the National Research Ethics Committee Service London South East
(reference number 14/LO/1043); Clinical Trials Authorisation was given by the MHRA (number
11412/0220/001-0005), and the European Union Drug Regulating Authorities Clinical Trials (EudraCT)
number was 2013-003272-12. The trial was run using the standard operating procedures of the
sponsor, Moorfields Eye Hospital NHS Foundation Trust. The sponsor provided the oversight of the
trial, and the KCTU collaborated with the sponsor to ensure efficient trial delivery. The trial was
reported in accordance with the Consolidated Standards of Reporting Trials statement.
Summary of changes made to protocol
After initial substantial amendments [substantial amendment (SA) 1 to SA3] at commencement of the trial
clarified the handling of several key issues (e.g. pregnancy, contraception and nurse injectors), subsequent
substantial amendments mainly dealt with the addition of sites or a change in principal investigator
(see Appendix 3, Table 30). SA6, approved by the Research Ethics Committee on 11 February 2016,
included changes to the protocol, in particular the eligibility criteria, to increase recruitment to the trial.
The key change requested by the trial team was to increase the upper limit of permissible visual acuity
at screening from 73 (Snellen equivalent 6/12) to 78 (Snellen equivalent 6/9) letters. This was to increase
recruitment across all trial sites because, as the protocol stood, patients in clinical practice with a visual
acuity of 6/9 may have been excluded from the trial, as their visual acuity was too good, and go on to
receive treatment in the NHS, and be lost to the trial. This change to the upper limit would potentially
allow patients with a visual acuity of 6/9 to enrol in the trial. However, the DMEC and TSC statisticians
were concerned that this could introduce a ceiling effect if an abnormally large number of patients with
good visual acuity and limited potential to improve were randomised, and could even lead to the trial
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erroneously declaring non-inferiority. Thus, the statisticians stated that they could not agree to this
change unless additional data from other studies was obtained by the chief investigator to determine
whether or not a significant ceiling effect was likely to occur. After consultation with the relevant trial
sponsors and/or chief investigators, the LEAVO chief investigator and co-lead were able to provide the
DMEC and TSC with unpublished results from recent clinical trials (the CRYSTAL55 study of RVO and
the US DRCR.net Protocol T sudy54 of DMO) that showed no significant ceiling effect and that a large
proportion of such cases gained significant visual acuity. Based on this new information, the TSC and
DMEC allowed the protocol change. Additional changes to the eligibility criteria were approved, including
an increase (from three to six) in the number of anti-VEGF injections a participant could have received
prior to randomisation. The rescreening interval was reduced from 4 to 2 weeks because a number of
participants who failed initial screening sought treatment elsewhere before rescreening was possible.
METHODS
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Chapter 3 Clinical results
Participant flow
The original contract commenced on 1 May 2014, with recruitment to start on 1 November 2014.
An early contract variation was requested by the LEAVO team, and approved by NIHR, for the
contract to commence on 1 June 2014 and for recruitment to start on 1 December 2014. Recruitment
was predicted to take 18 months and, therefore, was to finish on 31 May 2016, with last participant,
last visit to take place by 31 May 2018, and the trial to close on 31 October 2018. The first participant
was randomised on 12 December 2014, but the last was randomised on 16 December 2016, almost
exactly 24 months later. As a result, a contract variation was sought to extend the trial by 6 months
so that the last participant, last visit would occur by 30 November 2018, and the trial would close
on 30 April 2019. The last participant, last visit was actually on 21 November 2018.
Therefore, between December 2014 and December 2016, 586 patients were assessed across
44 UK NHS hospitals (see Appendix 1, Table 27) for eligibility. Of these patients, 123 were excluded:
117 were ineligible, one withdrew consent and five did not proceed for other reasons. Therefore,
463 were managed on protocol (see Appendix 3, Table 29), randomly assigned to receive ranibizumab
(n = 155), intravitreal aflibercept (n = 154) or bevacizumab (n = 154), and constituted the ITT population
Randomisation was balanced across treatment groups, across hospital sites and within baseline visual
acuity strata. The per-protocol population consisted of 145 participants in the ranibizumab arm, 146 in
the aflibercept arm and 152 in the bevacizumab arm. Among the ITT population, the 100-week visit
was completed by 135 participants in the ranibizumab arm, 133 in the aflibercept arm and 139 in the
bevacizumab arm; among the per-protocol population, the same visit was completed by 133 participants
in the ranibizumab arm, 128 in the aflibercept arm and 139 in the bevacizumab arm (Figure 2).
Recruitment
Overview
NIHR acknowledges the need for experienced trial management and recommends the involvement of
a specialised clinical trials unit to conduct trials. We were fortunate to have the multidisciplinary team
from the KCTU participate in the trial. As a LEAVO collaborator, the team provided a trial manager,
deputy trial manager and experienced monitors, in addition to a senior and a junior statistician, and
the expertise of their core team, including the Clinical Trials Unit operations manager, senior data
manager and trial methodologist. All these members attended TMG, TSC and DMEC meetings, when
appropriate. In addition, the KCTU team members were all available for advice and guidance on a daily
basis; working in conjunction with the trial manager, the KCTU was, ultimately, the cornerstone of the
trial.63 It recognised the need to open as many sites as quickly as possible and its senior team spent
many hours with the trial manager, ensuring that she was fully familiar with the trial and was able
to begin site initiations before recruitment commenced on 1 December 2014. The largest and most
experienced sites (e.g. Moorfields and Leeds) were initiated first. Unfortunately, a few weeks before
the initiation of the first site, the original trial manager was absent on sick leave and she announced
her resignation at the beginning of December 2014. Not unexpectedly, this had a significant impact on
site initiation and could have led to very prolonged trial delays. Fortunately, an experienced assistant
trial manager had just been appointed and agreed to step up to the trial manager position within
a few days of starting. Quite understandably, he took time to familiarise himself with the trial protocol
and procedures; therefore, the trial fell significantly behind with site initiations and recruitment.
The low point was 39 participants recruited by the end of May 2015, against a predicted target of
76 (51%). However, the new trial manager began to recover the situation in the second quarter
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of 2015, and the number of site initiations increased: we initiated only eight sites in the first 4 months
of recruitment, compared with 13 sites in the succeeding 2 months. As a result, actual recruitment
kept pace with predicted recruitment in October, November and December 2015. By November 2015,
that is after 12 months of recruitment, we had opened 38 sites, against a target of 40, and recruited
176 participants, against a target of 268 (66%). An additional eight sites were subsequently initiated,
to give 46 greenlighted sites open in the first quarter of 2016. By 31 May 2016, when recruitment
should have been completed, we had recruited 320 participants, against a target of 459 (70%); by



















ITT population, n = 155
• Did not receive allocated treatment, n = 1
PP population, n = 145
Reasons not in PP
• Not compliant with eligibility criteria, n = 4
• Received insuf f icient mandatory
    injections, n = 6
Attended 100-week visit in ITT
(n = 135)
Withdrawals, n = 20
Reasons
• Death of participant, n = 3
• Unable to locate/contact patient, n = 3
• No longer wished to take part, n = 8
• AE, n = 2
• Health deterioration, n = 2
• Patient moved away, n = 0
• Other, n = 2
Attended 100-week visit in PP
(n = 133)
Withdrawals, n = 12
Reasons
• Death of participant, n = 2
• Unable to locate/contact patient, n = 3
• No longer wished to take part, n = 4
• AE, n = 2
• Health deterioration, n = 1
• Patient moved away, n = 0
• Other, n = 0
Included in
• Primary outcome ITT,a n = 148
• Primary outcome PP,a n = 145
• Primary outcome principled sensitivity





ITT population, n = 154
• Did not receive allocated treatment, n = 0
PP population, n = 146
Reasons not in PP
• Not compliant with eligibility criteria, n = 3
• Received insuf f icient mandatory
    injections, n = 5
Attended 100-week visit in ITT
(n = 133)
Withdrawals, n = 21
Reasons
• Death of participant, n = 6
• Unable to locate/contact patient, n = 3
• No longer wished to take part, n = 6
• AE, n = 1
• Health deterioration, n = 2
• Patient moved away, n = 2
• Other, n = 1
Attended 100-week visit in PP
(n = 128)
Withdrawals, n = 18
Reasons
• Death of participant, n = 5
• Unable to locate/contact patient, n = 2
• No longer wished to take part, n = 5
• AE, n = 1
• Health deterioration, n = 2
• Patient moved away, n = 2
• Other, n = 1
Included in
• Primary outcome ITT,a n = 153
• Primary outcome PP,a n = 146
• Primary outcome principled sensitivity
    analysis – ITT, n = 154, PP, n = 146
Bevacizumab
(n = 154)
ITT population, n = 154
• Did not receive allocated treatment, n = 0
PP population, n = 152
Reasons not in PP
• Not compliant with eligibility criteria, n = 0
• Received insuf f icient mandatory
    injections, n = 2
Attended 100-week visit in ITT
(n = 139)
Withdrawals, n = 15
Reasons
• Death of participant, n = 4
• Unable to locate/contact patient, n = 1
• No longer wished to take part, n = 5
• AE, n = 2
• Health deterioration, n = 1
• Patient moved away, n = 1
• Other, n = 1
Attended 100-week visit in PP
(n = 139)
Withdrawals, n = 13
Reasons
• Death of participant, n = 4
• Unable to locate/contact patient, n = 0
• No longer wished to take part, n = 4
• AE, n = 2
• Health deterioration, n = 1
• Patient moved away, n = 1
• Other, n = 1
Included in
• Primary outcome ITT,a n = 153
• Primary outcome PP,a n = 152
• Primary outcome principled sensitivity
    analysis – ITT, n = 154, PP, n = 152
Excluded
(n = 123)
• Not meeting eligibility criteria, n = 117
• Withdrawal of consent, n = 1
• Other reasons, n = 5
Assessed for eligibility
(n = 586)
FIGURE 2 The LEAVO CONSORT diagram. a, Models include all participants who have had at least one follow-up visit.
PP, per protocol. Reproduced from Hykin et al.2 This is an open access article distributed under the terms of the CC-BY 4.0
license (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in
any medium. This includes minor additions and formatting changes to the original.
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Table 1 shows the number of participants recruited each month by site, and Table 2 shows the number
of participants whom each site recruited per trial arm.
Barriers to recruitment and corrective strategies
The following barriers to recruitment were identified:
l Availability of trial staff, for example masked injectors and trial co-ordinators. Despite fulfilling our
initial trial site requirements, several sites were unable to provide sufficient clinician unmasked
injector cover (e.g. Rugby) as a result of limited staff availability, or sufficient research co-ordinator
time for the trial (e.g. Addenbrooke’s and Hillingdon), the latter in some cases because NHS support
costs attributable to LEAVO were not available to the local trial team.We largely resolved the
former issue in a substantial amendment that allowed nurses and optometrists who were certified
intravitreal injectors in standard NHS clinics to provide unmasked injector cover for LEAVO.
We also approached a number of local ophthalmology CLRNs to provide additional co-ordinator time
for the trial based on CLRN support costs, and received very helpful support from Rupert Bourne,
CLRN National Lead for Ophthalmology, in this regard.
l Difficulties with the protocol. The following changes were made to the protocol (see Appendix 3,
Table 30) –
¢ The upper limit of the visual acuity eligibility at baseline was increased from 73 (Snellen
equivalent: ≈ 6/12) to 78 letters (Snellen equivalent: ≈ 6/9). Patients in clinical practice with
a visual acuity of 6/9 had previously been excluded from the trial as their visual acuity was too
good, and they were receiving NHS treatment instead. The change allowed patients with a visual
acuity of 6/9 to enrol in the trial.
¢ The inclusion criterion for diabetic retinopathy in the trial eye was changed from ‘any previously
documented diabetic retinopathy or diabetic macular oedema in the study eye’ to ‘any diabetic
retinopathy or diabetic macular oedema at baseline clinical examination of the study eye’.2
This was to prevent patients being excluded from the trial who presented with a documented
history of diabetic retinopathy, which may not have been reliable, rather than clinical evidence










































































































































































































































































FIGURE 3 Actual vs. projected recruitment per month.
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TotalDecember January February March April May June July August September October November December January February March April May June July August September October November December
Moorfields Eye
Hospital
2 3 1 5 3 5 4 2 4 6 3 4 4 3 2 2 3 0 4 4 3 2 5 3 77
King’s College
Hospital




4 2 2 4 3 2 2 1 1 21
St Paul’s Eye Unit,
Royal Liverpool
University Hospital
2 2 2 1 2 2 2 13
University Hospital
Southampton
2 4 3 2 1 1 1 14
Royal Victoria
Hospital, Belfast
1 3 4 1 1 1 1 1 1 14
Royal Blackburn
Hospital
1 1 1 1 4
Bradford Royal
Infirmary
1 3 2 3 1 1 1 1 1 1 1 2 18
Sussex Eye
Hospital
1 4 1 1 2 1 1 11
Bristol Eye
Hospital
2 2 1 1 1 1 1 2 1 1 13
West Suffolk
Hospital
1 1 1 2 2 1 1 1 1 11
Torbay Hospital 1 1 2 2 1 7
Essex County
Hospital
1 1 1 1 2 1 1 1 1 1 11
Hospital of
St Cross, Rugby












































TotalDecember January February March April May June July August September October November December January February March April May June July August September October November December
Frimley Park
Hospital















1 1 1 1 1 5
Darlington
Memorial Hospital




1 2 1 2 1 1 1 1 1 1 1 1 14





2 1 2 1 1 2 2 1 1 1 14
Manchester Royal
Eye Infirmary













1 1 1 2 5
Sunderland Eye
Infirmary




















































































































































































































































































































































TotalDecember January February March April May June July August September October November December January February March April May June July August September October November December
Royal Glamorgan
Hospital
1 2 1 1 1 1 2 3 1 1 14
Royal Hallamshire
Hospital
1 2 1 1 3 1 2 1 1 13
Addenbrooke’s
Hospital
1 1 2 2 1 1 3 11
Gartnavel General
Hospital
1 1 1 1 1 5
Royal Bolton
Hospital
1 1 1 2 1 6
Calderdale Royal
Hospital
1 1 1 1 2 6
Leicester Royal
Infirmary
1 1 1 1 1 5
Norfolk and
Norwich Hospital
2 1 1 4
Cheltenham
General Hospital
1 1 1 1 1 1 6
Hull Royal
Infirmary
3 1 1 1 6
Western Eye
Hospital






1 1 2 4
Total per month 2 4 5 8 11 9 22 14 22 19 30 30 29 21 23 28 24 19 34 24 17 14 25 24 5 463

































TABLE 2 The number of participants recruited to each trial arm, by site
Site
Participants (n)
Ranibizumab Aflibercept Bevacizumab Total
Moorfields Eye Hospital 25 24 28 77
King’s College Hospital 3 2 1 6
Wolverhampton Eye Infirmary, New Cross Hospital 8 6 7 21
St Paul’s Eye Unit, Royal Liverpool University Hospital 5 6 2 13
University Hospital Southampton 3 6 5 14
Royal Victoria Hospital, Belfast 6 3 5 14
Royal Blackburn Hospital 0 1 3 4
Bradford Royal Infirmary 3 7 8 18
Sussex Eye Hospital 6 1 4 11
Bristol Eye Hospital 5 2 6 13
West Suffolk Hospital 6 4 1 11
Torbay Hospital 3 3 1 7
Essex County Hospital 3 2 6 11
Hospital of St. Cross, Rugby 1 1 3 5
Birmingham and Midlands Eye Centre 5 5 6 16
Kent and Canterbury Hospital 2 2 0 4
Frimley Park Hospital 5 5 5 15
Whipps Cross University Hospital 0 1 0 1
James Paget University Hospital 4 3 0 7
Royal Surrey County Hospital 0 1 3 4
Harrogate District Hospital 0 1 1 2
York Teaching Hospital 0 4 1 5
Darlington Memorial Hospital 4 0 0 4
St James’s University Hospital, Leeds 6 4 4 14
Hillingdon Hospital 2 2 3 7
Eye, Ear and Mouth Unit, Maidstone Hospital 5 5 4 14
Manchester Royal Eye Infirmary 2 4 3 9
Royal Victoria Infirmary, Newcastle upon Tyne 5 3 4 12
Luton and Dunstable University Hospital 1 2 2 5
Cardiff Eye Unit, University Hospital of Wales 3 1 1 5
Sunderland Eye Infirmary 8 7 6 21
Royal Glamorgan Hospital 5 6 3 14
Royal Hallamshire Hospital 3 4 6 13
Addenbrooke’s Hospital 2 5 4 11
Gartnavel General Hospital 0 3 2 5
Royal Bolton Hospital 3 2 1 6
Calderdale Royal Hospital 2 3 1 6
Leicester Royal Infirmary 2 1 2 5
continued
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¢ The allowed number of previous anti-VEGF injections was increased from three to six in order to
allow patients who had had longer-term treatment for MO due to CRVO (i.e. six injections) to be
considered for the trial.
¢ Patients who had had recent pan-retinal photocoagulation for NVE, NVD or NVI were considered
eligible for the trial within 1 month of treatment rather than within 3 months, as treatment within
1 month would not have had an adverse outcome on anti-VEGF therapy 1 month later.
¢ The protocol was altered to change the rescreening interval to 2 weeks, except for visual acuity
eligibility, which remained at 4 weeks. Several patients had not enrolled in LEAVO because, for
example, they had forgotten to take blood pressure medication, leading to high blood pressure
and a screen fail. If they needed to wait 4 weeks before rescreening, as the protocol originally
stated, then they typically opted for NHS treatment in the interim; being able to rescreen after
2 weeks prevented them being lost to NHS care.
l Number of sites. Although we planned for 40 sites initially, four withdrew before being initiated,
and so we took an early decision to add additional sites. Initially, we planned for a further 12 sites,
which would have taken the total to 48 active sites. However, two of these withdrew, and 10 were
greenlighted, although one failed to recruit any participants. Nevertheless, these additional sites
made a very significant contribution to the last 6 months of recruitment.
l Site equipment. Several sites had issues with equipment, in particular with wide-angled fluorescein
angiography imaging devices and information technology support that allowed communication with
the KCTU randomisation software and MACRO trial database, and also allowed data export to the
reading centre. We worked with the sites and providers of equipment (e.g. Optos wide-angled
imaging) to overcome these issues as quickly as possible.
l Although we had held an investigator meeting prior to the trial start, a number of optometrists had
not been able to attend this and required certification before a site could be greenlighted to recruit
patients. To minimise certification delays, we arranged for prompt visits by either lead trial
optometrist to any site to undertake optometry certification.
l Other measures that were used to try to maximise recruitment included the following –
¢ A monthly newsletter to every site detailing progress63 and acknowledging each site that had
recruited one or more participants in the previous month.
¢ An e-mail from the chief investigator to each site team every 2 months encouraging
further recruitment.
¢ A thank-you e-mail to each site from the chief investigator after each participant was recruited.
¢ Reward vouchers each month to the site recruiting the most participants and ‘best site of
the month’.
¢ Very prompt replies to any site that had queries on any aspect of the trial. We think that this
point was critical in keeping sites focused on recruitment and willing to recruit over and above
their target, which was something we specifically asked large sites to do.
TABLE 2 The number of participants recruited to each trial arm, by site (continued )
Site
Participants (n)
Ranibizumab Aflibercept Bevacizumab Total
Norfolk and Norwich Hospital 1 2 1 4
Hull Royal Infirmary 0 2 4 6
Cheltenham General Hospital 4 2 0 6
Western Eye Hospital 1 4 5 10
James Cook University Hospital 2 1 0 3
Princess Alexandra Hospital, Harlow 1 1 2 4
Total 155 154 154 463
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Withdrawals
Appendix 3, Table 31, shows the number of participants who did not complete the week 100 visit in
the three arms, and the week of their last visit. Appendix 3, Table 32, shows the number of weeks
all withdrawal participants participated in the trial and the reasons for withdrawal. Withdrawals
were balanced across treatment arms; overall, more participants completed their week 100 visit
[87.9% (407/463)] than had been predicted in the sample size calculation (85%).
Baseline data
Baseline characteristics were well balanced between groups for age, sex and eye involved (Table 3). In
the ranibizumab, aflibercept and bevacizumab arms, the mean baseline BCVA was 53.6 (SD 15.1), 54.1
(SD 15.3) and 54.4 (SD 14.2) ETDRS letters, respectively. The numbers recruited to the three stratifier
subgroups for visual acuity were equal across arms. The median duration of CRVO in each treatment
group was < 1 month; the numbers of participants in the duration of CRVO subgroups of 3–6 months
and > 6 months were small and so these groups were combined for analysis purposes, a change that
was approved in the final version of the statistical analysis plan. Similarly, the number of participants
receiving prior treatment was so small that this stratifier was not analysed. OCT CST was 731.3 µm
(SD 227.6 µm), 673.2 µm (SD 189.4 µm) and 676.1 µm (SD 207.0 µm) for the ranibizumab, aflibercept
and bevacizumab arms, respectively, with the apparent difference between ranibizumab and the other
two groups being approximately 0.5 of a SD, and likely to be attributable to chance.










Age (years), mean (SD) 69.1 (13.0) 69.2 (13.0) 68.7 (13.2) 69.3 (12.8)
Female, n (%) 198 (42.8) 70 (45.2) 60 (39.0) 68 (44.2)
Right eye was trial eye, n (%) 226 (48.8) 81 (52.3) 67 (43.5) 78 (50.6)
Mean (SD) BCVA letter score in the trial eyea,b 54.1 (14.8) 53.6 (15.1) 54.1 (15.3) 54.4 (14.2)
BCVA letter score in trial eye, n (%)
19–38 85 (18.4) 31 (20.0) 27 (17.5) 27 (17.5)
39–58 166 (35.9) 56 (36.1) 55 (35.7) 55 (35.7)
59–78 212 (45.8) 68 (43.9) 72 (46.8) 72 (46.8)
Median (IQR) duration of CRVO (months)a 0.9 (0.4–1.7) 0.9 (0.5–1.8) 0.9 (0.4–1.7) 0.9 (0.4–1.7)
Duration of trial eye CRVO, n (%)
< 3 months 401 (86.6) 134 (86.5) 129 (83.8) 138 (89.6)
3–6 months 38 (8.2) 11 (7.1) 19 (12.3) 8 (5.2)
> 6 months 24 (5.2) 10 (6.5) 6 (3.9) 8 (5.2)
Previous treatment in trial eye, n (%)a
Nil 446 (96.5) 148 (96.1) 149 (96.8) 149 (96.8)
Anti-VEGF therapy 16 (3.5) 6 (3.9) 5 (3.2) 5 (3.2)
CRVO ischaemic status at baseline (trial eye), n (%)a
Non-ischaemic 406 (87.9) 137 (89.0) 135 (87.7) 134 (87.0)
Ischaemic 56 (12.1) 17 (11.0) 19 (12.3) 20 (13.0)
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Derivation of the intention-to-treat model and per-protocol populations
Participants included in the prespecified ITT LME model were derived as follows:
1. The BCVA data were available for 407 of 463 randomly assigned participants (ranibizumab, n = 135;
aflibercept, n = 133; and bevacizumab, n = 139) at 100 weeks. Table 4 shows the available BCVA
data at 12, 24, 52, 76 and 100 weeks by arm. The model included all participants who had at least
one of these follow-up visits; therefore, those without follow-up data did not contribute to
the analysis.
2. Only the 76-week measurement in one bevacizumab participant was excluded because of the
presence of retinal detachment within 3 months of BCVA recordings, and BCVA was > 3 SDs below
the mean at that time point (including all measurements).
3. Therefore, no participants were removed on this basis from the LME model analysis and the ITT and
per-protocol populations were not modified by this.
4. A total of 20 participants did not meet the per-protocol definition, so 443 participants constituted
the per-protocol population (see Figure 2).63










OCT (trial eye),a,c mean (SD)
CST (µm) 693.6 (209.8) 731.3 (227.6) 673.2 (189.4) 676.1 (207.0)
Total volume (mm3) 12.7 (2.8) 13 (2.9) 12.3 (2.6) 12.8 (2.9)
Lens status (trial eye), n (%)
Cataract 131 (28.4) 41 (26.6) 44 (28.6) 46 (29.9)
Pseudophakia 68 (14.7) 29 (18.8) 20 (13) 19 (12.3)
Blood pressure (mmHg),a mean (SD)
Systolic 143.0 (16.8) 143.1 (17.6) 142.6 (17.0) 143.1 (15.7)
Diastolic 79.7 (10.4) 80.1 (10.2) 79.1 (10.6) 79.9 (10.6)
a Not recorded for one ranibizumab participant, who was randomised in error.
b For one participant in each arm, the baseline best refracted visual acuity test was incomplete or not performed.
c For total volume, data were further missing for two ranibizumab participants and one bevacizumab participant.
Reproduced from Hykin et al.2 This is an open access article distributed under the terms of the CC-BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium. This includes minor additions and formatting changes to the original.
TABLE 4 Unadjusted refracted BCVA available at each milestone visit
Visit
Mean (SD) BCVA letter score; n participants
Total (N= 463) Ranibizumab (N= 155) Aflibercept (N= 154) Bevacizumab (N= 154)
Screening 54.1 (14.8); 459 53.6 (15.1); 153 54.1 (15.3); 153 54.4 (14.2); 153
12 weeks 68.4 (15.8); 443 67.5 (16.5); 146 70.4 (15.1); 148 67.3 (15.8); 149
24 weeks 65.8 (17.9); 432 65 (19.1); 145 67.3 (16.9); 146 64.9 (17.7); 141
52 weeks 66.3 (18.4); 413 65.4 (19.4); 139 67.2 (17.6); 139 66.4 (18.3); 135
76 weeks 65.9 (19.0); 397 65.7 (19.4); 136 66.2 (18.1); 128 65.9 (19.6); 133
100 weeks 66.2 (19.6); 407 65.6 (19.9); 135 68.4 (17.9); 133 64.6 (20.8); 139
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The mean gain in BCVA letter score was 12.5 with ranibizumab (SD 21.1), 15.1 with aflibercept
(SD 18.7) and 9.8 with bevacizumab (SD 21.4) at 100 weeks (Figure 4). First, the primary outcome
at 100 weeks was unable to show that bevacizumab was non-inferior in terms of BCVA in both the
ITT and per-protocol populations (Table 5). The 95% CI for the adjusted difference between arms at
100 weeks lay below the prespecified acceptable margin of –5 letters (Figure 5). Second, aflibercept
was non-inferior, but not superior, to ranibizumab in terms of BCVA in both the ITT and the per-
protocol populations (see Table 5 and Figure 5). The 95% CI for the adjusted difference between arms
at 100 weeks lay above the prespecified acceptable margin of –5 letters (see Figure 5). The mean BCVA
letter score at 24 weeks had decreased by approximately 3 letters across groups following pro re nata
injections at weeks 16 and 20, when fewer injections were given (ranibizumab injections, n = 123;
aflibercept, n = 76; and bevacizumab, n = 121), but increased gradually thereafter across groups to
week 100, during which period participants were seen at least every 8 weeks and received injections
promptly if re-treatment criteria were met (see Figure 4). Such peak-and-trough changes in visual
acuity were closely mirrored by OCT trough and peak CST results over the 2-year period.
The principled sensitivity analysis for missing data supported the primary outcome results (Figures 6
and 7). The sensitivity analysis for outliers was not conducted, as there were no outliers in the ITT and
per-protocol populations [see www.journalslibrary.nihr.ac.uk/programmes/hta/119203/#/documentation
(accessed 14 July 2020)]. The sensitivity analysis for concomitant treatments taken by one participant
in the trial supported the primary outcome results.
The sensitivity analysis assessed the potential impact on the treatment effect from including participants
with unobserved BCVA 24-month primary outcome data in the adjusted primary outcome model. In
this analysis, participants with unobserved data were, on average, specified to be able to have score
ranging from –20 to 20 BCVA letters away from the scores of their counterparts who did have outcome
data observed. This was applied to participants in three scenarios. Scenario 1 involved applying this to
participants in the investigative treatment arm (aflibercept) only. Scenario 2 involved applying this to





























Adjusted mean difference between groups at 100 weeks (95% CI):
af libercept vs. ranibizumab 2.23 (–2.17 to 6.63)
bevacizumab vs. ranibizumab –1.73 (–6.12 to 2.67)
Week
FIGURE 4 Adjusted mean BCVA letter score across groups to 100 weeks. Reproduced from Hykin et al.2 This is an open
access article distributed under the terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/), which
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TABLE 5 Primary outcome at 100 weeks
Mean (SE) BCVA
at screening
Mean (SE) BCVA at
100 weeks; n participants
Adjusted difference
between groups









Aflibercept Ranibizumab Aflibercept Ranibizumab
Aflibercept vs. ranibizumab ITT
54.1 (1.2) 53.6 (1.2) 68.4 (1.6); 133 65.6 (1.7); 135 2.23 (–2.17 to 6.63)a,b 0.0006 0.32
Aflibercept vs. ranibizumab per protocol
55.0 (1.2) 53.6 (1.3) 69.5 (1.5); 128 65.7 (1.7); 133 3.49 (–0.91 to 7.88)a,c < 0.0001 0.12
Bevacizumab Ranibizumab Bevacizumab Ranibizumab
Bevacizumab vs. ranibizumab ITT
54.4 (1.1)a 53.6 (1.2) 64.6 (1.8); 139 65.6 (1.7); 135 –1.73 (–6.12 to 2.67)b 0.071 0.44
Bevacizumab vs. ranibizumab per protocol
54.4 (1.2) 53.6 (1.3) 64.6 (1.8); 139 65.7 (1.7); 133 –1.67 (–6.02 to 2.68)c 0.066 0.45
SE, standard error.
a Non-inferior relative to ranibizumab.
b The LME model incorporates 454 participants (ranibizumab, n= 148; aflibercept, n = 153; and bevacizumab, n = 153)
with BCVA at 100 weeks.
c The LME model incorporates 443 participants (ranibizumab, n= 145; aflibercept, n = 146; and bevacizumab, n = 152)
with BCVA at 100 weeks.
Note
The 95% CI for the adjusted difference between arms at 100 weeks lay above the prespecified acceptable margin of
–5 letters.
Reproduced from Hykin et al.2 This is an open access article distributed under the terms of the CC-BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium. This includes minor additions and formatting changes to the original.
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Favours comparator Favours intervention
ITT  – bevacizumab vs. ranibizumab
   –1.73 (95% CI –6.12 to 2.67)
Non-inferiorNot non-inferior
PP – bevacizumab vs. ranibizumab
–1.67 (95% CI –6.02 to 2.68)
PP – aflibercept vs. ranibizumab
3.49 (95% CI –0.91 to 7.88)
ITT – aflibercept vs. ranibizumab
2.23 (95% CI –2.17 to 6.63)
= bevacizumab vs. ranibizumab:
lower limit of 95% CI is below –5
margin for ITT and PP analyses
= aflibercept vs. ranibizumab:
lower limit of 95% CI is above –5
margin for ITT and PP analyses
FIGURE 5 Forest plot of the primary outcome at 100 weeks. PP, per protocol. Reproduced from Hykin et al.2 This is an
open access article distributed under the terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/),
which permits unrestricted use, distribution, and reproduction in any medium. This includes minor additions and
formatting changes to the original.
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arms equally. The x-axis in Figures 6 and 7 represents the range of –20 to 20 BCVA letter scores that
those participants with unobserved data were, on average, specified to be able to have relative to the
scores of their counterparts who did have data outcome observed. This analysis follows previously
described methods.81 The treatment effect in the main analysis is shown at zero. Vertical bars are
95% CIs for the treatment effect. The 95% CI bars all lie above the non-inferiority margin of –5 letters,
supporting the non-inferiority of aflibercept in both the ITT (see Figure 6a) and the per-protocol
(see Figure 6b) populations.
For scenario 3, and within most of the ranges of scenarios 1 and 2, the lower CI limit lay below the
non-inferiority margin of –5 letters, supporting the main analysis conclusion that bevacizumab lacked
non-inferiority. The difference in the mean between those with unobserved BCVA data and those
with observed BCVA data would need to be assumed to be 12 letters higher for bevacizumab than
for ranibizumab in scenario 1 (or 12.4 letters higher in scenario 2) in order to change the main
analysis conclusion of a lack of non-inferiority in both the ITT (see Figure 7a) and the per-protocol
(see Figure 7b) populations.
Secondary visual acuity outcomes
Both aflibercept and bevacizumab were non-inferior to ranibizumab at 52 weeks (Table 6). The 95% CI
for the adjusted difference in BCVA between arms lay above the prespecified acceptable non-inferiority
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FIGURE 6 Sensitivity analysis for the missing-at-random assumption in the primary outcome analysis assessing
non-inferiority of aflibercept. (a) ITT; and (b) per protocol. Reproduced from Hykin et al.2 This is an open access article
distributed under the terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium. This includes minor additions and formatting changes to
the original.
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The proportions of participants with a ≥ 15-letter gain were 47%, 52% and 45% (Figure 8) in the
ranibizumab, aflibercept and bevacizumab arms, respectively, with 63%, 68% and 63%, respectively,
gaining ≥ 10 letters at 100 weeks (Figure 9).
The proportions of participants with a < 15-letter loss were 90%, 93% and 90% in the ranibizumab,
aflibercept and bevacizumab arms, respectively (Figure 10), and the proportion of participants with a
≥ 30-letter loss in BCVA was < 6% in each group (Figure 11).
There were no meaningful differences in the proportion of participants in each group who had
prespecified categorical outcomes, for example a final visual acuity of < 19 letters (i.e. eligible for
blind registration) (Table 7). Furthermore, there were no subgroup differences in the final visual acuity
outcome by baseline stratifiers (Tables 8–10).
The were no differences between subgroups in the treatment effects on final visual acuity for any of
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FIGURE 7 Sensitivity analysis for the missing-at-random assumption in the primary outcome analysis assessing
non-inferiority of bevacizumab. (a) ITT; and (b) per protocol. Reproduced from Hykin et al.2 This is an open access article
distributed under the terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium. This includes minor additions and formatting changes to
the original.
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Optical coherence tomography outcomes
The mean reductions in OCT CST from baseline to 100 weeks were –405 µm for ranibizumab
(95% CI –450 µm to 360 µm), –378 µm for aflibercept (95% CI –412 µm to –343 µm), and –334 µm
for bevacizumab (95% CI –374 µm to –293 µm). There were no clinically relevant differences across
treatment groups for the adjusted difference in CST at 100 weeks: aflibercept versus ranibizumab was
TABLE 6 Adjusted BCVA at 52 weeks
Mean (SE) BCVA
at screening













Aflibercept Ranibizumab Aflibercept Ranibizumab
Aflibercept vs. ranibizumab ITT
54.1 (1.2) 53.6 (1.2) 67.2 (1.5) (n= 139) 65.4 (1.6) (n= 139) 1.33 (–2.62 to 5.28)a,b 0.0008 0.51
Aflibercept vs. ranibizumab per protocol
55.0 (1.2) 53.6 (1.3) 68.4 (1.4) (n= 133) 65.5 (1.7) (n= 137) 2.15 (–1.81 to 6.1)a,c 0.0002 0.29
Bevacizumab Ranibizumab Bevacizumab Ranibizumab
Bevacizumab vs. ranibizumab ITT
54.4 (1.1) 53.6 (1.2) 66.4 (1.6) (n= 135) 65.4 (1.6) (n= 139) –0.02 (–3.97 to 3.94)a,b 0.0067 0.99
Bevacizumab vs. ranibizumab per protocol
54.4 (1.2) 53.6 (1.3) 66.4 (1.6) (n= 135) 65.5 (1.7) (n= 137) 0.05 (–3.88 to 3.98)a,c 0.0058 0.98
SE, standard error.
a Non-inferior relative to ranibizumab.
b The LME model incorporates 454 participants (ranibizumab, n= 148; aflibercept, n = 153; and bevacizumab, n= 153)
with BCVA at 52 weeks.
c The LME model incorporates 443 participants (ranibizumab, n= 145; aflibercept, n = 146; and bevacizumab, n= 152)
















































4.1% (95% CI –7.9% to 16.2%)
–2.4% (95% CI –14.3% to 9.4%)
0.7% (95% CI –11.0% to 12.5%)




FIGURE 8 Percentage of participants in each group with BCVA improvement of ≥ 15 ETDRS letters at 52 and 100 weeks.
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–29.3 µm (95% CI –60.9 µm to 2.3 µm); and bevacizumab versus ranibizumab was 21.9 µm (95% CI
–9.7 µm to 53.4 µm). The adjusted mean OCT CST across groups increased by approximately 50 µm
following pro re nata visits at weeks 16 and 20, closely mirroring the visual acuity data, and decreased
gradually thereafter to week 100 (Figure 12). There was no difference in mean macular volume in each
trial group at 100 weeks (see Appendix 3, Table 33).
The proportion of participants with an OCT CT of < 320 µm at 52 weeks was significantly higher in the
aflibercept group (76%) than in the ranibizumab group (63%), a difference of 12.4% (95% CI 1.7% to
23.1%). A similar difference was found at 100 weeks [aflibercept group (81%) and ranibizumab group
(66%), a 15.3% difference (95% CI 4.9% to 25.7%)], but a difference between the bevacizumab and
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FIGURE 10 Percentage of participants in each group with loss of < 15 ETDRS letters at 52 and 100 weeks.
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FIGURE 11 Percentage of participants per group with loss of ≥ 30 ETDRS letters at 52 and 100 weeks.
TABLE 7 Categorical visual acuity outcomes by treatment group
Outcome







≥ 73 ETDRS letters
(> 6/12 Snellen
equivalent) at 100 weeks
47 (63/135) 44 (59/133) 41 (57/139) –2.3 (–14.2 to 9.6) –5.7 (–17.4 to 6.1)
Participants with
≤ 58 ETDRS letters
(≤ 6/24 Snellen
equivalent) at 100 weeks
29 (39/135) 20 (26/133) 30 (42/139) –9.3 (–19.5 to 0.9) 1.3 (–9.5 to 12.1)
Participants with
< 19 ETDRS letters
(< 3/60 Snellen
equivalent) at 100 weeks
3 (4/135) 2 (2/133) 4 (6/139) –1.5 (–5.0 to 2.1) 1.4 (–3.1 to 5.8)
Participants with
≥ 73 ETDRS letters
(> 6/12 Snellen
equivalent) at 52 weeks
42 (59/139) 42 (59/139) 39 (53/135) 0 (–11.6 to 11.6) –3.2 (–14.8 to 8.4)
Participants with
≤ 58 ETDRS letters
(≤ 6/24 Snellen
equivalent) at 52 weeks
28 (39/139) 25 (35/139) 24 (32/135) –2.9 (–13.3 to 7.5) –4.4 (–14.7 to 6.0)
Participants with
< 19 ETDRS letters
(< 3/60 Snellen
equivalent) at 52 weeks
4 (5/139) 1 (2/139) 4 (5/135) –2.2 (–5.8 to 1.5) 0.1 (–4.3 to 4.5)
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Injection number
Part of this section is reproduced from Hykin et al.2 This is an open access article distributed under
the terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium. This text includes minor additions and
formatting changes to the original.
By 100 weeks, ranibizumab group participants had received a mean of 11.8 injections, compared with
10.0 injections for the aflibercept group and 11.5 injections for the bevacizumab group. The difference
between the aflibercept and ranibizumab groups was meaningful as early as week 24 [mean difference:
–0.4 at week 24 (95% CI –0.6 to –0.2); –1.1 at week 52 (95% CI –1.6 to –0.5); and –1.9 at week 100
(95% CI –2.9 to –0.8)] (Figure 14).
Post hoc bevacizumab versus aflibercept analysis
After being approved by the DMEC, a post hoc analysis was unable to demonstrate that bevacizumab was
non-inferior to aflibercept in the ITT analysis at 52 weeks (adjusted mean difference –1.35 letters, 95% CI
–5.29 to 2.59 letters) or at 100 weeks (adjusted mean BCVA difference was –3.96 letters, 95% CI –8.34 to
0.42 letters; p= 0.32). The results of the per-protocol analysis were similar. At 100 weeks, there was a
significant difference of 1.6 (95% CI 0.5 to 2.7) between the mean number of injections received by
participants randomised to bevacizumab and the mean number received by those randomised to aflibercept.
TABLE 8 Visual acuity outcomes stratified by baseline visual acuity
Visual acuity Mean (SE) at screening Mean (SE) at 100 weeks
Adjusted difference
between groups (95% CI)
Aflibercept Ranibizumab Aflibercept Ranibizumab
Aflibercept vs. ranibizumab ITTa p = 0.91b
BCVA≤ 38 letters 27.3 (1.2) 27.9 (1.1) 59.4 (4.2) (n= 25) 55.1 (3.9) (n= 30) 3.3 (–6.8 to 13.4)
BCVA 39–58 letters 51.2 (0.8) 51.3 (0.7) 65.8 (2.6) (n= 48) 65.2 (2.8) (n= 45) –0.5 (–8.0 to 7.0)
BCVA 59–78 letters 66.4 (0.6) 66.5 (0.5) 74.2 (1.8) (n= 60) 71.2 (2.3) (n= 60) 4.2 (–2.4 to 10.7)
Aflibercept vs. ranibizumab per protocolc p = 0.97b
BCVA ≤ 38 letters 28.7 (1.0) 27.9 (1.1) 61.7 (4.3) (n= 22) 54.9 (4.1) (n= 29) 5.3 (–5.1 to 15.7)
BCVA 39–58 letters 51.1 (0.8) 51.5 (0.7) 67.2 (2.6) (n= 46) 65.2 (2.8) (n= 45) 2.0 (–5.4 to 9.5)
BCVA 59–78 letters 66.4 (0.6) 66.6 (0.6) 74.2 (1.8) (n= 60) 71.5 (2.4) (n= 59) 4.0 (–2.5 to 10.4)
Bevacizumab Ranibizumab Bevacizumab Ranibizumab
Bevacizumab vs. ranibizumab ITTa p = 0.81b
BCVA ≤ 38 letters 28.8 (1.1) 27.9 (1.1) 53.8 (4.7) (n= 23) 55.1 (3.9) (n= 30) –2.8 (–12.9 to 7.3)
BCVA 39–58 letters 52.5 (0.7) 51.3 (0.7) 64.9 (2.3) (n= 50) 65.2 (2.8) (n= 45) –2.3 (–9.7 to 5.2)
BCVA 59–78 letters 65.5 (0.6) 66.5 (0.5) 68.2 (2.7) (n= 66) 71.2 (2.3) (n= 60) –1.0 (–7.5 to 5.5)
Bevacizumab vs. ranibizumab per protocolc p = 0.82b
BCVA ≤ 38 letters 28.8 (1.1) 27.9 (1.1) 53.8 (4.7) (n= 23) 54.9 (4.1) (n= 29) –2.6 (–12.6, 7.3)
BCVA 39–58 letters 52.5 (0.7) 51.5 (0.7) 64.9 (2.3) (n= 50) 65.2 (2.8) (n= 45) –2.2 (–9.6, 5.2)
BCVA 59–78 letters 65.6 (0.6) 66.6 (0.6) 68.2 (2.7) (n= 66) 71.5 (2.4) (n= 59) –1.1 (–7.5, 5.4)
SE, standard error.
a The LME model incorporates 454 participants (ranibizumab, n = 148; aflibercept, n = 153; and bevacizumab, n = 153).
b p-value from interaction test for differential effect between subgroup categories.
c The LME model incorporates 443 participants (ranibizumab, n = 145; aflibercept, n = 146; and bevacizumab, n = 152).
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TABLE 9 Visual acuity outcomes stratified by disease duration at baseline
Disease duration Mean (SE) at screening Mean (SE) at 100 weeks
Adjusted difference
between groups (95% CI)
Aflibercept Ranibizumab Aflibercept Ranibizumab
Aflibercept vs. ranibizumab ITTa p = 0.14b
CRVO < 3 months 54.4 (1.4) 53.9 (1.3) 68.2 (1.7) (n = 113) 66.5 (1.9) (n= 116) 0.8 (–3.9 to 5.6)
CRVO ≥ 3 months 52.6 (2.5) 51.5 (3.3) 69.3 (3.2) (n = 20) 60.6 (3.9) (n= 19) 10 (–1.3 to 21.4)
Aflibercept vs. ranibizumab per protocolc p = 0.21b
CRVO < 3 months 55.5 (1.3) 54.0 (1.4) 69.5 (1.7) (n = 108) 66.6 (1.9) (n= 114) 2.2 (–2.5 to 7.0)
CRVO ≥ 3 months 52.6 (2.5) 51.5 (3.3) 69.3 (3.2) (n = 20) 60.6 (3.9) (n= 19) 10.0 (–1.1 to 21.2)
Bevacizumab Ranibizumab Bevacizumab Ranibizumab
Bevacizumab vs. ranibizumab ITTa p = 0.33b
CRVO < 3 months 55.0 (1.2) 53.9 (1.3) 65.5 (1.8) (n = 127) 66.5 (1.9) (n= 116) –1.2 (–5.8 to 3.5)
CRVO ≥ 3 months 49.5 (4) 51.5 (3.3) 54.9 (5.2) (n = 12) 60.6 (3.9) (n= 19) –7.9 (–20.8 to 5)
Bevacizumab vs. ranibizumab per protocolc p = 0.32b
CRVO < 3 months 55.0 (1.2) 54 (1.4) 65.5 (1.8) (n = 127) 66.6 (1.9) (n= 114) –1.1 (–5.7 to 3.6)
CRVO ≥ 3 months 49.5 (4.2) 51.5 (3.3) 54.9 (5.2) (n = 12) 60.6 (3.9) (n= 19) –7.9 (–20.7 to 4.8)
SE, standard error.
a The LME model incorporates 454 participants (ranibizumab, n= 148; aflibercept, n= 153; and bevacizumab, n= 153).
b p-value from interaction test for differential effect between subgroup categories.
c The LME model incorporates 443 participants (ranibizumab, n= 145; aflibercept, n= 146; and bevacizumab, n= 152).
TABLE 10 Visual acuity outcomes stratified by ischaemic or non-ischaemic CRVO at baseline
Ischaemic or
non-ischaemic CRVO Mean (SE) at screening Mean (SE) at 100 weeks
Adjusted difference
between groups (95% CI)
Aflibercept Ranibizumab Aflibercept Ranibizumab
Aflibercept vs. ranibizumab ITTa p = 0.15b
Non-ischaemic CRVO 55.9 (1.2) 55.1 (1.2) 68.5 (1.7) (n= 115) 66.3 (1.8) (n = 122) 1.1 (–3.6 to 5.9)
Ischaemic CRVO 41.3 (3.8) 41.6 (4.1) 67.3 (3.6) (n= 18) 59.3 (6.5) (n = 13) 11.2 (–1.9 to 24.3)
Aflibercept vs. ranibizumab per protocolc p = 0.25b
Non-ischaemic CRVO 56.8 (1.2) 55.2 (1.3) 69.8 (1.6) (n= 111) 66.4 (1.8) (n = 120) 2.7 (–2.0 to 7.4)
Ischaemic CRVO 42.7 (3.7) 40.8 (4.3) 67.4 (3.8) (n= 17) 59.3 (6.5) (n = 13) 10.8 (–2.2 to 23.8)
Bevacizumab Ranibizumab Bevacizumab Ranibizumab
Bevacizumab vs. ranibizumab ITTa p = 0.85b
Non-ischaemic CRVO 55.5 (1.2) 55.1 (1.2) 65.3 (1.8) (n= 121) 66.3 (1.8) (n = 122) –1.7 (–6.4 to 3.0)
Ischaemic CRVO 47.2 (3.7) 41.6 (4.1) 60.2 (5.9) (n= 18) 59.3 (6.5) (n = 13) –0.4 (–13.4 to 12.7)
Bevacizumab vs. ranibizumab per protocolc p = 0.73b
Non-ischaemic CRVO 55.6 (1.2) 55.2 (1.3) 65.3 (1.8) (n= 121) 66.4 (1.8) (n = 120) –1.8 (–6.4 to 2.9)
Ischaemic CRVO 46.5 (3.8) 40.8 (4.3) 60.2 (5.9) (n= 18) 59.3 (6.5) (n = 13) 0.6 (–12.3 to 13.6)
SE, standard error.
a The LME model incorporates 454 participants (ranibizumab, n= 148; aflibercept, n= 153; and bevacizumab, n= 153).
b p-value from interaction test for differential effect between subgroup categories.
c The LME model incorporates 443 participants (ranibizumab, n= 145; aflibercept, n= 146; and bevacizumab, n= 152).
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Retinal imaging
Optical coherence tomography imaging
The OCT morphological grading for MO, subretinal detachment and vitreomacular interface
abnormality was available for 456 (98.4%) and 396 (85.5%) participants at baseline and week 100,
respectively, and showed no difference for any parameter across treatment arms in prevalence or
change with time. Across all subgroups, the percentage of participants with any MO and subretinal































Adjusted mean difference between groups at 100 weeks (95% CI):
af libercept vs. ranibizumab –29.3 (–60.9 to 2.3)
bevacizumab vs. ranibizumab 21.9 (–9.7 to 53.4) 
FIGURE 12 Adjusted mean OCT CST across groups to 100 weeks. Reproduced from Hykin et al.2 This is an open access article
distributed under the terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted















Week 24 Week 52 Week 100
12.4% (95% CI 1.7% to 23.1%)
–10.7% (95% CI –22.3% to 0.9%)
–18.7% (95% CI –30.1% to –7.4%)













–7.4% (95% CI –18.9% to 4.1%)
15.3% (95% CI 4.9% to 25.7%)
FIGURE 13 Percentage of participants with OCT CST of < 320 µm at 24, 52 and 100 weeks. Reproduced from Hykin
et al.2 This is an open access article distributed under the terms of the CC-BY 4.0 license (https://creativecommons.org/
licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium. This includes minor
additions and formatting changes to the original.
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Week 24 Week 52 Week 100
Difference in means (95% CI):
af libercept vs. ranibizumab
–1.9 (–2.9 to –0.8)Difference in means (95% CI):
af libercept vs. ranibizumab
–1.1 (–1.6 to –0.5)
Difference in means (95% CI):
af libercept vs. ranibizumab
–0.4 (–0.6 to –0.2) Ranibizumab
Af libercept
Bevacizumab
FIGURE 14 Mean number of injections across treatment groups by weeks 24, 52 and 100. Reproduced from Hykin et al.2
This is an open access article distributed under the terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/
by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium. This includes minor additions and
formatting changes to the original.
TABLE 11 The OCT anatomical outcomes for MO, subretinal fluid and vitreomacular traction abnormality, by
treatment group
Outcome All Ranibizumab Aflibercept Bevacizumab
MO
Baseline
Null (n) 7 3 1 3
No evidence, n (%) 5 (1) 2 (1) 2 (1) 1 (1)
Diffuse, n (%) 19 (4) 8 (5) 8 (5) 3 (2)
Cystic, n (%) 90 (20) 25 (16) 33 (22) 32 (21)
Mixed, n (%) 342 (75) 117 (77) 110 (72) 115 (76)
Week 52
Null (n) 53 21 13 19
No evidence, n (%) 147 (36) 56 (42) 62 (44) 29 (21)
Diffuse, n (%) 64 (16) 18 (13) 24 (17) 22 (16)
Cystic, n (%) 103 (25) 27 (20) 35 (25) 41 (30)
Mixed, n (%) 96 (23) 33 (25) 20 (14) 43 (32)
Week 100
Null (n) 67 22 24 21
No evidence, n (%) 150 (38) 55 (41) 59 (45) 36 (27)
Diffuse, n (%) 55 (14) 17 (13) 19 (15) 19 (14)
Cystic, n (%) 87 (22) 26 (20) 29 (22) 32 (24)
Mixed, n (%) 104 (26) 35 (26) 23 (18) 46 (35)
continued
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TABLE 11 The OCT anatomical outcomes for MO, subretinal fluid and vitreomacular traction abnormality, by
treatment group (continued )
Outcome All Ranibizumab Aflibercept Bevacizumab
Subretinal detachment
Baseline
Null (n) 26 9 8 9
No evidence, n (%) 126 (29) 39 (27) 45 (31) 42 (29)
Questionable, n (%) 9 (2) 6 (4) 1 (1) 2 (1)
Definite, n (%) 196 (43) 62 (41) 63 (41) 71 (48)
Week 52
Null (n) 55 22 13 20
No evidence, n (%) 352 (86) 113 (85) 124 (88) 115 (86)
Questionable, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
Definite, n (%) 56 (14) 20 (15) 17 (12) 19 (14)
Week 100
Null (n) 67 22 24 21
No evidence, n (%) 342 (86) 118 (89) 111 (85) 113 (85)
Questionable, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
Definite, n (%) 54 (14) 15 (11) 19 (15) 20 (15)
Vitreomacular interface abnormality
Baseline
Null (n) 9 3 1 5
No evidence, n (%) 250 (55) 87 (57) 88 (58) 75 (50)
Questionable, n (%) 8 (2) 3 (2) 2 (1) 3 (2)
Definite, n (%) 196 (43) 62 (41) 63 (41) 71 (48)
Week 52
Null (n) 53 21 13 19
No evidence, n (%) 221 (54) 73 (54) 76 (54) 72 (53)
Questionable, n (%) 4 (1) 0 (0) 3 (2) 1 (1)
Definite, n (%) 185 (45) 61 (46) 62 (44) 62 (46)
Week 100
Null (n) 67 22 24 21
No evidence, n (%) 219 (55) 74 (56) 77 (59) 68 (51)
Questionable, n (%) 9 (2) 4 (3) 4 (3) 1 (1)
Definite, n (%) 168 (42) 55 (41) 49 (38) 64 (48)
Notes
Null = not available because participant withdrew or image was not taken or not saved. Ungradable= grader was
unable to grade because of poor image quality or feature(s) obscured (e.g. by overlying MO).
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Spectral-domain OCT (Spectralis) image grading was undertaken for additional parameters, including DRIL,
COSTvisibility loss, EZ disruption, loss of ELM integrity and presence of intraretinal HRF. Of 463 participants,
337 were enrolled at sites where Spectralis OCTwas available; of these participants, 267 had gradable
images at baseline and at weeks 52 and 100 (Table 12). There was no difference in the prevalence of any
parameter across treatment groups at any time point. In all treatment groups, DRILwas observed to
decrease, and the ELM, EZ and COSTretinal layers became better defined with time.This may have
TABLE 12 Morphological grading of novel OCT parameters
All (N= 267),
n (%)









Absent 86 (32) 30 (33) 31 (35) 25 (29)
Present 149 (56) 51 (55) 48 (54) 50 (58)
Ungradable 32 (12) 11 (12) 10 (11) 11 (13)
Week 52
Absent 189 (71) 71 (76) 60 (67) 58 (68)
Present 61 (23) 18 (19) 21 (24) 22 (26)
Ungradable 17 (6) 4 (4) 8 (9) 5 (6)
Week 100
Absent 178 (67) 60 (65) 61 (69) 57 (66)
Present 68 (25) 23 (25) 24 (27) 21 (24)
Ungradable 21 (8) 9 (10) 4 (4) 8 (9)
HRF
Baseline
Absent 62 (23) 24 (26) 20 (22) 18 (21)
Present 204 (76) 68 (74) 68 (76) 68 (79)
Ungradable 1 (0) 0 (0) 1 (1) 0 (0)
Week 52
Absent 132 (49) 49 (53) 42 (47) 41 (48)
Present 135 (51) 44 (47) 47 (53) 44 (52)
Ungradable 0 (0) 0 (0) 0 (0) 0 (0)
Week 100
Absent 96 (36) 30 (33) 39 (44) 27 (31)
Present 168 (63) 62 (67) 48 (54) 58 (67)
Ungradable 3 (1) 0 (0) 2 (2) 1 (1)
ELM
Baseline
Intact 66 (25) 20 (22) 24 (27) 22 (26)
Not intact 44 (16) 17 (18) 18 (20) 9 (10)
Ungradable 157 (59) 55 (60) 47 (53) 55 (64)
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TABLE 12 Morphological grading of novel OCT parameters (continued )
All (N= 267),
n (%)








Intact 198 (74) 71 (76) 62 (70) 65 (76)
Not intact 50 (19) 18 (19) 20 (22) 12 (14)
Ungradable 19 (7) 4 (4) 7 (8) 8 (9)
Week 100
Intact 200 (75) 69 (75) 67 (75) 64 (74)
Not intact 49 (18) 19 (21) 16 (18) 14 (16)
Ungradable 18 (7) 4 (4) 6 (7) 8 (9)
EZ
Baseline
Intact 46 (17) 15 (16) 18 (20) 13 (15)
Not intact 61 (23) 21 (23) 21 (24) 19 (22)
Ungradable 160 (60) 56 (61) 50 (56) 54 (63)
Week 52
Intact 174 (65) 64 (69) 54 (61) 56 (66)
Not intact 75 (28) 25 (27) 29 (33) 21 (25)
Ungradable 18 (7) 4 (4) 6 (7) 8 (9)
Week 100
Intact 172 (64) 57 (62) 61 (69) 54 (63)
Not intact 75 (28) 30 (33) 22 (25) 23 (27)
Ungradable 20 (7) 5 (5) 6 (7) 9 (10)
COSTs
Baseline
Intact 16 (6) 8 (9) 5 (6) 3 (3)
Not intact 78 (29) 23 (25) 31 (35) 24 (28)
Ungradable 173 (65) 61 (66) 53 (60) 59 (69)
Week 52
Intact 54 (20) 13 (14) 25 (28) 16 (19)
Not intact 170 (64) 64 (69) 53 (60) 53 (62)
Ungradable 43 (16) 16 (17) 11 (12) 16 (19)
Week 100
Intact 65 (24) 17 (18) 25 (28) 23 (27)
Not intact 169 (63) 66 (72) 53 (60) 50 (58)
Ungradable 33 (12) 9 (10) 11 (12) 13 (15)
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represented better visualisation with time, as MO decreased, rather than a specific reconstitution of the
parameter. Further investigation and correlation of these findings with visual outcomes will be the subject
of a further publication.
Fundus fluorescein angiography image analysis
Of 463 participants at baseline, 461 underwent FFA. At 100 weeks, 407 completed the ITT analysis;
377 underwent FFA, and 30 did not because they declined or had experienced an adverse reaction to
the dye at baseline or there were intravenous cannulation/technical difficulties. Of the 377 participants
who underwent FFA, 53 could not be graded for other reasons (e.g. the participant had received
panretinal photocoagulation before or during the trial), and for 14 participants all images were
ungradable, leaving 310 participants with gradable images (Table 13). The percentages of participants
in each arm with two-step, or more, worsening in one or more quadrants appeared more frequent
in the aflibercept group than in the bevacizumab group, but, as the number of affected quadrants
increased, the result across groups tended to converge. Overall, the data showed no meaningful
difference between treatment groups in terms of the number of participants with at least two-step
worsening of non-perfusion in one or more quadrants.
The novel concentric ring method for analysing non-perfusion in disc areas, developed by the LEAVO
team during the trial, was applicable to 235 of 463 participants randomised who underwent wide-angled
Optos FFA. Of these, 184 had images successfully performed at both entry and exit; among these,
31 eyes were poor-quality images either at baseline or at exit. This left 153 gradable images that were
converted into disc areas of non-perfusion and form the basis of the comparison between trial groups
(Tables 14 and 15).
The median value of baseline non-perfusion for all participants was 28.6 disc areas (IQR 10.4–47.4 disc
areas), mostly in the peripheral retina. There was more non-perfusion in the periphery and, notably, in
the posterior pole in the ranibizumab (19%) and aflibercept (19%) groups than in the bevacizumab (2%)
group. This baseline imbalance between groups was seen at week 100, particularly in the percentage of
participants showing an increase in posterior non-perfusion, which may simply reflect higher baseline
non-perfusion and, therefore, greater likelihood of progressing. A detailed appraisal of these data is
currently being undertaken and will form the basis of a further report.83
Treatment allocation guess form
The optometrists assessing primary outcomes provided a response on the treatment allocation guess
form for 409 of their 463 participants: for 356, they said they did not know; for 53, they made a guess,
and were correct in 18 instances, which is consistent with chance. Of the 409 participants, 406 provided
a response: 386 did not know and 20 made a guess, of whom eight [i.e. 2% (8/406)] guessed correctly,
which is consistent with chance.
TABLE 13 Change in capillary non-perfusion based on FFA image characteristics available at baseline and week 100
Sectors with two-step, or more,
capillary non-perfusion worsening (n)







0 73 (70) 62 (65) 86 (79)
1 11 (10) 18 (19) 9 (8)
2 8 (8) 6 (6) 4 (4)
3 5 (5) 4 (4) 3 (3)
4 4 (4) 1 (1) 1 (3)
5 1 (1) 1 (1) 0 (0)
≥ 6 3 (3) 4 (4) 6 (6)
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TABLE 14 Amount of retinal non-perfusion per arm
Retinal area
Amount of retinal non-perfusion, median (IQR)
All (N= 153) Ranibizumab (N= 57) Aflibercepta (N= 48) Bevacizumab (N= 48)
Cells Disc areas Cells Disc areas Cells Disc areas Cells Disc areas
Baseline
Total area 3 (1 to 5) 28.6 (10.4 to 47.4) 2.5 (1 to 5.3) 24.6 (8.0 to 49.6) 3.3 (1.6 to 5) 30.2 (16.4 to 48.7) 3 (0.9 to 4.5) 28.9 (8.6 to 44.4)
Posterior (M+ R1) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0) 0 (0 to 0)
% (n) subjects with
posterior > 0
14 (21) 14 (21) 19 (11) 19 (11) 19 (9) 19 (9) 2 (1) 2 (1)
Peripheral (R2–R4) 3 (1 to 5) 28.4 (10.4 to 47.4) 2.5 (0.8 to 5) 24.6 (7.3 to 49.1) 3 (1.6 to 5) 30.2 (16.2 to 48.7) 3 (0.9 to 4.5) 28.9 (8.6 to 44.4)
Week 100
Total area 3 (1.5 to 6) 30.2 (15.5 to 55.1) 2.5 (1.3 to 7) 25.0 (13.0 to 61.4) 3.8 (2 to 9.4) 37.0 (20.7 to 72.9) 3 (1 to 4.5) 30.2 (10.4 to 44.4)
Posterior (M+ R1) 0 (0 to 0) 0 (0 to 0) 0 (0 to 1) 0 (0 to 4.4) 0 (0 to 1.9) 0 (0 to 5.5) 0 (0 to 0) 0 (0 to 0)
% (n) subjects with
posterior > 0
22 (33) 22 (33) 26 (15) 26 (15) 29 (14) 29 (14) 8 (4) 8 (4)
Peripheral (R2–R4) 3 (1.5 to 5.5) 30.2 (15.1 to 51.1) 2.5 (1.3 to 6.3) 25.0 (11.9 to 59.1) 3.5 (2 to 7.5) 35.2 (20.7 to 69.6) 3 (1 to 4.5) 30.2 (10.4 to 44.4)
Change in total area 0.0 (–1.0 to 2.0) 0.0 (–5.4 to 16.0) 0.0 (–1.0 to 002.0) 0.0 (–9.1 to 15.6) 1.0 (–1.0 to 3.0) 4.7 (–2.0 to 24.3) 0.0 (–1.0 to 2.0) 0.0 (–9.3 to 15.9)
Change in posterior 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.8) 0.0 (0.0 to 1.5) 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0)
% (n) subjects with an
increase in posterior
17 (26) 18 (27) 19 (11) 19 (11) 25 (12) 27 (13) 6 (3) 6 (3)
Change in peripheral 0.0 (–1.0 to 2.0) 0.0 (–7.1 to 15.8) 0.0 (–1.0 to 2.0) 0.0 (–9.9 to 15.8) 1.0 (1.0 to 2.0) 4.7 (0.0 to 18.0) 0.0 (–1.0 to 2.0) 0.0 (–9.3 to 15.9)


































Part of this section is reproduced from Hykin et al.2 This is an open access article distributed under
the terms of the CC-BY 4.0 license (https://creativecommons.org/licenses/by/4.0/), which permits
unrestricted use, distribution, and reproduction in any medium. This text includes minor additions and
formatting changes to the original.
There was one case of infectious endophthalmitis in a trial eye, which followed trabeculectomy bleb
infection rather than intravitreal injection. The frequencies of all ocular AEs and Antiplatelet Trialists’
Collaboration (APTC)-defined events were similar between trial arms (Table 16). At 52 weeks, the
proportions of participants who were persistent non-responders (defined as not more than a 5-letter gain
in visual acuity and an OCT CST decrease of < 50 µm after 24 weeks) were 1/139 for ranibizumab, 5/133
for aflibercept and 5/135 for bevacizumab; at 100 weeks, only one participant, in the bevacizumab group,
was a non-responder. During the trial, 25 (5.4%) eyes developed an ischaemic CRVO, 13 (2.8%) developed
anterior segment neovascularisation and 6 (1.3%) developed retinal neovascularisation, with no difference
across arms (see Table 16).
TABLE 15 Comparison of the changes from baseline in the amount of retinal non-perfusion between arms
Change from baseline
Difference in medians (95% CI)
Aflibercept – ranibizumab Bevacizumab – ranibizumab
Cells Disc areas Cells Disc areas
Change in total area 1.0 (0 to 2.0) 5.6 (0 to 14.1) 0.0 (–1.0 to 1.0) 0.0 (–7.8 to 6.0)
Participants with an increase
in posterior (%)
6.0 (–9.7 to 22.0) 8.0 (–8.0 to 24.1) –13.0 (–25.6 to 0.3) –13.0 (–25.6 to 0.3)
Change in peripheral 1.0 (0 to 2.0) 5.6 (0 to 13.4) 0.0 (–1.0 to 1.0) 0.0 (–7.8 to 6.5)



















1 (0.2) 0 (0) 0 (0) 1 (0.6) 0.0 (–2.4 to 2.4) –0.6 (–3.6 to 1.8)
Traumatic cataract 0 (0) 0 (0) 0 (0) 0 (0) 0.0 (–2.4 to 2.4) 0.0 (–2.4 to 2.4)
Retinal tear 1 (0.2) 1 (0.6) 0 (0) 0 (0) –0.6 (–3.6 to 1.9) –0.6 (–3.6 to 1.9)
Retinal detachment 3 (0.6) 0 (0) 1 (0.6) 2 (1.3) 0.6 (–1.8 to 3.6) 1.3 (–1.3 to 4.6)
Conversion to
ischaemic CRVO
25 (5.4) 8 (5.2) 10 (6.5) 7 (4.5) 1.3 (–4.2 to 7.0) –0.6 (–5.9 to 4.6)
Anterior segment
neovascularisation
13 (2.8) 5 (3.2) 5 (3.2) 3 (1.9) 0.0 (–4.5 to 4.5) –1.3 (–5.6 to 2.8)
Retinal
neovascularisation
6 (1.3) 1 (0.6) 4 (2.6) 1 (0.6) 2.0 (–1.4 to 5.9) 0.0 (–3.0 to 3.0)
Vitreous
haemorrhage
6 (1.3) 0 (0) 2 (1.3) 4 (2.6) 1.3 (–1.3 to 4.6) 2.6 (–0.2 to 6.5)
IOP elevation 27 (5.8) 13 (8.4) 9 (5.8) 5 (3.2) –2.5 (–8.6 to 3.4) –5.1 (–10.9 to 0.2)
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Eight ranibizumab, seven aflibercept and eight bevacizumab arm participants required panretinal
photocoagulation. Two pregnancies were reported during the trial: one in a participant and one in the
spouse of a participant. Both of these were followed to term with the delivery of normal neonates.
Systemic serious AEs occurred with an expected and similar frequency between groups (see Table 16),
and there were no meaningful differences between groups in the frequency of AEs in the same body
system (Table 17).



















5 (1.1) 2 (1.3) 2 (1.3) 1 (0.6) 0.0 (–3.4 to 3.4) –0.6 (–4.0 to 2.4)
Cardiovascular –
non-fatal MI
2 (0.4) 0 (0) 0 (0) 2 (1.3) 0.0 (–2.4 to 2.4) 1.3 (–1.3 to 4.6)
Cardiovascular –
non-fatal stroke
6 (1.3) 2 (1.3) 4 (2.6) 0 (0) 1.3 (–2.4 to 5.3) –1.3 (–4.6 to 1.3)
IOP, intraocular pressure; MI, myocardial infarction.
Reproduced from Hykin et al.2 This is an open access article distributed under the terms of the CC-BY 4.0 license
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any
medium. This includes minor additions and formatting changes to the original.













31 (6.7) 8 (5.2) 14 (9.1) 9 (5.8)
Respiratory 20 (4.3) 4 (2.6) 6 (3.9) 10 (6.5)
Hepatic 1 (0.2) 1 (0.6) 0 (0) 0 (0)
Gastrointestinal 19 (4.1) 8 (5.2) 8 (5.2) 3 (1.9)
Genitourinary 13 (2.8) 2 (1.3) 7 (4.5) 4 (2.6)
Endocrinal 1 (0.2) 0 (0) 0 (0) 1 (0.6)
Haematological 1 (0.2) 0 (0) 1 (0.6) 0 (0)
Musculoskeletal 10 (2.2) 1 (0.6) 4 (2.6) 5 (3.2)
Neoplastic 4 (0.9) 0 (0) 1 (0.6) 3 (1.9)
Neurological 6 (1.3) 1 (0.6) 3 (1.9) 2 (1.3)
Psychiatric 2 (0.4) 1 (0.6) 0 (0) 1 (0.6)
Immunological 0 (0) 0 (0) 0 (0) 0 (0)
Dermatological 2 (0.4) 0 (0) 2 (1.3) 0 (0)
Allergies 1 (0.2) 0 (0) 1 (0.6) 0 (0)
Ophthalmological 9 (1.9) 3 (1.9) 3 (1.9) 3 (1.9)
Ear, nose and throat 1 (0.2) 0 (0) 0 (0) 1 (0.6)
Other 9 (1.9) 3 (1.9) 3 (1.9) 3 (1.9)
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Comparison with Study of Comparative Treatments for Retinal Vein
Occlusion 2 safety data
Although it was not possible to perform a safety meta-analysis because of the lack of comparative
outcome data in CRVO, as described in Chapter 2, the data from SCORE2 during the initial comparative
6 months were compared with the safety data from the first 6 months of LEAVO (Table 18). A larger
number of conversions to ischaemic CRVO were recorded in LEAVO than in SCORE2. This may have
been because in LEAVO conversion to ischaemic CRVO was recorded as a direct question in each
trial visit sheet; because of early enrolment in LEAVO compared with SCORE 2; and because of
the treatment-naive status of most LEAVO participants at randomisation. There were more vitreous
haemorrhages recorded in LEAVO than in SCORE2, and more vascular deaths recorded in SCORE2
than in LEAVO. The prevalence of these events was low and it was not thought that there were any
meaningful differences between the two studies in the number or type of AEs.
TABLE 18 Comparison of LEAVO and SCORE2 AEs at 6 months
Event
LEAVO (n) SCORE2 (n)
Ranibizumab Aflibercept Bevacizumab Aflibercept Bevacizumab
Trial eye
Infectious endophthalmitis 0 0 1 – –
Non-infectious endophthalmitis 0 0 0 0 1
Neovascular glaucoma 1 1 0 1 0
Conversion to ischaemic CRVO 8 6 6 1 0
Retinal detachment 0 1 1 0 1
Vitreous haemorrhage 0 2 4 0 1
APTC events
Non-fatal MI 0 0 0 1 2
Non-fatal stroke 0 1 0 1 0
Vascular death 0 0 0 3 2
Excluding vascular death
Death from any other cause 1 1 0 1 1
Ocular and systemic AEs, not limited to trial eye
Participants with any AE 108 99 115 82 98
Total number of all AEs 301 337 323 184 263
Participants with any SAE 19 7 14 14 14
Total number of all SAEs 20 10 14 18 25
MI, myocardial infarction.
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Patient and public involvement
The lay panel members co-developed the contents and wording of the questions in the following
questionnaire.
1. Cost of the medication: if the cheaper medication Avastin was as good as Eylea and Lucentis in
improving your vision, and as safe, would you be happy to be given Avastin for your affected eye?
2. Licensed medications: if the cheaper medication Avastin was as good as Eylea and Lucentis in
improving your vision, and bearing in mind Avastin is as safe as the other two (see above), would
you be concerned about taking Avastin because it had not been licensed by the UK MHRA (i.e. the
UK regulatory body that approves new drugs for use in the UK)?
3. Effect of the medications: if the cheaper unlicensed medication Avastin was slightly better at improving
vision in your affected eye than the licensed medications Eylea and Lucentis (e.g. an improvement of
2 letters on a visual acuity chart. There are 5 letters on each line, so the difference would be just less
than half a line), under this circumstance, would you be happy to be given Avastin? If no, what would
be the reason?
4. Effect of the medications: if the cheaper unlicensed medication Avastin was slightly less good at
improving vision in your affected eye than the licensed medications Eylea and Lucentis (e.g. a loss of
2 letters on a visual acuity chart. There are 5 letters on each line, so the difference would be just
less than half a line), would you be happy to be given Avastin?
5. Effect of the medications: if the cheaper unlicensed medication Avastin was slightly less good (i.e. if
you closed your good eye you noticed a slight central blur in the affected eye when reading, but not
when looking in the distance and not when using both eyes together), but you were still able to do
all regular activities, such as drive, read books and magazines, work machinery, use power tools,
would you be happy to be given Avastin?
6. Effect of the medications: if you were asked to commence treatment with Avastin, would you be
more likely to agree to this if a licensed alternative (e.g. Eylea) was available that you could change
over to if your response to the Avastin was less than expected?
The feedback regarding the final questionnaire content was positive (i.e. it was an important trial to
have done, the text was easy to follow and the questions were clear). The results of the trial were
under embargo pending publication at the time the questionnaire was sent to patients [n = 22: seven
with a history of RVO (but not LEAVO participants), 15 with a history of diabetic eye disease and three
regular lay panel members]. The results of the patient and public involvement LEAVO questionnaire are
given in Table 19.
TABLE 19 Trial results: post-trial patient questionnaire feedback
Answer
Question, n (%) responses
1 2a 3 4 5 6
Yes 22 (100) 6 (27) 20 (91) 11 (50) 15 (68) 22 (100)
Maybe 0 (0) 2 (9) 2 (9) 3 (14) 1 (5) 0 (0)
No 0 (0) 13 (59) 0 (0) 8 (36) 6 (27) 0 (0)
a One nil response.
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Chapter 4 Health economic evaluation
Introduction
Economic evaluation forms an important part of health technology assessments by evaluating the
cost-effectiveness of interventions to determine whether or not they represent value for money.
In England, NICE evaluates interventions through its technology appraisal and guidelines programmes.
Each programme has a methods guide, which describes a reference case that should be used in cost-
effectiveness analyses.84,85 Our analyses use NICE’s preferred methods in conjunction with other good
practice guidelines86,87 to evaluate the cost-effectiveness of intravitreal ranibizumab, aflibercept and
bevacizumab for MO due to CRVO.
NICE’s preferred method for cost-effectiveness analysis of interventions delivered in an NHS setting
is cost–utility analysis (CUA).84,85 CUA allows comparisons to be made between disease areas by using
a common measure of outcome: cost per quality-adjusted life-year (QALY). QALYs combine morbidity
and mortality by using a ‘utility’ to measure health-related quality of life (HRQoL). Utilities are anchored
between 0 and 1, where 1 represents perfect health and 0 represents death (utilities of < 0 are permitted,
reflecting health states considered to be worse than death).
A CUA is used to compare two or more interventions, using incremental analysis. The outcome of a
CUA is an ICER, calculated by dividing the incremental (additional) costs by the incremental QALYs
associated with the intervention. The incremental costs are calculated as the difference between the
total costs for the intervention and the total costs for the comparator. The incremental QALYs are
calculated as the difference between the total QALYs for the intervention and the total QALYs for
the comparator.
The results of a CUA can be used in decision-making to determine whether or not interventions
represent good value for money. The simplest decisions concern dominance. An intervention is said to
‘dominate’ the comparator (and the comparator is ‘dominated’) when the intervention leads to lower
costs and more QALYs than the comparator. In this case, the decision to use the intervention instead
of the comparator is clear, as it reduces costs and improves outcomes. In the situation in which an
intervention is more costly and leads to more QALYs than the comparator, a decision rule is required
to determine whether or not the gain in QALYs is worth the additional cost. In this case, the ICER
can be compared with a threshold representing the maximum the funder is willing to pay for each
additional QALY.
NICE does not have a specific threshold, but considers a range of maximum acceptable ICERs when
deciding if an intervention is cost-effective. Interventions with ICERs of < £20,000 per QALY are
generally considered to be cost-effective, whereas decisions regarding interventions with ICERs of
between £20,000 and £30,000 per QALY will need to consider additional factors such as uncertainty,
innovation, whether or not the HRQoL benefits have been adequately captured, whether or not the
treatment meets specific criteria for life-extending treatments at the end of life, and the non-health
objectives of the NHS. At > £30,000 per QALY, a stronger case is required for NICE to consider an
intervention to be cost-effective.84
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Overview of health economic evaluation methods
Interventions
A full health economic evaluation was conducted, comparing three interventions for MO due to CRVO
using data collected as part of LEAVO. The interventions were as follows:
l Interventions (investigational treatments) –
¢ Arm A, treatment: an intravitreal injection of aflibercept (2.0 mg/0.05 ml) administered at baseline
and at 4, 8 and 12 weeks as a mandated injection. From week 16 to week 96, treatment was
given if one or more re-treatment criteria were met, as specified in the trial protocol.88 Beyond
the 100-week trial period, injections were given based on treatment continuation rules.
¢ Arm B, treatment: an intravitreal injection of bevacizumab (1.25 mg/0.05 ml) administered at
baseline and at 4, 8 and 12 weeks as a mandated injection. From week 16 to week 96, treatment
was given if one or more re-treatment criteria were met. Beyond the 100-week trial period,
injections were given based on treatment continuation rules.
l Comparator (standard care) –
¢ Arm C, control: an intravitreal injection of ranibizumab (0.5 mg/0.05 ml) administered at baseline
and at 4, 8 and 12 weeks as a mandated injection. From week 16 to week 96, treatment was
given if one or more re-treatment criteria were met. Beyond the 100-week trial period,
injections were given based on treatment continuation rules.
Method of economic evaluation
The economic evaluation comprises two parts: a model-based analysis (the primary analysis) and a
within-trial analysis (the secondary analysis). The model-based analysis evaluates the three interventions
over participants’ lifetimes, extrapolating clinical outcomes beyond the trial period and relating these
to costs and QALYs. The within-trial analysis evaluates the three interventions during the trial period
using the individual patient-level cost and HRQoL data collected during the trial. The economic evaluation
uses CUA. The methods for the economic evaluation were prespecified in health economic and decision-
modelling analysis plan (and associated addendum) documents, prior to database lock.89
The within-trial analysis provides the short-term cost-effectiveness evidence using individual patient-
level data on quality of life and costs; therefore, it avoids extrapolation uncertainty. The model-based
analysis provides the long-term cost-effectiveness evidence (extrapolating outcomes and costs beyond
the trial period); this is the preferred approach for resource allocation decision-making (in line with
NICE’s Guide to Methods of Technology Appraisal 201384). To support the development of the economic
model, a systematic literature review was undertaken to identify evidence to inform inputs and assumptions.
Settings
Perspective
The economic evaluation uses the NHS and Personal Social Services perspective, consistent with the
NICE methods guides.84,85 Included costs are those incurred by the NHS and Personal Social Services,
and so include costs for health-care resource use and interventions. Societal costs, lost productivity
and a patient’s personal expenditure (e.g. travel costs) are excluded.
Discounting
Future costs and health outcomes are discounted to reflect time preference. The discount rate for both
costs and QALYs is 3.5% per year, consistent with the NICE methods guides.84,85
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Time horizon
The model-based analysis uses a lifetime horizon, calculating costs and QALYs until all modelled patients
have died. The within-trial analysis uses the 100-week trial time horizon. NICE states that the time
horizon should be ‘long enough to reflect all important differences in costs or outcomes between the
technologies being compared’84 (© NICE 2013 Guide to Methods of Technology Appraisal 2013. Available
from www.nice.org.uk/process/pmg9/. All rights reserved. Subject to Notice of rights). Using a lifetime
horizon reflects the long-term differences between the interventions in terms of effectiveness, time on
treatment/discontinuation, and safety outcomes.
Presentation of results
Incremental and pairwise analyses
The economic evaluation reports fully incremental analyses, consistent with the NICE methods
guides,84,85 and pairwise analyses, to allow the comparison of each pair of interventions. For the model-
based analysis, the fully incremental analysis is presented in Results: model-based analysis, and the
pairwise comparisons are presented in Appendix 6, Tables 59–61. For the within-trial analysis, pairwise
comparisons are presented in Results: within-trial analysis, and the fully incremental analysis is presented
in Appendix 6, Table 66.
Characterisation of uncertainty
The model-based and within-trial analyses each present a base-case analysis and scenario analyses
using alternative settings. The base-case and scenario analyses from the model-based analysis use
probabilistic sensitivity analysis to incorporate parameter uncertainty (see Methods: within-trial analysis).
For deterministic results, see Appendix 6, Table 58.
The base-case and scenario analyses from the within-trial analysis use seemingly unrelated regression
to consider the correlation between total costs and QALYs (see Methods: within-trial analysis), and
the probabilistic sensitivity analysis is presented as an additional scenario using base-case settings
(see Results: within-trial analysis).
Quality assurance
The model was developed by two economic modellers. When one economic modeller added coding or
inputs to the model, the other modeller checked these to identify and resolve any errors. The model
was debugged by following simulated patients throughout the model, and verifying that the model was
picking up the correct inputs and that calculations were being performed as intended. Simulated patient
histories for a sample of patients were reviewed to ensure face validity. Results were compared with
those from previous models and the within-trial analysis to ensure external validity. The within-trial
analysis was checked for face validity, and coding was checked for errors by a second health economist.
Overview of systematic literature review
Objectives
A systematic literature review was undertaken in line with current recommendations.90,91 The aim of
this review was to identify evidence to inform inputs and assumptions for the long-term (> 2 years)
economic model of LEAVO. Data requirements for patients with MO secondary to CRVO who were
treated with intravitreal injections of ranibizumab (0.5 mg/0.05 ml), aflibercept (2.0 mg/0.05 ml) and
bevacizumab (1.25 mg/0.05 ml) comprised:
l relative clinical effectiveness and safety (including withdrawals and mortality)
l HRQoL estimates
l resource use and costs related to treatment, clinic visits, staffing and equipment
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l presence of ischaemic CRVO at baseline
l prior treatment for CRVO at baseline
l trial eye OCT CST
l trial eye BCVA
l non-trial eye OCT CST





Eight electronic databases were searched: MEDLINE, MEDLINE In-Process & Other Non-Indexed
Citations, The Cochrane Library, the Health Technology Assessment (HTA) database, NHS Economic
Evaluation Database (NHS EED), EMBASE, Cumulative Index to Nursing and Allied Health Literature
(CINAHL) and Web of Science. Searches were conducted on 28 June 2018, and the databases were
searched from the date of inception to 28 June 2018. Additional searches included checking reference
lists of relevant studies, grey literature searching and contacting authors.
Free-text terms and subject headings relating to the condition and interventions of interest were used
to develop a search strategy (see Appendix 6, Systematic literature review to support the long-term health
economic model). To identify systematic reviews, randomised trials, observational studies and economic
studies (including quality-of-life studies), appropriate search filters were applied in selected databases.
Study selection, data extraction, critical appraisal and synthesis
Study selection was completed using a two-stage process based on prespecified eligibility criteria
(see Appendix 6, Table 35). The titles and abstracts of retrieved records were screened. Potentially
relevant full-text articles were then retrieved for detailed examination. Studies were considered for
inclusion if they reported on patients with MO secondary to CRVO treated with selected anti-VEGFs
[ranibizumab (Lucentis) (0.5 mg/0.05 ml), aflibercept (Eylea) (2.0 mg/0.05 ml) or bevacizumab (Avastin)
(1.25 mg/0.05 ml) as a monotherapy, vs. a control, i.e. another active treatment or sham injection].
Prospective uncontrolled before-and-after studies were also reviewed for inclusion. Studies reporting
the natural history of CRVO were also sought for inclusion.
Data relating to study characteristics, population characteristics, interventions administered and
reported outcomes of interest were extracted into summary tables. After applying the rating of
hierarchies of evidence of data sources for economic models92 in study selection (see Appendix 6,
Table 55), the most appropriate methodological quality checklist endorsed by the Critical Appraisal
Skills Programme (CASP)93 was used for quality assessment of the included studies. The methodological
quality of individual studies was considered in study selection. Study selection, data extraction and
critical appraisal were undertaken by one reviewer and checked by a second reviewer. Disagreements
were resolved by discussion.
Tabular and narrative syntheses were completed because the clinical and methodological heterogeneity
of included studies precluded meta-analysis of available evidence.
Results
A total of 1338 unique records were retrieved through literature searches and supplementary searching.
Of these, three articles24,34,94 provided evidence of limited relevance for informing or validating the
LEAVO economic model (see Appendix 6, Figure 26). A summary of included studies is presented in
Table 20. For a list of excluded studies with reasons, see Appendix 6, Table 56.95
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TABLE 20 Summary of included studies in systematic review









Intervention(s) IVR IVR N/A
Treatment schedule TER Not reported N/A
Study name RETAIN LUMINOUS (NCT01318941) N/A
Study design; setting Non-RCT (open-label extension of CRUISE);
USA
Non-RCT (observational, non-interventional, multicentre, open-label,
single-arm study); 43 countries, 494 centres
Systematic review of
various study types





Mean age (years) 66.9 (SD not reported) 69.7 (SD 12.32) N/A
% female Not reported 41.5% N/A
Duration of CRVO at
baseline (months)
4.6 12.6 (SD 20.2) N/A
BCVA (letters) 50 44.7 (SD 23.88) N/A
SD-OCT (µm), mean (SD) 639 463.5 (212.5)a N/A
% of patients with ischaemic
CRVO
Not reported Not reported N/A
VFQ-25 composite score Not reported 73.0 (SD 20.62) N/A
Previous ocular history Not reported l RVO (16.5%)
l Glaucoma (10.4%)


















































































































































































































































































































































TABLE 20 Summary of included studies in systematic review (continued )
Characteristic Campochiaro et al.34 Novartis94 McIntosh et al.24
Medical history Not reported Cardiovascular risk factor,b 4–61.3% N/A
Outcomes
Primary study outcomes l Mean change in BCVA
l Percentage of patients with resolution
of MO
l Mean change in BCVA
l Mean change in CRT
l Ocular and systemic AEs
l Baseline visual acuity
l Percentage of patients





l Conversion of non-
ischaemic CRVO to
ischaemic CRVO
l Rate of fellow
eye involvement
Secondary outcomes l Percentage of patients gaining or losing
≥ 15 letters from baseline
l Percentage of patients with BCVA of
≥ 20/40
l Percentage of patients with BCVA of
≤ 20/200
l Mean change from baseline in CFT,
measured by the ZEISS Stratus OCT Model
3000 (Insight Eye Equipment, St Louis,
MO, USA)
l Percentage of patients with CFT of
≤ 250 µm at each study visit
l Ocular and systemic AEs
l Change in VFQ-25 scores from baseline
l Number of injections
l Number of visits and re-treatments
l Time interval between injections
l Reasons for re-treatment or treatment termination
Not reported
Quality assessment of included studies
Evidence rating (Coyle and
Lee92)
4c 4;c 2 to 3;d 1e 3d
Methodological quality
(CASP)











































Characteristic Campochiaro et al.34 Novartis94 McIntosh et al.24
Results
Visual acuity
Mean BCVA from baseline Mean follow-up: 51.4 months Month 24 Month 36 Month 48
% of participants with BVCA
of ≥ 20/40
43.8 Not reported Not reported Not reported Not reported
% of participants who
gained ≥ 15 letters
53.1 28.1 Not reported Not reported
MO
Mean retinal thickness Month 48 (CFT) Month 24 (CRT) Month 36 (CRT) Month 48 (CRT)
l All participants: 220.6 (n = 28)
l Participants with resolved MO:
171.3 (n= 13)
l Participants with unresolved MO:
263.4 (n= 15)
l p = 0.01
l TN: 372.9 (n = 32)
l TnN(R):
304.9 (n = 45)
l TnN(other):
321.5 (n = 19)











% of participants with CFT
of ≤ 250 µm
All participants: 43.8% (14/32) Not reported Not reported
Resource use
Mean number of injections per participant (ranibizumab), by time point




Month 36 3.6 l TN: 5.8
l TnN(R): 5.8
l TnN(other): 6.6


















































































































































































































































































































































TABLE 20 Summary of included studies in systematic review (continued )
Characteristic Campochiaro et al.34 Novartis94 McIntosh et al.24
Total number of injections (ranibizumab)















Number of visits Not reported 11.6 visits by month 48
Concomitant treatments Scatter photocoagulation (n = 2) 37.1% (CRVO primary treated eye set) received ocular concomitant
medications and significant non-drug therapies (not specified)
70.8% (CRVO safety set) received concurrent systemic medications











































Characteristic Campochiaro et al.34 Novartis94 McIntosh et al.24
AEs
Ocular events Four severe ocular AEs were reported
(BRVO and CRVO patients)
All ocular AEs: 10.4% (109/1048) Not reported
Ocular SAEs: 0.95% (10/1048)
Ocular severe AEs: 1.05% (11/1050)
Infectious endophthalmitis: not reported
Retinal detachment: not reported
Retinal (pigment epithelium) tear: not reported
Anterior chamber reaction:f not reported
Conjunctival haemorrhage: 0.57% (6/1048)
Vitreous haemorrhage: 0.38% (4/1048)
Cataract: 1.91% (20/1048)
Glaucoma: 0.95% (10/1048)
Ocular hypertension (raised intraocular pressure of > 21 mmHg):
0.57% (6/1048)
Increased intraocular pressure: 0.86% (9/1048)
Visual loss: 0.57% (6/1048)
Retinal ischaemia: 0.19% (2/1048)

















































































































































































































































































































































TABLE 20 Summary of included studies in systematic review (continued )
Characteristic Campochiaro et al.34 Novartis94 McIntosh et al.24
Systemic AEs 13 severe systemic AEs were reported,
including two deaths. Lack of clarity about the
incidence of remaining systemic events in
patients with CRVO
All systemic AEs: 10.69% (112/1048) Not reported
Serious systemic AEs: 6.01% (63/1048)
Severe systemic AEs: 3.82% (40/1048)
Death: 1.53% (16/1048)
Hospitalisation: not reported
Non-ocular haemorrhage (gastrointestinal, pulmonary, other
non-ocular bleeds): not reported
Arterial thromboembolism: not reported
Hypertension: 0.76% (8/1048)
Myocardial infarction: not reported
Cerebrovascular accident (stroke): 0.29% (3/1048)
Transient ischaemic attack: 0.29% (3/1048)
Systemic AEs, possibly related to ranibizumab and/or ocular injection:
0.29% (3/1048)
HRQoL
Change in HRQoL (VFQ-25
composite score) from
baseline
Not reported l Month 24: mean –8.3 (SD 15.47)












































Characteristic Campochiaro et al.34 Novartis94 McIntosh et al.24
Natural history
Baseline visual acuity 50.0 ETDRS letters 44.7 ETDRS letters Initial visual acuity
generally poor < (20/40)
in all patients. Patients
with ischaemic CRVO











Not reported Not reported MO resolution occurs in
approximately 30–31% of
non-ischaemic CRVO
eyes by 15 months post
occlusion
MO resolves in up to
73% of ischaemic CRVO
eyes by 15 months post
occlusion
Development of NV Not reported Not reported 33% of non-ischaemic
CRVO eyes develop NV
by 12–15 months post
occlusion
Up to 20% of ischaemic
CRVO eyes develop NV
by 8 or 9 months post
occlusion
Development of NVG Not reported Not reported NVG develops in 23–60%
of ischaemic CRVO eyes

















































































































































































































































































































































TABLE 20 Summary of included studies in systematic review (continued )
Characteristic Campochiaro et al.34 Novartis94 McIntosh et al.24
Development of VH Not reported Not reported VH develops in 10% of











Fellow eye involvement Not reported Not reported Bilateral RVO is present
in 0.4–43% of CRVO
cases at presentation
Within 3 years, 1.4% of
patients with CRVO
develop a CRVO in the
fellow eye
Within 30 months, 5% of
patients with CRVO
develop a BRVO in the
fellow eye
Within 1 year 5% of
patients with CRVO
develop any RVO in the
fellow eye
BRVO, branch retinal vein occlusion; CFT, central foveal thickness; CRT, central retinal thickness; IVR, intravitreal ranibizumab; N/A, not applicable; NV, neovascularisation;
RETAIN, extended follow-up of patients with macular edema due to bRanch rETinal vein occlusion or centrAl retinal veIn occlusioN previously treated with intravitreal ranibizumab;
TER, treat-and-extend regimen; TN, treatment-naive eyes; TnN(R), treatment non-naive (ranibizumab) eye; TnN(other), treatment non-naive (other ocular treatments) eyes;
VH, vitreous haemorrhage.
a Reported for primary treated eye.
b Includes hypertension (58.7–63.9%), hypercholesterolemia/hyperlipidaemia (23.9–37.0%), diabetes (18.8–24.8%) and obesity (7.6–15.3%).
c Relates to clinical effect sizes and AEs.
d Relates to baseline clinical data.
e Relates to resource use.
f Includes acute intraocular inflammation, uveitis (inflammation of the anterior chamber) and hypopyon.












































None of the studies provided a head-to-head comparison of the clinical effectiveness outcomes of
interest. Two non-randomised studies, the extended follow-up of patients with macular edema due to
bRanch rETinal vein occlusion or centrAl retinal veIn occlusioN previously treated with intravitreal
ranibizumab (RETAIN) study (n = 32 participants)34 and the LUMINOUS study (n = 1048 participants),94
provided long-term clinical effectiveness data for ranibizumab only. Participants in the RETAIN study
had previously completed two pivotal multicentre US-based Phase III RCTs [CRUISE, for patients with
CRVO, and RanibizumaB for the treatment of macular edema following bRAnch Retinal Vein Occlusion
(BRAVO), for patients with BRVO]9,33,96 and a subsequent follow-up trial.38 The mean follow-up period
of the RETAIN study was 49.7 months (with a maximum follow-up of 60 months).34 The LUMINOUS
study was a 5-year international multicentre post-authorisation study (n = 43 countries, 494 centres)
that evaluated the long-term effectiveness and safety of ranibizumab for all its indications in the
real-world setting. Participants with CRVO made up 3.5% (n = 1048) of the entire study population
of LUMINOUS (n = 30,153 patients). Evidence relating to the natural history for CRVO was obtained
from a systematic review (n = 31 studies, 3271 eyes).24
Summary of findings
No clinical effectiveness evidence was identified relating to the long-term (i.e. > 2 years’ follow-up)
head-to-head comparison of intravitreal injections of ranibizumab (0.5 mg/0.05 ml), aflibercept (2.0 mg/
0.05 ml) and bevacizumab (1.25 mg/0.05 ml) in patients with MO secondary to CRVO. There was
extensive variation in the reporting and assessment of outcomes of interest.
Long-term visual outcomes were influenced by treatment schedules, CRVO subtype and MO
resolution.34,94 Monthly injections with ranibizumab provided an initial improvement in BCVA and MO
resolution. However, this effect was reduced when treatment schedules were on an ‘as-needed’ basis
or when follow-up intervals were less frequent.34 Improved long-term outcomes were observed in
patients with early MO resolution [resolved MO vs. unresolved MO at year 4: mean BCVA 73.2
ETDRS letters (20/32) vs. 56.1 ETDRS letters (20/80); mean central foveal thickness (CFT), 171.30 µm
vs. 263.40 µm, respectively].34 Less than 5% (30/1048) of patients provided relevant data for visual
acuity outcomes beyond 2 years of follow-up in the LUMINOUS study. Therefore, the observed general
trends in improved vision (gain of 10 or 15 letters in visual acuity, n = 2–8 patients; gain of > 10 letters
or a final BCVA of ≥ 73 letters, n = 1 patient, at 48 months) and MO resolution [mean change from
baseline –257.1 µm (SD 179.91 µm), n = 7 patients, at 36 months] need to be interpreted with
caution.34 No data were available for mean change from baseline visual acuity according to ETDRS
letter categories (LUMINOUS) beyond month 24 for the entire population with CRVO.
Evidence relating to the risk of systemic and ocular AEs following long-term ranibizumab use was
mixed because of inadequate sample sizes and inconsistent definitions and reporting. The review also
found that most patients with CRVO present with MO.24 Of the 32 patients enrolled in the RETAIN
study, 14 experienced MO resolution (43.8%).34 A statistically significant difference in change in CFT
was noted between patients with resolved MO and those with unresolved MO (263.4 µm vs. 220.6 µm;
p = 0.01). The authors reported that ‘more than half still required an average of 6 injections during
year 4 to control oedema, and only 25% of those patients had BCVA of 20/40 or better’.34
The mean number of injections of 0.5 mg of ranibizumab administered in RETAIN was 19.2 over
54 months of follow-up (n = 28 patients).34 The mean number of injections per patient administered
in years 2, 3 and 4 of the study was 4.5, 3.6 and 3.3, respectively. By contrast, the mean number of
injections per patient was 5.9 in LUMINOUS, by month 48.94 A total of 6224 ranibizumab injections
were received by patients with CRVO.94 Although the majority of patients received treatment in only
one eye, an estimated 3% were treated in both eyes.94 Differences in prior intravitreal treatment status
did not influence the number of injections received between subgroups.
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Available evidence suggests that, after 3 years of treatment, patients receiving ranibizumab tend to
experience improved quality of life [VFQ-25 composite score change from baseline of 3.6 (SD 10.70)].
The LUMINOUS study94 reflected real-world management to a greater degree than the RETAIN
study.34 This could explain the higher rate of withdrawals observed. For detailed results of the
systematic review, see Appendix 6, Tables 36–54 and Figure 27.
Conclusion
Overall, there was limited evidence to adequately compare the long-term clinical effectiveness and
cost-effectiveness of anti-VEGFs used in the management of MO secondary to CRVO. Comparative
long-term studies of available vascular therapies for patients with MO secondary to CVRO are needed
to inform treatment choices. For a detailed report of this systematic review, see Appendix 6, Systematic
literature review to support the long-term health economic model.
Methods: model-based analysis
Model design
A discrete event simulation is used for the health economic model. Discrete event simulations are
structured around a set of mutually exclusive events and model the pathway of individual patients
through those events according to the time at which each event happens. Each individual patient has
specific characteristics that may influence which events happen and when. A patient’s history through
the model is recorded and can influence if and when future events happen. Events can occur at any
time. Discrete event simulations are so named because they model a discrete sequence of events,
but they operate in continuous time (rather than in discrete time intervals).
A discrete event simulation model has five key advantages in this application:
1. Health states are not required – each individual patient’s visual acuity can be tracked over time on a
continuous scale.
2. The trial eye and non-trial eye can be modelled separately using data on the change in visual acuity
over time.
3. Each patient’s history (previous visits and visual acuity) can be tracked, so the treatment
continuation rule (see Chapter 2, Treatment schedule) from LEAVO can be used.
4. The follow-up visit times can be modelled by fixing the time to milestone visits and using the
treatment continuation rule from LEAVO to determine other visit times.
5. Individual patients can have different baseline characteristics, to incorporate heterogeneity.
The model diagram is shown in Figure 15. The model was built and all analyses were run in Simul8
Professional Edition (SIMUL8 Corporation, Boston, MA, USA). Once a patient is simulated and has
baseline characteristics and an intervention assigned, their times to events are set; these times may
be fixed or sampled from a distribution. For times to each event, see Model inputs. The event with the
shortest time is the next event that the patient experiences, at which point their characteristics, QALYs
and costs are updated. The patient then waits until the next event. The model ends when either the
patient has died or the model time horizon is reached. The process is repeated for a large number of
patients, and the total costs and QALYs are calculated. The same patients are then simulated through
the model again, but with a different intervention. The total costs and QALYs are compared for each
intervention to calculate cost-effectiveness results.
At each model event, costs, utilities, total costs and QALYs are updated. Each model event (i.e. visit to
ophthalmologist, ocular AE, withdrawal, new-onset MO in the non-trial eye, annual change in visual
acuity, death, model end) is explained in more detail in the following subsections.
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When a modelled patient visits the ophthalmologist, their visual acuity (measured using BCVA letter
score) and CST are updated in both eyes, and decision rules are used to determine whether or not the
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FIGURE 15 Health economic model structure. Reproduced with permission from Pennington et al.95 This article is
licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other
third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a
credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is
not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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Within the 100-week trial period, the model uses the same treatment continuation rules as specified in
the LEAVO protocol:88
l All patients (except those who have withdrawn) attend visits and have a mandated injection at
baseline and at 4, 8 and 12 weeks.
l All patients attend visits at weeks 16 and 20, but have an anti-VEGF injection only if their BCVA is
> 83 letters and they meet one of the following the re-treatment criteria:
¢ decrease in visual acuity of ≥ 6 letters between the previous and the current visit, attributed to
an increase in OCT CST
¢ increase in visual acuity of ≥ 6 letters between the previous and the current visit
¢ an OCT CST of > 320 µm
¢ an OCT CST increase of > 50 µm from the lowest previous visit.
l From weeks 24 to 96, the same re-treatment criteria as at weeks 16–20 are applied. If the patient
does not meet the re-treatment criteria and was not treated at either of the two previous visits,
the time to their next visit is increased from 4 weeks to 8 weeks.
Beyond the trial period, the treatment continuation rules are informed by advice from five clinicians
involved in LEAVO (PH, SS, AL, YY and Michael Williams) and by guidance from the Royal College of
Ophthalmologists.8 The following rules are applied:
l If the patient has not had an injection since year 1, they do not receive an injection and do not visit
the ophthalmologist again.
l Within the first 5 years, the same re-treatment criteria as used in LEAVO are applied to determine
whether or not a patient has an injection, but the time to the next visit is increased to 12 weeks.
If the patient does not meet the re-treatment criteria and was not treated at either of the two
previous visits, they do not receive an injection and do not visit the ophthalmologist again.
l After 5 years, patients no longer receive injections. They have three further follow-up visits with the
ophthalmologist, 12 weeks apart.
For patients who will not visit the ophthalmologist again, the time to visit is set to infinity, and the time
to annual change in BCVA score is set at 1 year.
Ocular adverse event
Patients who have an ocular AE are assumed to incur a cost for treating the AE, and remain on treatment.
As patients may have more than one AE, the time to AE is resampled from the same distribution.
Withdrawal
Patients who withdraw are assumed to immediately discontinue their assigned intervention and
receive no treatment. They no longer visit their ophthalmologist to be assessed for or to receive
treatment. As patients cannot withdraw more than once, the time to withdrawal is set at infinity.
New-onset macular oedema in the non-trial eye
Patients may develop MO in the non-trial eye. When this occurs, to reflect the associated change in
visual acuity and CST associated with MO, the patient is assigned a new BCVA and CST measurement
for the non-trial eye. This is sampled from the baseline characteristics of the trial eye for patients of
the same sex and similar age.
Patients who develop MO in the non-trial eye are assumed to receive the same intervention in their
non-trial eye as was assigned to their trial eye. Patients who are still on their assigned treatment
(and who have not discontinued because of treatment continuation rules or withdrawal) will receive
treatment in both eyes, whereas patients who have discontinued or withdrawn from treatment in their
trial eye will receive treatment in the non-trial eye only. If a patient is still receiving treatment in their
trial eye, their initial visit for the non-trial eye will occur at the same time as the next visit for the trial eye.
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After this point, the same treatment continuation rule is applied to each eye to determine when the
next visit for each eye occurs. If a patient is not still receiving treatment in their trial eye, the patient
immediately has a visit for the non-trial eye and follows treatment continuation rules for that eye only.
As patients cannot redevelop MO in the non-trial eye, the time to new-onset MO is then set at infinity.
Annual change in visual acuity
Visual acuity is used to predict utility and resource use.While patients are still visiting the ophthalmologist,
their visual acuity is updated at each visit. Once the patient no longer receives injections or no longer has
follow-up visits, their visual acuity is tracked using an annual change event. After each annual change, the
time to the next annual change is set at 1 year.
Death
When a modelled patient dies, they move immediately to the model end event.
Model end
Once a modelled patient reaches the model end, their costs and QALYs are reported.
Model inputs
Baseline characteristics
The model uses the baseline characteristics of LEAVO participants to preserve the relationship
between characteristics. Each modelled patient has the baseline age, sex, trial and non-trial eye BCVA
and CST of one of 452 LEAVO participants for whom all of these variables were available at baseline.
This approach is consistent with other simulation models in ophthalmology.97
Central subfield thickness and visual acuity
The re-treatment algorithm assesses both OCT CST and BCVA, so both must be modelled for treated
eyes. BCVA in both eyes is important for predicting HRQoL, so BCVA is modelled for both eyes.
Treated eyes
Growth models (longitudinal analyses to estimate growth trajectories over a period of time) are fitted
to CST and BCVA from the LEAVO data. In these models, CST (or BCVA) at weeks 12, 24, 52, 76 and
100 are estimated as a function of time, baseline CST (or BCVA), age at baseline, intervention, number
of injections and time since last injection. Sex is found not be a significant predictor of CST or BCVA,
so it is excluded. Intervention is not a significant predictor of CST or BCVA, but it is included to reflect
numerical differences between the interventions.
The equation for yit, the BCVA score for patient i at time t, is as follows:
yit = η1i + η2i × t + γ1t × number of injections + γ2t × days since injection + εit , (1)
where






+ α3 × tn2 + α4 × tn3 + ξ1i (2)
and






+ β3 × tn2 + β4 × tn3 + ξ
2
i , (3)
where tn2 = 1 for aflibercept and 0 otherwise, and tn3 = 1 for bevacizumab and 0 otherwise, and ξ is
an error term.
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(The equation for CST follows the same structure, but uses CST at baseline/100 instead of BCVA at
baseline/10.)
Whereas η, α and β (age at baseline, CST or BCVA at baseline and intervention) are time-invariant
covariates, γ1 and γ2 (number of injections and time since last injection) are time-variant covariates,
with values available at 12, 24, 52 and 76 weeks only. To estimate CST and BCVA in the economic
model, these covariates are used at the week 12, 24, 52, 76 and 100 visits. For other visits, the
following approaches are used:
l Weeks 4 and 8 – CST and BCVA are calculated at week 12, and linear interpolation is used to
estimate CST and BCVA at the week 4 and week 8 visits.
l Visits from week 16 to week 100, excluding weeks 24 and 52 – CST and BCVA are calculated for
the closest milestone visits before and after the non-milestone visits, and interpolation is used to
estimate BCVA at the non-milestone visits.
l Visits beyond week 76 – the time-varying covariates appear similar towards the end of LEAVO,
and so models that restricted these covariates to be the same at weeks 76 and 100 were compared
with unrestricted models. Log-likelihood tests indicated that the null hypothesis that the restricted
models were true should not be rejected. The restricted models suggest that the effect of the
number of injections and time since last injection flatten towards the end of LEAVO and can,
therefore, be used to extrapolate beyond 100 weeks.
Untreated eyes
Untreated eyes are considered to be eyes that never received treatment or eyes whose treatment has
ended or been withdrawn. The same assumption is used for treated eyes whose most recent injection
was at least 1 year ago.
Central subfield thickness is not modelled for the non-trial eye unless the patient develops MO in the
non-trial eye, in which case CST and BCVA for the non-trial eye are modelled using the same approach
as for the trial eye.
Best corrected visual acuity is modelled for untreated eyes using natural history data. The Beaver
Dam Eye Study98 was a large population-based study that recorded BCVA in patients over 5 years.
This study98 reported the letters gained or lost in the left and right eyes for people aged < 55, 55–64,
65–74 and ≥ 75 years, and has been used in previous CRVO economic models.51 Combining the right
and left eye data, the annual average decrease in BCVA is –0.02 letters [standard error (SE) 0.04
letters] for those aged 55–64 years, 0.26 letters (SE 0.04 letters) for those aged 65–74 years and
0.76 letters (SE 0.06 letters) for those aged ≥ 75 years. There is no change for people aged < 55 years.
These data appear consistent with a study of the natural history in CRVO,99 which reports that
increasing age was positively associated with visual acuity deterioration, and over 2–5 years in
eyes with non-ischaemic CRVO MO, 14% improved, 47% stayed the same and 39% worsened.
Ocular adverse events
The model considers the same ocular AEs as reported in the safety analysis in LEAVO: infectious
endophthalmitis, traumatic cataract, retinal tear, retinal detachment, conversion to ischaemic CRVO,
anterior segment neovascularisation, retinal neovascularisation, and vitreous haemorrhage and
intraocular pressure elevation. As relatively few patients experienced these AEs in LEAVO (e.g. only
one patient had infectious endophthalmitis), modelling the time to specific events would be highly
uncertain and, in some cases, impossible. Therefore, the model considers the time to any ocular AE,
using the data for all ocular AEs (and applying a cost per average AE; see Adverse event costs). When
the date of the AE was missing, multiple imputation was used to impute the date based on the trial
arm and whether or not an AE occurred.
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Survival analysis was used to fit parametric models to extrapolate time to event beyond the trial
period. The log-rank test found no statistically significant difference between the time to first AE and
time to subsequent AEs (p = 0.128), and the number of subsequent AEs was small, so the time to first
AE is used as the time to first or subsequent AEs in the model.
Although the time to AE is not statistically significantly different between the interventions (p = 0.683),
they are modelled separately to reflect numerical differences in the deterministic analysis. The probabilistic
analysis considers the uncertainty around point estimates, reflecting that the interventions are not
significantly different. According to the Akaike information criterion (AIC) and Bayesian information
criterion (BIC), the Weibull was the best-fitting parametric model. As no data are available on the ocular
AE rates for any of the three interventions beyond the trial period (see Overview of systematic literature
review), external validation is not possible. The Weibull is therefore used to model the time to AEs. All
three interventions have the same shape parameter of 0.745, demonstrating that the probability of having
an ocular AE decreases over time.
Withdrawal
Survival analysis was used to fit parametric models to extrapolate time to withdrawal beyond the
trial period. The three interventions are modelled separately to reflect numerical differences, despite
non-statistically significant differences in the data (p = 0.572). The AIC and BIC are similar between
parametric models, and no external validation was possible because of a lack of data. The Weibull
distribution is used to model time to withdrawal event, with shape parameter of 1.385, demonstrating
that the probability of withdrawing increases over time.
New-onset macular oedema
Eight of 463 patients in LEAVO either had new-onset MO recorded as an AE or received an anti-VEGF
injection in the non-trial eye. This is a small number of observations to fit parametric models to using
survival analysis; instead, it is assumed that the occurrence of new-onset MO follows an exponential
distribution. The rate of new-onset MO is calculated as 0.009 per year.100
Mortality
As only 13 LEAVO participants died, the data are not sufficiently mature to be analysed and included in
the model. Instead, the model applies an age- and sex-standardised mortality ratio to the probability of
death101 for the general UK population102 in order to represent the increased mortality associated with
CRVO.
Number of simulated patients
A drawback of individual-level simulation approach is introducing first-order uncertainty (also known as
stochastic uncertainty), whereby the mean cost and benefit outcomes may vary between different model
runs even if the same input parameters for a given individual (patient) are used.103 To reduce this type
of uncertainty, 7000 patients are simulated for each model run. This ensured that a sufficient number
of combinations of different patient characteristics are achieved, and that first-order uncertainty
is accounted for by allowing a uniform coverage of a random number seed. Appendix 6, Figure 28,
shows that total costs and QALYs are stable when ≥ 7000 patients are sampled.
Health-related quality of life
The model considers patients’ BCVA over their lifetimes. To include patients’ utilities over time, the
model predicts utility from BCVA and other demographic variables. This prediction is termed a ‘mapping’
or ‘crosswalk’ and may be used in economic evaluation to convert clinical measures to health utilities
when either utility data are not directly available or there is a need to relate clinical outcomes to health
utilities in the long term. Developing a mapping requires a data set that contains both the clinical
measure and the utility measure. LEAVO provided this data set for BCVA and three measures of utility.
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Health-related quality-of-life measures




As specified in the health economic analysis plan and the trial protocol, the VFQ-25 was chosen as the
primary measure, with the EQ-5D and EQ-5D-V used in secondary analyses.9,12 The EQ-5D has been
shown to perform poorly in eye disorders, including AMD.107 Although the VFQ-25 may not meet the
NICE reference case,84 non-EQ-5D utility values have been used in economic evaluations in many
cases, including eye conditions.108
Each HRQoL questionnaire was collected at the six milestone visits of LEAVO: baseline and weeks 12, 24,
52, 76 and 100. Utility scores from the VFQ-25 were calculated using the Visual Function Questionnaire-
Utility Index (VFQ-UI) for each patient.109 This tariff uses six items (questions 6, 11, 14, 18, 20 and 25),
representing six of the VFQ-25 subscales.110 Using the crosswalk, the EQ-5D health states were converted
to the three-level scale, as this is preferred by NICE.111,112 Utility scores for the EQ-5D-V were calculated
by first taking the EuroQol-5 Dimensions, three-level version (EQ-5D-3L), score and then subtracting the
EQ-5D-V score as a utility decrement applied to the individual patient-level data.106
Mapping from best corrected visual acuity to utility
Data from all milestone visits were combined to maximise the number of observations using a
complete-case analysis. At each observation, variables were generated for the visual acuity in the
better-seeing eye (BSE) and the worse-seeing eye (WSE), according to whether BCVA was greater in
the trial eye or the non-trial eye.
Standard statistical models are often a poor fit to the distribution of utility data113 (particularly EQ-5D
data), so adjusted limited dependent variable mixture models (ALDVMMs) are used. Mixture models
can be used to represent latent classes (discrete variables that are inferred rather than directly
observed) within an overall population, or to provide a very flexible semiparametric framework for
modelling distributions with unusual shapes. Limited dependent variables are those whose range of
possible values are restricted. ALDVMMs, therefore, represent a flexible framework for developing
models to reflect the distribution of utility data.
The ALDVMMs were estimated with one to four components (classes).114 Models were fitted for the
three utility measures. The independent variables used to predict utility in the components were age,
sex, BSE BCVA and WSE BCVA. The interaction between the BSE and the WSE was considered as a
variable, but its inclusion worsened model fit; therefore, it was excluded from the model specification.
BSE BCVA and WSE BCVA are used to determine the probability of a patient belonging to the
different components. Intervention is not included as an independent variable, as its impact on
utility is expected to be through changing BCVA and not through a treatment-specific effect.
To determine the number of components that should be used for each utility measure, model fit was
compared using the mean error, mean absolute error (MAE), root-mean-square error (RMSE), AIC, BIC
and visual inspection. In each utility measure, the mean error, MAE and RMSE were generally similar for
models with two, three and four components for which component membership was predicted by the
BCVA score of the BSE and the WSE. The AIC and BIC, which penalise models with more parameters to
reduce overfitting, indicated that the best-fitting model for VFQ-UI has three components, whereas the
best-fitting models for the EQ-5D and the EQ-5D-V have two components. Appendix 3, Table 34, shows
the model parameters.
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The utility in each component is calculated as follows:
1. A temporary variable u is calculated by multiplying the within-component coefficients by the
individual patient’s characteristics (as per a regression equation).










4. Parameter c is calculated as –
c = φ(a)− φ(b). (6)
5. Parameter d is calculated as –
d =Φ(a)−Φ(b). (7)
6. If parameter c is between –0.00000001 and 0.00000001 parameters, c is set to 0 and d is set to 1.














+ (ul ×Φ(b)), (8)
where uu is the highest feasible utility next to 1, l is the lowest feasible utility, σ is the variance of
the component, φ is the probability density function for the normal distribution with mean 0 (SD 1),
and Φ is the cumulative distribution function for the normal distribution with mean 0 (SD 1).
The probability of belonging to each component is calculated by the exponentiation of the product of
the between-components by an individual patient’s characteristics. For the last component, this will
equal 1. The probabilities are then normalised by dividing by the sum of all probabilities.
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FIGURE 16 The VFQ-UI mapping comparison of observed and predicted scores: (a) VFQ-UI score vs. BSE BCVA score;
(b) VFQ-UI score vs.WSE BCVA score; (c) VFQ-UI score vs. BSE ETDRS score; and (d) VFQ-UI score vs. WSE ETDRS score.
(continued )
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FIGURE 16 The VFQ-UI mapping comparison of observed and predicted scores: (a) VFQ-UI score vs. BSE BCVA score;
(b) VFQ-UI score vs. WSE BCVA score; (c) VFQ-UI score vs. BSE ETDRS score; and (d) VFQ-UI score vs.WSE ETDRS score.
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The expected utility within each component is multiplied by the probability of belonging to each
component. The sum of these gives a patient’s utility. The relationship between visual acuity and
utility for the BSE and the WSE is provided in Figure 16. A Microsoft Excel® (Microsoft Corporation,
Redmond, WA, USA) tool that calculates a patient’s utility score (VFQ-UI, EQ-5D, EQ-5D-V) based on
our mappings is provided.115
Resource use and costs
Costs were calculated using Great British pounds for 2017/18; when costs were not available for this
year, they were inflated using the Hospital and Community Health Service (HCHS) index.116
Intervention costs
The list price is £551.00 for the ranibizumab injection and £816.00 for the aflibercept injection.117
These prices are used in the base-case analysis. A discount is applied to these costs in scenario analyses
to explore the impact of confidential Patient Access Schemes (PASs). The list price of bevacizumab
is £243.00; however, this is the cost of a large infusion vial of the drug.117 As discussed in Chapter 2,
Intervention: bevacizumab (1.25 mg/0.05 ml), during LEAVO, the injections of bevacizumab were separated
from the larger bottle into pre-filled syringes by the Liverpool and Broadgreen Pharmacy Aseptic Unit.88
This compounding of the drug was deemed to be legal in a judicial review in 2018, which cited the price
per injection as £28.55 It is assumed that this price includes any costs associated with compounding the
drug, such as staff time and storage costs. This price is used in the base-case analysis. Patients incur an
injection cost for each eye that is treated.
Visit costs
When a simulated patient visits the ophthalmologist to be assessed against re-treatment criteria, and
possibly treated with an anti-VEGF injection, costs are incurred for the visit itself, the OCT examination
(if performed) and the drug cost of the injection.
The cost of the initial visit is £140.04: a first multiprofessional consultant-led outpatient ophthalmology
visit. Subsequent visits cost £105.19: a follow-up multiprofessional consultant-led outpatient
ophthalmology visit.118 Patients who are receiving treatment in both eyes incur 1.5 times the visit costs,
representing clinician advice that approximately half of all patients would have both eyes treated in a
single visit, and the other half would require two separate visits.
The cost of the OCT examination is £108.21: a minor vitreous retinal outpatient ophthalmology
procedure.118 This is incurred for each eye for which re-treatment criteria are assessed.
Disease management costs
A bespoke resource use questionnaire was developed to capture resource use relating to a participant’s
eye condition during the 100-week trial. Participants were asked to complete the questionnaire at
baseline and at weeks 12, 24, 52, 76 and 100. Although resource use questionnaires can be vulnerable
to recall bias, the questionnaire captured 9 of the 10 questions recommended as core items in
standardised resource measures,119 collecting information relating to hospital admissions, health-care
contacts and continuous care and support of patients.
The model includes resource use for the following:
l visits to the eye consultant, general practitioner (GP), general practice nurse, accident and
emergency (A&E), eye A&E and optometrist
l low-vision appointments
l telephone calls to the eye hospital helpline, ophthalmologist and GP.
Resource use data were analysed from the resource use questionnaire in LEAVO, with completed
measures combined for all patients across the trial period to maximise the number of observations.
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Resources with < 10 observations were excluded. Participants who developed new-onset MO or who
had an AE were excluded from the analysis to prevent double-counting of the resource use associated
with these events.
Ordinary least squares regression was performed to estimate the relationship between WSE BCVA
and resource use per 3-month period (a higher BCVA score predicted less resource use). When WSE
BCVA was not a statistically significant predictor of resource use, the model used the mean resource
use for all patients.
The resource use questionnaire asked patients to indicate the number of events, such as the number of
visits to eye casualty, number of telephone calls with health-care professionals or number of hours of
care received, over the previous 3 or 6 months. However, the duration of each visit was not recorded;
therefore, average estimates were used based on the NHS Reference Costs 2017/18118 or the Unit Costs
of Health and Social Care 2018,116 when relevant.
When a patient reported a hospital admission, if an associated procedure was named as the reason for
the admission, average resource costs associated with the procedure were used based on the NHS
reference costs. The number of bed-days reported by a participant was then used to adjust the cost
by adding or subtracting the difference between the number of bed-days reported by the participant
and the number expected for the procedure, multiplied by the cost of an excess bed-day. If the same
concomitant procedure was also reported for this participant, costs were only counted once using the
information provided by the participant relating to length of stay. If no reason was recorded for the
admission, then the cost of a non-elective excess bed-day was used.118
The costs and parameters for the resource use regressions are shown in Appendix 3, Table 34.
Adverse event costs
As the model considers any ocular AE, modelled patients who experience ocular AEs incur the average
cost for an ocular AE, based on the proportion of participants in LEAVO experiencing each ocular AE.
This is calculated by multiplying the number of each type of ocular AE by the cost for treating that
ocular AE, and dividing the total by the number of participants in LEAVO who experienced ocular
AEs. The cost per ocular AE is the same for the three interventions at £317.96. Costs for each ocular
AE are from NHS Reference Costs 2017/18118 or the British National Formulary,117 and are shown in
Appendix 3, Table 34.
Blindness costs
Modelled patients may become blind when the BCVA score of both eyes is at ≤ 35 letters, consistent
with the definition of severely sight-impaired from the Royal National Institute of Blind People120 and
previous models in MO.51,112 Blindness was tracked at visit and annual BCVA change, both of which are
events at which BCVA scores can change. BCVA scores can fluctuate throughout a patient’s lifetime,
meaning that a patient can experience more than one blindness episode in their life.
Two sets of costs associated with blindness are defined from literature: one-off costs and recurrent
costs.112,121 When a patient becomes blind for the first time, one-off costs associated with blindness are
incurred, including blind registration, low-vision aids and low-vision rehabilitation. As long as a patient
remains blind, they incur recurrent costs, including community care, residential care, treatment for
depression and hip replacement.
The costs of blindness registration, daily community care and weekly residential care are £60.50,
£27.64 and £115.40, respectively.116 Low-vision rehabilitation and hip replacement unit costs are
estimated at £153 and £4170, respectively.118 The costs of low-vision aids and the annual costs of
depression are estimated from Meads and Hyde122 and TA460,123 respectively, both of which are
inflated to 2018 values using the HCHS indices.116
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The proportion of blind patients receiving each service is taken from Colquitt et al.121
The costs and proportion of patients incurring these costs are shown in Appendix 3, Table 34.
Addressing uncertainty
The base-case analysis uses the VFQ-UI, and scenario analyses consider the EQ-5D and EQ-5D-V.
Scenario analyses consider shorter time horizons and a cost of £243 for bevacizumab.
Patient Access Schemes are in place for ranibizumab and aflibercept, offering a discount on the list
price.13,51 However, the level of discount is confidential and so is unknown. Therefore, we consider
threshold analyses to determine the level of discount that would be needed to change the decision
about the most cost-effective intervention.
Results are presented for the base-case, EQ-5D, EQ-5D-V and 100-week scenarios using probabilistic
sensitivity analysis to incorporate parameter uncertainty. Whereas deterministic analysis (see Appendix 6,
Model-based analysis results: additional data) uses point estimate (mean) inputs, probabilistic sensitivity
analysis simultaneously samples all uncertain inputs from their associated distributions. Microsoft Excel
was used to sample uncertain parameters from their distributions and to maintain relationships between
related parameters. Mean total costs and QALYs are calculated for the modelled patient cohort for each
simulation. 95% CIs around the mean and total costs and QALYs are presented using the SE to reflect
the uncertainty around the mean. The mean of the mean total costs and QALYs for each intervention are
calculated from all of the simulations and used to calculate mean probabilistic ICERs. The uncertainty
around the mean probabilistic ICER is calculated using the incremental net monetary benefit (INMB)
approach to avoid the mathematical limitations of interpreting uncertainty around a ratio.124
Running probabilistic sensitivity analysis on a discrete event simulation model is computationally expensive,
but it is vital that a sufficient number of simulations are performed so that the model results converge. The
number of simulations required for the results to converge can be calculated by comparing the upper and
lower bounds of the INMB with zero for a defined cost-per-QALY threshold.124 Using the tutorial provided
by Hatswell et al.124 and a threshold of £30,000 per QALY, very few probabilistic simulations are required for
the analyses. This is because the ICERs are so far away from the threshold of £30,000 per QALY that there
is very little uncertainty associated with the decision about which intervention is most cost-effective (the
INMB CIs exclude zero). Probabilistic sensitivity analysis is presented using 500 simulations for all scenarios.
This is sufficient to ensure that the INMBs have converged for each comparison of two interventions.
Methods: within-trial analysis
Method of economic evaluation
The methods for the within-trial analysis were prespecified in a health economic analysis plan prior to
database lock.89 The primary outcome of the within-trial health economic analysis was to establish the
short-term cost-effectiveness of:
l aflibercept compared with ranibizumab
l bevacizumab compared with ranibizumab
l aflibercept compared with bevacizumab.
A fully incremental analysis (ranking the alternative treatment options by total costs and ruling out
dominated and extendedly dominated options from the comparison) was also performed. The economic
analysis used individual patient-level data collected as part of LEAVO. The total costs and QALYs over
the 100-week follow-up period of the trial were used to calculate the incremental cost per QALY gained.
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An ITT population was used, including all of the participants randomised to each treatment group.
Analyses were conducted using Stata® version 15 (StataCorp LP, College Station, TX, USA) and
R (The R Foundation for Statistical Computing, Vienna, Austria).
Health-related quality of life
The individual patient-level QALYs were calculated from the utility scores for each HRQoL
questionnaire at baseline and at subsequent follow-up time points using linear interpolation.
Resource use
The costing approach included identification of resource use, measurement and valuation.125 The
resource use associated with delivery of the intervention, hospital admissions, health-care contacts,
continuous care and support and concomitant medications and procedures, and the costs associated
with blindness, were measured.
Identification of resource use
The within-trial analysis included costs related to a participant’s eye condition as collected using the
resource use questionnaire (see Disease management costs); the delivery of the intervention; and
concomitant medications.
Information relating to concomitant medications was collected by health-care professionals.
Resource use relating to the delivery of the intervention was captured at each visit, and included
drug costs, outpatient appointment costs and the costs of any tests commonly conducted at
these appointments.
Ocular AEs were captured using the resource use questionnaire and from data relating to concomitant
procedures and medications. To capture the relevant costs associated with blindness, the costs of blind
registration and low-vision aids were applied to participants who became partially or severely sighted
during the trial. A participant was deemed to be partially sighted or severely sight-impaired if their
BCVA score was ≤ 58 letters in both eyes.120 These costs were applied once during the course of
the trial, namely at the first time a participant met this criterion, as low-vision aids are thought to
be incurred biannually.50 It is assumed that the same proportion of participants who can register as
severely sighted also register as partially sighted and the same costs are incurred for low-vision aids
to give a conservative estimate of the cost of blindness. This analysis differs from the model-based
analysis to include cost associated with blindness for partially sighted patients.
Measurement of resources
The costs of medications were costed according to standard NHS sources, when available.117
Valuation of resources
Unit costs, summarised in Appendix 6, Table 57, were applied to each resource use event at the
individual patient level to calculate their total cost of resource use over the 100-week trial.
Intervention costs used in the within-trial analysis are similar to those used in the model-based
analysis (see Intervention costs).
Analytical methods
The base-case CUA was based on multiple imputation using chained equations to account for
missing data. The VFQ-UI was used to calculate QALYs. The ICER was estimated comparing
bevacizumab and aflibercept with ranibizumab, and aflibercept with bevacizumab. If applicable,
the ICER was then compared with the NICE cost-effectiveness threshold range of £20,000–30,000
per QALY gained.
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Missing data
Missing data can give misleading estimates in a within-trial cost-effectiveness analysis. A complete-case
analysis uses only patients with no missing data on the key cost and benefit outcomes. This is undesirable
because it reduces the sample size and affects the power of the study.126 The following assumptions
were made:
l When a patient died, their utility scores at all subsequent milestone visits were set at zero. Their
costs at the next milestone visit were then assumed to be half the costs recorded at the previous
visit, unless their next visit was at 52 weeks, in which case the costs were assumed to be the same
as the week 24 costs.
l When a participant withdrew from the trial, if a withdrawal appointment was carried out, cost and
utility data were assigned to the nearest milestone visit and all subsequent costs were set at zero
and utilities were recorded as missing.
Once the assumptions had been applied to the data, patterns of missing data were assessed using the
following descriptive analyses:
l proportion of missing data by treatment arm, at each follow-up period, to assess whether or not
missing data differed by arm
l missing data patterns to determine whether or not data were missing for all items or individual
items of utility scores and resource use items over the trial follow-up.
The multiple imputation chained equation method with predictive mean matching was used to impute
missing values of costs, QALYs and baseline covariates. The year 1 QALY imputation model included
the following covariates: age, sex, ethnicity, previous treatment, baseline utility, time since diagnosis,
baseline BCVA in the trial eye and baseline BCVA in the non-trial eye. The year 2 QALY imputation
model also included the imputed year 1 QALY data, as per recommendations by Faria et al.126 The year 1
cost imputation model included the same covariates as the year 1 QALY model, as well as baseline
resource use and site. The year 2 cost imputation model also included the imputed year 1 costs. The
number of imputations was based on the highest percentage of missing data for the variables of
interest (baseline utility, QALYs and total cost). The imputation was performed per randomisation arm
for all imputed variables except baseline covariates for which data were missing, for which imputation
was performed across all observations.
Seemingly unrelated regression
A seemingly unrelated regression (SUR) model was used to estimate the difference in mean total
costs and QALYs between treatment arms, taking into account the correlation between total costs
and QALYs.127 The SUR model estimated the full variance–covariance matrix, which was further used
to address uncertainty.128 The regression equation for total costs included the randomisation arm.
The regression equation for QALY included the randomisation arm and baseline utility in order to
control for imbalances in baseline utility between treatment arms.127,129 The model assumed a normal
distribution for both costs and QALYs.128 Marginal effects in each treatment arm were calculated using
the SUR, without adjusting for baseline utility.
Addressing uncertainty
A parametric approach was used to address the uncertainty around the CUA estimates using the
following key parameters estimated from the SUR output:
l difference in mean QALYs
l SE of mean differential QALYs
l difference in mean total costs
l SE of mean differential total costs
l covariance between total costs and QALYs.
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To illustrate uncertainty, cost-effectiveness confidence ellipses and net monetary benefit (NMB) lines
with CIs were produced for each pairwise comparison of treatments. In addition, a cost-effectiveness
acceptability curve (CEAC) was constructed, illustrating the probability that each treatment was the
most cost-effective compared with all alternative treatments at a range of threshold values that varied
from £0 to £400,000. To calculate the probability that a treatment was the most cost-effective option,
costs and QALYs for each treatment were sampled using a bivariate normal distribution.
Scenario analyses were calculated using SUR output as in the base-case analyses. The scenario analyses
were as follows:
1. QALYs estimated using the EQ-5D, using imputed data
2. QALYs estimated using the EQ-5D-V, using imputed data
3. drug price discounts – the CUA carried out using imputed data and applying a 30% and 50%
discount to the drug prices of ranibizumab and aflibercept, reflecting possible confidential PASs
offered by pharmaceutical companies to the NHS
4. list price for bevacizumab – the CUA carried out using the list price for bevacizumab taken from the
British National Formulary (£243)
5. complete-case analysis – the CUA carried out using complete-case data from LEAVO only




The results are presented in Table 21. In the base-case analysis, bevacizumab generates the most
QALYs, followed by ranibizumab and aflibercept. Aflibercept generates the highest costs, followed
by ranibizumab and bevacizumab. The CIs for the incremental costs and QALYS do not contain zero,
demonstrating that there is a difference in both costs and effects for the three interventions (however,
for QALYs this is numerically small). Bevacizumab dominates (i.e. it is more effective and less costly
than) both ranibizumab and aflibercept. The 95% CIs for the NMB at £30,000 per QALY do not contain
zero. At a threshold of £20,000–30,000 per QALY, bevacizumab is the most cost-effective intervention
(ranibizumab dominates aflibercept).
The cost-effectiveness scatterplots (Figure 17) display the variation in the incremental costs and QALYs
in the probabilistic samples. These are akin to presenting the SD; although they display the dispersion
of the set of values, they do not present the uncertainty around the mean. The 95% CIs using the
SE present the uncertainty around the mean, and show a difference in incremental QALYs for the
three comparisons.
The CEAC (Figure 18) shows that, at £20,000 and at £30,000 per QALY, bevacizumab has the highest
probability of being cost-effective (99.6% and 98.4%, respectively). Even at a threshold of £100,000
per QALY, bevacizumab has the highest probability of being cost-effective (92.8%). The probabilistic
results demonstrate that bevacizumab is the most cost-effective intervention.
The difference in QALYs is due to the difference in the effectiveness of the three interventions
(see Table 5) and the relationship between visual acuity and utility. The difference in costs is due to the
difference in the cost of the intravitreal anti-VEGF injections (intervention costs), as demonstrated by
the cost breakdown in Table 22. The trial eye CST and visit costs are higher for bevacizumab than for
aflibercept and ranibizumab because patients require more injections of bevacizumab. However, the
drug costs are lower for bevacizumab because the cost of the injection is much lower.
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TABLE 21 Model-based analysis: base-case and scenario analysis results
Analysis
Total (95% CI) Incremental (95% CI)
ICER (£) (95% CI)Costs (£) QALYs Costs (£) QALYs
Base-case analysis
Bevacizumab 18,353 (17,782 to 18,925) 9.678 (9.572 to 9.785)
Ranibizumab 30,226 (29,386 to 31,066) 9.635 (9.512 to 9.757) 11,873 (11,458 to 12,288) –0.044 (–0.074 to –0.013) Dominated (INMB:a –14,316 to –12,067)
Aflibercept 35,026 (33,990 to 36,062) 9.569 (9.429 to 9.710) 16,673 (16,036 to 17,310) –0.109 (–0.161 to –0.057) Dominated (INMB:a –21,864 to –18,040)
Scenario analysis: EQ-5D for utilities
Bevacizumab 18,353 (17,782 to 18,925) 8.782 (8.740 to 8.823)
Ranibizumab 30,226 (29,386 to 31,066) 8.795 (8.754 to 8.836) 11,873 (11,458 to 12,288) 0.013 (0.008 to 0.018) 908,532 (659,881 to 1,476,254)
Aflibercept 35,026 (33,990 to 36,062) 8.832 (8.790 to 8.874) 4800 (4445 to 5154) 0.037 (0.032 to 0.043) 128,513 (110,116 to 152,663)
Scenario analysis: EQ-5D-V for utilities
Bevacizumab 18,353 (17,782 to 18,925) 8.346 (8.282 to 8.410)
Ranibizumab 30,226 (29,386 to 31,066) 8.351 (8.283 to 8.419) 12,791 (12,148 to 13,434) 0.005 (–0.007 to 0.017) 2,491,676 (INMB:a –12,327 to –11,155)
Aflibercept 35,026 (33,990 to 36,062) 8.369 (8.289 to 8.449) 4800 (4445 to 5154) 0.018 (0.000 to 0.035) 268,963 (INMB:a –4930 to –3602)
Scenario analysis: 100-week time horizon
Bevacizumab 6349 (6293 to 6405) 1.641 (1.631 to 1.651)
Ranibizumab 15,254 (14,962 to 15,545) 1.641 (1.631 to 1.651) 8905 (8650 to 9161) 0.000 (0.000 to 0.001) 34,067,841 (217,070 to 10,420,696)
Aflibercept 18,844 (18,438 to 19,249) 1.646 (1.636 to 1.655) 3590 (3400 to 3780) 0.005 (0.004 to 0.005) 793,348 (688,418 to 926,352)
Scenario analysis: bevacizumab list price from the BNF117 (£243)
Bevacizumab 23,530 (22,884 to 24,176) 9.678 (9.572 to 9.785)
Ranibizumab 30,226 (29,386 to 31,066) 9.635 (9.512 to 9.757) 6696 (6400 to 6992) –0.044 (–0.074 to –0.013) Dominated (INMB:a –9084 to –6937)
Aflibercept 35,026 (33,990 to 36,062) 9.569 (9.429 to 9.710) 11,496 (10,961 to 12,030) –0.109 (–0.161 to –0.057) Dominated (INMB:a –16,636 to –12,905)
BNF, British National Formulary.
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FIGURE 17 Model-based analysis: cost-effectiveness scatterplots. (a) Ranibizumab vs. bevacizumab; (b) aflibercept vs.
ranibizumab; and (c) aflibercept vs bevacizumab.
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Scenario analyses
For the results of scenario analysis, see Table 21. In the scenarios using the EQ-5D and EQ-5D-V, the
costs are unchanged from the base case using VFQ-UI, and the total QALYs for the three interventions
are similar. Using the EQ-5D, aflibercept generates the most QALYs, followed by ranibizumab. This is
different from the findings for the VFQ-UI base case because the relationship between visual acuity and
utility differs for the three utility measures. In these scenarios, although ranibizumab and aflibercept
are slightly more effective than bevacizumab, they are not cost-effective because they are much more
expensive. The ICER for ranibizumab versus bevacizumab is £908,532 (95% CI £659,881 to £1,476,254)
and for aflibercept versus ranibizumab is £128,513 (95% CI £110,116 to £152,663). Using the EQ-5D-V,
the results indicate the same trends, but the CI for the incremental effectiveness of ranibizumab
compared with bevacizumab contains zero, indicating that the difference is not statistically significant.
The CI around the INMB is presented for this comparison, as the ICER may contain dominated results
when ranibizumab is less effective than bevacizumab. Aflibercept is more effective than bevacizumab
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FIGURE 18 Model-based analysis: CEAC.
TABLE 22 Model-based analysis: base-case disaggregated costs
Type of cost
Costs (£) (95% CI)
Ranibizumab Aflibercept Bevacizumab
Treatment costs
Trial eye intervention costs 11,785 (11,387 to 12,184) 17,156 (16,582 to 17,730) 634 (614 to 654)
Trial eye CST and visit
costs
5427 (5351 to 5503) 5372 (5299 to 5444) 5622 (5542 to 5701)
Non-trial eye drug costs 771 (750 to 792) 1051 (1021 to 1081) 40 (39 to 41)
Non-trial eye CST and
visit costs
268 (262 to 274) 249 (242 to 255) 276 (270 to 282)
Disease management costs 9588 (9049 to 10,127) 10,058 (9435 to 10,681) 9283 (8807 to 9759)
Ocular AEs costs 1322 (1238 to 1405) 109 (101 to 117) 1392 (1301 to 1483)
Blindness costs 1065 (918 to 1212) 1031 (886 to 1176) 1107 (957 to 1257)
Total costs 30,226 (29,386 to 31,066) 35,026 (33,990 to 36,062) 18,353 (17,782 to 18,925)
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Using a 100-week time horizon, as in LEAVO, bevacizumab is slightly less effective than ranibizumab and
aflibercept, but the ICERs for ranibizumab versus bevacizumab and for aflibercept versus bevacizumab are
£34,067,841 and £2,610,554 per QALY, respectively (see Appendix 6, Table 62). However, in this analysis,
the 95% CIs for the incremental QALYs for ranibizumab versus bevacizumab contain zero, demonstrating
that ranibizumab is not statistically significantly better. Bevacizumab remains the most cost-effective
intervention in this scenario.
In the scenario using the list price of £243 per vial of bevacizumab, the costs for ranibizumab and
aflibercept and the QALYS for the three interventions are unchanged from the base-case analysis, but the
cost of bevacizumab has increased (see Appendix 6, Table 63). However, bevacizumab remains significantly
cheaper than ranibizumab and aflibercept, demonstrated by the fact that the CIs for the incremental
costs do not contain zero. Bevacizumab continues to dominate ranibizumab and aflibercept.
In deterministic analysis using a 5- and 10-year time horizon, bevacizumab remains the most
cost-effective intervention at £20,000–30,000 per QALY (see Appendix 6, Table 58).
In deterministic analysis, to have comparable costs to bevacizumab, at £28 per injection, the PAS
discounts for aflibercept and ranibizumab would need to be at least 95%.
Results: within-trial analysis
A total of 462 patients were included in the health economic analysis, with one patient excluded
because they had been randomised in error. Thirteen people died and 42 participants withdrew
or were lost to follow-up during the trial, and their subsequent costs and QALYs were adjusted,
as described in Method of economic evaluation.
Data completeness
Over the 100-week data collection period, data were missing for some participants for baseline utility,
QALY parameters for the three quality-of-life measures and total costs. For the extent of these missing
data, see Appendix 6, Table 64. The highest proportion of missing data (56%) was recorded for total
costs. There were only small differences in the proportion of missing data between the treatment arms.
Appendix 6, Figures 29–32, explores the patterns of missing data for cost and HRQoL outcomes. The
plots suggest that costs and utilities can be combined at each time period without any major loss of
information. The plots suggested that the data were non-monotonic and missing at random; therefore,
it was appropriate to use multiple imputation.126
Utilities
Figure 19 summarises the mean VFQ-UI utility score at each milestone visit, with 95% CIs. There is
overlap between the intervals at each of the time points, suggesting no statistical differences between
the three arms at all follow-up time points. The mean utility scores from the EQ-5D and the EQ-5D-V
are provided (see Appendix 6, Figures 34 and 35, and Table 65).
Costs
Table 23 gives a breakdown of the total costs for each of the three treatment arms. Complete-case
data were used for estimating the mean costs for each item, and the mean total costs were calculated
from imputed data. The mean total costs in each arm are driven by the intervention costs, accounting
for 84%, 87% and 76% of the total costs for ranibizumab, aflibercept and bevacizumab, respectively.
Appendix 6, Figure 33, shows histograms of the distribution of total costs by treatment arm. In each
arm, few patients incurred extreme high costs, resulting in little skewedness in the cost data.
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Base-case analysis
In the base-case analysis (Table 24), the difference in mean total costs between aflibercept and
ranibizumab was £1245 (95% CI £421 to £2070); between bevacizumab and ranibizumab arms, the
difference was –£6760 (95% CI –£7546 to –£5973); and between aflibercept and bevacizumab, it was
£7984 (95% CI £7209 to £8759). Bevacizumab dominated (less costly and with no difference in benefit)
ranibizumab, with a probability of cost-effectiveness of 1.00 at the threshold of £20,000 per QALY.
Aflibercept was more costly, with a mean QALY difference of 0.004 (95% CI –0.0430 to 0.0518), than
ranibizumab, with an ICER of £283,595 per QALY gained and a probability of cost-effectiveness of 0.04
at the threshold of £20,000 per QALY. Aflibercept was dominated by bevacizumab [more costly, with a
mean QALY difference of –0.015 (95% CI –0.0618 to 0.0322)], with a probability of cost-effectiveness
of 0.00 at the thresholds of £20,000 and £30,000 per QALY.
Uncertainty analysis
The CEAC generated from the parametric analysis, in the base-case analysis, is presented in Figure 20.
The CEAC illustrates the probability that each treatment is the most cost-effective, compared with
alternative treatments, at a range of threshold values. Bevacizumab has the highest probability of












































FIGURE 19 Within-trial analysis: mean utility scores calculated using the VFQ-UI over 100 weeks. Table shows number
of observations at each time point. Reproduced with permission from Pennington et al.95 This article is licensed under
a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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TABLE 23 Within-trial analysis: disaggregated costs for complete cases and total costs based on multiple imputation at 100 weeks
Cost
Cost per patient (£)
Mean (SD); n Mean (95% CI)
Ranibizumab Aflibercept Bevacizumab Aflibercept vs. ranibizumab Bevacizumab vs. ranibizumab Aflibercept vs. bevacizumab
Blindness 1.94 (15.28); 125 4.70 (23.51); 129 2.96 (18.79); 123 2.76 (–2.05 to 7.57) 1.02 (–3.85 to 5.88) –1.74 (–6.57 to 3.08)
Concomitant medications 69.03 (342.27); 154 22.86 (26.40); 154 124.37 (907.96); 154 –46.17 (–171.35 to 79.01) 55.34 (–69.84 to 180.52) 101.51 ( –23.67 to 226.69)
Concomitant procedures 173.23 (567.30); 154 222.60 (749.14); 154 217.57 (880.10); 154 49.37 (–116.66 to 215.4) 44.34 (–121.69 to 210.37) –5.03 (–171.06 to 161)
Continuous care and support 7.11 (54.99); 99 38.76 (172.27); 88 10.43 (82.93); 90 31.66 (–0.75 to 64.07) 3.32 (–28.89 to 35.54) –28.33 (–61.5 to 4.83)
Health-care contacts 729.36 (815.88); 91 710.46 (920.25); 92 740.14 (1065.62); 81 –18.89 (–289.62 to 251.84) 10.78 (–268.94 to 290.51) 29.68 (–249.33 to 308.68)
Hospital admissions 54.17 (479.35); 149 34.08 (239.58); 149 89.32 (689.04); 148 –20.10 (–134.43 to 94.23) 35.15 (–79.37 to 149.67) –55.24 (–169.76 to 59.28)
Intervention 10,991.74 (3973.57); 154 12,445.31 (4231.59); 154 4784.99 (1247.34); 154 1453.57 (687.9 to 2219.23) –6206.74 (–6972.41 to –5441.08) 7660.31 (6894.65 to 8425.98)






















































per QALY (at £30,000
per QALY)
Aflibercept vs. ranibizumab
Cost (£) 14,328 (3773); 154 13,014 (3605); 154 1245 (421 to 2070) –
QALY 1.651 (0.2374); 154 1.627 (0.2471); 154 0.004 (–0.0430 to 0.0518) –
ICER £283,595 0.04 (0.10)
Bevacizumab vs. ranibizumab
Cost (£) 6292 (3371); 154 13,014 (3605); 154 –6760 (–7546 to –5973) –
QALY 1.666 (0.2426); 154 1.627 (0.2471); 154 0.018 (–0.0282 to 0.0648) –
ICER Bevacizumab is dominant 1.00 (1.00)
Aflibercept vs. bevacizumab
Cost (£) 14,328 (3773); 154 6292 (3371); 154 7984 (7209 to 8759) –
QALY 1.651 (0.2374); 154 1.666 (0.2426); 154 –0.015 (–0.0618 to 0.0322) –
ICER Aflibercept is dominated 0.00 (0.00)
a Adjusted for baseline utility score.
Reproduced with permission from Pennington et al.95 This article is licensed under a Creative Commons Attribution 4.0
International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,
as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third party material in this article are included in the
article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included
in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds
the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence,
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FIGURE 20 Within-trial analysis: CEAC.
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The confidence ellipses graphs (see Appendix 3, Figure 21a–c) represent the point estimate of the ICER
in the cost-effectiveness plane, with 50%, 75% and 95% CIs around the point estimate. The ICER for
bevacizumab compared with ranibizumab falls in the south-east quadrant of the cost-effectiveness
plane, with the 95% confidence ellipse wholly under the horizontal axis but spanning the vertical axis,
suggesting certainty around the difference in costs but uncertainty around the difference in QALYs
between the two interventions. The ICER for aflibercept compared with ranibizumab falls in the
north-east quadrant, again with the 95% confidence ellipse wholly above the horizontal axis but
spanning the vertical axis, suggesting certainty in the difference in costs but uncertainty in the
difference in QALYs. Uncertainty is also illustrated (see Appendix 6, Figure 36) using the INMB.
Scenario analysis
The results from secondary analyses using the EQ-5D and the EQ-5D-V to estimate QALYs are
summarised in Table 25. Although the three HRQoL measures (VFQ, EQ-5D and EQ-5D-V) generated
slightly different results, the differences between the three interventions in terms of QALYs were
small and uncertain in each analysis. The overall conclusion regarding the most cost-effective treatment
is unchanged. Bevacizumab consistently dominates ranibizumab, and, although aflibercept might be
slightly more clinically effective than bevacizumab and ranibizumab, it is more costly, resulting in a
low probability of cost-effectiveness for both treatments at the £20,000 per QALY threshold.
The results from the fully incremental analysis show that bevacizumab dominates all alternative
treatment options (i.e. it is less costly and more effective); therefore, ranibizumab and aflibercept are
ruled out by dominance (see Appendix 6, Table 66).
The results from scenario analyses when discount rates of 30% and 50% are applied to the drug costs
of ranibizumab and aflibercept are shown in Table 26. These findings suggest that the within-trial
cost–utility base-case analysis results are not sensitive to these discount rates. Although the probability
of aflibercept being cost-effective, compared with ranibizumab, increased to 11% and 24% at the
£20,000 per QALY threshold for the 30% and 50% discounts, respectively, this was still a low probability.
Bevacizumab was still cheaper and more effective than ranibizumab, and aflibercept was more costly
and less effective than bevacizumab.
Results from scenario analyses using the list price of £243 for bevacizumab, complete-case data and a
52-week time horizon are summarised in Appendix 6, Tables 67–69. The same conclusions can be drawn
from these analyses as from the base-case analysis, with bevacizumab remaining the most cost-effective
treatment option.
Summary of findings from the economic evaluation
Main findings from the model-based analysis
The model-based analysis found that bevacizumab is consistently the most cost-effective intervention
at a threshold of £20,000–30,000 per QALY. Bevacizumab, aflibercept and ranibizumab generate
very similar QALYs, but bevacizumab leads to substantial cost savings, even when it is assumed that
bevacizumab vials cannot be split, which would incur a higher cost per injection. The cost savings
associated with bevacizumab are due to the much lower drug cost. For aflibercept and ranibizumab to
have comparable costs to bevacizumab, and therefore have a chance of being cost-effective, the PAS
discounts on the two licensed products would need to be at least 95%.
The findings were robust to sensitivity analyses, but the use of different utility measures led to
differences in the absolute QALYs and ordering of each intervention. This indicates that the estimates
of the differences in HRQoL are uncertain, but were consistently small across instruments.
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TABLE 25 Within-trial analysis: results from secondary analyses using the EQ-5D and EQ-5D-V to estimate QALYs,











Cost (£) 14,271 (3857); 154 13,068 (3636); 154 1196 (406 to 1986) –
QALY 1.560 (0.3801); 154 1.513 (0.3744); 154 0.0184 (–0.0412 to 0.0779) –
ICER £65,023 0.13 (0.26)
Bevacizumab vs. ranibizumab
Cost (£) 6273 (3384); 154 13,068 (3636); 154 –6783 (–7575 to –5990) –
QALY 1.535 (0.3759); 154 1.513 (0.3744); 154 0.0098 (–0.0493 to 0.0690) –
ICER (£) Bevacizumab is dominant 1.00 (1.00)
Aflibercept vs. bevacizumab
Cost (£) 14,271 (3857); 154 6273 (3384); 154 8035 (7246 to 8824)
QALY 1.560 (0.3801); 154 1.535 (0.3759); 154 0.008 (–0.0529 to 0.0683)
ICER £1,041,476 0.00 (0.00)
EQ-5D-V
Aflibercept vs. ranibizumab
Cost (£) 14,273 (3720); 154 13,000 (3661); 154 1325 (499 to 2151)
QALY 1.516 (0.3856); 154 1.472 (0.3666); 154 0.0433 (–0.0404 to 0.1269)
ICER £30,624 0.32 (0.49)
Bevacizumab vs. ranibizumab
Cost (£) 6268 (3368); 154 13,000 (3661); 154 –6713 (–7499 to –5926) –
QALY 1.500 (0.3757); 154 1.472 (0.3666); 154 0.0340 (–0.0471 to 0.1151) –
ICER Bevacizumab is dominant 1.00 (1.00)
Aflibercept vs. bevacizumab
Cost (£) 14,273 (3720); 154 6268 (3368); 154 8012 (7232 to 8793) –
QALY 1.516 (0.3856); 154 1.500 (0.3757); 154 0.0032 (–0.0837 to 0.0902) –
ICER £2,483,943 0.00 (0.00)
a Adjusted for baseline utility score.
Reproduced with permission from Pennington et al.95 This article is licensed under a Creative Commons Attribution 4.0
International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,
as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third party material in this article are included in the
article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit https://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes
to the original table.
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Main findings from the within-trial analysis
The within-trial health economic analysis found strong evidence that bevacizumab is considerably
cheaper than ranibizumab and aflibercept, even when potential discount rates are applied to the
two licensed products. There was no evidence to suggest a difference in HRQoL between the three
treatments regardless of the HRQoL questionnaire used to measure utility; however, the estimates
of QALY difference are uncertain. Bevacizumab is more cost-effective option than ranibizumab
and aflibercept. Aflibercept is highly unlikely to be cost-effective in the short term (100 weeks),
compared with ranibizumab or bevacizumab, using the commonly used cost-effectiveness threshold
of £20,000–30,000 per QALY. The cost-effectiveness results are driven by the higher intervention
cost for aflibercept, with no additional benefit in terms of QALYs.
TABLE 26 Within-trial analysis: results from scenario analyses using discount rates of 30% and 50% applied to







per QALY (at £30,000
per QALY)Intervention Comparator
Discount of 30% applied to aflibercept and ranibizumab drug costs
Aflibercept vs. ranibizumab
Cost (£) 11,727 (2900); 154 10,893 (2848); 154 833 (203 to 1464) –
QALY 1.651 (0.2426); 154 1.627 (0.2471); 154 0.004 (–0.0430 to 0.0518) –
ICER £189,133 0.11 (0.19)
Bevacizumab vs. ranibizumab
Cost (£) 6227 (2700); 154 10,893 (2848); 154 –4656 (–5280 to –4033) –
QALY 1.666 (0.2374); 154 1.627 (0.2471); 154 0.018 (–0.0282 to 0.0649) –
ICER Bevacizumab is dominant 1.00 (1.00)
Aflibercept vs. bevacizumab
Cost (£) 11,727 (2900); 154 6227 (2700); 154 5476 (4837 to 6116)
QALY 1.651 (0.2426); 154 1.627 (0.2471); 154 –0.015 (–0.0618 to 0.0322)
ICER Aflibercept is dominated 0.00 (0.00)
Discount of 50% applied to aflibercept and ranibizumab drug costs
Aflibercept vs. ranibizumab
Cost (£) 10,042 (2553); 154 9499 (2538); 154 497 (–71 to 1053) –
QALY 1.651 (0.2426); 154 1.627 (0.2471); 154 0.004 (–0.0430 to 0.0518) –
ICER £111,622 0.24 (0.32)
Bevacizumab vs. ranibizumab
Cost (£) 6201 (2419); 154 9499 (2538); 154 –3288 (–3842 to –2734) –
QALY 1.666 (0.2374); 154 1.627 (0.2471); 154 0.018 (–0.0282 to 0.0649) –
ICER Bevacizumab is dominant 1.00 (1.00)
Aflibercept vs. bevacizumab
Cost (£) 10,042 (2553); 154 6201 (2419); 154 3809 (3252 to 4365) –
QALY 1.651 (0.2426); 154 1.666 (0.2374); 154 –0.015 (–0.0618 to 0.0322) –
ICER Aflibercept is dominated 0.00 (0.00)
a Adjusted for baseline utility score.
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Comparison of model-based and within-trial findings
The model-based and within-trial analyses both concluded that bevacizumab is the most cost-effective
intervention for treating MO due to CRVO. Both analyses found small differences in QALYs between
the three treatments, and substantial cost savings for bevacizumab. Despite the different approaches
used for estimating utilities in the model- and trial-based analyses, the cost-effectiveness conclusion
remained the same, indicating the robustness of the economic evaluation results.
The total QALYs for each intervention were similar for bevacizumab (model, 1.641; trial, 1.666),
aflibercept (model, 1.646; trial, 1.651) and ranibizumab (model, 1.641; trial, 1.627). The total costs for
each intervention were also similar for bevacizumab (model, £6349; trial, £6292), aflibercept (model,
£18,844; trial, £14,328) and ranibizumab (model, £15,254; trial, £13,014). The similarities between the
model- and trial-based costs and QALYs can be viewed as validation of the model-based analysis.
However, there are some differences between the model- and trial-based results. The model-based
analysis leads to higher costs for each intervention, despite the exclusion of concomitant medications
and procedures (although these make up < £250 per intervention in the trial-based analysis). The
differences in costs may be explained by higher intervention drug and administration costs in the
model. The within-trial analysis uses information recorded in LEAVO on whether or not a participant
had an injection at each visit, whereas the model uses data from LEAVO in combination with the LEAVO
re-treatment criteria to allow extrapolation beyond the trial period. The difference between the analyses
indicates that some modelled patients receive the intervention when they did not in LEAVO.
The model results follow the same trend as the trial, in that the number of injections was smaller for
aflibercept than for bevacizumab or ranibizumab, but the absolute number of injections in each arm
is larger. The re-treatment criteria in the model dictate that patients will be re-treated if their CST is
> 320 µm, and the CST data used in the model suggest that, on average, bevacizumab and aflibercept
patients have a CST above this threshold throughout the trial. Variation between individual patients
may have meant that a greater proportion of patients in the trial than in the model had a CST below
the threshold. Alternatively, the difference may have arisen because the re-treatment criteria in the trial
stipulated that patients should have a CST of > 320 µm due to intraretinal or subretinal fluid, and the
model does not consider the reason for CST values. There may have been patients in the trial who had a
CST of > 320 µm for other reasons who were not treated, but who would be assumed to be treated in
the model. In addition, participants in LEAVO might have missed appointments, which would lead to
reduced injection frequency.
There are also differences between the QALYs in the model-based and within-trial analyses. The model-
and trial-based analyses both find no significant difference between bevacizumab and ranibizumab, but
the model finds that aflibercept generates significantly more QALYs than the other two interventions.
This is because the model-based analysis uses BCVA in both eyes (as well as age and sex) to predict
utility (and utility is higher for patients with better visual acuity), but the within-trial analysis uses utility
data directly. The trial utility data will capture other factors relating to patients’ utility that may not
relate to their BCVA, thus adding noise to the data. The relationship between visual acuity and utility is
complex, non-linear and, in the observed LEAVO data for WSE, non-monotonic at times (see Figure 16).
The mapping used ALDVMMs to try to capture the complex relationship and the distribution of
utility data, but found some unusual features: typically ALDVMMs for EQ-5D contain at least three
components, with one component representing patients with utility at or below zero. However, in this
case, BCVA in the BSE or the WSE did not correlate with EQ-5D scores below zero, and so the model
does not contain these separate components, as the covariates cannot predict membership of it.
Some of the QALY differences may also be due to differences in mortality. The within-trial analysis
uses mortality data directly, and so includes the deaths of three participants in the ranibizumab group,
six in the aflibercept group and four in the bevacizumab group. The model instead links mortality to
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baseline age, sex and the presence of CRVO; because these are the same for the modelled patients on
each treatment, there is no mortality difference between the treatments.
The model-based analysis does not include blind registration and low-vision aid costs for patients who
are partially sighted, consistent with previous analyses.13,51 The within-trial analysis captures these
costs and includes blind registration and low-vision aid costs using the same estimates as for patients
with severe sight impairment. As cost of blindness was a small proportion of the total costs in both the
within-trial and model-based analyses, this difference does not influence the results.
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Chapter 5 Discussion
Summary and interpretation of findings
Clinical effectiveness and side-effect profile
The results of this prospective multicentre Phase III RCT demonstrate that repeated intravitreal injections
of the three anti-VEGF agents markedly improves BCVA in patients with MO secondary to CRVO over
100 weeks. Aflibercept was non-inferior to ranibizumab in the management of CRVO-related MO at
100 weeks, but it was not superior. The trial was unable to demonstrate that bevacizumab was non-
inferior to ranibizumab, as the lower 95% CI extended beyond the non-inferiority margin of –5 letters.
The results were consistent in that both the ITT and the per-protocol analyses gave similar results for
both comparisons. Furthermore, subsequent sensitivity analyses supported the reliability of the two non-
inferiority comparisons. Although post hoc analyses should be interpreted with caution, a comparison of
bevacizumab with aflibercept could not demonstrate that bevacizumab was non-inferior to aflibercept.
In clinical terms, the result confirms aflibercept, as well as ranibizumab, use for MO due to CRVO,
which was important to demonstrate as both are used widely in UK clinical practice but previously
had not been compared directly for this condition. Bevacizumab, on the other hand, could be worse
than ranibizumab and aflibercept, or it could be no worse. Practically, this means that, if a patient was
being advised on treatments for MO due to CRVO with anti-VEGF therapy, the three agents could
not be presented to the patient as being completely equivalent. Clinicians would have a low level of
confidence in recommending that a patient who was receiving ranibizumab or aflibercept switch to
bevacizumab therapy.
Other visual outcome results across the three groups were similar, with no meaningful differences
between ranibizumab, aflibercept and bevacizumab in the number of participants in each group achieving
key secondary end points, such as a gain of ≥ 15 BCVA letters or remaining stable (i.e. a < 15-letter loss
of visual acuity). The former means that, for patients commencing therapy, there is a 45–50% chance of
achieving a three-line improvement in visual acuity. Patients can easily comprehend this by reference
to a visual acuity chart when discussing the likely benefits of therapy with their clinician. All patients
can be advised that, with regular attendance and adherence to treatment recommendations, there is
at least a 90% chance that visual acuity will not deteriorate further. It is reassuring, from a patient
perspective, to note that < 4% of participants in the bevacizumab arm experienced a significant loss
of vision of ≥ 30 letters, in keeping with data pertaining to ranibizumab and aflibercept in this and in
previous studies.29–31,33
As anticipated, visual acuity improved rapidly during the initial monthly mandated injection phase,
but a small mean decrease in visual acuity occurred across all three arms of the trial between weeks
16 and 24, which coincided with the pro re nata injection phase at week 16. Previous studies employed
a protocol of six mandated monthly injections from week 0 to week 24.9,21,27,29,31 During the trial design,
we reviewed the available data and concluded that four mandated injections would be sufficient
because in CRUISE the increase in visual acuity had reached a plateau by 4 months.9 This may have
been because the study enrolled a carefully selected population of people with non-ischaemic CRVO,
who were likely to respond well to therapy. However, we now recognise that subsequent studies27,29,31,58
that introduced broader and more generalisable eligibility criteria indicate that the initial gain in visual
acuity takes longer to maximise. Thus, our findings suggest that the loading phase should be extended
to 6 months. Had we employed the longer loading phase, it is possible that the gain in visual acuity
achieved by the LEAVO participants at week 24 could have been some ≥ 3 letters higher, and more in
keeping with gains at 6 months in other studies.27,29,31
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It is also worth noting that SCORE227 and other studies, for example COPERNICUS,29,31 did not
maintain such early gains through 1 and 2 years, most likely because follow-up in year 2 was too
infrequent to identify and treat those patients who needed regular medication. Notably, the final gain
in visual acuity at week 100, compared with baseline, is higher in LEAVO than in any other previously
reported study on this condition, and could possibly have been even higher.
We believe that this reflects the importance of timely monitoring in the second year of the study,
which should initially be every 4 or 8 weeks, in keeping with the LEAVO protocol. Longer intervals of
follow-up in other studies probably led to loss of initial visual gains.31,34,38 It is possible that follow-ups
every 4 or 8 weeks could be extended for selected patients, but this approach was not tested in
LEAVO. The adjusted mean visual acuity gains at each time point after baseline had a consistent
hierarchy throughout the trial, in that aflibercept group values were higher than ranibizumab group
values, which, in turn, were higher than bevacizumab gains. Even at week 76, when the differences
between the groups were small, this hierarchy was maintained.
As expected, the three anti-VEGF agents caused a significant and immediate reduction in adjusted
OCT CST during mandated injection phase of baseline to 12 weeks. However, the CST increased by
approximately 50 µm over the next three visits, as the number of injections administered reduced
markedly. This was because intense treatment during the mandated phase meant that re-treatment
criteria were frequently not met at the visits at 16 and 20 weeks, leading to a rebound increase
in CST by week 24, which closely mirrored the decrease in visual acuity. However, as participants
entered the remaining 18 months of the trial, their visits were regularly scheduled every 4 or 8 weeks,
resulting in patients who met criteria for re-treatment being treated promptly. This meant that OCT
values gradually decreased through to week 100, mirrored by a gradual increase in visual acuity
during the same time period, in contrast to other studies in which OCT data did not closely reflect
visual acuity changes.27 A previously unreported finding was that a significantly greater percentage
of participants in the aflibercept arm than in the ranibizumab arm had an OCT CST of < 320 µm at
weeks 52 and 100. This suggests that aflibercept is more effective than ranibizumab at resolving
MO in the longer term, a finding previously reported in exudative AMD and DMO.43,54 Interestingly,
bevacizumab was no less effective than ranibizumab in this regard, unlike in other retinal disorders.54
Fewer injections were required for aflibercept than for ranibizumab over 100 weeks, a difference that has
been reported previously only in a treat-and-extend protocol.57 The difference was significant as early as
24 weeks, and gradually increased by approximately 0.5 of an injection every 6 months. The post hoc
analysis also found that fewer aflibercept than bevacizumab injections were required. This probably
reflects the higher binding affinity of aflibercept to the VEGF molecule and a prolonged duration of
action. This, coupled with a greater visual acuity gain and more patients achieving a normal thickness
OCT CST at 2 years, would be a potential advantage of aflibercept over ranibizumab for MO due to CRVO.
No meaningful differences were seen between groups in OCT morphological grading at baseline or at
100 weeks.
Fundus fluorescein angiography did not detect differences across groups at baseline or exit, but, when
the whole cohort is considered, there was overall change in distribution of non-perfusion at week 100,
which we are further investigating.
No new safety concerns were identified in LEAVO to suggest any discrepancies in the overall safety
profile of the three anti-VEGF agents, which is in keeping with previous reports. The chance of severe
visual loss while undergoing anti-VEGF therapy remains low (i.e. in the order of 5% over 2 years) and
has been noted in all previous studies.9,27,29–31,57 This is typically due to development of an ischaemic
CRVO, that is an increase in severity of the original occlusion to a point at which retinal blood inflow
leads to compromised macular perfusion and possible neovascular complications. Patients were
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
100
promptly treated with panretinal photocoagulation in such cases, and anti-VEGF therapy for MO may
have coincidentally limited the risk of neovascularisation.
When this trial was conceived, it was thought that small amounts of anti-VEGF agents were absorbed
into the systemic circulation from an intraocular injection, resulting in a reduction in circulating VEGF
concentrations and, possibly, in an increased risk of APTC events, although this cause–effect relationship
has not been established. Hence, we planned, in the grant application, to perform a meta-analysis
of all comparative anti-VEGF safety data from CRVO studies that we anticipated would be carried out
simultaneously with LEAVO. In practice, only the comparative US SCORE2 study27 and a small aflibercept
versus bevacizumab trial have been conducted.59 In addition, the SCORE2 investigators re-randomised
their patients at 6 months, depending on whether or not the patients met predefined criteria of being
good or poor responders.58 Thus, a comparison was not possible beyond 6 months, and the comparative
prevalence of AEs of anti-VEGF agents used in the two studies up to 6 months showed no difference.
No study to date in multiple conditions, including nvAMD, DMO,61 branch and central retinal condition
and less common conditions such as pathological myopia, has shown an increased risk of APTC events
with bevacizumab, and we do not believe that this issue would be a barrier to the use of this drug in
the NHS. The recent judicial review by Mrs Justice Whipple53 emphasised this point and she commented
that ensuring that enough compounding pharmacies were available to ensure the large-scale safe
production of significant amounts of the drug remained a key issue.
After the trial results were made available, we formulated a questionnaire to gather patient feedback,
and received responses from members of the LEAVO CRVO users group that was formed prior to trial
initiation, additional patients with RVO, the Barts Health/QMUL lay panel and Barts Heath diabetic
patients who had a history of eye disease. We found that two-thirds of patients would consider
bevacizumab treatment if the outcome could be worse than licensed alternatives but with such a
small difference that it would be very unlikely to prevent them from carrying out their regular daily
activities. All said that they would be more likely to agree to this if a licensed alternative was available
should they not respond as expected to bevacizumab; provision would probably need to be made for this.
Limitations
The interpretation of the results should be considered in the context of patient eligibility and the trial
treatment protocol. It is possible that the trial enrolled people whose eyes had limited potential for
visual improvement because of a severe CRVO and compromised retinal perfusion and eyes with good
visual acuity that had limited potential to improve because of a ceiling effect. Findings from secondary
analyses were supportive but should be interpreted with caution as there was no adjustment for
multiple testing. Aflibercept was considered an investigative agent because it was unlicensed when
the trial commenced; therefore, all comparisons with bevacizumab were post hoc.
Generalisability (external validity)
The trial was undertaken in a wide range of UK ophthalmic centres. The trial eligibility criteria were
purposely as broad as possible to ensure that a population would be recruited who represented
patients presenting for NHS standard care. Unlike previous studies, patients with visual acuity of
< 6/60 or with a relative afferent pupillary defect were not excluded. The protocol was amended
to extend the upper limit of visual acuity from 74 (6/12) to 78 (6/9) letters to allow patients with
MO but relatively good vision to enrol in the trial and not opt for NHS standard care. Patients with
predisposing conditions (e.g. hypertension and glaucoma) were included and there was no restriction
on concomitant medications or procedures during the trial; for example, a participant could undergo
cataract surgery if his/her clinician deemed this necessary. The 4- to 8-week follow-up regimen in
the second year ensured that the first-year visual acuity gains were maintained; we feel that this was
an important part of the trial protocol for NHS centres to replicate. The centres involved in the trial
ranged from small NHS departments through secondary referral centres to specialised ophthalmic-only
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tertiary referral units. All centres and ophthalmologists were able to deliver the trial, and no special
expertise or equipment beyond subspecialty retinal expertise was necessary. We believe that the trial
is potentially applicable to all UK and overseas ophthalmic centres. We do not believe that there are
any related outcomes that the trial did not assess that may affect applicability, and we believe that the
2-year primary outcome and follow-up intervals were appropriate. The concentrations of anti-VEGF
therapy in the plasma after 4 weeks are immeasurably low and, because patients did not receive
injections after week 96, we would not anticipate any harms occurring beyond week 100 relevant to
the trial. The only exception to this might be pregnancy, but both the participant and the spouse of
a participant in the trial who were pregnant carried to term with the delivery of normal neonates.
Clearly, not all patients in clinical care will respond in the same manner as those in the trial cohort,
but we would expect discrepancies only in magnitude rather than in direction, and mostly related to
non-adherence to a robust treatment protocol. Overall, the patient feedback from the trial was very
positive and we have no reason to believe that any subgroup of patients would decline to receive
anti-VEGF therapy in a similar way to the trial protocol.
Overall evidence
Comparative clinical data
The only previous well-powered comparison of anti-VEGF drugs for MO secondary to CRVO prior
to LEAVO was SCORE2,27 which randomised 361 patients to aflibercept or bevacizumab, and treated
them monthly from baseline to month 5 (six injections). The primary outcome was at 6 months. This
differed from LEAVO, in which participants received monthly injections from baseline to month 3 (four
injections) followed by pro re nata treatment at mandated visits at weeks 16 and 20, with milestone
visual acuity assessments at 6 months. Greater mean BCVA letter gains were achieved in the first
6 months of SCORE2 than in LEAVO [aflibercept: SCORE2, mean 18.9 letters; LEAVO, mean 13.4
letters (SD 16.4 letters)]. This may be explained by the longer initial period of mandated monthly
injections in SCORE227 or by differences in eligibility criteria. The baseline BCVA and case mix were
dissimilar in these trials, with SCORE2 including patients with hemiretinal vein occlusion and LEAVO
including patients with a baseline upper BCVA letter score of 78 (6/9), compared with 74 (6/12) in
SCORE2. It is unknown whether or not the initial BCVA gains in SCORE2 could have been maintained
through 2 years as the initial patient cohort was re-randomised at 6 months, depending on good
and poor response to initial therapy.58 The CRYSTAL study was a prospective single-arm study of
ranibizumab therapy in CRVO with MO that followed up patients for 2 years, with a review at least
every 8 weeks in year 2. Although this was a non-comparative study, the follow-up regimen was
effective in maintaining first-year visual acuity gains in the second year, even though the number
of injections in year 2 averaged only 3.3. This suggests that regular follow-up, with the targeting
of patients in need of treatment, is of key importance.56 Therefore, LEAVO is, to our knowledge,
the only large clinical trial of MO due to CRVO to report comparative three-drug outcome data
beyond 6 months with sustained visual acuity gains through 100 weeks across treatment arms.
Health economics analysis
The cost-effectiveness analysis found that bevacizumab was the most cost-effective intervention when
compared with licensed agents (ranibizumab and aflibercept). In the treatment of MO due to CRVO,
the model-based and within-trial analyses found small differences between the QALYs generated by
aflibercept, ranibizumab and bevacizumab, but found that bevacizumab led to substantially lower costs.
The finding that bevacizumab was the most cost-effective intervention was robust to scenario analyses
that varied assumptions and data inputs. If bevacizumab was the standard of care and aflibercept or
ranibizumab were new interventions being appraised by NICE, it is highly unlikely that they would be
recommended as a cost-effective use of NHS resources.
Treatment with bevacizumab saves £5560 per year when compared with aflibercept, or £4546 per
year when compared with ranibizumab (see Appendix 6, Table 69). If the estimated 5700 people
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diagnosed with MO due to CRVO each year in England and Wales8 were treated with bevacizumab
instead of aflibercept, the NHS would save approximately £32M in 1 year (approximately £26M if
the patients treated with bevacizumab instead of ranibizumab). Because the cost savings are due
to a difference in intervention costs, this result would hold across other health-care systems,
as long as the cost per injection for bevacizumab is lower than for aflibercept and ranibizumab.
This trial provides evidence of the cost-effectiveness of anti-VEGF treatment in MO due to CRVO,
for which evidence is currently limited. A recent systematic review of the three interventions across
retinal conditions did not identify any cost-effectiveness evidence in RVO.58 This review identified
two large US trials that provided evidence that ranibizumab and aflibercept are not cost-effective
compared with bevacizumab in other retinal conditions (nvAMD and DMO). The cost-effectiveness
findings for MO in the LEAVO trial are consistent with these findings.
The analyses adhered to good practice guidelines,84,86,87,125,126 and had the strengths of being based
on data from a well-conducted multicentre randomised trial and having good retention rates over
a 100-week follow-up. A key strength of the economic evaluation is the use of three different HRQoL
outcome measures, including both disease-specific (VFQ-UI and EQ-5D-V) and generic (EQ-5D) measures.
A range of scenario analyses have also been performed providing evidence based on a range of discounted
prices for the alternative medications. In the health economics literature, there is always a debate over
the relative merits of condition-specific versus generic preference-based measures (in this case VFQ-UI vs.
EQ-5D). The argument is that generic measures are not sensitive to particular disease-specific improvements;
therefore, the VFQ-UI was seen as a better alternative for the LEAVO population. In addition, bolt-ons to
generic measures, such as the EQ-5D-V, were proposed as an alternative approach to retain comparability
across different disease areas while improving sensitivity. In this trial, we used the three alternative
approaches; we found that the VFQ-UI generated more QALYs for each of the three interventions.
However, the incremental QALYs were similar across the three quality-of-life measures.
The strengths of the model-based analysis lie in the model design and the data inputs. A discrete event
simulation facilitates the use of a continuous BCVA scale, and avoids arbitrarily grouping patients. This
enables the detection of small differences in visual acuity, which are linked to utility and costs, to ensure
that the differences between the three treatments are reflected. The model structure further enables
consideration of both eyes, and their relationship to utility. The utility mappings follow best practice
guidelines113 and up-to-date statistical methods to capture the distributions of utility. The inclusion of
age and sex as variables in the utility mappings improved the model fit. In this trial population, quality
of life is more likely to be affected by BCVA in both eyes (WSE and BSE). Therefore, our mappings were
used to predict utility for each modelled patient using three quality-of-life measures (VFQ-UI, EQ-5D
and EQ-5D-V) as a function of age, sex and BCVA in both eyes. Analysing resource use data from
LEAVO allowed this to be linked to visual acuity to reflect the changing resource use associated with
improvements or deterioration, which has not previously been captured in economic models for MO.12,13
The use of growth models fitted to longitudinal BCVA and CST data allowed the extrapolation of these
inputs over time, and avoided the need to make assumptions regarding effectiveness and injection
frequency beyond the trial, as in previous models.12,13
There are large numbers of missing data in the health economic analysis, but the multiple imputation
model for the trial-based analysis suggests that the results are robust. Resource use questionnaires
are vulnerable to recall bias. However, in LEAVO, the resource use questionnaire was designed
especially for the trial. Resource use is also a small proportion of the overall total cost in each arm,
so any changes are unlikely to change the health economic conclusions. Furthermore, results from
the complete-case analysis provided similar conclusions, and bevacizumab remained the most
cost-effective option.
The primary outcome in LEAVO concerned visual acuity in the trial eye. The model-based analysis
considered both the trial and the non-trial eyes and their relationship to utility. However, consideration
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should be given to the relationship between these outcomes and the reality for patients; although
clinical measures assess visual acuity in each eye separately, patients’ overall sight is determined
by their visual acuity in both eyes together. Patients’ day-to-day functioning and quality of life may
therefore not relate closely to the assessment of visual acuity in the trial eye, and this may explain
why the differences in the utilities and QALYs between arms were not significant in the economic
evaluation. The mapping from BCVA to utility used a robust estimator of the variance used in the
statistical model. A limitation of this was the inclusion of repeated observations of the same patients
to increase the number of observations available. A cluster-robust estimator of the SEs could have
been used that is robust in the presence of correlation between observations for each individual.
This does not change the estimated coefficients from the ALDVMM; it affects only the SEs used in
the probabilistic sensitivity analyses.
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Chapter 6 Conclusions
Implications for health care
LEAVO was unable to demonstrate that bevacizumab is non-inferior, that is it may be worse or may
not be worse than ranibizumab and aflibercept in the management of MO due to CRVO. Clinicians
would have a low level of confidence in recommending that bevacizumab is equivalent in clinical
effectiveness to the licensed medications for the management of this condition. No differences were
detected in the side-effect profile of the treatments in this trial, in keeping with previous trials in this
indication. Patients’ quality of life was not significantly different between treatment arms. This suggests
that the clinical differences between the treatments were not sufficiently great to affect participants’
regular daily activities, as appraised in this trial. However, it is possible that, in certain situations,
patients may undertake or would wish to undertake a visual task in which a difference in visual acuity
in one eye may be noticeable to them. It is also important to note that CRVO is typically a unilateral
condition, and the vision-related quality of life is dependent on the BSE. Therefore, this finding is
not applicable to other retinal conditions such as nvAMD and DMO, as a result of which a larger
proportion of patients have bilateral visual impairment.
Compared with aflibercept and ranibizumab, bevacizumab was the most cost-effective treatment for
MO due to CRVO. If aflibercept and ranibizumab were to be appraised by NICE in a multitechnology
appraisal with bevacizumab, it is highly unlikely that they would be considered cost-effective. Treating
patients with bevacizumab would certainly lead to cost savings to the NHS and other health-care
systems. However, because the trial could not demonstrate that bevacizumab was non-inferior to
the licensed medication, the trial results would need to be discussed in detail with patients, their
representatives and funders before the treatment proceeded. The post-trial patient questionnaire
responses suggest that approximately two-thirds of patients may be amenable to this approach,
assuming that the licensed medications were available in reserve.
Recommendations for research
Additional patient involvement in this area would be required to help quantify more exact numbers of
patients willing to consider bevacizumab therapy for MO due to CRVO, and the key factors that would
dissuade other patients and whether or not these could be mitigated. This would probably require the
full involvement of patients, patient advocate groups and funders to determine if bevacizumab could
be introduced in this way. Further larger-scale clinical trials may also be justified for this condition.
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Appendix 1 The LEAVO study group
LEAVO study group
The LEAVO study group thanks all the patients who participated in the study, and all of the site
investigators and research teams.
TABLE 27 The LEAVO Study Group
Site Principal investigator
Moorfields Eye Hospital NHS Foundation Trust, London Sobha Sivaprasad
King’s College Hospital, London Haralabos Eleftheriadis
New Cross Hospital, Wolverhampton & Midland Counties Eye Infirmary,
Wolverhampton
Yit Yang
Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool Michael Briggs
University Hospital Southampton NHS Foundation Trust, Southampton Andrew Lotery
Royal Victoria Hospital, Belfast, and Queen’s University Belfast Michael Williams
Department of Ophthalmology, Royal Blackburn Hospital, Blackburn Salwa Abugreen
Bradford Ophthalmology Research Network, Bradford Teaching Hospitals NHS
Foundation Trust, Bradford
Faruque Ghanchi
Sussex Eye Hospital, Brighton Edward Hughes
Bristol Eye Hospital, Bristol Adam Ross
Department of Ophthalmology, West Suffolk NHS Foundation Trust, Suffolk Nitin Gupta
Ophthalmology Department, Torbay Hospital, Devon Stephen Turner Yinka Osoba
Essex County Hospital, Colchester Jignesh Patel
Macular Unit, Hospital of St. Cross, Rugby Sergio Pagliarini
Birmingham and Midlands Eye Centre, Birmingham Peck-Lin Lip
Kent and Canterbury Hospital, Canterbury Nishal Patel Afsar Jafree
Ophthalmology Department, Frimley Park Hospital NHS Foundation Trust, Surrey Geeta Menon
Whipps Cross University Hospital, Barts Health NHS Trust, London Sudeshna Patra
James Paget University Hospital, Norfolk Ben Burton
Department of Ophthalmology, Royal Surrey County Hospital, Guildford, Surrey Simon Taylor
Harrogate and District NHS Foundation Trust, Harrogate, North Yorkshire Sarah Mackenzie
York Teaching Hospital NHS Foundation Trust, York Richard Gale
Darlington Memorial Hospital, County Durham and Darlington NHS Foundation Trust Komala Vadivelu
St James’s University Hospital, Leeds Martin McKibbin
Ophthalmology Department, Hillingdon Hospitals NHS Foundation Trust, London Sheena George
Maidstone and Tunbridge Wells NHS Trust, Kent Goncalo Almeida
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TABLE 27 The LEAVO Study Group (continued )
Site Principal investigator
Royal Victoria Infirmary, Newcastle upon Tyne James Talks
Luton and Dunstable NHS University Hospital, Hertfordshire Venki Sundaram
University Hospital of Wales, Cardiff Sanjiv Banerjee
Sunderland Eye Infirmary, Sunderland Maged Habib
Royal Glamorgan Hospital, North Glamorgan NHS Trust Raghu Ram
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Christopher Brand
Addenbrooke’s Hospital, Cambridge Doug Newman
Department of Ophthalmology, Gartnavel General Hospital, Glasgow David Gilmour
Ophthalmology Department, Bolton NHS Foundation Trust, Bolton Simon Kelly
Calderdale Royal Hospital, Halifax Rehna Khan
University Hospitals of Leicester NHS Trust, Leicester Theo Empeslidis
Department of Ophthalmology, Norfolk and Norwich Hospital, Norwich Colin Jones
Cheltenham General Hospital, Gloucestershire Emily Fletcher
Department of Ophthalmology, Hull and East Yorkshire Hospitals NHS Trust, Hull Louise Downey
Western Eye Hospital, London Saad Younis
James Cook University Hospital, South Tees NHS Foundation Trust, South Tees Philip Severn
Princess Alexandra Hospital, Harlow, Essex Priya Prakash
APPENDIX 1
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
Appendix 2 The LEAVO study committees
We would like to thank the following for their valuable contribution to this study:
Trial Steering Committee members – Susan Downes (chairperson, Oxford Eye Hospital, UK), Irene Stratton
(Gloucestershire Hospitals NHS Foundation Trust, UK), Hiten Dodhia (Lambeth and Southwark Councils,
Public Health, London, UK), Greg Fell (Sheffield Council, Public Health, Sheffield, UK), Riaz Asaria (Royal
Free London NHS Foundation Trust, London, UK), Jonathan Byrne (King’s College NHS Foundation Trust,
London, UK), Vanessa Burgess (NHS Lambeth Clinical Commissioning Group, London, UK), Alison Powling
(Community Diabetes, Barts Health NHS Trust, London, UK) and Mrs Melba Ryde (lay representative).
Data Monitoring Committee members – Sarah Walker (chairperson, Oxford University, Oxford, UK),
Consuela Moorman (Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust) and
Baljean Dhillon (Centre for Clinical Brain Sciences, University of Edinburgh).
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Appendix 3 Additional data: tables and
figures
TABLE 28 Analyses used for secondary outcomes
Type of variable Outcome Method
Continuous BCVA at 52 weeks LME model
Mean OCT CST at 52 and 100 weeks LME model
Macular volume at 52 and 100 weeks LME model
VFQ-25 composite score, distance and near subscales
at 52 and 100 weeks
LME model
Number of injections by 100 weeks Difference in means with 95% CI
Change in retinal non-perfusion at week 100
as assessed by disc areas of non-perfusion
(in approximately 27 sites)
Difference in medians with 95% CI
Categorical Participants with a ≥ 15 and ≥ 10 ETDRS letter
improvement, < 15 ETDRS letter loss and ≥ 30 ETDRS
letter loss (severe visual loss) at 52 and 100 weeks
Differences in proportions with 95% CI
Participants scoring ≥ 73 ETDRS letters, ≤ 58 ETDRS
letters and ≤ 19 letters at 52 and 100 weeks
Differences in proportions with 95% CI
consistent with a chi-squared test
Participants with OCT CST of < 320 µm at 52 and
100 weeks
Differences in proportions with 95% CI
consistent with a chi-squared test
Persistent non-responder participants at 52 and
100 weeks
Differences in proportions with 95% CI
Participants developing ocular neovascularisation by 52
and 100 weeks
Differences in proportions with 95% CI
Participants with OCT anatomical features (e.g. diffuse
intraretinal oedema, subretinal fluid, vitreomacular
interface abnormality, EZ disruption, DRIL) at 52 and
100 weeks
Differences in proportions with 95% CI
Participants with change in area of retinal
non-perfusion
Differences in proportions with 95% CI
Prevalence of local and systemic side effects Differences in proportions with 95% CI
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visit4 8 12 16 20 24 28–48 52 56–72 76 80–96 100
Variable treatment visits 4–8 weeks 4–8 weeks 4–8 weeks 13–97 weeks
Informed consent ✗




Urine pregnancy test for women of
child-bearing age
✗
Patient demographics and medical and
ophthalmic history
✗
AEs ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Concomitant medication review ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Blood pressure ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
BCVA (ETDRS) in both eyes (✗2 if with
refraction)
✗2 ✗ ✗ ✗ ✗2 ✗ ✗ ✗2 ✗ ✗2 ✗ ✗2 ✗ ✗2 ✗2
Standard ophthalmic examination of both eyes ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
OCT on both eyes ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗ ✗
Wide-angle or seven-field colour fundus
photography
✗ ✗ ✗ ✗
Wide-angle or seven-field FFA ✗ ✗ ✗
VFQ-25, EQ-5D and EQ-5D-V ✗ ✗ ✗ ✗ ✗ ✗ ✗
Resource use questionnaire ✗ ✗ ✗ ✗ ✗ ✗ ✗
Treatment allocation guess form ✗ ✗
Administer IMP (✗3 if pro re nata treatment) ✗ ✗ ✗ ✗ ✗3 ✗3 ✗3 ✗3 ✗3 ✗3 ✗3 ✗3
a Most patients were screened and underwent the baseline examination on the same day, although it was possible to do this on a different day, in which case inclusion/exclusion




































classification MHRA date approved REC date approved HRA date approved Changes to documents
SA#1 l To cover MHRA grounds for
non-acceptance
l Changes to protocol and patient
information sheet
Substantial 24 July 2014 4 September 2014 N/A l Protocol and patient information
sheet: changes to ensure that
patients use contraception for
6 months after their last intravitreal
injection of anti-VEGF therapy
l Protocol: changes to
exclusion criteria
SA#2 l Changes to protocol, patient
information sheet, ICF
l Also includes minor amendments
to the protocol
Substantial 27 February 2015 10 November 2014 N/A l Protocol: changes to inclusion
and exclusion criteria; treatment
allocation guess form; re-
treatment criteria; criteria for
restarting therapy; management




l Patient information sheet: to
reflect that visual acuity will
form part of the routine eye
exam; guidance on contraception
l ICF: to reflect new patient
information sheet
SA#3 New principal investigator at
existing site, removal of site,
addition of new site
Substantial 16 March 2015 17 February 2015 N/A l Patient information sheet:
amended following review of
new SPCs; allows sites to use
nurse injectors
l ICF: to reflect new patient
information sheet
SA#4 Adding sites: Calderdale Royal
Hospital, Leicester Royal Infirmary,
Norfolk and Norwich Hospital,
Cheltenham General Hospital





















































































































































































































































































































































classification MHRA date approved REC date approved HRA date approved Changes to documents
SA#5 Adding sites: Hull Royal Infirmary,
Gartnavel General Hospital,
Western Eye Hospital, James Cook
University Hospital, Princess
Alexandra Hospital, Aberdeen Royal
Infirmary; new principal investigator
at existing site: Cheltenham General
Hospital
Substantial N/A 4 August 2015 N/A None
SA#6 Changes to protocol, patient
information sheet, ICF




l Patient information sheet: changes
to clarify who performs the
injections and who prescribes
antibiotic drops
ICF: to reflect new patient
information sheet
SA#7 New principal investigator at
existing site: Darlington Memorial
Hospital
Substantial N/A 11 August 2016 N/A None
SA#8 New principal investigator at
existing site: Canterbury Hospital
Substantial N/A 19 June 2017 20 June 2017 None
SA#9 Change of SPC regarding reference
safety information
Substantial 2 August 2017 25 July 2017 22 August 2017 None
SA#10 New principal investigator at existing
site: Darlington Memorial Hospital
Substantial N/A 16 July 2018 16 July 2018 None
SA#11 New principal investigator at
existing site: Torbay Hospital
Substantial N/A 4 September 2018 4 September 2018 None

































TABLE 31 Last visit week of withdrawal patients
Time point
Trial arm (n)
Total (n)Ranibizumab Aflibercept Bevacizumab
Baseline 3 0 0 3
4 weeks 1 0 2 3
8 weeks 2 1 0 3
12 weeks 0 2 0 2
16 weeks 0 1 0 1
20 weeks 0 0 2 2
24 weeks 1 1 0 2
28 weeks 3 0 1 4
32 weeks 1 2 0 3
36 weeks 0 0 0 0
40 weeks 2 1 2 5
44 weeks 0 0 0 0
48 weeks 0 0 1 1
52 weeks 0 2 2 4
56 weeks 2 1 0 3
60 weeks 0 0 0 0
64 weeks 0 2 2 4
68 weeks 0 3 1 4
72 weeks 1 3 0 4
76 weeks 1 1 1 3
80 weeks 0 1 0 1
84 weeks 0 0 0 0
88 weeks 1 0 0 1
92 weeks 1 0 1 2
96 weeks 1 0 0 1
Total 20 21 15 56
TABLE 32 Reasons for and time to withdrawal
Date withdrawn Date randomised
Weeks in
trial (n) Reason for withdrawal Trial arm
30 June 2015 9 April 2015 12 Health deterioration Ranibizumab
14 September 2015 24 June 2015 12 Participant no longer wish to take part Aflibercept
6 November 2015 10 September 2015 8 Unable to locate/contact participant Bevacizumab
6 November 2015 25 September 2015 6 Participant no longer wish to take part Ranibizumab
8 December 2015 8 December 2015 0 Other Ranibizumab
continued
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TABLE 32 Reasons for and time to withdrawal (continued )
Date withdrawn Date randomised
Weeks in
trial (n) Reason for withdrawal Trial arm
8 January 2016 31 March 2015 40 Other Bevacizumab
12 April 2016 19 May 2015 47 Participant no longer wishes to take part Bevacizumab
26 May 2016 1 September 2015 38 Participant no longer wishes to take part Aflibercept
1 June 2016 23 December 2015 23 Participant no longer wishes to take part Bevacizumab
7 June 2016 13 October 2015 34 AE Ranibizumab
21 June 2016 23 September 2015 39 Patient moving away from area Aflibercept
22 July 2016 16 June 2015 57 Participant no longer wishes to take part Ranibizumab
29 July 2016 18 April 2016 15 Other Ranibizumab
19 August 2016 9 June 2016 10 Death of participant Ranibizumab
30 August 2016 29 January 2016 31 Unable to locate/contact participant Aflibercept
26 September 2016 3 November 2015 47 Health deterioration Ranibizumab
12 October 2016 17 June 2015 69 Patient moving away from area Bevacizumab
17 October 2016 28 August 2015 59 Participant no longer wishes to take part Ranibizumab
19 October 2016 11 December 2015 45 Participant no longer wishes to take part Ranibizumab
29 October 2016 18 February 2016 36 Death of participant Aflibercept
31 October 2016 14 April 2016 29 Death of participant Bevacizumab
8 November 2016 25 April 2016 28 Participant no longer wishes to take part Aflibercept
9 November 2016 8 April 2015 83 Unable to locate/contact participant Aflibercept
26 November 2016 26 January 2016 44 Participant no longer wishes to take part Bevacizumab
18 December 2016 13 June 2016 27 Death of participant Aflibercept
3 January 2017 26 August 2016 19 Death of participant Aflibercept
3 January 2017 26 August 2015 71 Health deterioration Aflibercept
12 January 2017 17 September 2015 69 Unable to locate/contact participant Aflibercept
1 February 2017 13 April 2016 42 Participant no longer wishes to take part Ranibizumab
9 February 2017 6 November 2015 66 Participant no longer wishes to take part Bevacizumab
20 February 2017 23 October 2015 69 Other Aflibercept
2 March 2017 28 April 2016 44 Participant no longer wishes to take part Ranibizumab
9 March 2017 22 October 2015 72 Death of participant Ranibizumab
10 March 2017 23 October 2015 72 Participant no longer wishes to take part Bevacizumab
21 March 2017 27 October 2015 73 AE Aflibercept
15 May 2017 3 March 2016 63 Death of participant Ranibizumab
25 May 2017 31 December 2015 73 Participant no longer wishes to take part Aflibercept
19 June 2017 16 October 2015 87 Death of participant Aflibercept
1 August 2017 12 October 2015 94 Death of participant Bevacizumab
5 September 2017 22 March 2016 76 Health deterioration Bevacizumab
14 September 2017 25 February 2016 81 AE Bevacizumab
10 November 2017 14 November 2016 52 Participant no longer wishes to take part Aflibercept
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TABLE 32 Reasons for and time to withdrawal (continued )
Date withdrawn Date randomised
Weeks in
trial (n) Reason for withdrawal Trial arm
13 November 2017 2 June 2016 76 Unable to locate/contact participant Ranibizumab
17 November 2017 21 October 2015 108 Unable to locate/contact participant Ranibizumab
27 November 2017 14 June 2016 76 Death of participant Aflibercept
4 December 2017 28 October 2016 57 Death of participant Bevacizumab
17 January 2018 28 October 2016 64 Death of participant Bevacizumab
1 March 2018 17 June 2016 89 Participant no longer wishes to take part Ranibizumab
29 March 2018 23 June 2016 92 Participant no longer wishes to take part Aflibercept
5 May 2018 18 October 2016 81 Death of participant Aflibercept
4 June 2018 10 October 2016 86 Patient moving away from area Aflibercept
13 August 2018 24 November 2016 90 AE Bevacizumab
13 September 2018 11 October 2016 100 Participant no longer wishes to take part Ranibizumab
5 October 2018 29 November 2016 96 Health deterioration Aflibercept
13 November 2018 30 November 2016 102 AE Ranibizumab
27 November 2018 4 November 2016 108 Unable to locate/contact participant Ranibizumab
TABLE 33 Comparison of OCT macular volume at 52 and 100 weeks




At screening 12.3 (0.2) 13.0 (0.2)
At 52 weeks 9.1 (0.2); n= 140 9.2 (0.2); n= 138
At 100 weeks 8.6 (0.1); n= 133 8.9 (0.1); n= 135
Adjusted difference
At 52 weeks –0.1 (–0.6 to 0.4)




At screening 12.8 (0.2) 13.0 (0.2)
At 52 weeks 9.4 (0.2); n= 135 9.2 (0.2); n= 138
At 100 weeks 9.1 (0.2); n= 135 8.9 (0.1); n= 135
Adjusted difference
At 52 weeks 0.2 (–0.3 to 0.7)
At 100 weeks 0.3 (–0.2 to 0.7)
a The LME model incorporates 455 participants (ranibizumab, n= 149; aflibercept, n = 153; and bevacizumab, n= 153)
with both CST and macular volume at either 52 weeks or 100 weeks.
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TABLE 34 The input parameters for the health economic models
Parameter Distribution Mean (SE) Source of mean Source for SE
Intervention and related costs
Ranibizumab injection N/A £551.00 BNF117 N/A
Aflibercept injection N/A £816.00 BNF117 N/A
Bevacizumab injection N/A £28.00 Judicial review53 N/A
CST cost Gamma £108.21 l Department of Health
and Social Care118
l NHS codes BZ87A




Social Care130First visit cost Gamma £140.04 l Department of Health
and Social Care118
l NHS codes WF02B
Follow-up visit cost Gamma £105.19 l Department of Health
and Social Care118
l NHS codes WF02A
Costs associated with resource use
A&E visit cost Gamma £160.23 (£9.34) l Department of Health
and Social Care118
l Weighted average for
NHS codes VB01Z
to VB11Z





Visit cost of ocular A&E Gamma £118.02 (£2.67) l Department of Health
and Social Care118
l NHS codes WF01B




Social Care130Visit cost of eye
consultant
Gamma £95.13 (£1.85) l Department of Health
and Social Care118
l NHS codes WF01A
Call cost to
ophthalmologist
Gamma £28.20 (£4) l Department of Health
and Social Care118
l NHS codes WF01D
Visit cost of optometrist/
optician
Gamma £76.50 (£10.50) l Department of Health
and Social Care118
l NHS codes WF01B
Visit cost for low-vision
appointment
N/A £153.00 Estimated to be double the visit cost of optometrist/
optician
Visit cost of GP Gamma £37.40 (£3.74) Curtis and Burns116 10% assumption around
the mean
Visit cost of practice
nurse
Gamma £17.79 (£1.78)
Call cost to GP Gamma £28.00 (£2.80)
Resource use parameters (every 3 months)
A&E visit: WSE Multinormal –0.001 Analysis of LEAVO data
A&E visit: constant 0.103
Eye A&E visit: WSE Multinormal –0.002
Eye A&E visit: constant 0.183
GP visit: WSE Multinormal –0.004
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
136
TABLE 34 The input parameters for the health economic models (continued )
Parameter Distribution Mean (SE) Source of mean Source for SE
GP visit: constant 0.441
GP call: WSE Multinormal –0.001
GP call: constant 0.082

































Beta 33% (0.05%) Colquitt et al.121 Margrain131
Percentage requiring
low-vision rehabilitation








Beta 39% (5.8%) Colquitt et al.121 Galaria et al.132
Percentage requiring
blindness registration
Beta 95% (0.05%) Colquitt et al.121 Owen et al.133




Curtis and Burns116 10% assumption around
mean
Cost of hip replacement
(annual)





Cost of low-vision aids
(one-off)
Gamma £194.41 (£19.44) Meads,122 Curtis116 10% assumption around
mean
continued
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TABLE 34 The input parameters for the health economic models (continued )
Parameter Distribution Mean (SE) Source of mean Source for SE
Cost of low-vision
rehabilitation (one-off)
Gamma £153 Estimated to be double the visit cost of optometrist/
optician
Cost of residential care
(annual)
Gamma £6000.80 (£600.08) Curtis and Burns116 10% assumption around
mean
Cost of treatment for
depression (annual)




Gamma £60.50 (£6.05) Curtis and Burns116 10% assumption around
mean
AEs





























Mortality: hazard ratios for CRVO
Female: aged 0–49 years Log-normal 0.83 (2.89) Bertelsen et al.101 Calculated from CIs
Female: aged 50–59
years
Log-normal 1.49 (1.86) Bertelsen et al.101 Calculated from CIs
Female: aged 60–69
years
Log-normal 1.94 (1.27) Bertelsen et al.101 Calculated from CIs
Female: aged 70–79
years
Log-normal 0.94 (1.25) Bertelsen et al.101 Calculated from CIs
Female: aged ≥ 80 years Log-normal 1.04 (1.23) Bertelsen et al.101 Calculated from CIs
Male: aged 0–49 years Log-normal 1.49 (1.88) Bertelsen et al.101 Calculated from CIs
Male: aged 50–59 years Log-normal 1.71 (1.54) Bertelsen et al.101 Calculated from CIs
Male: aged 60–69 years Log-normal 1.17 (1.3) Bertelsen et al.101 Calculated from CIs
Male: aged 70–79 years Log-normal 1.24 (1.14) Bertelsen et al.101 Calculated from CIs
Male: aged ≥ 80 years Log-normal 1.26 (1.22) Bertelsen et al.101 Calculated from CIs
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TABLE 34 The input parameters for the health economic models (continued )
Parameter Distribution Mean (SE) Source of mean Source for SE
BCVA and CST modelling
BCVA: baseline age/10
on intercept























injection at 12 weeks
Normal –0.00083 (0.005)
BCVA: days since
injection at 24 weeks
Normal –0.00536 (0.001)
BCVA: days since
injection at 52 weeks
Normal 0.00069 (0.001)
BCVA: days since
injection at ≥ 76 weeks
Normal –0.00026 (0.0001)
BCVA: number of
injection at 12 weeks
Normal 0.10891 (0.072)
BCVA: number of
injection at 24 weeks
Normal 0.06345 (0.035)
BCVA: number of
injection at 52 weeks
Normal –0.00871 (0.021)
BCVA: number of
injection at ≥ 76 weeks
Normal –0.01121 (0.019)
BCVA: intercept Multinormal 4.811
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TABLE 34 The input parameters for the health economic models (continued )











CST: days since injection
at 12 weeks
Normal 0.00231 (0.007)
CST: days since injection
at 24 weeks
Normal 0.02045 (0.003)
CST: days since injection
at 52 weeks
Normal 0.00239 (0.001)
CST: days since injection
at ≥ 76 weeks
Normal 0.00144 (0.001)
CST: number of injection
at 12 weeks
Normal –0.00612 (0.103)
CST: number of injection
at 24 weeks
Normal –0.0594 (0.056)
CST: number of injection
at 52 weeks
Normal 0.06798 (0.027)
CST: number of injection
at ≥ 76 weeks
Normal 0.06327 (0.022)
CST: intercept Multinormal 3.76348
CST: slope Multinormal –2.75221
Annual BCVA change
Age 55–64 years: mean Normal 0.0200 (0.002) Klein et al.98 10% assumption around
mean
Age 55–64 years: SD Normal 0.0400 (0.004) Klein et al.98 10% assumption around
mean
Age 65–74 years: mean Normal –0.2600 (0.026) Klein et al.98 10% assumption around
mean
Age 65–74 years: SD Normal 0.0400 (0.004) Klein et al.98 10% assumption around
mean
Age 65–74 years: mean Normal –0.7600 (0.076) Klein et al.98 10% assumption around
mean
Age 65–74 years: SD Normal 0.0602 (0.060) Klein et al.98 10% assumption around
mean
Utility parameters: VFQ-UI
Component 1: BSE/10 Multinormal –0.00025 Analysis of LEAVO data
Component 1: WSE/10 –0.00033
Component 1: age/10 0.00922
Component 1: male 0.00110
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TABLE 34 The input parameters for the health economic models (continued )
Parameter Distribution Mean (SE) Source of mean Source for SE
Component 1: constant 0.88490
Component 2: BSE/10 0.02353
Component 2: WSE/10 0.01637
Component 2: age/10 0.03448
Component 2: male 0.00751
Component 2: constant 0.18926
Component 3: BSE/10 0.00372
Component 3: WSE/10 –0.00187
Component 3: age/10 0.00638
Component 3: male –0.00413



















Component 1: log-sigma –4.78402
Component 2: log-sigma –2.24672
Component 3: log-sigma –3.49052
Utility parameters: EQ-5D
Component 1: BSE/10 Multinormal 0.01626 Analysis of LEAVO data
Component 1: WSE/10 0.01022
Component 1: age/10 –0.02851
Component 1: male 0.02663
Component 1: constant 0.86003
Component 2: BSE/10 0.01693
Component 2: WSE/10 –0.02069
Component 2: age/10 0.04236
Component 2: male 0.20485
Component 2: constant 0.01774
continued
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TABLE 34 The input parameters for the health economic models (continued )










Component 1: log-sigma –1.99075
Component 2: log-sigma –1.32132
Utility parameters: EQ-5D-V
Component 1: BSE/10 Multinormal 0.00378 Analysis of LEAVO
Component 1: WSE/10 –0.00730
Component 1: age/10 0.04348
Component 1: male 0.20676
Component 1: constant 0.03574
Component 2: BSE/10 0.02012
Component 2: WSE/10 0.01255
Component 2: age/10 –0.01937
Component 2: male 0.01592










Component 1: log-sigma –1.25309
Component 2: log-sigma –1.93060
BNF, British National Formulary; N/A, not applicable.
APPENDIX 3




































































FIGURE 21 Within-trial analysis: confidence ellipses VFQ; VFQ-UI measure. (a) Aflibercept vs. bevacizumab;
(b) aflibercept vs. ranibizumab; and (c) bevacizumab vs. ranibizumab.
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Appendix 4 Procedure for assessing the
primary outcome
Refracted visual acuity was performed by a certified optometrist who had signed and dated thesite delegation log before study participation and was masked to patient treatment allocation.
All procedures were performed in a certified visual acuity lane. The visual acuity examiners received
the participants into the visual acuity lanes with a visual acuity worksheet form, trial number and
detail of trial eye and non-trial eye to be refracted, but with no previous subject records or worksheet
forms. BCVA was measured following refraction at screening and at 12, 24, 52, 76 and 100 weeks
(and unscheduled visits if they were to be considered as milestone visits, including a withdrawal visit)
in all participants in both eyes. At all other visits, visual acuity was recorded by masked personnel
using the refraction results from the previous refraction visit.
Equipment and room set-up
The ETDRS chart R was used for refraction. The lightbox was illuminated with two cool daylight 20-W
fluorescent tubes. New tubes were kept on for 96 hours before use. Room lights were turned off, and
the chart lights were turned on. Any windows were covered. The illumination of the room was such
that, with the room set up for testing, but with the chart light switched off, not more than 161.4 lux
fell on the centre of the chart. The height of the chart needed to be such that the top of the third row
of letters was 124.5 cm (± 5 cm) from the floor. Full aperture trial lenses were used with a trial frame.
Refraction
The right eye was refracted first, with the participant seated 4 m from the chart. The fellow eye was
occluded with a pad and tape. At the baseline visit, the initial acuity was measured with the participant’s
own spectacles or unaided if the participant did not have distance spectacles. The spectacles were analysed
with a focimeter. Retinoscopy was performed to provide a starting point for subjective refraction.
At follow-up visits, the previous refraction was used as the starting point. If the initial acuity was ≥ 6/60
(four letters read correctly), refraction was performed at 4 m. If the acuity was < 6/60, refraction was
performed at 1 m. Subjective refraction was performed using the format below. Plus/minus was offered
in intervals appropriate to the level of acuity.
The sphere was checked as follows. Plus was added if it improved or made no difference to the visual
acuity. This was continued until the offered plus blurred the visual acuity. Minus was added only if the
subject read at least one more letter and the plus was rechecked. The cylinder axis was rechecked
using a round letter on a row one or two lines above the lowest row the participant could read.
The cylinder power was rechecked using a round letter on the lowest row the subject could read.
The sphere was refined as before, offering plus, minus, then plus. The refraction recorded was the
4-m result. If the participant was tested at 1 m, 0.75 dioptre sphere (DS) was taken from the result
to adjust for the 4-m distance. The procedure was repeated for the left eye.
Protocol for measuring ETDRS acuities
Best corrected visual acuity was measured using ETDRS chart 1 for the right eye and chart 2 for the left
eye. Participants were not shown the charts until the test began. Each eye was tested at 4 m initially,
even if the refraction had been performed at 1 m. The right eye was tested first, followed by the left.
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The participant was seated 4 m from the chart. The distance was marked with clear and permanent floor
markings. The left eye was occluded with a pad and tape and the lens correction from the subjective
refraction was placed in the trial frame. What was required of the participant was then explained: there
were 5 letters on each row, the letters were to be read slowly, there were no numbers on the chart,
even if they were unsure of a letter they should guess, they could not go back and change their mind
once they had attempted the next letter, and they could move their head or eye to give the best
possible visual acuity as long as they did not lean forward.
The participant began by reading the top row of the chart and continued by reading every letter on
each smaller line. The examiner recorded the results, circling each letter read correctly, putting a cross
through each letter read incorrectly and leaving unmarked any letter for which no attempt was made.
Participants were permitted to change their mind about a letter provided that the subsequent letter
had not already been read. If a participant gave a choice of two letters, the examiner asked them
to select one response only. The examiner did not read any letters out loud during the test, nor did
they tell the participant if a letter had been identified correctly. If the participant lost their place, the
examiner pointed to the next line to be read, but then moved away from the chart. The participant was
asked and encouraged to move on to the next line as long as they correctly identified at least one letter
on the previous line. The test was stopped when the participant could no longer guess, provided that
mistakes had been made on previous guesses. Ideally, the aim was for four letters to be missed in a row.
If a participant could not read ≥ 20 letters at 4 m, the test was repeated at 1 m. In this case, only
the first six rows needed to be attempted, and 0.75 DS was added to the prescription in the trial
frame to correct for the shorter test distance. A rigid measuring device was used to ensure that the
distance was correct, and care was taken to ensure that the participant did not move forward during
testing. The visual acuity score was the number of letters read correctly at 4 m, plus the number
of letters read correctly at 1 m. If a participant did not need to be tested at 1 m, that is they could
read ≥ 20 letters at 4 m, then the score was the number of letters read correctly at 4 m, plus 30.
The participant was given the credit for the 30 letters at 1 m, even though they did not have to read
them. The approximate Snellen equivalent was also recorded (in metres). This was taken as the lowest
row with one or no errors. If a participant could not read any letters on the ETDRS chart at 1 m, then
their ability to detect hand movements or light perception was measured.
Testing for hand movement vision
The examiner held their hand steady approximately 0.5 m in front of the participant with all of their
fingers outstretched. A light was shone directly on the hand from behind the participant. The fellow
eye was completely occluded with a pad and tape. The examiner moved their hand from side to side or
up and down at a constant speed of one back and forth presentation per second. The participant was
asked ‘In which direction am I moving my hand?’. This was to be repeated five times. Four out of five
correct responses indicated hand movement vision. If this was not achieved, light perception was to
be tested for.
Testing for light perception/no light perception
Light perception should be measured with an indirect ophthalmoscope in a darkened room. The indirect
ophthalmoscope is focused at 1 m, with the rheostat on maximum voltage. The beam was directed in
and out of the eye at least four times, and the participant was asked to respond when they see the
light. Light perception was recorded if the examiner was convinced that the participant saw the light.
If not, the acuity was ‘no light perception’.
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Appendix 5 Optical coherence tomography
and fundus fluorescein angiography
image grading
Specific grading of individual morphological optical coherence
tomography features
Normal macula cross-sectional architecture with a Spectralis OCT device is shown in Figure 22, and key
abnormal macula morphological features are shown in Figure 23.
l Vitreomacular interface abnormality:
¢ Epiretinal membrane was defined as present if one or more of the following conditions were
met – a macular pseudohole, a difference in optical reflectivity between membrane and retina,
or a visible membrane tuft or edge.
¢ Vitreomacular traction was present if a highly reflective band was observed on the surface of
the retina at specific sites and elevated off the surface elsewhere, whether continuous or not













FIGURE 22 Normal macula architecture with a Spectralis OCT device.
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l Disorganisation of the retinal inner layers was defined as an area of the inner retina where the
boundary between the ganglion cell layer, inner plexiform layer complex, inner nuclear layer and
outer plexiform layer could not be separately identified in the central five line scans. The total
amount of DRIL in each line scan was added and the average extent per line scan was calculated.
If the total exceeded 50%, DRIL was graded positive. Lesser amounts and no DRIL were graded
absent, and if shadowing prevented assessment, it was deemed ungradable. The averaged horizontal
extent of DRIL per line scan was recorded.
l Macular oedema was classified as:
¢ Diffuse retinal thickening, defined as sponge-like retinal swelling with reduced intraretinal
reflectivity and the absence of hyporeflective spaces.
¢ Cystoid macula oedema, defined as intraretinal cystoid spaces of low reflectivity with highly
reflective septa separating cystoid-like cavities. Intraretinal cysts were further defined based on
the greatest horizontal diameter of the largest cyst (small cysts, < 250 mm; medium cysts,
≥ 250 mm to < 500 mm; and large cysts, ≥ 500 mm).
¢ The mixed pattern was graded present if diffuse retinal thickening and cystoid macula oedema
were present together.
l Hyper-reflective foci: intraretinal abnormally bright dots distributed throughout all retinal layers,
without a characteristic intraretinal location and optimally visualised under ‘black-on-white’ options.
Any number of HRF was graded as ‘present’; if none was visible, the grading was ‘absent’.69,70
l External limiting membrane: the faint narrow line superior to the EZ was graded as intact if
visible throughout the entire foveal line scan, not intact if disrupted or completely absent under
high-contrast settings, and ungradable if there was shadowing of the oedematous retina.
l Ellipsoid zone: the EZ is synonymous with the third hyper-reflective band and is a distinct band just
above the high-reflectance layer of the retinal pigment epithelium–choriocapillaris complex and COST
line (see below), best detected in greyscale mode, and was graded as intact if visible throughout
the foveal centre line scan, not intact if disrupted or completely absent based on continuity under
high-contrast settings, or ungradable if there was shadowing of the oedematous retina.
l Cone outer segment tips: the COST line was defined as the hyper-reflective band between the
retinal pigment epithelium and EZ bands and was graded as intact if visible throughout the entire
foveal line scan, not intact if disrupted or absent in part or all of the central line scan and
ungradable if image quality precluded grading.
l Subretinal detachment: this was characterised as present by a shallow elevation of the retina,
with an optically clear space between the retina and the retinal pigment epithelium.
Fundus fluorescein angiography grading
Standard fundus fluorescein angiography grading
For the standard 13-sector ETDRS retinal grading grid, see Figure 24. The size and extent of the macula
and zones are given in the figure, and the contained table summarises a two-step change in capillary
non-perfusion.
Novel concentric ring template for calculating retinal non-perfusion
For the novel concentric ring retinal template for calculating non-perfusion, see Figure 25. This was
modified to a concentric ring template suited to the central Optos ultra-widefield image. The superior
and inferior segments of rings 3 and 4, which are usually ungradable, were removed to ensure consistent
measurements. Each cell of the grid was individually graded by determining whether or not the area of
retina within the sector was perfused. A glassy, homogeneous appearance to the retina with pruning
or absence of retinal capillaries was used to confirm a diagnosis of non-perfusion and each cell was
graded as either ‘ischaemic’ (i.e. > 50% of total area non-perfused) or ‘perfused’ (i.e. < 50% of total
area non-perfused).
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MT1T2 N1 N2 N3T3
I2
I3
Change in capillary non-perfusion
None






None 1 to 25% 26 to 50% 51 to 75% 76 to 100%
Week 100
The grid projected onto the angiographic grid was as follows:
   Macula: the area with a radius of 3.6 mm centred on the fovea
   Zone 1: the area with a radius of 8.1 mm minus the macula
   Zone 2: the area with a radius of 12.6 mm minus macula and zone 1
   Zone 3: the area with a radius of 17.5 mm minus macula, zone 1 and zone 2
Zones 1, 2 and 3 were further divided into superior (S), temporal (T), inferior (I)
and nasal (N), giving each retinal image 13 sectors (macula, S1 to S3, T1 to T3, I1
to I3 and N1 to N3). Each sector was graded for CNP at baseline and week 100
as none, 1 to 25%, 26 to 50%, 51 to 75%, 76 to 100% and cannot grade
*≥ 2 step CNP worsening is shaded in grey in the grid below
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FIGURE 25 Novel concentric ring retinal template. Reproduced with permission from Nicholson et al.83 This article is
licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation,
distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s)
and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other
third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a
credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is
not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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Appendix 6 Health economics: additional
information
Systematic literature review to support the long-term health economic model
Background
Description of the health problem
Central retinal vein occlusion is a vascular condition of the eye associated with significant visual
loss and impaired quality of life.36,134 RVO is the second most common cause of visual loss.1 The
obstruction causes a reduction in blood supply to the eye and results in a condition referred to as
retinal ischaemia. In severe cases, blood supply may be entirely cut off, leading to non-perfusion of the
retinal capillaries. Reduced perfusion of the retinal vessels triggers an increased production of VEGF
and other mediators, which leads to the formation of new vessels (neovascularisation) and increased
permeability and leakage in parts of the retina (MO).37 MO is the most important cause of visual loss
in patients with CRVO.37 It is the most notable complication of CRVO, followed by retinal ischaemia.16
Other complications of CRVO include vitreous haemorrhage, NVG and tractional retinal detachment.
Epidemiology
Prevalence rates of CRVO range from 0.1% to 0.5%, with a 15-year incidence rate of 0.1% to 0.2%.1
A systematic review3 reporting a pooled analysis from population-based studies (15 studies, 68,751
participants) conducted in the USA, Asia, Australia and Europe estimated that there are approximately
2.5 million (CI 1.9 million to 3.1 million) people living with CRVO. The review also demonstrated that
the prevalence and incidence of CRVO increases with age.1
Subtypes of central retinal vein occlusion
Both CRVO and BRVO are generally classified into non-ischaemic or ischaemic type.16 This classification is
based on the area of capillary non-perfusion and is essential in the prognosis of CRVO. Although ischaemic
CRVO has been defined in the Central Retinal Vein Occlusion Study20 as ‘fluorescein angiographic evidence
of 410 disc areas of capillary nonperfusion on seven-field fundus fluorescein angiography’, there is currently
no agreed consensus on its definition. Better functional prognosis has been reported for patients with the
non-ischaemic subtype than for those with ischaemic eyes.16 Patients with ischaemic CRVO tend to have
poorer vision (visual acuity of < 6/60) following treatment, whereas those with non-ischaemic CRVO may
experience resolution of the condition without complications.16
Anti-vascular endothelial growth factor agents treatments
The introduction of therapies that target and block the activities of VEGF (referred to hereafter as
anti-VEGFs) has significantly transformed the management options for patients with CRVO. Available
intravitreal treatments include Lucentis (ranibizumab), Eylea (aflibercept) and Avastin (bevacizumab),
the last of which is used currently used as an off-label intravitreal injection. The clinical effectiveness and
safety of intravitreal anti-VEGFs in patients with ocular conditions have been studied extensively.32,36,53,135
However, significant differences in study characteristics and methodological designs exist; furthermore,
there is a lack of head-to-head comparisons and long-term data. LEAVO is a pivotal trial that shows
promise in addressing some of the previously mentioned concerns.
Review methods
Aim
The aim of this review was to systematically identify evidence to inform inputs and assumptions for
the long-term (> 2 years) economic model of LEAVO. Data requirements for patients with MO
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secondary to CRVO treated with intravitreal injections of ranibizumab (0.5 mg/0.05 ml), aflibercept
(2.0 mg/0.05 ml) or bevacizumab (1.25 mg/0.05 ml) included:
l relative clinical effectiveness and safety (including withdrawals and mortality)
l HRQoL estimates
l resource use and costs related to treatment, clinic visits, staffing and equipment
l presence of ischaemic CRVO at baseline
l prior treatment for CRVO at baseline
l trial eye OCT CST
l trial eye BCVA
l non-trial eye OCT CST




The review was undertaken in line with current recommendations.90,91
Electronic database searches
Studies were identified through electronic database searches and supplementary searches.
The following databases were searched from the date of inception up to 28 June 2018:
l MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations
l Cochrane Central Register of Controlled Trials
l Cochrane Database of Systematic Reviews





l Web of Science Core Collection (Science Citation Index, Social Sciences Citation Index, Conference
Proceedings Citation Index – Science and Conference Proceedings Citation Index – Social Science
& Humanities).
Free-text terms and subject headings relating to MO, RVO, ranibizumab, aflibercept and bevacizumab,
plus relevant synonyms for each concept, were used to develop a search strategy. The search strategy
was then cross-checked against a Cochrane review of anti-VEGF for MO secondary to CRVO32 to
ensure that all relevant terms were included. Methodological search filters were applied in selected
databases to identify systematic reviews, randomised trials, observational studies and economic studies
(including quality-of-life studies). No search filters were applied to the CINAHL search as a limited
number of references (n = 73) was retrieved. Furthermore, the search in Web of Science was refined
by document type (review, article, proceedings paper, meeting abstract) because there are no available
search filters. No additional limits were applied to the searches; details of the search strategy in
MEDLINE are presented (see Search strategy).
Supplementary searches
Reference lists of key studies identified as potentially relevant were checked for additional references.
Grey literature and authors of potentially eligible studies were also consulted. Literature-searching was
iterative to ensure that sufficient data had been retrieved to populate the model. All records obtained
were uploaded to an electronic bibliographic database, EndNote X8 [Clarivate Analytics (formerly
Thomson Reuters), Philadelphia, PA, USA].
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Study selection
Study selection was informed by inclusion criteria (Table 35); the process was completed using a
two-stage method. One researcher screened the titles and abstracts of retrieved records. Potentially
relevant full-text articles were then obtained for detailed examination. A second reviewer checked
selection decisions at each stage. Disagreements were resolved through consensus. In the case of
multiple publications of the same study, the most recent version with up-to-date information was
considered for inclusion.
Eligible data sources were studies with comparative or non-comparative study designs (systematic reviews,
RCTs and non-RCTs) reporting long-term (i.e. ≥ 2 years) outcomes of clinical effectiveness, safety and
quality of life in patients with MO secondary to CRVO who were treated with ranibizumab (Lucentis)
(0.5 mg/0.05ml), aflibercept (Eylea) (2.0 mg/0.05ml) or bevacizumab (Avastin) (1.25 mg/0.05ml). Patients
were included if treatment was administered as a monotherapy compared with a control (e.g. another
active treatment or sham injection). Prospective uncontrolled before-and-after studies were also reviewed
for inclusion. In addition, studies reporting the natural history of CRVO were sought for inclusion.
The hierarchy of evidence recommendation relating to evidence of data sources for economic models
by Coyle and Lee92 (see Recommendations for data sources) informed the selection of full-text articles.
Narrative reviews, case reports, non-human studies, editorials, expert opinions and non-English-language
papers were excluded. Papers with insufficient and unclear information to ascertain the study aim(s),
participant characteristics, CRVO diagnosis, treatment schedules and relevant outcome measurements
were also excluded from the review.
Data extraction, quality assessment and data synthesis
Data relating to study characteristics (first author’s name, publication date, study type, setting, follow-up
duration), population characteristics (sample size, recruitment or identification, age, sex and comorbidities),
TABLE 35 Systematic literature review: eligibility criteria
Characteristic Eligibility criteria
Population Patients with MO due to CRVO, aged ≥ 18 years
Interventions l Ranibizumab (Lucentis) (0.5 mg/0.05 ml)
l Aflibercept (Eylea) (2.0 mg/0.05 ml)
l Bevacizumab (Avastin) (1.25 mg/0.05 ml)
Comparisons Comparisons between any of the interventions listed above
Comparisons between listed interventions and no active treatment, best supportive care, placebo, sham
Combination of any of the above comparisons
Outcomes l Relative clinical effectiveness and safety (including mortality)
l BCVA at baseline and change in BCVA
l CRT at baseline and change in CRT
l AEs as outlined in HEDMAP document
l Economic data
l HRQoL estimates (e.g. VFQ-25, VFQ-UI, EQ-5D, EQ-5D-5L, EQ-5D-V)
l Resource use and costs related to treatment, clinic visits, staffing and equipment
l Baseline visual acuity
l Presence of ischaemic CRVO at baseline
l Prior treatment for CRVO at baseline
l Recurrence rates of MO
l Injection frequency
Time horizon > 2 years
Study design Systematic reviews, randomised trials and observational studies reporting economic evaluations and
quality of life
CRT, central retinal thickness; HEDMAP, health economics and decision-modelling analysis plan.
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interventions administered and reported outcomes of interest were abstracted into summary tables by
one reviewer. Reported outcomes according to study eye (primary treated eye), non-study eye (secondary
treated eye), BSE and WSE or both eyes were obtained, when these were reported. Data extraction of
outcomes of interest was double-checked by a second researcher. Discrepancies were resolved by discussion.
After applying the rating of hierarchies of evidence of data sources for economic models in study
selection (see Table 55),92 the most appropriate quality checklist endorsed the CASP93 was used to
assess the methodological quality of included studies. Tabular and narrative syntheses were presented
because the available data could not be meta-analysed.
Results
Quantity and quality of available research
A total of 1338 unique records were retrieved through literature searches. Of these, three articles24,34,94
provided potentially relevant evidence for inclusion in this review. Figure 26 shows an outline of
the selection of included studies. Table 36 presents the available relevant data sources and their
methodological ratings. A summary of excluded full-text papers with reasons for exclusion is provided








































• Outcome data, < 2 years,
     n = 18
• No usable data, n = 38
• Multiple report, n = 1
• Review article, n = 1
• Not available/no response




Studies included in review
(n = 3)
FIGURE 26 Systematic literature review: flow diagram of study selection.
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TABLE 36 Systematic literature review: summary of available data sources and methodological ratings of included studies
Characteristic Campochiaro et al.34 Novartis International AG94 McIntosh et al.24
Sample size
(CRVO)
32 patients 1048 patients 3271 eyes
Intervention(s) IVR IVR Not reported
Treatment
schedule
TER Not reported Not reported














l Age: 66.9 years
l Duration of CRVO at
baseline: 4.6 months
l BCVA: 50.0 ETDRS letters
l CFT: 639.8 µm
l Age: 69.7 years
l Female: 41.5%
l White: 78.8%
l BCVA: 44.7 ETDRS letters




l Mean change in BCVA
l Percentage of patients
with resolution of MO
l Mean change in BCVA
l Mean change in CRT and the
frequency and severity of ocular
and systemic AEs
l Baseline visual acuity
l Percentage of patients





l Conversion of non-
ischaemic CRVO to
ischaemic CRVO




l Percentage of patients
gaining or losing ≥ 15
letters from baseline
l Percentage of patients
with BCVA of ≥ 20/40
l Percentage of patients
with BCVA of ≤ 20/200
l Mean change from
baseline in CFT by
Stratus OCT
l Percentage of patients
with CFT of ≤ 250 µm at
each study visit
l Ocular and systemic AEs
l Change in VFQ-25 scores
from baseline
l Number of injections
l Number of visits and
re-treatments
l Time interval between injections





4a 4;a 2 to 3;b 1c 3b
Methodological
quality (CASP)
Unclear quality Unclear quality Good quality
CRT, central retinal thickness; IVR, intravitreal ranibizumab; TER, treat-and-extend regimen.
a Relates to clinical effect sizes and AEs.
b Relates to baseline clinical data.
c Relates to resource use.
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Relative clinical effectiveness and safety
Included studies: long-term efficacy and safety
No evidence relating to the long-term (i.e. > 2 years’ follow-up) head-to-head comparison of intravitreal
injections of ranibizumab (0.5 mg/0.05ml), aflibercept (2.0 mg/0.05ml) and bevacizumab (1.25mg/0.05ml)
in patients with MO secondary to CRVO was found. Two studies34,94 contributed data to the review of
clinical effectiveness of intravitreal ranibizumab injection:
l the RETAIN study,34 a prospective, open-label, single-arm multicentre extension study34
l the LUMINOUS study,94 a post-authorisation multicentre safety study for all licensed indications
of ranibizumab.
Both studies included patients with ocular conditions other than CRVO. Hereafter, patients with CRVO
in the RETAIN34 and LUMINOUS94 studies are referred to as ‘patients’, unless otherwise specified.
The RETAIN study: study and patient characteristics (central retinal vein occlusion subset) The RETAIN
study enrolled a subset of patients with BRVO (n = 34) and CRVO (n = 32), originating from two pivotal
multicentre Phase III RCTs9,33,96 and a subsequent follow-up (HORIZON) trial.38 Patients who completed
CRUISE (392 participants, 95 locations)9,33 or the BRAVO study (397 participants, 93 locations)96 could
immediately enter the RVO cohort of HORIZON.38 HORIZON included 304 patients (intravitreal
ranibizumab 0.5 mg, n = 99; intravitreal ranibizumab 0.3 mg, n = 107; and sham, n = 98) who had
completed 12 months of follow-up in CRUISE.9,33 From months 12 to 24, patients were reviewed every
3 months, or more frequently if needed, and were eligible to receive 0.5 mg of intravitreal ranibizumab
on an ‘as-needed’ (pro re nata) basis.38 The duration of follow-up for patients in HORIZON varied (mean
duration 14 ± 4.7 months, range 1–24 months) because the study was terminated early following FDA
approval for ranibizumab for treating RVO.38
The mean time from HORIZON study exit to RETAIN study entry was 92.7 days (range 68–150 days).34
Patients with CRVO who entered the RETAIN study were representative of those enrolled in CRUISE.34
In the RETAIN study, the mean age, visual acuity and central point thickness at baseline of enrolled
patients with CRVO were 66.9 years, 50.0 ETDRS letters and 639.8 µm, respectively. Primary outcomes
of the RETAIN study were mean improvement in BCVA and proportion of patients with resolved MO
(defined as no intraretinal or subretinal fluid in the macula for at least 6 months after the last injection).
Other reported outcomes were as follows:
l percentage of patients gaining or losing ≥ 15 letters from baseline
l percentages of patients with Snellen-equivalent BCVA of ≥ 20/40 or ≤ 20/200
l mean change from baseline in CFT, as measured by the Stratus OCT device
l percentage of patients with CFT of ≤ 250 µm at each study visit
l incidence and severity of ocular and systemic AEs.
Follow-up of patients was completed monthly for 12 months and then every 3 months for the duration
of the study. At each study visit, patients were eligible to receive therapies based on treatment criteria
protocol (Table 37).
TABLE 37 Systematic literature review: treatment criteria during follow-up visit (the RETAIN study)
Criteria Treatment
1. Presence of intraretinal fluid involving the fovea IVR (0.5 mg)
2. Intraretinal fluid persisting after two consecutive
IVR and BCVA < 20/30
IVR (0.5mg)+ scatter panretinal photocoagulation
IVR, intravitreal ranibizumab.
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Scatter photocoagulation and grid laser therapy were administered as adjunctive treatments in patients
who needed repeated ranibizumab injections at consecutive visits. The mean follow-up period of the
RETAIN study was 49.7 months (with a maximum follow-up of 60 months).34 Of 32 enrolled patients,
27 (84%) completed 2 years of follow-up. Reasons for loss to follow-up or withdrawal were death
(n = 2), resolution of MO (n = 2) and persistence of MO (n = 1).34
Prior treatments (the RETAIN study) Patients who entered the RETAIN study had previously completed
two pivotal multicentre Phase III RCTs9,33,96 and a subsequent follow-up trial (HORIZON).38 Patients
who had received laser photocoagulation for MO 4 months before entering the study were excluded
from CRUISE.33 Further details of prior treatments in patients were not available in the extension
study.34 The mean number of prior injections with ranibizumab per eye was not reported.
Medical and ocular history (the RETAIN study) There was limited information relating to previous
medical and ocular conditions in enrolled patients.
LUMINOUS: study and patient characteristics (central retinal vein occlusion subset) The LUMINOUS
study was a 5-year international multicentre post-authorisation study (43 countries, 494 centres) that
evaluated the long-term effectiveness and safety of ranibizumab for all its indications in the real-world
setting. The study population included patients with neovascular (wet) AMD, visual impairment due to
MO secondary to CRVO or BRVO, DMO and choroidal neovascularisation secondary to pathological
myopia. Of the entire study population in LUMINOUS (n = 30,153), patients with CRVO made up
3.5% (n = 1048). The mean age of patients was 69.7 years. Women made up 41.5% of the subgroup
with CRVO. Baseline BCVA and CFT were 44.7 ETDRS letters and 551.5 µm, respectively.
The primary outcomes were mean change in BCVA, mean change in central retinal thickness (CRT)
and the frequency and severity of ocular and systemic AEs among patients during the study period.
Secondary outcomes of interest included the VFQ-25 scores (change from baseline), total number
of injections, number of visits and re-treatments, time interval between injections, and reasons for
re-treatment or treatment termination.
Safety and effectiveness outcomes in the LUMINOUS study were presented according to various
analysis sets and patient subgroups. Table 38 shows a summary of relevant classifications.
Prior treatments (LUMINOUS) At baseline, 55.1% of patients with CRVO (primary treated eye set)
had received ranibizumab. The mean number of prior injections with ranibizumab per eye was
4.5 (SD 4.29 injections) over a mean treatment duration of 38.7 weeks (SD 45.8 weeks). Additional
previous intravitreal treatments other than ranibizumab were other anti-VEGFs (in 16.5% of patients,
mean of 7.2 treatments per eye) and steroids (in 11.5% of patients, mean of 1.8 treatments per eye).
Approximately 22.3% of all patients in the CRVO subgroup had received laser therapy, the most
common type being panretinal photocoagulation.94
Medical and ocular history (LUMINOUS) A medical history of systemic comorbidity was reported for
4–61.3% of patients with CRVO. Previous ocular conditions were reported for 6.0–16.5% of participants.
Ongoing medical and ocular treatments (LUMINOUS) Up to 70.8% of patients [62.7% treatment-naive
eyes, 75.2% of treatment non-naive (ranibizumab) eyes and 71.5% of treatment non-naive (other ocular
treatments) eyes] received non-ocular medicines or non-drug treatments during the study. Ocular
concomitant medicines and non-drug treatments in the primary treated eye were administered in
37.1% of patients [31.5% of treatment-naive eyes, 40.6% of treatment non-naive (ranibizumab) eyes
and 36.1% of treatment non-naive (other ocular treatments) eyes].94
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Table 39 presents the baseline characteristics of patients in the RETAIN study and LUMINOUS.
Efficacy outcomes
Outcomes of interest included relevant functional and anatomical outcomes reported in the RETAIN34
study and in LUMINOUS.94
Visual outcomes (the RETAIN study)34 The mean baseline visual acuity in the RETAIN study for the
study population was 50.0 letters.94 The mean improvement in BCVA was 14.0 ETDRS letters from
CRUISE baseline (32 patients), resulting in a final visual acuity score of 64 letters (20/50) in patients
with available data at year 4 of the RETAIN study. However, this improvement was not statistically
significant when compared with the improvement of 13.1 letters (p = 0.3) from the end of CRUISE
(i.e. the HORIZON baseline) until the end of the RETAIN study.34 It is unclear whether this outcome is
based on a per-protocol analysis because the authors also reported that patients who completed the
RETAIN study had a mean BVCA of 61.3 letters (20/63), an increase of 12.6 letters from the CRUISE
baseline. Overall, 43.8% of patients had a final visual acuity of 20/40 after 51.4 months of follow-up,
with 53.1% of patients experiencing a 15-letter gain in visual acuity at the end of the study. Patients
with resolved MO had better visual outcomes than those with unresolved MO [BCVA at the year 4
visit 73.2 letters (20/32) vs. 56.1 letters (20/80), respectively; p = 0.1]. A final visual acuity of ≥ 20/40
was reported in 64.3% of patients with resolved MO, in contrast to 27.8% of patients with unresolved
MO (p = 0.04), translating into a visual acuity gain of 25.2 letters versus 4.3 letters (p = 0.002) in the
respective subgroups. Six patients experienced reduced vision ranging from a loss of 3 to 33 ETDRS
letters during the study. For reported visual outcomes in the RETAIN study, see Tables 40 and 41.
TABLE 38 Systematic literature review: summary of reported analysis sets and patient subgroups (adapted from
LUMINOUS94)
Analysis set Definition
Enrolled set All consenting patients with at least one baseline assessment
Safety set Patients in the enrolled set who had received at least one dose of ranibizumab prior to
study entry or during the study, and had at least one safety assessment after the first
ranibizumab dose
Primary treated eye set l All primary treated eyes in patients included in the safety set. The primary treated
eye was the first eye treated with ranibizumab during the study
l If both eyes were first treated on-study on the same date, or if both eyes were
pretreated and did not receive treatment on-study, then the eye with the earlier
diagnosis date was the primary treated eye
l If both eyes had the same diagnosis date but were not treated during the study,
the eye that was pretreated at study entry was regarded as the primary treated eye
Secondary treated eye set l All secondary treated eyes in patients included in the safety set
l If both eyes had the same diagnosis date, the eye that did not meet the criteria for
primary treated eye was considered the secondary treated eye
Fellow treated eye set The fellow eye referred to a non-ranibizumab-treated eye, including information prior
to study entry visit/treatment history
Treatment-naive eyes Eyes that had not been pre treated with any intravitreal treatmentsa
Treatment non-naive
(ranibizumab) eye




Eyes previously treated with at least one ocular treatment other than ranibizumab
a Includes ranibizumab, VEGF inhibitor, corticosteroid focal/grid laser, panretinal laser photocoagulation and
cyclodiode laser.
Adapted with permission from Novartis International AG.94
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Visual outcomes (LUMINOUS) The mean BCVA for all patients with CRVO (1048 patients) at
baseline was 44.7 letters.94 Baseline visual acuity for patients in the treatment-naive, treatment non-
naive (ranibizumab) and treatment non-naive (other ocular treatments) subgroups were 40.6 letters,
49.5 letters and 35.9 letters, respectively. Less than 5% (30/1048) of patients provided relevant data
for visual acuity outcomes beyond 2 years of follow-up. Overall, between two and eight patients across
different subgroups gained > 10 or 15 letters in visual acuity, with only one patient achieving a gain of
> 10 letters or a final BCVA of ≥ 73 letters in the treatment non-naive (ranibizumab) subgroup after
long-term follow-up (up to 48 months).94 Table 42 presents the mean change in visual acuity from
baseline for patients with CRVO in LUMINOUS.94
TABLE 39 Systematic literature review: baseline characteristics of the RETAIN study and LUMINOUS
Study characteristic RETAIN study30,34
LUMINOUS94
All patients
Reported according to pre
treatment in primary treated eye
Sample size (n patients) 32 1048a,b l TN: 327
l TnN(R): 577
l TnN(other): 164
Age (years), mean (SD) 66.9 (SD not
reported)
69.7 (12.32)b l TN: 68.9 (13.03)
l TnN(R): 70.5(12.13)
l TnN(other): 68.3 (11.23)
Female (%) NR 41.51b l TN: 6.0
l TnN(R): 22.14
l TnN(other): 13.45
Duration of disease at
baseline, mean (SD)
mean 4.6 months 391.5 (626.83) days;a
n = 1048
l TN: 67.0 (121.54)
l TnN(R): 551.8 (687.80)
l TnN(other): 485.9 (764.32)
BCVA (ETDRS letters),
mean (SD)
50 44.7 (23.88)b l TN: 40.6 (23.86)
l TnN(R): 49.5 (23.35)
l TnN(other): 35.9 (21.74)
SD-OCT (µm), mean SD 639.8 463.5 (212.53);a n = 656 l TN: 551.5 (219.95)
l TnN(R): 393.3 (184.69)
l TnN(other): 510.2 (199.62)
Ocular history NR RVO (16.5%), glaucoma
(10.4%), cataract operation
(9.1%) and cataract (6.0%)
–











NR, not reported; TN, treatment-naive eyes; TnN(R), treatment non-naive (ranibizumab) eye; TnN(other), treatment
non-naive (other ocular treatments) eyes.
a Reported for primary treated eye.
b Reported for safety set.
c Includes hypertension (58.7–63.9%), hypercholesterolemia/hyperlipidaemia (23.9–37.0%), diabetes (18.8–24.8%) and
obesity (7.6–15.3%).
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Central foveal thickness and macular oedema outcomes (the RETAIN study) The assessment of MO
in the RETAIN study was based on the mean change in CFT from baseline, measured by a Stratus OCT
device, at each study visit; the proportion of patients with CFT of ≤ 250 µm at each study visit; and the
proportion of patients with resolved MO. Resolution of MO was defined as the absence of intraretinal
or subretinal fluid in the macula for ≥ 6 months after the last injection. At study entry into CRUISE,
enrolled patients had a mean baseline CFT of 639.8 µm, which reduced to 253.6 µm at month 24
(n = 32 patients). Of the 32 patients enrolled in the RETAIN study, 14 experienced MO resolution
(43.8%). Mean CFT reported at year 4 in the RETAIN study was 171.3 µm, 263.4 µm and 220.6 µm for
patients with resolved MO, patients with unresolved MO and all patients, respectively. A statistically
significant difference in CFT change was noted between patients with resolved MO and those with
unresolved MO (p = 0.01) (Table 43a and b). Patients with resolved MO had worse CFT at baseline
than those with unresolved MO [mean 616.6 µm (SD 238.4 µm) vs. mean 497.9 µm (SD 218.8 µm);
p = 0.04, respectively]. Two patients with resolved MO left the study prematurely. Of those with
resolved MO (n = 14), eight patients (57%), two patients (14%), three patients (21%) and one patient
(7%) received their last injection in years 1, 2, 3 and 4 of the follow-up period, respectively.34
TABLE 41 Systematic literature review: visual outcomes – final values at the end of the study (the RETAIN34 study)
Visual outcome Value
Mean BCVA, end of the RETAIN study, from CRUISE study entry (ETDRS), all patients 61.3 (20/63)
Mean BCVA, score, end of the RETAIN study, from CRUISE study entry (ETDRS)a 64.0 (20/50)
% of patients with BVCA of ≥ 20/40 (n = 32), mean follow-up 51.4 months 43.80
% of patients gaining ≥ 15 letters from baseline (n = 32), mean follow-up 51.4 months 53.10
Improvement in BCVA, from CRUISE baseline (ETDRS)b 12.60
Improvement in BCVA, from CRUISE baseline (ETDRS)a 14.00
Improvement in BCVA, at the end of CRUISE (ETDRS)b 13.60 (p = 0.5)
Improvement in BCVA, at the end of CRUISE (ETDRS)a 13.10 (p = 0.3)
a Data reported for 28 patients with CRVO for whom data were available 4 years after the CRUISE baseline.
b Data reported for patients with CRVO who completed the RETAIN study (full analysis set).
TABLE 40 Systematic literature review: visual outcomes – change over time (the RETAIN34 study)
Visual outcome Baseline
Month
6 12 18 24 30 36 42 48




























50.4 55.4 60.3 54.9 54.1 55.1 56.3 52.3 56.1
(20//80)
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TABLE 42 Systematic literature review: mean change from baseline visual acuity according to ETDRS letter categories
(adapted from LUMINOUS94)
Visual acuity, change in ETDRS letters
Month
12 24 36 48
CRVO, primary treated eye set
Gain of ≥ 10 letters (%) 34.9 38.1 NR NR
Gain of ≥ 15 letters (%) 28.8 28.1 NR NR
Treatment naive
Primary treated eyes with baseline and post-baseline values (n) 152.0 48.0 9.0 0.0
Gain of ≥ 5 letters, n (%) 96 (63.2) 28 (58.3) 8 (88.9) 0.0
Gain of ≥ 10 letters, n (%) 77 (50.7) 20 (41.7) 7 (77.8) 0.0
Gain of ≥ 15 letters, n (%) 66 (43.4) 13 (27.1) 5 (55.6) Not assessed
Visual acuity of ≥ 73 letters, n (%) 38 (25.0) 10 (20.8) 3 (33.3) 0.0
Treatment non-naive (ranibizumab)
Primary treated eyes with baseline and post-baseline values (n) 297.0 71.0 14.0 1.0
Gain of ≥ 5 letters, n (%) 113 (38.0) 30 (42.3) 7 (50.0) 1 (100)
Gain of ≥ 10 letters, n (%) 77 (25.9) 22 (31.0) 6 (42.9) 1 (100)
Gain of ≥ 15 letters, n (%) 59 (19.9) 19 (26.8) 4 (28.6) Not assessed
Visual acuity of ≥ 73 letters, n (%) 59 (19.9) 16 (22.5) 4 (28.6) 1 (100)
Treatment non-naive (other ocular treatments)
Primary treated eye with baseline and post-baseline values (n) 90.0 41.0 4.0 0.0
Gain of ≥ 5 letters, n (%) 48 (53.3) 20 (48.8) 2 (50.0) 0.0
Gain of ≥ 10 letters, n (%) 34 (37.8) 19 (46.3) 2 (50.0) 0.0
Gain of ≥ 15 letters, n (%) 30 (33.3) 13 (31.7) 2 (50.0) Not assessed
Visual acuity of ≥ 73 letters, n (%) 9 (10.0) 3 (7.3) 0.0 0.0
NR, not reported.
Adapted with permission from Novartis International AG.94
TABLE 43a Systematic literature review: CFT, Stratus OCT III – change from baseline (the RETAIN34 study)
Patient category Baseline
Month
6 12 18 24 30 36 42 48


























601.7 392.4 261.3 362.3 355.8 344.8 263.5 346.5 263.4
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Central retinal thickness and macular oedema outcomes (LUMINOUS) In the primary treated eye set,
the mean CRT was 551.5 µm (SD 219.95 µm) for patients with data at baseline (n= 224).94 At 36 months,
CRT (seven patients) was 290.3 µm (SD 129.2 µm). Although there was a trend of CRT reducing over time,
the greatest decrease was observed at month 36 in both the treatment-naive and treatment non-naive
(other ocular treatments) subgroups. A similar rate of resolution was not observed in patients who had
received previous injections of ranibizumab (Table 44).
Figure 27 shows trends in CFT change in patients included in the RETAIN34 study and in LUMINOUS.94
Number of injections (the RETAIN study)34 The mean number of injections of ranibizumab (0.5 mg)
administered in the RETAIN study was 19.2 over 54 months of follow-up (28 patients). The mean
number of injections administered in years 2, 3 and 4 of the study was 4.5, 3.6 and 3.3, respectively.
Fewer injections were administered to patients with resolved MO than to those with unresolved MO
(Table 45a–c). At the end of the RETAIN study, there was a statistically significant difference in the
total mean number of injections received by patients with unresolved MO, compared with those with
resolved MO (28.5 vs. 8.7 injections; p < 0.01).34
TABLE 43b Systematic literature review: CFT, Stratus OCT III – final
values at year 4 (the RETAIN34 study)
Patients with Mean CFT (µm) p-value
Resolved MO 171.30 0.01
Unresolved MO 263.40
TABLE 44 Systematic literature review: CRT – change from baseline and values at study visits in primary treated eyes
(adapted from LUMINOUS94)
Primary treated eye Baseline
Month
12 24 36 48
Treatment naive (n) 224 101 32 7 NR
CRT (µm) (SD)
Value at visit 551.5 (219.95) 399.6 (218.10) 372.9 (151.35) 290.3 (129.20) NR
Mean change N/A –176.4 (219.83) –186.0 (225.46) –257.1 (179.91) NR
Treatment non-naive
(ranibizumab) (n)
341 192 45 11 NR
CRT (µm) (SD)
Value at visit 393.3 (184.69) 347.1 (159.35) 304.9 (117.71) 411.2 (172.10) NR
Mean change N/A –49.0 (205.18) –97.7 (210.46) 6.1 (249.31) NR
Treatment non-naive
(other ocular treatments) (n)
91 51 19 2 NR
CRT (µm) (SD)
Value at visit 510.2 (199.62) 382.8 (147.71) 321.5 (119.54) 375.0 (77.78) NR
Mean change N/A –157.4 (207.74) –231.1 (163.44) –277.0 (135.76) NR
N/A, not applicable; NR, not reported.
Adapted with permission from Novartis International AG.94
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TABLE 45b Systematic literature review: mean number
of ranibizumab injections per year (the RETAIN34 study)
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FIGURE 27 Systematic literature review: trends in CFT change over time in patients with MO due to CRVO. a, Study
groups: 1, LUMINOUS, treatment naive (CRT); 2, LUMINOUS, treatment non-naive (ranibizumab) (CRT); 3, LUMINOUS,
treatment non-naive (other ocular treatments) (CRT); 4, RETAIN study, all patients (CFT); 5, RETAIN study, resolved MO
(CFT); 6, RETAIN study, unresolved MO (CFT).
TABLE 45c Systematic literature review: total mean number of ranibizumab injections by the end of the study
(the RETAIN34 study)
Group Mean number of injections p-value
Mean follow-up 54.0 months 19.20
Unresolved MO 28.50 0.001
Resolved MO 8.70
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Number of injections (LUMINOUS)94 A total of 6224 ranibizumab injections were administered to
patients with CRVO, of which 239 injections were administered in the secondary treated eye set.
Although the majority of patients received treatment in only one eye, an estimated 3% were treated in
both eyes. Treatment was administered over a mean duration of 323.5 days (primary treated eye set:
1048 patients). The mean treatment duration according to pre-treatment status in primary treated eye
was 290.3 days, 337.8 days and 345.5 days for eyes that were treatment naive, treatment non-naive
(ranibizumab) and treatment non-naive (other ocular treatments), respectively. The mean duration
between consecutive injections (primary treated eye set) was 10.6 weeks. The shortest treatment
interval was reported for treatment-naive patients (Table 46a and b). By month 48, the mean number
of injections per patient was 5.9. Differences in pre-treatment status did not influence the number of
injections received between subgroups.
Reasons provided for administering treatment in the primary treated eye set during the treatment
period (baseline to month 60) were abnormal OCT findings (82.3%), abnormal FFA findings (8.2%), ‘no
further confirmation of disease activity beyond unstable visual acuity’ (15.2%) and ‘none of the above’
(31.6%).94 Common reasons for treatment termination in the primary treated eye set were treatment-
switching to another anti-VEGF other than ranibizumab, and the decision of the treating physician or
patient. Data for the secondary treated eye set were limited or not available from the report.94
TABLE 46b Systematic literature review: mean number of ranibizumab injections, secondary treated eye,a and duration
between treatments (adapted from LUMINOUS94)
Patient category Mean number of injections
Mean number of injections, per patient, secondary treated eye
CRVO (all), n = 1048 5.6
Mean (SD) duration between consecutive injections (weeks)
CRVO (all), n = 1048 10.57 (9.16)
Treatment naive, n = 327 9.28 (6.83)
Treatment non-naive (ranibizumab), n = 577 11.12 (9.63)
Treatment non-naive (other ocular treatments), n= 144 11.61 (11.68)
a The mean number of injections is the total number of injections received by the end of the study. Reported only for
patients with data at baseline visit.
Adapted with permission from Novartis International AG.94




3 12 24 36 48
CRVO (all) n = 1048 2.0 (0.99) 4.2 (2.78) 5.6 (4.55) 5.9 (5.13) 5.9 (5.25)
Treatment naive, n = 327 2.4 (0.87) 4.3 (2.53) 5.5 (4.18) 5.8 (4.82) 5.8 (5.01)
Treatment non-naive (ranibizumab), n = 577 1.6 (0.94) 4.1 (2.83) 5.5 (4.53) 5.8 (4.95) 5.8 (5.05)
Treatment non-naive (other ocular treatments), n= 144 2.3 (0.97) 4.5 (3.09) 6.2 (5.37) 6.6 (6.37) 6.7 (6.40)
a The mean number of injections is the total number of injections received by the end of the study. Reported only for
patients with data at baseline visit.
Adapted with permission from Novartis International AG.94
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Safety outcomes
Adverse event data were provided in two studies: the RETAIN34 study (n = 32 patients) and
LUMINOUS94 (n = 1048 patients). Overall, the reported safety outcomes were identical in both studies.
Ocular and non-ocular AEs were reported and were similar in both studies. Based on the updated
health economic and decision-modelling analysis plan, only ocular AEs are reported here.
Safety outcomes (the RETAIN study)34
A small number of severe AEs were observed in patients with BRVO and CRVO in the RETAIN study.
There was insufficient information to identify whether AEs occurred during the CRUISE or HORIZON
studies or afterwards.
Ocular adverse events Four severe ocular AEs were reported, the most serious event being a
superior hemiretinal vein occlusion in one patient. The remaining events were vitreous traction (two
patients) and severe reaction to a local antiseptic (one patient). However, it is unclear whether or not
these events occurred in patients with CRVO only. On the other hand, six patients with CRVO in the
RETAIN study experienced visual loss, ranging from 3 to 33 ETDRS letters (Table 47). Reasons for
visual loss included persisting or recurrent MO, the presence of an epiretinal membrane and poor
visual improvement during the CRUISE and HORIZON studies.34
Safety outcomes (LUMINOUS)94
The mean duration of observed period for safety outcomes in the patients with CRVO was 530.0 days,
with a cumulative duration of 1521.7 person-years for the primary treated eye set. Available data on
systemic and ocular AEs in LUMINOUS are presented in Tables 47 and 48.
TABLE 47 Systematic literature review: AEs in patients in CRUISE9 and HORIZON38
Ocular AE















Endophthalmitis 0 0 0 0 0
Rhegmatogenous
retinal detachment
0 0 NR 0 NR





5 (3.9) 2 (1.8) NR 2 (1.6) NR
Vitreous haemorrhage 9 (7.0)a 2 (1.8)a 1 (1.0) 7 (5.4) 0
Lens damageb 0 0 0 0 0
Cataractc 0 2 (1.8)a 0 9 (7.0) 0
IOP increased NR NR 0 NR 0
MO NR NR 1 (1.0) NR 2 (2.0)
Visual acuity reduced NR NR 3 (3.1) NR 1 (1.0)
IOP, intraocular pressure; NR, not reported.
a One event reported as serious.
b Referred as traumatic cataract.35
c Cataract in some cases was possibly related to the intraocular injection procedure.
From months 12 to 24, all reported AEs were considered serious ocular events. Four severe ocular events were
reported in the RETAIN study: vitreous traction (n = 2 patients), vitreous haemorrhage (n= 1) and retinal tear (n = 1).
No further details were reported to link AEs to type of RVO or treatment group.
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Ocular adverse events LUMINOUS94 Ocular AEs were reported in 10.4% (109/1048) of patients
with CRVO in the primary treated eye set [treatment naive, 11.32% (37/327); treatment non-naive
(ranibizumab), 9.71% (56/577); and treatment non-naive (other ocular treatments), 11.11% (16/144)].
Among these, 0.95% of AEs were considered to be severe. Cataracts were the most common AE in
the primary treated eye set, affecting 20 eyes (1.91%). The incidence of severe ocular AEs and serious
ocular AEs in the primary treated eye was low (1.05% and 0.95%, respectively). Twenty-three patients
(2.2%) experienced ocular AEs in the primary treated eye suspected to be related to ranibizumab
and/or ocular injection. Data relating to ocular AEs in the secondary treated eye and fellow treated
eye sets were not available.
Discontinuation of treatment (LUMINOUS)
Discontinuation of treatment with ranibizumab in the LUMINOUS study was reported as withdrawals
(Table 50) and discontinuation of treatment as a result of AEs (Table 51).94 It is unclear whether or not
the discontinuation rates at specified time points included the proportion of patients who discontinued
treatment because of AEs. Up to 87.5% (7/8) of patients stopped treatment prematurely by year 4.















Ocular AEs (all) (incidence rate
per 100-person years)
164 53 87 24
Ocular AEs, % (n)
All 10.4 (109) 11.32 (37) 9.71 (56) 11.11 (16)
Ocular SAEs 0.95 (10) 1.22 (4) 0.69 (4) 1.39 (2)
Ocular severe AEs 1.05 (11) 1.22 (4) 1.21 (7) 0
Infectious endophthalmitis NR NR NR NR
Retinal detachment NR NR NR NR
Retinal (pigment epithelium) tear NR NR NR NR
Anterior chamber reactiona NR NR NR NR
Conjunctival haemorrhage 0.57 (6) 0.92 (3) 0.52 (3) 0
Vitreous haemorrhage 0.38 (4) 0.31 (1) 0.52 (3) 0 (0)
Cataract 1.91 (20) 1.22 (4) 1.91 (11) 3.47 (5)
Glaucoma 0.95 (10) 1.53 (5) 0.87 (5) 0
Ocular hypertension (raised IOP
of > 21mmHg)
0.57 (6) 1.22 (4) 0.17 (1) 0.69 (1)
Increased IOP 0.86 (9) 0.61 (2) 1.04 (6) 0.69 (1)
Visual loss 0.57 (6) 0.61 (2) 0.52 (3) 0.69 (1)
Retinal ischaemia 0.19 (2) 0.31 (1) 0. (0) 0.69 (1)
Retinal neovascularisation 0.19 (2) 0 (0) 0.17 (1) 0.69 (1)
MO 0.57 (6) 0.31 (1) 0.87 (5) 0
IOP, intraocular pressure; NR, not reported.
a Includes acute intraocular inflammation, uveitis (inflammation of the anterior chamber) and hypopyon.
Adapted with permission from Novartis International AG.94
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The most common reason was loss to follow-up (42.9%). Ranibizumab discontinuation because of
AEs was rare. Discontinuation was more commonly related to systemic AEs (1.24%) than to ocular
AEs (0.38%).94
Health-related quality-of-life outcomes: LUMINOUS
Data relating to the HRQoL of patients with CRVO treated with intravitreal ranibizumab were obtained
from the LUMINOUS94 study (Table 52). HRQoL was assessed at baseline and then at yearly intervals
in the safety set, using the VFQ-25 non-preference-based scoring system.104 Slight improvements in
VFQ-25 composite scores were reported for patients in the treatment-naive and treatment non-naive
TABLE 49 Systematic literature review: ocular AEs possibly related to ranibizumab and/or ocular injection in patients














Ocular severe AEs, possibly
treatment-related
1.05 (11) 0.38 (4) 0.67 (7) NR
Ocular AEs, possibly treatment-
related (ranibizumab or other
ocular treatment)
2.20 (23) 3.36 (11) 1.56 (9) 2.08 (3)
Ocular AEs, possibly treatment-
related (ranibizumab only)
0.67 (7) 0.92 (3) 0.52 (3) 0.69 (1)
Conjunctival haemorrhage 0.48 (5) 0.92 (3) 0.35 (2) 0
Cataract 0.095 (1) 0 0.17 (1) 0
Ocular hypertension 0.57 (6) 1.22 (4) 0.17 (1) 0.69 (1)
Increased IOP 0.10 (1) 0 017 (1) 0
Visual field defect 0.095 (1) 0.31 (1) 0 0
IOP, intraocular pressure; NR, not reported.
Adapted with permission from Novartis International AG.94





1 2 3 4
Patients (n) 1047 481 119 8







l Lost to follow-up
(5.5%)















a Percentages do not add up to 100 because only the most common reasons for withdrawal have been
presented here.
b Hypertension and hypercholesterolaemia.
Adapted with permission from Novartis International AG.94
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subgroups from baseline to the 12-month follow-up time point. From month 24 to month 36, small to
moderate decreases in HRQoL scores were observed in a decreasing number of patients with baseline
and post-baseline data (number of patients, 1 to 31 out of 214 patients included in the safety set).
The mean VFQ-25 composite score at month 36 was higher than the baseline score only for patients
in the treatment non-naive (ranibizumab) subgroup [mean 85.7 points (SD 12.20 points) vs. 79.9 points
(SD 17.90 points), representing an improvement of 3.6 points (SD 10.70 points)].
TABLE 51 Systematic literature review: discontinuation of treatment as a result of AEs in the primary treated eye by















Any AE (systemic and ocular) 1.62 (17) 2.14 (7) 1.56 (9) 0.69 (1)
Systemic AEsa 1.24 (13) 1.84 (6) 1.04 (6) 0.69 (1)
Ocular AEs 0.38 (4) 0.31 (1) 0.52 (3) 0
Details of ocular AEs
Retinal haemorrhage 0.10 (1) 0 0.17 (1) 0
Vitreous haemorrhage 0.10 (1) 0 0.17 (1) 0
Tachyphylaxis 0.10 (1) 0 0.17 (1) 0
Retinal injury 0.10 (1) 0.31 (1) 0 0
a Same data reported for discontinuations due to serious systemic AEs.
Adapted with permission from Novartis International AG.94





Treatment naive, primary treated eyes with baseline and
post-baseline value (n)
214 70 19 5
VFQ-25 composite score, mean (SD) 73.0 (20.62) 74.4 (22.89) 71.6 (19.66) 67.6 (20.89)
Mean (SD) change from baseline in VFQ-25 score 1.5 (10.47) –2.3 (11.56) –7.4 (23.15)
Treatment non-naive (ranibizumab), primary treated eyes
with baseline and post-baseline value (n)
306 86 31 12
VFQ-25 composite score, mean (SD) 79.9 (7.90) 82.9 (17.85) 82.6 (17.83) 85.7 (12.20)
Mean (SD) change from baseline in VFQ-25 score –0.8 (11.65) –0.0 (11.89) 3.6 (10.70)
Treatment non-naive (other ocular treatments), primary
treated eye with baseline and post-baseline value (n)
104 42 21 1
VFQ-25 composite score, mean (SD) 71.4 (20.38) 72.1 (24.49) 62.4 (21.17) 35.3
Mean (SD) change from baseline in VFQ-25 score 1.0 (9.38) –8.3 (15.47) –49.3
Adapted with permission from Novartis International AG.94
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Resource use: patients’ visits and concurrent treatment
Evidence relating to resource use and costs was reported in the RETAIN34 and LUMINOUS94 studies.
Data for the number of injections received by patients in both studies were presented earlier (see
Appendix 6, Table 45a and b, for the RETAIN study34 and Appendix 6, Table 46a and b, for LUMINOUS94).
Number of visits (LUMINOUS)
The authors of LUMINOUS94 indicated that patients with CRVO (i.e. the safety set) had a mean of
11.6 visits by month 48 [treatment naive, 11.0 visits; treatment non-naive (ranibizumab), 11.4 visits;
and treatment non-naive (other ocular treatments), 13.7 visits]. The comparability of number of visits
at months 36 and 48 was noted (Table 53).94
Concomitant treatments
Two patients with CRVO received scatter photocoagulation in the RETAIN study.34 However, further
details were missing. On the other hand, data from LUMINOUS94 showed that 37.1% of the CRVO
primary treated eye set [31.5% of the treatment-naive eyes, 40.6% of the treatment non-naive
(ranibizumab) eyes and 36.1% of the treatment non-naive (other ocular treatments) eyes] received
ocular concomitant medications and significant non-drug therapies (not specified). Concurrent systemic
medications and significant non-drug therapies (not specified) reported in the CRVO safety set were
administered more frequently than ocular treatments [70.8% of all patients: 62.7% of treatment-naive,
75.2% of treatment non-naive (ranibizumab) and 71.5% of treatment non-naive (other ocular
treatments) subgroups].94
Natural history (McIntosh et al.24)
Evidence relating to the natural history of CRVO was obtained from a systematic review by McIntosh
et al.24 The review conducted literature searches up to November 2008 and included English-language
articles (53 studies, 57 citations). Eligible studies were limited to observational studies of the
natural history of RVO and all clinical trials evaluating interventions for CRVO. A total of 31 studies
(3271 eyes) were assessed as of adequate quality and included studies evaluating patients with
different CRVO subtypes [585 ischaemic eyes (20%), 1495 ischaemic subtype – unspecified (50%),
730 non-ischaemic eyes (25%) and 149 hemi-CRVO (5%)].24
Natural history outcomes
For reported outcomes related to the natural history of CRVO as outlined below, see Table 54:
l baseline visual acuity
l MO development
l MO resolution
l development of neovascularisation
l development of NVG
l development of vitreous haemorrhage
l conversion from non-ischaemic to ischaemic RVO
l fellow eye involvement.
Visual acuity observed in patients at the onset of CRVO is initially low, ranging from 20/40 to 20/200.
Conversion from non-ischaemic CRVO to ischaemic CRVO occurs in up to 27% of patients. In general,
patients with ischaemic CRVO present with worse vision than those with the non-ischaemic subtype.24
Although most patients with CRVO at the time of presentation have MO, up to 73% experience
resolution of this complication within 15 months of CRVO onset (i.e. post occlusion). CRVO in both
eyes has been reported in 0.4% to 43% of patients. Within 1–3 years, up to 5% of patients with
unilateral CRVO may develop a RVO in the fellow eye.24
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VA Initial VA generally poor (20/40) and generally decreases over
time. I-CRVO has lower mean initial VA (< 20/200) and lower







MO resolves in approximately 30% of non-ischaemic CRVO eyes II A
MO resolution in up to 73% of ischaemic CRVO by 15 months
post-occlusion
II B
Development of NV NV develops in up to 33% of NI-CRVO eyes 12 to 15 months
post-occlusion
II A
NV develops in up to 20% of ischaemic CRVO eyes by 8 to
9 months post-occlusion
III A
Development of NVG NVG development occurs in 23%-60% of ischaemic CRVO by
12 to 15 months post-occlusion
III A





Conversion to i-CRVO occurs in up to 27% of niCRVO eyes




Bilateral RVO is present in 0.4% to 43% of CRVOs at
presentation
II C
1.4% of patients with CRVO develop a CRVO in the fellow eye
within 3 years
III B
5% of patients with CRVO develop a BRVO in the fellow eye
within 30 months
III C
5% of patients with CRVO develop any RVO in the fellow eye
within 1 year
III B
BRVO, branch retinal vein occlusion; CRVO, central retinal vein occlusion; MO, macular oedema; NV, neovascularisation;
NVG, neovascular glaucoma; RVO, retinal vein occlusion; VA, visual acuity; VH, vitreous haemorrhage.
a Importance of clinical outcome:
Strength of evidence. A=most important or crucial to a good clinical outcome; B=moderately important to clinical
outcome; C= possibly relevant but not critical to clinical outcome; I= data providing strong evidence in support of
the clinical recommendation; II= strong evidence in support of the recommendation but the evidence lacks some
qualities, thereby preventing its justifying the recommendation without qualification; III= insufficient evidence to
provide support for or against recommendation, panel, or individual expert opinion.
b The authors also reported that the pooled mean VA decrease from baseline to ≥ 12 months was 3 letters for
non-ischemic CRVO eyes and 35 letters for ischaemic eyes.
c No data. Most studies included patients with MO at baseline. Only two studies136,137 of small study populations
(n= 3 eyes) reported development of MO from baseline.
Reprinted from Ophthamology, vol. 117, McIntosh RL, Rogers SL, Lim L, Cheung N, Wang JJ, Mitchell P, et al., Natural
history of central retinal vein occlusion: an evidence-based systematic review, pp. 1113–23.e15, 2010,24 with
permission from Elsevier.
TABLE 53 Systematic literature review: number of visits by patients according to pre-treatment status in the primary
treated eye (safety set) (adapted from LUMINOUS94)
Patients
Mean (SD) number of visits up to month
12 24 36 48
All patients (N= 1048) 7.4 (3.51) 10.8 (6.08) 11.5 (6.91) 11.6 (7.06)
Treatment naive (N= 327) 7.2 (3.46) 10.2 (5.72) 10.9 (6.44) 11.0 (6.63)
Treatment non-naive (ranibizumab) (N= 577) 7.5 (3.50) 10.7 (6.05) 11.4 (6.76) 11.4 (6.91)
Treatment non-naive (other ocular treatments) (N = 144) 7.9 (3.62) 12.3 (6.75) 13.6 (8.13) 13.7 (8.18)
Adapted with permission from Novartis International AG.94
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
170
Discussion
The review was conducted to identify evidence to inform inputs and assumptions for the long-term
(> 2 years) economic model of LEAVO, a non-inferiority clinical trial comparing the clinical effectiveness
and cost-effectiveness of intravitreal injections of ranibizumab (0.5 mg/0.05 ml), aflibercept (2.0 mg/
0.05 ml) and bevacizumab (1.25 mg/0.05 ml) in patients with MO secondary to CRVO. No relevant
long-term comparative evidence was identified by the systematic review. Although long-term data
were identified for patients treated with ranibizumab, there was a lack of long-term evidence for
patients with MO secondary to CRVO who received aflibercept and bevacizumab. Three studies
provided evidence that was considered potentially useful to inform the long-term model. One systematic
review provided natural history data24 and two non-randomised studies reported outcomes beyond
24 months for patients treated with ranibizumab.34,94 Major concerns with these sources of evidence
include the dearth of recent natural history evidence,24 small sample sizes beyond 2 years of treatment,24,34,94
and heterogeneity in clinical study design and reporting.34,94 The RETAIN study34 was a 4-year extension trial
of a Phase III trial (CRUISE),9,33 which followed up less than one-tenth of patients [8.2% (32/392)] enrolled
in the original study. Furthermore, only 3% (30/1048) of patients evaluated in the 5-year observational,
non-interventional, multicentre, open-label, single-arm study (LUMINOUS)94 provided relevant visual
acuity data beyond 2 years of follow-up.
In general, patients with CRVO have reduced visual acuity (44.7 letters94 to 50 letters,34 or 20/40 to
20/40024) and signs of MO24 (mean SD-OCT CST, 463.5 µm94 to 639.8 µm34) at the time of presentation.
Although there is some evidence that treatment with intraocular ranibizumab improves visual acuity
beyond 2 years (a 15-letter gain in visual acuity for 53.1% of patients; mean follow-up of 51.4 months),
it is likely that greater improvement may be experienced in the earlier phase of treatment.34 Visual
acuity improved by 14.0 ETDRS letters from the CRUISE baseline (32 patients), resulting in a final visual
acuity score of 64 letters (20/50) in patients with available data at year 4.34 However, this improvement
was not statistically significant when compared with the improvement of 13.1 letters (p = 0.3) from the
end of the CRUISE study until the end of the RETAIN study.34 Differences in treatment regimens such
as fixed-dose regimen of injections every 6 months and pro re nata dosing may explain this observation.
Available data suggest that earlier treatment is likely to result in greater functional improvement than
delayed therapy.35 This could explain the lack of statistically significant difference in BCVA in the CRUISE
and RETAIN studies. The presence of MO was a predictor of visual acuity outcome. Improvements in
visual acuity tend to be greater in patients with resolved MO than in those with unresolved MO [year 4
visit, 73.2 letters (20/32) vs. 56.1 letters (20/80); p = 0.1].34 A statistically significantly higher proportion
of treated patients achieved better final visual acuity of ≥ 20/40 (64.3% and 27.8% for resolved MO and
unresolved MO respectively; p = 0.04) and greater visual acuity gain (25.2 and 4.3 ETDRS letters for
resolved MO and unresolved MO, respectively; p = 0.002).34
Up to 43.8% of patients in the RETAIN34 study had resolved MO at year 4. A statistically significant
difference in CFT change was noted between patients with resolved MO and those with unresolved MO
(p = 0.01).34 Shorter-term real-world data comparing patients with CRVO receiving ranibizumab with
patients with CRVO receiving aflibercept reported complete resolution in 50% and 42.9% of patients in
the ranibizumab and aflibercept treatment groups, respectively.35 Although clinical trials tend to provide
better outcomes than real-world data,35 fewer patients in the RETAIN34 study experienced resolution of
MO than patients in the shorter, real-world study. This may be explained by the differences in CFT at
baseline: (RETAIN), 639.8 µm;34 real-world study,35 573.8 µm (ranibizumab group) versus 599.1 µm
(aflibercept group).
After 3 years of treatment, patients receiving ranibizumab tended to experience improved quality of
life [VFQ-25 composite score, change from baseline 3.6 (SD 10.70)].94 Reported mortality was generally
low across all three included studies.24,34,94 The rate of systemic or ocular AEs was approximately 10%.
Previous studies,24,32,34,36,51,94,135,138,139 albeit with short-term data addressing the safety of intraocular
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anti-VEGF use in the treatment of MO due to CRVO, have not demonstrated major systemic and
ocular AEs between anti-VEGF treatments. Although existing literature for long-term data suffers
from inadequate sample sizes, inconsistent definitions and other methodological weaknesses, the
findings of this review were in line with those of earlier work.
The mean number of injections of ranibizumab (0.5 mg) administered in the RETAIN study was 19.2 over
54 months of follow-up (n = 28 patients).34 At the end of the RETAIN study, there was a statistically
significant difference in the total mean number of injections received by patients with unresolved
MO, and the total number received by those with resolved MO (28.5 vs. 8.7 injections, respectively;
p < 0.01).34 By contrast, by month 48, the mean number of injections per patient in LUMINOUS was
5.9. Differences in pre-treatment status did not influence the number of injections received between
subgroups. This was similar to the mean number of injections reported in real-life data elsewhere
evaluating 62 (62 eyes) treatment-naive patients with CRVO treated with intravitreal ranibizumab
(0.5 mg) (6.8 injections) and aflibercept (0.2 mg) (6.1 injections).35 Common reasons for treatment
termination, such as treatment-switching to an anti-VEGF other than ranibizumab, could explain the
observed difference in the number of injections in the RETAIN study34 and LUMINOUS.94 A recently
published network meta-analysis found no difference between ranibizumab, aflibercept, bevacizumab
and triamcinolone in improving vision.135 The authors noted that treating physicians may tend to prefer
aflibercept over other anti-VEGFs because it requires fewer injections.94
Visual acuity outcome is largely dependent on initial acuity.94 In addition, visual acuity at baseline is a
strong predictor of visual acuity at 3 years for eyes with good vision and eyes with poor vision, but
a poor predictor for intermediate acuities.20 Visual acuity was low in patients at the onset of CRVO,
ranging from 20/40 to 20/200.94 Conversion from non-ischaemic CRVO to ischaemic CRVO occurs
in up to 27% of patients. In general, patients with ischaemic CRVO present with worse vision than
patients with the non-ischaemic subtype.94 Further evidence shows that patients with ischaemic
CRVO tend to have poorer vision (visual acuity of < 6/60) following treatment, whereas those with
non-ischaemic CRVO may experience resolution of the condition without complications.16 Patients
with ischaemic CRVO were not eligible for enrolment in CRUISE,9 but there was uncertainty about the
conversion rate of non-ischaemic eyes to ischaemic eyes in the extension study, RETAIN, and whether
or not efficacy outcomes may have been influenced by a number of confounders (e.g. concomitant
treatments and comorbidities) in the long term.
A majority of patients with CRVO have MO at the time of presentation; however, up to 73% experience
resolution within 15 months of CRVO onset (i.e. post occlusion).24 CRVO in both eyes has been reported
in 0.4–43% of patients. Within 1–3 years, up to 5% of patients with unilateral CRVO may develop a RVO
in the fellow eye.24 Included studies34,94 did not provide sufficient data to assess fellow eye involvement.
It is important to note the strengths of this systematic review, which was conducted in line with
standard recommendations and informed by a multidisciplinary team comprising an information
specialist, a systematic reviewer, health economists and cost-effectiveness modellers. On the other
hand, a few limitations are noted here. Data relating to potential model inputs were checked by a
second researcher; one researcher selected studies and performed data extraction and synthesis.
The last search was carried out in June 2018. For these reasons, it is possible that key studies may
have been missed.
Conclusion
Overall, the approach to identify evidence for the long-term LEAVO model was robust. There was
limited evidence to inform the long-term clinical effectiveness and cost-effectiveness of anti-VEGFs
used in the management of MO secondary to CRVO. A proficient understanding of comparative and
long-term efficacy and safety of anti-VEGFs is needed.
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Search strategy
Database searched: MEDLINE/MEDLINE In Process & Other Non-Indexed Citations.
Date range searched: from inception.
Date of search: 18 June 2018.
1. exp Macular Edema/
2. exp Macula Lutea/
3. exp EDEMA/
4. (macula* adj3 oedema).tw.
5. (macula* adj3 edema).tw.
6. 6. (CME or CMO).tw.
7. or/1-6
8. exp Retinal Vein Occlusion/
9. exp Retinal Vein/
10. ((vein* or venous or occlu* or obstruct* or clos* or stricture* or steno* or block* or embolism*) adj3
(central or retina*)).tw.
11. (CRVO or CVO or RVO).tw.
12. or/8-11
13. 7 and 12
14. exp Angiogenesis Inhibitors/
15. exp Angiogenesis Inducing Agent
16. exp Endothelial Growth Factors/
17. exp Vascular Endothelial Growth Factors/
18. exp RANIBIZUMAB/
19. (ranibizumab or lucentis or rhuFab*).tw.
20. ZL1R02VT79.rn.
21. (aflibercept or eylea).tw.
22. 15C2VL427D.rn.
23. exp BEVACIZUMAB/
24. (bevacizumab or avastin).tw.
25. 2S9ZZM9Q9 V.rn.
26. (anti adj2 VEGF*).tw.
27. (endothelial adj2 growth adj2 factor*).tw.
28. or/14–28
29. 13 and 28.
Recommendations for data sources
TABLE 55 Data components for economic models
Category Data componenta
1 Clinical effect sizes, AEs and complications




a The data components were further divided into levels.92
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Excluded studies, with reasons
TABLE 56 Excluded studies, with reasons
First author
and year Title Reason(s) for exclusion/notes
Bradshaw 2016140 Systematic literature review of treatments for
management of complications of ischemic central retinal
vein occlusion
l Cost-effectiveness
l No usable data
Braithwaite 2010141 Anti-vascular endothelial growth factor for macular edema
secondary to central retinal vein occlusion
Follow-up of < 2 years
Braithwaite 201432 Anti-vascular endothelial growth factor for macular
oedema secondary to central retinal vein occlusion
Follow-up of < 2 years
Brand 2014142 Luminous: results from the 2014 interim analysis to
provide further real-world evidence for clinical
ranibizumab use
l LUMINOUS study
l No response from authors
Brown 201033 Ranibizumab for macular edema following central retinal
vein occlusion: six-month primary end point results of a
Phase III study
l IVR vs. sham




Natural history and clinical management of central retinal
vein occlusion
Natural history, data available in
included review reported by
McIntosh et al.24
Chatziralli 2018143 Ranibizumab for retinal vein occlusion: predictive factors
and long-term outcomes in real-life data
Natural history; full text not available
Cornel 2015144 Anti-vascular endothelial growth factor indications in
ocular disease
Follow-up of < 2 years
Daradbounis 2014145 Long-term results of ranibizumab treatment in patients with
macular oedema due to retinal venous occlusive disease
l IVR – efficacy
l Inter-library loan, not available
Deramo 2003134 Vision-related quality of life in people with central retinal
vein occlusion using the 25-item National Eye Institute
Visual Function Questionnaire
l VFQ
l No usable data
Casselholm de Salles
201957
Injection frequency of aflibercept versus ranibizumab in a
treat-and-extend regimen for central retinal vein
occlusion: a randomized clinical trial
l Number of injections
l Inter-library loan, not available
DeCroos 2014146 Neovascular events in eyes with central retinal vein
occlusion undergoing serial bevacizumab or ranibizumab
intravitreal injections: a retrospective review
l IVR and IVB
l Follow-up of < 2 years
Deonandan 2017147 Anti-vascular endothelial growth factor drugs for the
treatment of retinal conditions: a review of the safety
Follow-up of < 2 years
Edwards 2012148 Comparisons of the clinical effectiveness of treatments for
macular oedema (MO) caused by retinal vein occlusion
(RVO)
Follow-up of < 2 years
Figueroa 201228 Potential anti-vascular endothelial growth factor therapies
for central retinal vein occlusion
l IVR (efficacy)
l Review article
Ford 201436 Treatments for macular oedema following central retinal
vein occlusion: systematic review
Follow-up of < 2 years
Ford 2014135 Drug treatment of macular oedema secondary to central
retinal vein occlusion: a network meta-analysis
Follow-up of < 2 years
Freund 2015149 Treat-and-extend regimens with anti-VEGF agents in
retinal diseases: a literature review and consensus
recommendations
l Rx-pattern
l No usable data
Gallego-Pinazo
2012150
Safety and efficacy of ranibizumab in macular edema
following retinal vein occlusion
No usable data
Gerding 2015151 Ranibizumab in retinal vein occlusion: treatment
recommendations by an expert panel
No usable data
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TABLE 56 Excluded studies, with reasons (continued )
First author
and year Title Reason(s) for exclusion/notes
Glanville 2014152 Efficacy and safety of widely used treatments for macular
oedema secondary to retinal vein occlusion: a systematic
review
No usable data
Heier 201238 Ranibizumab for macular edema due to retinal vein
occlusions: long-term follow-up in the HORIZON trial
l Injection frequency (HORIZON)
l No usable data
Hernando 2018153 Vision-related quality of life in patients diagnosed with
retinal pathology
l Quality of life
l Follow-up of < 2 years
Jager 2004154 Risks of intravitreous injection: a comprehensive review No usable data
Jiang 2017155 Update on the use of anti-VEGF intravitreal therapies for
retinal vein occlusions
l Summaries of IVR-related trials
l No usable data
Jumper 2018156 Anti-VEGF treatment of macular edema associated with
retinal vein occlusion: patterns of use and effectiveness in
clinical practice (ECHO study report 2)
l Injections/baseline variables
l No usable data
Kinge 2010157 Efficacy of ranibizumab in patients with macular edema
secondary to central retinal vein occlusion: results from
the sham-controlled ROCC study
l IVR vs. sham
l No usable data
Konidaris 2018158 Outcomes of switching treatment to aflibercept in
patients with macular oedema secondary to central retinal
vein occlusion refractory to ranibizumab
l Treatment-switching from IVR
to IVA
l No usable data
Kornhauser 2016159 Bevacizumab treatment of macular edema in CRVO and
BRVO: long-term follow-up. (BERVOLT study:
Bevacizumab for RVO long-term follow-up)
l IVR and IVB
l No usable data
Kumar 2013160 A clinical study to evaluate the efficacy of intravitreal
anti-VEGF therapy in treating macular oedema due to
retinal venous occlusions
l IVR (multiple treatments)
l No usable data
Larsen 201655 Individualized ranibizumab regimen driven by stabilization
criteria for central retinal vein occlusion: twelve-month
results of the CRYSTAL study
No usable data
Liu 2017161 Branch and central retinal vein occlusion: clinical pearls
from trials of ranibizumab
l Review of BRAVO, CRUISE,
SHORE, BRIGHTER and
CRYSTAL studies
l No usable data





A study evaluating dosing regimens for treatment with
intravitreal ranibizumab injections in subjects with
macular edema following retinal vein occlusion
l Clinical trial record.
Results available
l Follow-up of < 2 years
Nghiem-Buffet
2017164
Treatment patterns of ranibizumab intravitreal injection
and dexamethasone intravitreal implant for retinal vein
occlusion in the USA
l Rx-pattern (USA, 2017)
l Follow-up of < 2 years
Nicolò 2017165 Real-life management of patients with retinal vein
occlusion using I-Macula Web platform
Follow-up of < 2 years
Nuzzi 2015166 Local and systemic complications after intravitreal
administration of anti-vascular endothelial growth factor
agents in the treatment of different ocular diseases:
a five-year retrospective study
l AEs (IVB; IVR)
l No usable data
Pacella 2012167 Testing the effectiveness of intravitreal ranibizumab
during 12 months of follow-up in venous occlusion
treatment
Follow-up of < 2 years
Patel 2016168 Central retinal vein occlusion: a review of current
evidence-based treatment options
l RCTs of IVB in CRVO
l Follow-up of < 2 years
continued
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TABLE 56 Excluded studies, with reasons (continued )
First author
and year Title Reason(s) for exclusion/notes
Penedones 2014169 Safety monitoring of ophthalmic biologics: a systematic
review of pre- and post-marketing safety data
No usable data
Pielen 201337 Efficacy and safety of intravitreal therapy in macular
edema due to branch and central retinal vein occlusion:
a systematic review
Follow-up of < 2 years
Poku 2014170 The safety of intravitreal bevacizumab monotherapy in
adult ophthalmic conditions: systematic review
No usable data
Qian 2017171 Comparison between anti-VEGF therapy and
corticosteroid or laser therapy for macular oedema
secondary to retinal vein occlusion: a meta-analysis
Follow-up of < 2 years
Rayess 2016172 Post injection endophthalmitis rates and characteristics
following intravitreal bevacizumab, ranibizumab, and
aflibercept
No usable data
Regnard 2016173 Anti-VEGF treatment of macular edema using a treat-and-
extend regimen in retinal vein occlusion in clinical practice
l Rx-pattern – injections
l No usable data
Risard 2011174 Intravitreal ranibizumab for macular edema secondary to
central retinal vein occlusion
Follow-up of < 2 years; no
baseline data
Scott 2017175 SCORE2 report 5: vision-related function in patients with
macular edema secondary to central retinal or hemiretinal
vein occlusion
No usable data
Sharma 2015176 Baseline characteristics of Canadian patients with
neovascular age-related macular degeneration (nvAMD),
diabetic macular oedema (DMO) and retinal vein occlusion
(RVO) enrolled in the LUMINOUS study
No usable data
Sigford 2015138 Global reported endophthalmitis risk following intravitreal
injections of anti-VEGF: a literature review and analysis
No usable data
Sophie 2013177 Long-term outcomes in ranibizumab-treated patients with
retinal vein occlusion; the role of progression of retinal
nonperfusion
l Number of injections, resolution
of MO
l No usable data
Spaide 200939 Prospective study of intravitreal ranibizumab as a
treatment for decreased visual acuity secondary to central
retinal vein occlusion
No usable data
Tabandeh 2014178 Endophthalmitis associated with intravitreal injections:
office-based setting and operating room setting
l IVR and IVB
l No usable data
Taylor 2014179 A United Kingdom-based economic evaluation of
ranibizumab for patients with retinal vein occlusion (RVO)
l No usable data
Thulliez 2014180 Cardiovascular events and bleeding risk associated with
intravitreal anti-vascular endothelial growth factor
monoclonal antibodies: systematic review and
meta-analysis
No usable data
Thulliez 201851 Overview of systematic reviews and meta-analyses on
systemic adverse events associated with intravitreal
anti-vascular endothelial growth factor medication use
No usable data
Vorum 2016181 Real world evidence of use of anti-VEGF therapy in
Denmark
l Rx-pattern
l No usable data
Wang 2016182 A review of randomized trials of approved pharmaceutical
agents for macular edema secondary to retinal vein
occlusion
No usable data
Wecker 2017183 Five-year visual acuity outcomes and injection patterns in
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TABLE 56 Excluded studies, with reasons (continued )
First author
and year Title Reason(s) for exclusion/notes
Xu 2017139 Safety and complications of intravitreal injections
performed in an Asian population in Singapore
No usable data
Yeh 2015184 Therapies for macular edema associated with central
retinal vein occlusion: a report by the American Academy
of Ophthalmology
l Quality of life/costs
l No usable data
Yuan 2014185 Comparison of intravitreal ranibizumab and bevacizumab
for the treatment of macular edema secondary to retinal
vein occlusion
No usable data
Ziemssen 2017186 Demographics of patients receiving intravitreal anti-VEGF
treatment in real-world practice: healthcare research data
versus randomized controlled trials
No usable data
BRIGHTER, Efficacy and Safety of Ranibizumab With or Without Laser in Comparison to Laser in Branch Retinal Vein
Occlusion; CNV, choroidal neovascularisation; DME, diabetic macular oedema; IVA, intravitreal aflibercept; IVB, intravitreal
bevacizumab; IVR, intravitreal ranibizumab; SHORE, Study Evaluating Dosing Regimens for Treatment with Intraviteral






























































FIGURE 28 Model-based analysis: stabilisation graphs. (a) QALYs; and (b) costs. Reproduced with permission from
Pennington et al.95 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to
the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence
and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/
by/4.0/. The figure includes minor additions and formatting changes to the original figure. (continued )
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FIGURE 28 Model-based analysis: stabilisation graphs. (a) QALYs; and (b) costs. Reproduced with permission from
Pennington et al.95 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits
use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to
the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless
indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence
and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/
by/4.0/. The figure includes minor additions and formatting changes to the original figure.
TABLE 57 Within-trial analysis: unit costs applied for the valuation of resource use
Description
Unit
cost (£) Source HRG code Notes
Intervention costs
Ranibizumab 551.00 BNF117 – 1.65 mg/0.165 ml solution for
injection in pre-filled syringes
(Novartis, supplied from routine
NHS hospital stock)
Aflibercept 816.00 BNF117 – 2 mg/50 µl solution for injection
vials (Bayer Pharmaceuticals
AG, supplied from routine NHS
hospital stock)
Bevacizumab 28.00 Judicial review53 – Cost per pre-filled syringe
1.25 mg/0.05 ml (Roche,
supplied by the Royal Liverpool
and Broadgreen Pharmacy
Aseptic Unit)
Baseline appointment 140.04 Department of Health
and Social Care118
WF02B Consultant led, ophthalmology
Follow-up appointments 105.19 Department of Health
and Social Care118
WF02A Consultant led, ophthalmology
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TABLE 57 Within-trial analysis: unit costs applied for the valuation of resource use (continued )
Description
Unit
cost (£) Source HRG code Notes
OCT 108.21 Department of Health
and Social Care118
BZ87A Outpatient procedure
Colour fundus photography 116.23 Department of Health
and Social Care118
BZ89A l Outpatient procedure
l Weighted average of
ophthalmology and optometry
FFA 108.21 Department of Health
and Social Care118
BZ87A Outpatient procedure
Procedures and hospital admissions
Hospital admission 337.36 Department of Health
and Social Care118
Index: NEL_XS Non-elective inpatients excess
bed-days




l Unit cost per occupied
bed-day
l Initial assessment incurred
once per stay


















213.04 Department of Health
and Social Care118
BZ87A WF02A
Cyclodiode laser treatment 143.26 Department of Health
and Social Care118
BZ95Z
Argon laser 120.66 Department of Health
and Social Care118
BZ86B
Entropion repair 137.52 Department of Health
and Social Care118
BZ45B
Epilation 125.53 Department of Health
and Social Care118
BZ46A
Incision and curettage 125.53 Department of Health
and Social Care118
BZ46A
Left needling of bleb with
5-fluorouracil
143.26 Department of Health
and Social Care118
BZ95Z
Lester Jones tube insertion 125.53 Department of Health
and Social Care118
BZ46A
Paracentesis 143.26 Department of Health
and Social Care118
BZ95Z
Medial canthoplasty 137.52 Department of Health
and Social Care118
BZ45B




Vitrectomy 2319.38 Department of Health
and Social Care118
BZ80A–BZ84B
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TABLE 57 Within-trial analysis: unit costs applied for the valuation of resource use (continued )
Description
Unit
cost (£) Source HRG code Notes










Blepharoplasty 2768.81 Department of Health
and Social Care118
BZ41B
Peripheral iridotomy 860.28 Department of Health
and Social Care118
BZ04 A,B Inflated costs using HCHS index
Yag capsulotomy 860.28 Department of Health
and Social Care118
BZ04 A,B Inflated costs using HCHS index
Low-vision aids 194.41 Department of Health
and Social Care118
– l Inflated to 2017/18 prices
using HCHS index
l Assumed that 33.3% of
patients use low-vision aids
Blind registration 60.50 Meads and Hyde122 – l Blind registration consists
of a GP appointment to
complete the BD8 form and
a community occupational
therapist assessment
l 94.5% of eligible people will
register as blind
Continuous care and support
Care home cost 1154.00 Curtis and Burns116 – l Local authority own-provision
residential care for older
people (aged ≥ 65 years)
establishment cost plus
personal living expenses
l 10% of people will be
funded by NHS
Home help (social services) 27.64 Curtis and Burns116 – Average taken over weekday,
weekend and day, night
Day centre 58.00 Curtis and Burns116 – Local authority own–provision
day care for older people
(aged ≥ 65 years)
Health-care contacts
Visit
Ophthalmology consultant 95.13 Department of Health
and Social Care118
WF01A
GP 37.40 Curtis and Burns116 – l Including direct care staff
costs, and with qualification
costs
l Per-patient contact lasting
9.22 minutes
Practice nurse 17.79 Curtis and Burns116 – l Nurse (general practice)
based on band 5 patient-
related work and including
qualifications
l Duration of contact is
15.5 minutes per surgery
consultation
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TABLE 57 Within-trial analysis: unit costs applied for the valuation of resource use (continued )
Description
Unit
cost (£) Source HRG code Notes




Weighted average of all codes
of those admitted and those
non-admitted




Rapid access and optician
Ophthalmology outpatient
doctor




Optician or optometrist 76.50 Department of Health
and Social Care118
WF01B Non-consultant-led optometry
Blood sample 2.83 Department of Health
and Social Care118
DAPS08









56.79 Department of Health
and Social Care118
WF02B Non-consultant-led optometry
Neurologist for double vision 284.66 Department of Health
and Social Care118
WF01B l Consultant-led neurology
l Non-consultant-led
orthoptist





Eye hospital for a low-vision
appointment




l Doubled to reflect
complexity of appointment
Call
Helpline 28.66 Curtis and Burns116 Band 6 specialist nurse (hospital
based), 15.5-minute consultation
A&E eye department
Staff nurse in eye clinic








Orthoptist 37.60 Department of Health
and Social Care118
WF01D Non-consultant-led orthoptist




NHS 24 13.59 Turner et al.187
GP 28.00 Curtis and Burns116 l Including direct staff costs
and qualifications
l Telephone consultation from
2015 is 7.1 minutes
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TABLE 57 Within-trial analysis: unit costs applied for the valuation of resource use (continued )
Description
Unit
cost (£) Source HRG code Notes
Practice nurse 6.90 Curtis and Burns116 l Nurse (general practice)
based on band 5 patient-
related work and including
qualifications
l Telephone consultation from
2015 with an advanced
nurse is 6 minutes
Home visit
GP 56.16 Curtis and Burns116
Practice nurse 32.89 Curtis and Burns116 –
Optometrist 76.50 Department of Health
and Social Care118
Concomitant medications
Acetazolamide 250mg tablets 13.87 BNF117 –
Acyclovir 200 mg tablets 0.97 BNF117 –
Acyclovir 400 mg tablets 2.35 BNF117 –
Acular 0.5% eye drops 3.00 BNF117 –
Alphagan 0.2% eye drops 2.55 BNF117 –






Aspirin 75 mg gastroresistant
tablets
0.61 BNF117 –
Atropine 1% eye drops 131.88 BNF117 –
Azarga 10mg/ml/5 mg/ml eye 11.05 BNF117 –
Azopt 10mg/ml eye drops 2.00 BNF117 –







Brochlor 1% eye ointment 1.96 BNF117 –
Celluvisc 0.5% eye drops 0.4 ml
unit dose
4.80 BNF117 –






Clinitas 0.4% eye drops 0.5 ml
unit dose
5.70 BNF117 –
Clinitas Carbomer 0.2% eye gel 2.80 BNF117 –
Clopidogrel 75 mg tablets 1.31 BNF117 –
Co-codamol 30 mg/500 mg
caplets
3.23 BNF117 –
Codeine 15 mg tablets 0.77 BNF117 –
Codeine 30 mg tablets 0.87 BNF117 –
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TABLE 57 Within-trial analysis: unit costs applied for the valuation of resource use (continued )
Description
Unit





500 mg powder for solution for
injection vials
17.71 BNF117 –







Dropodex 0.1% eye drops
0.4 ml unit
10.48 BNF117 –
DuoTrav 40 µg/ml/5 mg/ml eye 13.95 BNF117 –
Evolve Carmellose 0.5% eye
drops preservative free
4.99 BNF117 –
Exocin 0.3% eye drops 2.17 BNF117 –
Ganfort 0.3 mg/ml/5 mg/ml
eye drops
14.16 BNF117 –
Hyabak 0.15% eye drops
preservative free
7.99 BNF117 –
Hydromoor 0.3% eye drops
0.4 ml unit dose preservative
free
5.75 BNF117 –
Hylo-Forte 0.2% eye drops
preservative free
9.50 BNF117 –
Hylo-Tear 0.1% eye drops
preservative free
8.50 BNF117 –
Hypromellose 0.3% eye drops 1.21 BNF117 –
Ibuprofen 400mg tablets 0.84 BNF117 –
Ilube 5% eye drops 16.90 BNF117 –
Iopidine 5 mg/ml eye drops 10.88 BNF117 –
Lacri-lube eye ointment 3.01 BNF117 –
Latanoprost 50 µg/ml/Timolol





Levofloxacin 5 mg/ml eye drops 6.95 BNF117 –
Liquifilm Tears 1.4% eye drops 1.93 BNF117 –
Liquivisc 0.25% eye gel 4.50 BNF117 –





Maxidex 0.1% eye drops 1.42 BNF117 –
Maxitrol eye drops 1.68 BNF117 –
Maxitrol eye ointment 1.44 BNF117 –
continued
DOI: 10.3310/hta25380 Health Technology Assessment 2021 Vol. 25 No. 38
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Hykin et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
183
TABLE 57 Within-trial analysis: unit costs applied for the valuation of resource use (continued )
Description
Unit
cost (£) Source HRG code Notes
Minims artificial tears 0.44%
eye drops 0.5 ml unit
9.33 BNF117 –
Minims fluorescein sodium 1%
eye drops 0.5 ml unit dose
9.25 BNF117 –
Minims oxybuprocaine
hydrochloride 0.4% eye drops
0.5 ml unit dose
10.56 BNF117 –
Minims phenylephrine
hydrochloride 2.5% eye drops
0.5 ml unit dose
11.87 BNF117 –
Minims proxymetacaine 0.5%
eye drops 0.5 ml unit dose
12.12 BNF117 –
Minims saline 0.9% eye drops
0.5 ml unit dose
7.43 BNF117 –
Minims tropicamide 0.5% eye
drops 0.5 ml unit dose
11.18 BNF117 –
Mitomycin 2 mg powder for
solution for injection
55.89 BNF117 –
Monopost 50 µg/ml eye drops
0.2 ml unit dose
8.49 BNF117 –
Moxivig 0.5% eye drops 9.80 BNF117 –
Mydrilate 0.5% solution 8.08 BNF117 –
Opatanol 1 mg/ml eye drops 4.68 BNF117 –
Optive 0.5% eye drops 7.49 BNF117 –
Ozurdex 700 µg intravitreal
implant in applicator
870.00 BNF117 –
Paracetamol 1 g tablets 2.49 BNF117 –







Pred Forte 1% eye drops 1.82 BNF117 –
Predsol 0.5% ear/eye drops 2.00 BNF117 –






Tears Naturale eye drops 1.89 BNF117 –
Timolol 0.5% eye drops 0.88 BNF117 –
Tiopex 1mg/g eye gel 0.4 g
unit dose
7.49 BNF117 –
Tobradex 3 mg/ml/1 mg/ml
eye drops
5.37 BNF117 –
Travatan 40 µg/ml eye drops 3.26 BNF117 –
Trusopt 20 mg/ml eye drops
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TABLE 57 Within-trial analysis: unit costs applied for the valuation of resource use (continued )
Description
Unit
cost (£) Source HRG code Notes
Vancocin 500 mg powder for
solution for infusion vials
5.49 BNF117 –
Virgan 0.15% eye gel 19.99 BNF117 –
Viscotears 2 mg/g liquid gel 2.80 BNF117 –
Vitaros 3 mg/g cream 40.00 BNF117 –
Xailin 0.2% eye gel 2.80 BNF117 –
Xailin Fresh 0.5% eye drops
0.4 ml unit dose
4.80 BNF117 –
Xailin HA 0.2% eye drops 7.19 BNF117 –
Xalacom eye drops 6.37 BNF117 –




BNF, British National Formulary; HRG, Healthcare Resource Group.
Reproduced with permission from Pennington et al.95 This article is licensed under a Creative Commons Attribution 4.0
International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,
as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third party material in this article are included in the
article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit https://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes
to the original table.
TABLE 58 Model-based analysis: deterministic results
Analysis
Total (95% CI) Incremental (95% CI)
ICER (£) (95% CI)Costs (£) QALYs Costs (£) QALYs
Base-case analysis
Bevacizumab 14,302 10.3642
Ranibizumab 27,015 10.3564 12,712 –0.0078 Dominated
Aflibercept 27,894 10.3607 13,592 –0.0035 Dominated
Scenario analysis: EQ-5D for utilities
Bevacizumab 14,302 8.8834
Ranibizumab 27,015 8.8753 12,712 –0.0081 Dominated
Aflibercept 27,894 8.8906 13,592 0.0072 1,891,888
Scenario analysis: EQ-5D-V for utilities
Bevacizumab 14,302 8.5432
Ranibizumab 27,015 8.5327 12,712 –0.0105 Dominated
Aflibercept 27,894 8.5464 13,592 0.0032 4,209,328
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TABLE 58 Model-based analysis: deterministic results (continued )
Analysis
Total (95% CI) Incremental (95% CI)
ICER (£) (95% CI)Costs (£) QALYs Costs (£) QALYs
Scenario analysis: 100-week time horizon
Bevacizumab 6278 1.6749
Ranibizumab 15,881 1.6748 9603 –0.0001 Dominated
Aflibercept 16,711 1.6806 10,432 0.0057 1,820,265
Scenario analysis: 5-year time horizon
Bevacizumab 6278 1.6749
Ranibizumab 15,881 1.6748 9603 –0.0001 Dominated
Aflibercept 16,711 1.6806 10,432 0.0057 1,820,265
Scenario analysis: 10-year time horizon
Bevacizumab 11,725 6.5389
Ranibizumab 23,900 6.5400 12,175 0.0011 10,710,733
Aflibercept 24,600 6.5491 700 0.0091 77,086
Scenario analysis: bevacizumab list price from the BNF117 (£243)
Bevacizumab 20,947 10.3642
Ranibizumab 27,015 10.3564 6068 –0.0078 Dominated
Aflibercept 27,894 10.3607 6948 –0.0035 Dominated
BNF, British National Formulary.
TABLE 59 Model-based analysis: base-case results, pairwise comparisons
Outcome Intervention, mean (SD) Comparator, mean (SD) Difference, mean (95% CI)
Ranibizumab vs. bevacizumab
Cost (£) 30,226 (9582) 18,353 (6520) 11,873 (11,458 to 12,288)
QALY 9.635 (1.395) 9.678 (1.219) –0.044 (–0.074 to –0.013)
ICER (£) Dominated (INMB: –14,316 to –12,067)
Aflibercept vs. ranibizumab
Cost (£) 35,026 (11,820) 30,226 (9582) 4,800 (4445 to 5154)
QALY 9.569 (1.599) 9.635 (1.395) –0.065 (–0.097 to –0.033)
ICER (£) Dominated (INMB: –7917 to –5603)
Aflibercept vs. bevacizumab
Cost (£) 35,026 (11,820) 18,353 (6520) 16,673 (16,036 to 17,310)
QALY 9.569 (1.599) 9.678 (1.219) –0.109 (–0.161 to –0.057)
ICER (£) Dominated (INMB: –21,864 to –18,040)
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TABLE 60 Model-based analysis: EQ-5D scenario analysis results, pairwise comparisons
Outcome Intervention, mean (SD) Comparator, mean (SD) Difference, mean (95% CI)
Ranibizumab vs. bevacizumab
Cost (£) 30,226 (9582) 18,353 (6520) 11,873 (11,458 to 12,288)
QALY 8.795 (0.468) 8.782 (0.476) 0.013 (0.008 to 0.018)
ICER (£) 908,532 (659,881 to 1,476,254)
Aflibercept vs. ranibizumab
Cost (£) 35,026 (11,820) 30,226 (9582) 4800 (4445 to 5154)
QALY 8.832 (0.478) 8.795 (0.468) 0.037 (0.032 to 0.043)
ICER (£) 128,513 (110,116 to 152,663)
Aflibercept vs. bevacizumab
Cost (£) 35,026 (11,820) 18,353 (6520) 16,673 (16,036 to 17,310)
QALY 8.832 (0.478) 8.782 (0.476) 0.050 (0.044 to 0.057)
ICER (£) 330,697 (292,449 to 381,601)
TABLE 61 Model-based analysis: EQ-5D-V scenario analysis results, pairwise comparisons
Outcome Intervention, mean (SD) Comparator, mean (SD) Difference, mean (95% CI)
Ranibizumab vs. bevacizumab
Cost (£) 30,226 (9582) 18,353 (6520) 11,873 (11,458 to 12,288)
QALY 8.351 (1.960) 8.346 (0.731) 0.005 (–0.007 to 0.017)
ICER (£) 2,491,676 (INMB: –12,327 to –11,155)
Aflibercept vs. ranibizumab
Cost (£) 35,026 (11,820) 30,226 (9582) 4800 (4445 to 5154)
QALY 8.639 (0.913) 8.351 (1.960) 0.018 (0.000 to 0.045)
ICER (£) 268,963 (INMB: –4930 to –3602)
Aflibercept vs. bevacizumab
Cost (£) 35,026 (11,820) 18,353 (6520) 16,673 (16,036 to 17,310)
QALY 8.639 (0.913) 8.346 (0.731) 0.023 (–0.001 to 0.047)
ICER (£) 737,383 (INMB: –17,033 to –14,981)
Note
The INMB is at £30,000 per QALY.
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TABLE 62 Model-based analysis: 100-week time horizon scenario analysis results, pairwise comparisons
Outcome Intervention, mean (SD) Comparator, mean (SD) Difference, mean (95% CI)
Ranibizumab vs. bevacizumab
Cost (£) 15,254 (3324) 6349 (638) 8905 (8650 to 9161)
QALY 1.641 (0.115) 1.641 (0.115) 0.000 (0.000 to 0.001)
ICER (£) 34,067,841 (217,070 to 10,420,696)
Aflibercept vs. ranibizumab
Cost (£) 18,844 (4629) 15,254 (3324) 3590 (3400 to 3780)
QALY 1.646 (0.112) 1.641 (0.115) 0.005 (0.004 to 0.005)
ICER (£) 793,348 (688,418 to 926,352)
Aflibercept vs. bevacizumab
Cost (£) 18,844 (4629) 6349 (638) 12,495 (12,119 to 12,871)
QALY 1.646 (0.112) 1.641 (0.115) 0.005 (0.004 to 0.006)
ICER (£) 2,610,554 (2,199,924 to 3,200,947)
TABLE 63 Model-based analysis: £243 list price for bevacizumab scenario analysis results, pairwise comparisons
Outcome Intervention, mean (SD) Comparator, mean (SD) Difference, mean (95% CI)
Ranibizumab vs. bevacizumab
Cost (£) 30,226 (9582) 23,530 (7372) 6696 (6400 to 6992)
QALY 9.635 (1.395) 9.678 (1.219) –0.044 (–0.074 to –0.013)
ICER (£) –153,559 (INMB: –9084 to –6937)
Aflibercept vs. ranibizumab
Cost (£) 35,026 (11,820) 30,226 (9582) 4800 (4445 to 5154)
QALY 9.569 (1.599) 9.635 (1.395) –0.065 (–0.097 to –0.033)
ICER (£) Dominated (INMB: –7917 to –5603)
Aflibercept vs. bevacizumab
Cost (£) 35,026 (11,820) 23,530 (7372) 11,496 (10,961 to 12,030)
QALY 9.569 (1.599) 9.678 (1.219) –0.109 (–0.161 to –0.057)
ICER (£) –105,573 (INMB: –16,636 to –12,905)
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Within-trial analysis results: additional data
TABLE 64 Within-trial analysis: summary of missing data with the difference between treatment arms
Parameter
n (%) Difference in percentage missing













4 (0.03) 6 (0.04) 4 (0.03) 14 (0.03) 0.013 0.000 0.013
Baseline utility
(EQ-5D-V)
12 (0.08) 19 (0.12) 18 (0.12) 49 (0.11) 0.045 0.039 0.006
Baseline utility
(VFQ-UI)
6 (0.04) 6 (0.04) 4 (0.03) 14 (0.03) 0.000 –0.013 0.013
QALYs (EQ-5D
without vision)
42 (0.27) 46 (0.30) 55 (0.36) 143 (0.31) 0.026 0.084 –0.058
QALYs (EQ-5D-V) 67 (0.44) 75 (0.49) 74 (0.48) 216 (0.47) 0.052 0.045 0.006
QALYs (VFQ-UI) 32 (0.21) 45 (0.29) 52 (0.34) 129 (0.28) 0.084 0.130 –0.045












































FIGURE 30 Within-trial analysis: pattern of missing VFQ-UI data. Green shading indicates missing data for one or more patients.
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FIGURE 31 Within-trial analysis: pattern of missing EQ-5D (without the vision bolt-on) data. Green shading indicates



































































FIGURE 33 Within-trial analysis: histograms of complete-case cost data by treatment arm. (a) Ranibizumab (n= 65);
(b) aflibercept (n = 71); and (c) bevacizumab (n= 67). (continued )
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FIGURE 33 Within-trial analysis: histograms of complete-case cost data by treatment arm. (a) Ranibizumab (n = 65);
(b) aflibercept (n = 71); and (c) bevacizumab (n= 67).
TABLE 65 Within-trial analysis: mean baseline utility and QALY estimated using the three HRQoL questionnaires
HRQoL questionnaire
Mean (SD); n patients
Ranibizumab Aflibercept Bevacizumab
VFQ-UI
Baseline (complete case) 0.849 (0.1322); 148 0.868 (0.1295); 147 0.869 (0.1156); 148
QALY (imputed) 1.627 (0.2471); 154 1.651 (0.2374); 154 1.666 (0.2426); 154
EQ-5D (without vision bolt-on)
Baseline (complete case) 0.790 (0.2118); 150 0.813 (0.2204); 148 0.801 (0.2055); 150
QALY (imputed) 1.472 (0.3666); 154 1.516 (0.3856); 154 1.500 (0.3757); 154
EQ-5D-V
Baseline (complete case) 0.767 (0.2065); 142 0.783 (0.2029); 135 0.739 (0.2410); 136
QALY (imputed) 1.513 (0.3744); 154 1.560 (0.3801); 154 1.535 (0.3759); 154
Note
QALYs are adjusted for baseline utility.
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FIGURE 34 Within-trial analysis: mean utility scores using the EQ-5D (without vision bolt-on) over 100 weeks. Table shows
number of observations at each time point. Reproduced with permission from Pennington et al.95 This article is licensed
under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to
the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by
statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The figure includes minor additions and
formatting changes to the original figure.
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FIGURE 35 Within-trial analysis: mean utility scores using the EQ-5D-V over 100 weeks. Table shows number of
observations at each time point. Reproduced with permission from Pennington et al.95 This article is licensed under a
Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and
reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line
to the material. If material is not included in the article’s Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the
copyright holder. To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/. The figure includes
minor additions and formatting changes to the original figure.
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95% CI (λ = 20,000)
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FIGURE 36 Within-trial analysis: NMB and 95% CIs. (a) Aflibercept vs. ranibizumab; (b) aflibercept vs. bevacizumab; and
(c) bevacizumab vs. ranibizumab. Cor, covariance between total costs and QALYs; dC, mean difference in costs; dQ, mean
difference in QALYs; sd(dC), standard error of mean differential costs; sd(dQ), standard error of mean differential QALYs.
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TABLE 66 Within-trial analysis: fully incremental analyses for three HRQoL measures
Mean total (SD) Incremental (95% CI)a
ICER (£)/
dominanceCost (£) QALY Cost (£) QALY
VFQ-UI
Bevacizumab 6292 (3371) 1.666 (0.2426) – – –
Ranibizumab 13,014 (3605) 1.627 (0.2471) 6734 (5970 to 7498) –0.019 (–0.065 to 0.0284) Dominated
Aflibercept 14,328 (3773) 1.651 (0.2374) 7984 (7209 to 8759) –0.015 (–0.0618 to 0.0322) Dominated
EQ-5D (without vision bolt-on)
Bevacizumab 6273 (3384) 1.535 (0.3759) – – –
Ranibizumab 13,068 (3636) 1.513 (0.3744) 6769 (5987 to 7550) –0.0102 (–0.0710 to 0.0504) Dominated
Aflibercept 14,271 (3857) 1.560 (0.3801) 8035 (7246 to 8824) 0.008 (–0.0529 to 0.0683) 104,1476
EQ-5D-V
Bevacizumab 6268 (3368) 1.500 (0.3757) – – –
Ranibizumab 13,000 (3661) 1.472 (0.3666) 6748 (5948 to 7547) –0.035 (–0.1172 to 0.0480) Dominated
Aflibercept 14,273 (3720) 1.516 (0.3856) 8012 (7232 to 8793) 0.0032 (–0.0837 to 0.0902) 2,483,943
a Adjusted for baseline utility score.












Cost (£) 14,328 (3883); 154 13,013 (3673); 154 1245 (406 to 2085) –
QALY 1.651 (0.2426); 154 1.627 (0.2471); 154 0.004 (–0.0430 to 0.0518) –
ICER (£) 284,255 0.04 (0.10)
Bevacizumab vs. ranibizumab
Cost (£) 8933 (3474); 154 13,013 (3673); 154 –4103 (–4949 to –3257) –
QALY 1.666 (0.2374); 154 1.627 (0.2471); 154 0.018 (–0.0282 to 0.0648) –
ICER (£) Bevacizumab is dominant 1.00 (1.00)
Aflibercept vs. bevacizumab
Cost (£) 14,328 (3883); 154 8933 (3474); 154 5342 (4552 to 6133) –
QALY 1.651 (0.2426); 154 1.666 (0.2374); 154 –0.015 (–0.0618 to 0.0322) –
ICER (£) Aflibercept is dominated 0.00 (0.00)
a Adjusted for baseline utility score.
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Cost (£) 9214 (2235); 154 8164 (2163); 154 1002 (516 to 1487) –
QALY 0.8798 (0.1208); 154 0.865 (0.1230); 154 0.004 (–0.0178 to 0.0256) –
ICER (£) 256,547 0.00 (0.02)
Bevacizumab vs. ranibizumab
Cost (£) 3621 (2017); 154 8164 (2163); 154 –4546 (–4999 to –4093) –
QALY 0.8842 (0.1171); 154 0.865 (0.1230); 154 0.007 (–0.0143 to 0.0290) –
ICER (£) Bevacizumab is dominant 1.00 (1.00)
Aflibercept vs. bevacizumab
Cost (£) 9214 (2235); 154 3621 (2017); 154 5560 (5082 to 6039) –
QALY 0.8798 (0.1208); 154 0.8842 (0.1171); 154 –0.004 (–0.0256 to 0.0168) –
ICER (£) Aflibercept is dominated 0.00 (0.00)
a Adjusted for baseline utility score.
Reproduced with permission from Pennington et al.95 This article is licensed under a Creative Commons Attribution 4.0
International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format,
as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons
licence, and indicate if changes were made. The images or other third party material in this article are included in the
article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not
included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or
exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this
licence, visit https://creativecommons.org/licenses/by/4.0/. The table includes minor additions and formatting changes
to the original table.












Cost (£) 14,013 (3507); 66 12,608 (2342); 65 1405 (204 to 2606) –
QALY 1.691 (0.1931); 66 1.656 (0.1605); 65 0.011 (–0.0413 to 0.0629) –
ICER (£) 130,020 0.07 (0.14)
Bevacizumab vs. ranibizumab
Cost (£) 6459 (3045); 62 12,608.2 (2342.29); 65 –6149 (–7369 to –4929) –
QALY 1.651 (0.1507); 62 1.656 (0.1605); 65 –0.007 (–0.0596 to 0.0458) –
ICER (£) 890,736 1.00 (1.00)
Aflibercept vs. bevacizumab
Cost (£) 14,013 (3507); 66 6459 (3045); 62 7554 (6338 to 8769) –
QALY 1.691 (0.1931); 66 1.651 (0.1507); 62 0.018 (–0.0345 to 0.0704) –
ICER (£) 426,551 0.00 (0.00)
a Adjusted for baseline utility score.
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